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Abstract 
Parkinson’s disease (PD) is a progressive, age-related, neurodegenerative disorder 
characterised by loss of dopaminergic neurones in substantia nigra pars compacta (SNpc) with 
the formation of α-synuclein rich Lewy bodies. The exact mechanism behind SNpc cell death 
is still unclear but at the molecular level, oxidative stress and mitochondrial dysfunction are 
thought to be involved.  
Sirtuins (SIRTs) are NAD
+
 dependent protein deacetylases and/or ADP-ribosyltransferases, 
that modulate apoptosis, gene expression, stress resistance and anti-oxidant defence 
mechanisms by targeting histone and non-histone proteins. Recent evidence has suggested 
that SIRT1 and SIRT3 are neuroprotective and SIRT2 promotes neuronal death. This study 
investigated the role of SIRTs in oxidative stress mediated cell death and PD. 
The toxicity of diquat and rotenone, which produce oxidative and mitochondrial stress, were 
measured in dopaminergic SH-SY5Y cells and the effect of over-expression and inhibition of 
deacetylase activity of SIRTs on cell viability after toxin treatment was determined. Over-
expression of SIRT1, SIRT2 and SIRT3 protected the cells from toxin induced cell death. The 
protection conferred by SIRT1 was partially independent of its deacetylase activity, which 
was mediated through the repression of NF-кB expression. On the other hand, protection 
exerted by SIRT2 and SIRT3 was entirely dependent on their enzymatic activity and was 
induced through higher expression of SOD2. SIRTs also reduced the formation of α-synuclein 
aggregates although only SIRT3 was co-localised with α-synuclein.   
In post-mortem brain tissue obtained from patients with Parkinson’s disease, Parkinson’s 
disease with dementia, dementia with Lewy bodies and Alzheimer’s disease, the activity of 
SIRT1 was observed to be down-regulated whereas, SIRT2 showed increased activity 
compared to controls. The increased activity of SIRT2 is possibly a compensatory effect to 
combat oxidative stress. SIRT3 was observed to be active in microglial cells in disease, 
implying an activation of anti-oxidant defence mechanism towards neuronal stress in 
neurodegenerative disorders. 
In conclusion, the main results of this thesis suggest that SIRTs rescue cells from oxidative 
stress and reduce the formation of α-synuclein aggregates. The mechanism through which 
they confer the protection is through enhancement of anti-oxidant pathways and repression of 
inflammatory responses.  
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Chapter 1 Introduction 
The ageing process and regulation of lifespan are complex processes controlled by multiple 
factors. Calorie restriction (CR) and physical activities extend lifespan and one family of 
proteins, the Sirtuins (SIRTs), are thought to be key mediators of this effect. SIRTs are 
nicotinamide adenine diphosphate (NAD
+
) dependent class III histone deacetylases (HDAC) 
that target lysine (K/Lys) residue of histones and non-histone proteins, and their enzymatic 
activity can inhibit or induce the activity of multiple proteins involved in cellular repair 
activities, gene expression, stress resistance and maintenance of energy levels.  
SIRTs have been linked to neurodegenerative disorders such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington disease (HD) and Amyotrophic lateral sclerosis (ALS).  
This study intended to determine the possible roles of SIRTs in Parkinson’s disease (PD) and 
also to analyse their effect on modulation of oxidative stress. 
  
1.1  Sirtuins 
SIRTs are NAD
+
 dependent lysine deacetylases (KDACs) that possess deacetylase and/or 
mono-ribosyltransferase activity and are conserved from bacteria to humans (Brachmann et 
al., 1995; Dutnall and Pillus, 2001; Blander and Guarente, 2004). Silent information 
regulator2 (SIR2), the founding member of the family was found in the yeast, Saccharomyces 
cerevisae as a histone deacetylase and gene silencer that was required for cell mating (Rine et 
al., 1979; Shore et al., 1984). SIR2 regulates ribosomal DNA recombination, gene silencing, 
DNA repair, chromosomal stability and longevity (Sinclair et al., 2006). The yeast SIR 
complex (sir2, sir3 and sir4) plays an important role in heterochromatin gene silencing 
through regulation of histone deacetylation at ribosomal DNA (rDNA) loci, telomeres and 
mating type loci (HML and HMR) (Gasser and Cockell, 2001). SIR2 increases the lifespan in 
yeast by regulating rDNA; it supresses the formation of toxic extrachromosomal rDNA circles 
(ERCs) and also promotes DNA repair (Sinclair and Guarente, 1997; Guarente, 2000). 
Similarly, SIR2 orthologue, SIR2.1 in Caenorhabditis elegans is also reported to increase 
lifespan which is dependent on daf-16 transcription factor (a member of forkhead box 
subgroup O family) (Blander and Guarente, 2004). Likewise in Drosophila melanogaster, an 
increase (2-5 fold) in the dosage of dSIR2 can increase the lifespan of the fly (Rogina and 
Helfand, 2004; Whitaker et al., 2013). 
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In mammals, there are seven homologues of SIR2, SIRT1-7 which are dependent on oxidised 
NAD
+
 unlike other HDACs. They belong to class III HDACs, which have a highly conserved 
central NAD
+
 binding domain and a catalytic domain, termed the Sirtuin core domain (Greiss 
and Gartner, 2009). Whereas Class I and II HDACs require Zn
2+
 in their catalytic domain and 
are inhibited by trichostatin A (TSA), SIRTs do not require Zn
2+
 in the catalytic domain and 
are not inhibited by TSA (Dokmanovic et al., 2007). Thus, considering the importance of 
histone deacetylation in the regulation of gene expression, SIRTs have been proposed to 
provide a molecular link between cellular metabolic status, as expressed by the NAD
+
/NADH 
levels, and adaptive transcriptional responses (Milner, 2009). SIRTs are thus uniquely 
responsive to the redox state of a cell and metabolic stresses, and can function as molecular 
sensors of the nutritional status of the cell. 
 
1.1.1 Classification and localisation of SIRTs 
Although SIRTs are conserved as a family, the amino (N) and carboxyl (C) domains are 
different, vary in length and are susceptible to post translational modification thus conferring 
the distinct biological functions: 
i) different enzymatic activities 
ii) unique binding patterns  
iii) different cell localisation and expression patterns (Frye, 2000; Haigis and Sinclair, 
2010). 
Based upon the conservation of a ~275 amino acid conserved domain, the SIRTs are 
classified into five different classes, I-IV and class U (Frye, 2000; Greiss and Gartner, 2009).  
Class I SIRTs show robust deacetylase activity and all yeasts SIRs and mammalian SIRT1-3 
belong to this class. Class I is divided into two subgroups wherein SIRT1 belongs to Class Ia 
and SIRT2 and SIRT3 belong to Class Ib. Class II SIRTs exhibit ADP-ribosyltransferase 
activity and comprise a few prokaryotic SIRTs that are involved in metabolic regulation 
(Vaquero, 2009) and SIRT4 which inhibits glutamate dehydrogenase (Haigis et al., 2006).  
Class III SIRTs include most of the bacterial SIRTs and SIRT5. SIRT5 shows no deacetylase 
activity but possesses demalonylase, desuccinylase and deglutarylase activity (Hirschey and 
Zhao, 2015). Class IV contains SIRT6 with ADP ribosyltransferase and deacetylase activity 
and SIRT7 with deacetylase activity (Kim and Kim, 2013). These sirtuins are not present in 
prokaryotes (Frye, 2000). Class U comprises uncharacterised bacterial SIRTs (Table 1.1). 
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Table 1.1 Classification and chromosomal location of human Sirtuins.  
*Taken from North, B.J. and Verdin, E. (2004) 'Sirtuins: Sir2-related NAD-dependent protein 
deacetylases', Genome Biol, 5(5), p. 224.  (North and Verdin, 2004)) 
 
SIRT1 is a nuclear protein but under different environmental cues and tissue type, it can 
shuttle to the cytoplasm (Tanno et al., 2007). SIRT2 is primarily a cytoplasmic protein that 
can translocate to the nucleus during G2/M phase transition (Vaquero et al., 2006). SIRT3-5 
are mitochondrial proteins; SIRT3 is the major mitochondrial deacetylase that has also been 
reported to translocate between the nucleus and mitochondria depending upon the cellular 
stress (Shih and Donmez, 2013). SIRT6 is predominantly a nuclear protein and is associated 
with heterochromatin (Kugel and Mostoslavsky, 2014). SIRT7 is localised in the nucleolus 
and is associated with rDNA promoter and transcribed region (Tsai et al., 2012) (Figure 1.1 
and Table 1.1).  
Name Class Chromosomal 
Location 
Yeast Mouse 
Sirt1 Ia 10q21.3 Sir2, Hst1 Sir2β 
Sirt2 Ib 19q13.2 Hst2 Sir2l2 
Sirt3 Ib 11p15.5 Hst2 Sir2l3 
Sirt4 II 12q24.31  Sirt4 
Sirt5 III 6p23  Sirt5 
Sirt6 Iva 19p13.3  Sirt6 
Sirt7 IVb 17q25.3  Sirt7 
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Figure 1.1 Sub-cellular localisation of SIRTs. SIRT1, SIRT6 and SIRT7 are nuclear proteins, SIRT2 cytoplasmic and SIRT3, SIRT4 and SIRT5 are 
mitochondrial. Depending on the cellular stress and activity SIRT1 gets localised to the cytoplasm, SIRT2 and SIRT3 to the nucleus. Cellular stress and diet 
changes the level of NAD
+
/NADH and NAM which triggers the enzymatic activity of SIRTs which may impact DNA repair, metabolism and cell survival. 
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Sirtuins Subcellular 
Localisation 
Activity  Targets Biological 
Functions 
Null 
phenotype 
Therapeutic 
Strategies 
Potential link with 
diseases 
SIRT1 Nucleus Deacetylase p53,Ku70, H3, 
H4, PPAR- γ, 
PGC-1 α, NF-
κB, p300, 
FOXO, LXR, 
HDAC1, etc. 
Regulation of cell 
survival and 
metabolism, Stress 
response control, 
ROS scavenging, 
apoptosis 
Developmental 
defects, lethal in 
some 
backgrounds 
Activation Ageing, obesity, insulin 
resistance, 
inflammation, diabetes, 
heart failure, axonal 
degeneration, dual role 
in cancer, 
neuroprotective in some 
neurodegenerative 
disorders 
SIRT2 Cytoplasm Deacetylase 
 
α-tubulin, 
histone H4, 
p53, FOXO,  
NF-κB , 
PEPCK1 
Regulation of 
microtubule 
stability, cell cycle 
regulation, 
genomic stability, 
OL differentiation, 
ROS scavenging, 
apoptosis 
Developmentally 
normal 
Inhibition/ 
Activation? 
Dual role in cancer, 
associated with α- 
synuclein mediated 
toxicity 
SIRT3 Mitochondria 
and nucleus 
Deacetylase AceCS2, PGC-
1α, GDH 
Complex I, 
SOD2, Ku70, 
FOXO3a, 
OGG, IDH2 
and other 
mitochondrial 
proteins  
Activation of 
mitochondrial 
function (ATP 
production), 
regulation of 
thermogenesis, 
ROS scavenging, 
mtDNA repair, 
apoptosis 
Developmentally 
normal 
Activation Adaptive 
thermogenesis, cardiac 
hypertrophy, dual role 
in cancer, 
neuroprotective in AD, 
HD and AHL models. 
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Table 1.2 Enzymatic activity and biological processes regulated by mammalian Sirtuins. The table summarises the cellular location, enzymatic 
activity, the biological processes regulated by SIRTs. It also highlights the possible therapeutic approach towards SIRTs.   
*Adapted from Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5:253-95. PMID: 20078221 and 
Yamamoto et al. Sirtuin functions in health and diseases. Molecular Endocrinology 21(8): 1745-1755. PMID: 17456799 (Haigis and Sinclair, 2010) 
Abbreviations: PPAR- γ: peroxisome proliferator-activated receptor gamma; NF-κB: nuclear factor kappa; FOXO: Forkhead box subgroup O; LXR: liver X 
receptor; AceCS2: acetyl-CoA-synthetase 2; PGC-1α: peroxisome proliferator activated receptor gamma coactivator 1 alpha; GDH: glutamate 
dehydrogenase; IDE: insulin degrading enzyme; ANT: adenine nucleotide translocator; CPS1:  carbamoyl phosphate synthetase; OGG: oxoguanine-DNA 
glycosylase-1; IDH2: Isocitrate dehydrogenase 2; SOD2: Manganese superoxide dismutase; mt: mitochondrial; ROS: reactive oxygen species; OL: 
oligodendrocyte 
 
SIRT4 Mitochondria ADP-ribosyl 
transferase 
GDH, IDE, 
ANT 
Down regulation of 
insulin secretion in 
response to amino 
acids 
Developmentally 
normal 
Inhibition? Inhibits amino acid 
stimulated insulin 
secretion 
SIRT5 Mitochondria Deacetylase,  
demalonylase, 
desuccinylase 
and 
deglutarylase 
CPSI Urea Cycle Developmentally 
normal 
Unknown Unknown 
SIRT6 Chromatin ADP-ribosyl 
transferase 
DNA 
polymerase β, 
histone H3, NF-
κB 
DNA 
repair/control, 
ADP 
ribosyltransferase 
activity 
Premature ageing Activation Age- related disease 
SIRT7 Nucleolus Deacetylase RNA 
polymerase I 
Regulation of 
rRNA synthesis 
and ribosome 
production 
Smaller size, 
short lifespan, 
heart defects 
Activation Highly expressed in 
thyroid cancers, 
overexpressed in node-
positive breast cancer. 
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1.1.2 NAD
+
 and Sirtuins enzymatic activity 
NAD
+
 and its reduced form NADH are known for their role in metabolism and energy 
homeostasis. SIRTs require NAD
+
 as a cofactor for the enzymatic reaction thus coupling them 
with the metabolic status of the cell. Deacetylation of SIRTs substrates can inhibit or induce 
activities, whereas ADP-ribosylation has so far only been shown to be inhibitory. 
SIRTs are substrate specific protein deacetylases which remove an acetyl group from acetyl 
lysine-modified proteins. During the enzymatic reaction, a glycosidic bond is cleaved from 
NAD
+
 producing nicotinamide (NAM) and the acetyl group from the protein is transferred to 
the ADP-ribose forming 2’-O-acetyl-ADP-ribose (OAADPR), which is found to have 
biological functions as a signalling molecule. The generated NAM is an endogenous inhibitor 
of sirtuins which inhibits SIRT activity in a non-competitive way with NAD
+
 and under stress 
PNC1/NAMPT initiates the biosynthesis of NAD
+
 from NAM. The activity of SIRTs is 
controlled by the cellular ratio of NAD
+
/NADH; NAD
+
 is an activator and NADH is an 
inhibitor (Figure 1.2). Sirtuins (SIRT4 and SIRT6) also catalyse ADP-ribosylation, in which 
the ADPR group of NAD
+
 is either transferred to the nucleophilic N-terminal of the enzymes 
themselves or on to their substrates. SIRT5 removes acyl groups from malonylated or 
succinylated proteins forming O-malonyl-ADP-ribose or O-succinyl-ADP-ribose, 
respectively. 
  
 8 
 
Figure 1.2 Reaction mechanism of Sirtuins and its regulation by calorie restriction and 
stress. Sirtuin enzymatic reaction utilises a molecule of NAD+ realising NAM, O- AADPR and 
deacetylated protein. NAM is an endogenous inhibitor of Sirtuins which is converted to NAD
+
 by 
PNC1/NAMPT under stress or calorie restriction. 
 
1.1.3 Sirtuin 1 (SIRT1) 
SIRT1 shares the most homology with yeast SIR2 and is the best studied mammalian sirtuin 
(Haigis and Sinclair, 2010). SIRT1 is involved in many physiological and pathological 
processes that regulate development and differentiation, metabolism, apoptosis, cell 
proliferation, DNA repair, circadian rhythm, lifespan, cell cycle regulation and genomic 
stability through protein deacetylation (Cheng et al., 2003; McBurney et al., 2003; Cohen et 
al., 2004; Haigis and Guarente, 2006). SIRT1 is primarily a nuclear protein but can also be 
localised to the cytoplasm, probably depending upon the cell type, stress status and molecular 
interactions (Tanno et al., 2007). It is by far the largest SIRT and contains two nuclear 
localisation signals (NLS), NLS1 and NLS2 and also possesses two nuclear export signals 
(NES), NES1 and NES2.  
The Sirt1 gene is located at chromosome 10q21.3 and consists of 11 exons (PubMed entry; 
Gene ID: 23411). There are two isoforms of SIRT1 protein annotated in the UniProt database 
(Q96EB6 (SIRT1_HUMAN)), which are produced by alternative splicing. SIRT1FL 
(Q96EB6) is the canonical SIRT1 sequence, of 747 amino acids with predicted molecular 
weight 80kDa but the observed molecular weight on Western blot is ~120kDa possibly due to 
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post translational modifications (Lynch et al., 2010). SIRT1FL shows robust deacetylase 
activity whereas, delta-exon 8 has minimal deacetylase activity. The expression of delta-
exon8 is stress inducible in contrast to SIRT1FL which is constitutively expressed. Also, 
delta-exon8 exhibits distinct RNA/protein stability and protein-protein interactions compared 
to SIRT1FL (Lynch et al., 2010). Another study showed one more isoform of SIRT1, called 
SIRT1-Δ2/9, which is generated by frameshift splicing between exon 2 and exon 9 of SIRT1 
pre-mRNA and lacks the catalytic core domain of SIRT1FL (Shah et al., 2012). 
SIRT1 regulates gene expression by targeting specific gene promoters and modulates 
chromatin function by deacetylating histone proteins (Milner, 2009). SIRT1 also regulates 
gene expression by deacetylating non-histone proteins that are transcriptional activators, or 
transcriptional repressors, thereby regulating the transcriptional processes of the cell both 
positively and negatively (Rahman and Islam, 2011). SIRT1 is active under basal conditions 
during development and appears to control cell and tissue differentiation (Milner, 2009). 
SIRT1 knock-out mice show elevated prenatal death and any surviving mice have severe 
developmental problems with cardiovascular, neurologoical and retinal defects and sterility 
(Cheng et al., 2003; McBurney et al., 2003).  
SIRT1 has a wide range of substrates which includes various transcriptional regulators and 
enzymes such as histones H1, H3 and H4, p53, p300, p300/CBP associated factor (PCAF), 
members of FOXO (forkhead box type O) family, NBS1, E2F1, peroxisome proliferator-
activated receptor gamma (PPAR-γ), PPARγ co-activator (PGC-1α), p73, myoblast 
determination protein (MyoD), nuclear factor kappa B (NF-κB), acetyl coA- synthetase 
1(AceCS1), endothelial nitric-oxide synthase (eNOS), autophagy components- Atg5, Atg7 
and Atg8, Ku70, and target of rapamycin complex 2 (TORC2) (Vaziri et al., 2001; Brunet et 
al., 2004; Picard et al., 2004; Yeung et al., 2004; Bouras et al., 2005; Hallows et al., 2006; 
Wang et al., 2006; Mattagajasingh et al., 2007; Lee et al., 2008; Amat et al., 2009; Liu et al., 
2009). 
 
1.1.3.1 Regulation of SIRT1 
SIRT1 expression and activity is controlled at transcriptional, post-transcriptional and post-
translational levels by NAD
+
/NADH levels and interacting proteins. SIRT1 protein level is 
modulated during oxidative stress, CR and by activating compounds such as resveratrol 
(RSV; a natural polyphenol found in red grapes and red wine) which enhances the enzymatic 
activity of SIRT1 and in turn regulates the cellular processes by either activating or inhibiting 
targets (Figure 1.3).  
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Transcriptional regulation of SIRT1 
Under cellular stress or DNA damage, SIRT1 is positively regulated by the transcription 
factor E2F1. Cell cycle and apoptosis regulator E2F1 binds to the Sirt1 promoter at a 
consensus site located at bp position -65 and induces SIRT1 transcription, however, SIRT1 
deacetylates E2F1 and inhibits E2F1 induced transcription of target genes including itself  
(Wang et al., 2006). The tumour suppressor hypermethlyated in cancer 1 (HIC1) forms a 
transcription repression complex with Sirt1 and negatively regulates its transcription by 
binding to the Sirt1 promoter at two sites (bp positions -1116 and -1039) and represses SIRT1 
transcription (Chen et al., 2005b). p53 also negatively regulates SIRT1 transcription by 
binding at two sites within the Sirt1 promoter (-182 and -158). During starvation, FOXO3a 
binds to p53 and removes it from the Sirt1 promoter resulting in increased SIRT1 expression 
(Nemoto et al., 2004). In a feedforward loop, FOXO1 enhances the expression of SIRT1 by 
directly binding to the promoter and depletion of FOXO1 leads to reduced levels of SIRT1 
mRNA as well as protein (Xiong et al., 2011). Importantly, SIRT1 deacetylates and activates 
FOXO1, thus it amplifies its own transcription (Xiong et al., 2011). In another feedback loop, 
SIRT1 deacetylates and activates HIF-2 which in turn binds to the Sirt1 promoter and 
enhances its expression under hypoxia (Chen et al., 2011a). Poly-ADP-ribose polymerase 2 
(PARP2) is another negative regulator of SIRT1 expression which is independent of the 
bioavailabilty of NAD
+
. PARP2 decreases SIRT1 expression by directly binding to the 
proximal region -91bp of the Sirt1 promoter (Bai et al., 2011a) and depletion or knockdown 
of PARP2 increases SIRT1 expression as well as its activity and promotes oxidative 
metabolism through SIRT1 (Bai et al., 2011a; Geng et al., 2013). 
Post transcriptional modulation of SIRT1 
The post transcriptional modification of SIRT1 is modulated by two classes of proteins- RNA 
binding proteins (RBP) and microRNAs (miRNA). Human antigen R (HuR), a RNA binding 
protein interacts with the 3’ untranslated region of SIRT1 mRNA and stabilises the mRNA 
and also increases SIRT1 expression. In contrast, upon oxidative stress, checkpoint kinase 2 
(CHK2) mediates dissociation of HuR from SIRT1 by CHK2 hyperphosphorylating HuR and 
reducing its affinity for SIRT1 mRNA and leading to degradation of SIRT1 (Abdelmohsen et 
al., 2007). Several miRNAs modulate SIRT1 gene expression by downregulating its 
translation and/or by destabilising the mRNA. More than 16 miRNAs downregulate SIRT1 
expression during differentiation of mouse embryonic stem cells and maintain low levels of 
SIRT1 in differentiated cells (Saunders et al., 2010; Yamakuchi, 2012). 
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Post translational regaulation of SIRT1 
Phosphorylation 
Phosphorylation is a major form of post translational modification (PTM) on SIRT1 and 
SIRT1 is reversibly phosphorylated at a number of sites. SIRT1 is phosphorylated on at least 
13 different residues.  Phosphorylation by cyclin B/CDK1 at Thr530 and Ser540 increases 
SIRT1 activity leading to normal cell cycle progression (Sasaki et al., 2008).  Under oxidative 
stress, SIRT1 is phosphorylated by cJUN N-terminal kinase (JNK1) at three residues Ser27, 
Ser47 and Thr530 which increases SIRT1 enzymatic activity and its nuclear localisation. 
Phosphorylation by JNK1 under stress induces substrate specificity of SIRT1 towards histone 
H3 rather than p53 (Nasrin et al., 2009). Other kinases such as casein kinase II (ck2) (Kang et 
al., 2009) and the dual specificity tyrosine phosphorylation-regulated kinases (DYRK1A and 
DYRK3) (Guo et al., 2010) phosphorylate and enhance SIRT1 activity. In contrast, 
phosphorylation of SIRT1 by mammalian target of rapamycin complex 1 (mTORC1) at Ser47 
inhibits the deacetylase activity of SIRT1which promotes cancer cell survival (Back et al., 
2011). Phosphorylation by mammalian Sterile 20-like kinase 1 (MST1) also inhibits the 
enzymatic activity of SIRT1 promoting acetylation and stabilisation of p53 (Yuan et al., 
2011).  Under lethal DNA damage, kinase homeodomain-interacting protein kinase2 (HIPK2) 
associates with SIRT1 and phosphorylates it at Ser682 inhibiting SIRT1 activity and 
facilitating the activity of p53 towards pro-apoptotic signal transduction and cell death 
(Conrad et al., 2016). 
Sumoylation 
The second most common PTM on SIRT1 is sumoylation. SUMO1, a small ubiquitin-like 
modifier, attaches to Lys734 close to the C-terminus and increases the activity of SIRT1 
(Yang et al., 2007). Upon stress, desumoylase sentrin-specific protease-1 (SNEP1) associates 
with SIRT1 and reduces SIRT1 activity and thereby promotes p53 acetylation and activity 
(Yang et al., 2007).  
SIRT1 is physiologically transnitrosylated by nitrosylated glyceraldehyde-3-phosphate 
dehydrogenase (SNO-GAPDH) leading to the inhibition of enzymatic activity of SIRT1 
(Kornberg et al., 2010). In another PTM, SIRT1 is carbonylated at cystine residues by 
oxidants and aldehydes under oxidative stress induced by cigarette smoke exposure leading to 
decreased activity of SIRT1 and marking it for proteasomal degradation (Caito et al., 2010).  
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Calorie restriction (CR) and SIRT1 
CR is linked with lifespan extension in lower organisms, fish, mice and rats where calories 
are restricted by 20-40% without compromising the essential nutrient requirements (Koubova 
and Guarente, 2003). In Saccharomyces cerevisae, Drosophila melanogaster, Caenorhabditis 
elegans, CR modulates lifespan extension through SIR2 (Lin et al., 2000; Howitz et al., 2003; 
Rogina and Helfand, 2004; Allard et al., 2009). In mammals, CR upregulates SIRT1 in 
various tissues including heart, brain, kidney, white and brown adipose tissue and muscles 
(Kwon and Ott, 2008). The exact mechanism by which CR regaulates SIRTs is still not clear. 
Guarente and colleagues proposed that CR decreases the levels of NADH, a SIRT1 inhibitor 
and increases SIRT1 activity (Lin et al., 2004). Further studies reported that CR activates 
PNC1 (NAMPT in mammals) that depletes NAM and increases NAD
+
 levels thus elevating 
SIRT1 activity (Anderson et al., 2003; Canto and Auwerx, 2009). Upregulation of SIRT1 
through CR increases DNA damage repair and also reduces the apoptotic activities leading to 
improved cell survival. 
Modulation of SIRT1 by NAD
+
 levels 
SIRT1 requires NAD
+
 as a cofactor for its enzymatic activity and hence it is regulated by 
NAD
+
/NADH levels. Other protein families that require NAD
+
 for their activity consume 
NAD
+
 thus making it less available for SIRTs, two such families are PARP and cADP-ribose 
synthases (CD-38 and CD-157) (Houtkooper et al., 2010). NAD
+
 levels can be increased by 
two processes- a) by enhancing NAD
+
 synthesis from its precursors such as tryptophan, 
nicotinic acid, NAM, and nicotinamide riboside (Houtkooper et al., 2010) and b) by inhibiting 
NAD
+
 consumers such as PARPs and cADP-ribose synthases and enhance the enzymatic 
activity of SIRT1 (Aksoy et al., 2006; Bai et al., 2011b).  
SIRT1 regulation by protein-protein interaction 
The activity of SIRT1 is also controlled by association with different protein complexes 
which may either activate or inhibit SIRT1 activity. The association of SIRT1 with the active 
regulator of SIRT1 (AROS) at the N-terminus results in increased activity towards p53 (Kim 
et al., 2007a). Under genomic stress, deleted in breast cancer 1 (DBC1) negatively regulates 
SIRT1 by directly binding to its catalytic domain, hence restricting its association with target 
proteins, specifically p53. Depletion of DBC1 enhances SIRT1 deacetylase activity towards 
p53 resulting in inhibition of p53 mediated apoptosis (Zhao et al., 2008). 
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Small molecule modulators 
SIRT1 activating compounds (STACs) include natural and synthetic compounds that bind to 
the conserved N-terminal domain of SIRT1 (Sinclair and Guarente, 2014). The natural 
activators of SIRT1 consist of biopolyphenols, namely resveratrol, quercetin, fisetin, 
piceatannol and butein that enhance the deacetylase activity of SIRT1 and extend lifespan in 
lower organisms   (Howitz et al., 2003; Wood et al., 2004). Synthetic compounds include 
SRT1720 and SRT2183, and analogues of NAM. NAM analogues inhibit NAM mediated 
SIRT1 inhibition causing indirect activation of SIRT1 (Sauve et al., 2005). The exact 
mechanisms by which STACs work is unclear but the majority of studies report that STACs 
directly bind to SIRT1 and through allosteric mechanisms activate the enzyme, whereby 
STACs lower the Michaelis constant (Km) of the substrate and NAD
+
, and to some extent 
increase the enzymatic velocity leading to enhanced SIRT1 activity and improved cell 
survival and increased mitochondrial biogenesis and activity (Dai et al., 2010; Funk et al., 
2010; Hubbard et al., 2013; Dai et al., 2015). Conversely, SIRT inhibitors namely EX-527, 
sirtinol, splitomycin, cambinol and tenovin inhibit its enzymatic activity. EX-527 forms a 
trimeric complex with SIRT1 and NAD
+
 and prevents the product release (Gertz et al., 2013), 
sirtinol, on the other hand inhibits SIRT1 activity by SIRT1 precipitation, cambinol competes 
with the SIRT substrates and tenovins mimic NAM (Liu et al., 2009). Inhibition of SIRT1 
activity by these compounds promotes cell death under genomic stress. 
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Figure 1.3 Key regulators of SIRT1 and their effect on its activity. The expression and activity of SIRT1 is modulated by different transcription 
factors, enzymes and compounds. These regulators work at different levels, some including E2F1 and HIC1 at transcriptional levels, HuR stabilises the 
SIRT1 mRNA whereas miRNAs destabilise the mRNA post transcriptionally, phosphorylation and sumoylation are two common post translational 
modifications seen in SIRT1. 
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1.1.3.2 Biological functions of SIRT1 
SIRT1: Gene expression and Genomic stability 
SIRT1 regulates various cellular processes and among them are chromatin remodelling, 
transcriptional silencing and genomic stability. In a mouse model, SIRT1 maintains genomic 
stability through the repression of repetitive DNA and in response to DNA damage it 
promotes the repair of double-strand breaks (DSB) thus increasing survival rate (Oberdoerffer 
et al., 2008). SIRT1 also regulates the maintenance of telomeres and ablates age-related 
telomere loss and SIRT1 also maintains global genomic stability via homologous 
recombination spread across telomeres, centromeres and chromosome arms under DNA 
damage (Palacios et al., 2010). SIRT1 facilitates the formation of constitutive 
heterochromatin (CH) as well as facultative heterochromatin (FH), leading to silencing of 
repetitive heterochromatin sequences as well as some other genes (Vaquero, 2009). SIRT1 
promotes deacetylation of histones H1 (K26), H3 (K9, K16 and K56) and H4 (K16) thus 
repressing rRNA transcription and conferring protection to cells from energy deprivation and 
cell death (Vaquero et al., 2004; Murayama et al., 2008). The chromatin associated with FH is 
also modulated by suppressor of variegation 3–9 homologue 1 (SUV39H1), which in turn is 
activated by deacetylation at K266 by SIRT1 (Vaquero et al., 2007), thus ensuring genomic 
integrity. Under oxidative stress, SIRT1 maintains CH structure through stabilising SUV39H1 
protein, whereby it inhibits polyubiquitination of SUV39H1 at K87 by the E3 ubiquitin ligase 
MDM2 thus preventing protein degradation and leading to maintenance of genomic structure 
(Bosch-Presegue et al., 2011).  
SIRT1: Development and differentiation 
SIRT1 plays a vital role in gametogenesis and embryogenesis. Using a mouse model, 
McBurney et al., showed that SIRT1 null mice were smaller and feeble with increased post-
natal death and exhibited developmental defects in retina and heart (McBurney et al., 2003). 
Furthermore, both the sexes were sterile, while there was reduction in sperm count in males 
notably due to elevated DNA damage caused due to SIRT1 deficiency, females failed to 
ovulate even though the oocyte number remained unaffected (McBurney et al., 2003; 
Coussens et al., 2008). Also high levels of SIRT were found in the heart and nervous system 
during embryogenesis in the mouse model, suggesting a role for SIRT1 in cardiogenesis and 
neurogenesis (Sakamoto et al., 2004). These findings do suggest that SIRT1 is essential for 
normal embryogenesis and reproduction. 
In addition to being vital in embryogenesis, SIRT1 also maintains several homeostatic 
processes during post-natal development and adulthood. SIRT1 is a key regulator in post-
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natal vascular endothelial homeostasis by controlling angiogenesis, vascular tone and 
endothelial function. During vascular growth, SIRT1 is highly expressed in the vasculature 
and uniquely regulates sprouting angiogenesis by endothelial cells (EC) (Potente et al., 2007). 
SIRT1 deficient zebrafish show dysregulated endothelial sprouting and vessel navigation 
leading to defective blood vessel formation and blunt ischemia-induced neovascularisation. 
SIRT1 binds to and deacetylates FOXO1 and restrains its anti-angiogenic activity, which may 
explain why SIRT1 has an effect on blood vessels (Potente et al., 2007). SIRT1 also regulates 
blood vessel formation by ECs through negatively regulating Notch signalling. SIRT1 
deacetylate the lysine residues in Notch1 intracellular domain (NICD) and limits Notch 
signalling. Inhibition or inactivation of SIRT1 in zebrafish and mice led to impaired vascular 
growth (Guarani et al., 2011). In a rat myocardial infarction model, aged mesenchymal stem 
cells (MSC) transplanted with SIRT1 showed improved cardiac function (Liu et al., 2014b). 
Over-expression of SIRT1 in these rats inhibited aged MSCs senescence and reinstated the 
pro-angiogenetic activity of MSCs leading to better survival. 
SIRT1 plays a crucial role in muscle cell differentiation and metabolism and is required for 
skeletal muscle cell proliferation (Rathbone et al., 2009), survival of myoblasts (Saini et al., 
2012) and muscle cell differentiation (Fulco et al., 2003). SIRT1 negatively regulates 
myogenesis by forming a complex with acetyltransferases PCAF and MyoD which controls 
the activity of myogenic factor MEF2 (myocyte enhancer factor 2) and represses the 
myogenic gene program, hence, the levels of endogenous SIRT1 are reduced during the 
muscle cell differentiation (Fulco et al., 2003). Conversely, selective deletion or inhibition of 
SIRT1 in muscle cells impairs muscle regeneration, reduces the size of myoblasts and 
deregulates the myogenic programme in satellite cells (Ryall et al., 2015).  
SIRT1 modulates the process of differentiation in human and mouse embryonic stem cells.  
SIRT1 mRNA levels are higher in mouse embryonic stem cells than the differentiated 
embryonic cells and during differentiation the levels of SIRT1 are downregulated post-
transcriptionally by miRNAs (Saunders et al., 2010). In another study it was shown that 
mRNA reduction of SIRT1 depends on inhibition of CARM1 (coactivator-associated arginine 
methyltransferase 1–dependent). CARM1 methylates HuR and increases HuR/SIRT1 binding 
and stabilises SIRT1 mRNA and SIRT1 protein levels. SIRT1 binds to gene promoters and 
epigenetically represses specific developmental genes DLL4, PAX6 and TBX3 thus inhibition 
of CARM1 leads to destabilisation of SIRT1 during development and differentiation 
(Calvanese et al., 2010). SIRT1 also modulates pluripotency in murine embryonic stem cells 
through telomere elongation which is mediated through MYC-dependent regulation of the 
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mTert gene (De Bonis et al., 2014). Altogether, SIRT1 regulates embryonic cell functions. 
SIRT1 is also reported to be expressed in human placenta. The levels of SIRT1 mRNA are 
high in placenta where it downregulates the expression of p53 through NDRG1 (N-Myc 
down-regulated gene 1), thus promoting the cell survival during oxygen deficiency in the 
placenta (Chen et al., 2006). 
SIRT1 and cell survival 
SIRT1 and p53: p53 plays an important role in various cellular processes involved in cellular 
growth, DNA repair and apoptosis. p53 is modified post-translationally by phosphorylation 
and acetylation. Acetylation of p53, stabilises and enhances it activity. Under cellular stress, 
SIRT1 modulates the function of p53 by directly deacetylating the K382 residue and thus 
inhibiting the activity of p53. Deacetylation of p53 by SIRT1 leads to inhibition of p53 
mediated expression of p21 and PUMA, the targets of p53 that regulate cell senescence and 
apoptosis (Yamakuchi et al., 2008). SIRT1 regulates acetylation of p53 by direct 
deacetylation, and indirectly by inhibiting p300, which acetylates and stabilises p53; 
deacetylation of p300 on the Lys residues 1020/1024 by SIRT1 inactivates p300 (Bouras et 
al., 2005). Also, SIRT1 deacetylates HDAC1 and promotes the deacetylation of p53. Under 
cellular stress, the level of SIRT1 is decreased which leads to hyperacetylation of p53 as well 
as accumulation of acetylated inactive HDAC1 (Yang et al., 2015). Under DNA damage and 
oxidative stress, SIRT1 mediated deacetylation of p53 inactivates the transcriptional activity 
of p53 and represses p53 modulated cell cycle arrest and apoptosis (Brooks and Gu, 2011). 
Thus, increased levels of SIRT1 and activity rescue cells from p53 mediated cell death. 
Apart from regulating p53-dependent apoptosis, SIRT1 enhances cell survival by inhibiting 
other cell death mechanisms.  SIRT1 modulates Bax-mediated apoptosis by deacetylating and 
activating Ku70, which, sequesters Bax away from mitochondria and prevents apoptosis 
triggered by Bax (Cohen et al., 2004). In another pathway, SIRT1 deacetylates forkhead box 
O (FOXO) transcription factors. Under stress, FOXOs (FOXO1, FOXO3 and FOXO4) 
promote apoptosis by modulating FAS and Bim (Huang and Tindall, 2007). Apart from 
mediating apoptosis, FOXOs also promote cell survival by activating superoxide dismutase 2 
(SOD2) and catalase (Huang and Tindall, 2007). SIRT1 deacetylates FOXOs and promotes 
the expression of genes involved in cell survival whilst decreasing the expression of genes 
involved in apoptosis (Brunet et al., 2004). SIRT1 also modulates caspase-independent cell 
death pathways by deacetylating and inactivating PARP-1 (Rajamohan et al., 2009) and 
SIRT1 also protects cells from misfolded proteins and heat shock by deacetylating and 
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activating HSF1 (Westerheide et al., 2009). Thus, SIRT1 senses environmental stress and 
promotes cell survival. 
SIRT1 in metabolism 
SIRT1 plays important roles in metabolic pathways such as insulin secretion, gluconeogenesis 
and fatty acid oxidation by deacetylating a number of important transcription factors 
including PPAR-γ, PPAR-α, PGC-1α, the FOXO family, IRS-2, mitochondrial uncoupling 
protein 2 (UCP-2), liver kinase B-1(LKB1), liver X receptor (LXR), farnesoid X receptor 
(FXR) and sterol-regulatory-element binding protein (SREBP). SIRT1 regulates lipid 
homeostasis and gluconeogenesis by deacetylating and thus activating PGC-1α and by 
deacetylating and deactivating signal transducer and activator of transcription 3 (STAT3), an 
inhibitor of gluconeogenesis (Nemoto et al., 2005; Rodgers et al., 2005; Nie et al., 2009; 
Purushotham et al., 2009). SIRT1 also modulates insulin sensitivity by enhancing the 
expression and secretion of insulin in pancreatic β-cells. This action of SIRT1 is partially 
mediated by inhibition of UCP-2 in pancreatic islet β-cells, SIRT knock out mice produce less 
ATP and insulin and this effect is mediated by UCP-2 (Bordone et al., 2006). SIRT1 also 
enhances insulin secretion by repressing the transcription of Ptpn1, which represses insulin 
secretion (Sun et al., 2007). SIRT1 also modulates whole body cholesterol and lipid 
homeostasis by deacetylating and upregulating the transcription of LXR (Li et al., 2007b). 
SIRT1 inhibits glycolysis by directly deacetylating and repressing Hypoxia-inducible factor 
1-alpha (HIF1α) thus leading to inhibition of glucose oxidation through TCA cycle (Lim et 
al., 2010) and stimulation of fatty acid oxidation. These findings show that SIRT1 plays an 
important role in metabolic pathways of cells, enhances mitochondrial biogenesis and 
promotes anti-ageing activities and protects cells from stress and metabolic dysfunction. 
SIRT1- dual role in cancer 
The role of SIRT1 in cancer has been extensively studied and its role as a tumour supressor or 
tumour promoter is under debate. Since SIRT1 deacetylates and deactivates p53,  its been 
suggested that SIRT1 may play a role in cancer development. Several studies have indicated 
that SIRT1 levels are significantly increased in human prostate cancer (Huffman et al., 2007), 
acute myeloid leukaemia (Sasca et al., 2014), acute lymphoblastic leukaemia (Jin et al., 
2015), primary colon cancer (Stunkel et al., 2007) and  non-melanoma skin cancers (Hida et 
al., 2007). However, SIRT1 could act as a tumour suppressor since SIRT1 plays an important 
role in maintenance of genomic stability and DNA repair. SIRT1 has been shown to reduce 
intestinal tumorigenesis and colon cancer growth in a mouse model of cancer (Firestein et al., 
2008) and can inhibit the apoptosis inhibitor, Survivin in BRCA1-mutant cancer lines (Wang 
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et al., 2008). Survivin is overexpressed in various cancers and is a proven drug target in 
cancer treatments (Altieri, 2008). SIRT1 thus supresses cancer cell growth by negatively 
regulating Survivin.  
 
1.1.4 Sirtuin 2 (SIRT2) 
Sirtuin 2 (SIRT2), the mammalian orthologue of yeast Sir2 protein, Hst2p (Perrod et al., 
2001) is a cytoplasmic protein that shuttles to the nucleus depending upon the cell cycle 
(North and Verdin, 2007a). The Sirt2 gene is located at chromosome 19q13 and has 17 exons 
(Pubmed Entry; Gene ID: 22933). SIRT2 has four isoforms as annotated in UniProt (Q8IXJ6 
(SIRT2_HUMAN) referred to as SIRT2 isoform1 (MW 43.1kDa), SIRT2 isoform2 (MW 
39.5kDa), SIRT2 isoform3 (MW 41.3kDa) and SIRT2 isoform 4 (MW 30kDa) which are 
produced by alternative splicing of isoform1, the canonical sequence.  
As with SIRT1, SIRT2 regulates several physiological processes and among all Sirtuins, it is 
the only cytoplasmic SIRT. In the cytoplasm, SIRT2 co-localises with α-tubulin and by 
deacetylating α-tubulin, modulates cellular shape, motility and cell division (North et al., 
2003). Another cytoplasmic substrate of SIRT2 is phosphoenolpyruvate carboxykinase 1 
(PEPCK1), which is stabilised by SIRT2 by deacetylation, linking SIRT2 with metabolic 
regulation (Jiang et al., 2011). SIRT2 deacetylates p65, a subunit of NF-кB, and regulates the 
expression of NF-кB genes involved in inflammatory responses (Rothgiesser et al., 2010). 
Apart from modulating cytoplasmic proteins, SIRT2 also targets substrates in the nucleus. By 
deacetylating p53, SIRT2 modulates apoptosis (Peck et al., 2010), through deacetylation of 
FOXO1 and FOXO3, SIRT2 also modulates metabolism, oxidative stress, DNA repair and 
apoptosis (Jing et al., 2007; Wang et al., 2007). SIRT2 maintains genomic stability by 
positively regulating APC/C activity (Kim et al., 2011a), modulates chromatin condensation 
during metaphase by deacetylating histone H4 during G2/M transition (Vaquero et al., 2006) 
and by interacting with homeobox transcription factor 10 (HOXA 10) and other 
transcriptional factors, SIRT2 may act as a modulator of development (Bae et al., 2004). 
 
1.1.4.1 Regulation of SIRT2 
SIRT2 is regulated at transcriptional, post-transcriptional, post-translational levels and also by 
NAD
+
/NADH levels and protein interactions (Figure 1.4). Post-translationally the activity of 
SIRT2 is modulated by phosphorylation, acetylation and protein degradation. Phosphorylation 
of SIRT2 reduces the activity of SIRT2 and phosphorylation of SIRT2 at Ser331 during late 
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G2 phase by CDKs inhibits the deacetylase activity and prevents the SIRT2-mediated delay in 
cell cycle progression (North and Verdin, 2007b; Pandithage et al., 2008). SIRT2 is also 
phosphorylated at Ser368 and 372 which reduces SIRT2 deacetylase activity (Nahhas et al., 
2007). De-phosphorylation of Ser368 residue of SIRT2 by CDC-14B down-regulates the 
levels of SIRT2 possibly via 26S proteasome mediated degradation (Dryden et al., 2003).  
SIRT2 activity is also down-regulated via acetylation by KAT (Lysine acetyl transferase) 
p300 (Han et al., 2008).  
The stability and activity of SIRT2 is enhanced by at least two of its binding partners- 14-3-3 
β/γ proteins and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2).  14-3-3 β/γ 
proteins that play important role in various regulatory processes such as signal transduction 
and apoptosis, interact with SIRT2 and enhance its deacetylase activity towards p53 (Jin et 
al., 2008). ERK1 and 2 interact with SIRT2 and enhance its protein level, stability and the 
enzymatic activity (Choi et al., 2013). As with other SIRTs, activity of SIRT2 is also 
regulated by NAD
+
/NADH levels and a lower ratio inhibits SIRT2 activity. NAM is an 
endogenous inhibitor of all SIRTs including SIRT2 and its activity is also inhibited by other 
smaller molecules such as AGK2 and sirtinol (Outeiro et al., 2007). SIRT2 plays an important 
role in modulation of cell cycle, cell motility and microtubule structures and inhibiting SIRT2 
may hamper these processes and may result in aneuploidy and disrupted cell structure. 
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Figure 1.4 Regulation of SIRT2 and its activity. HDAC6, 14-3-3 β/γ, HOXA 10 and ERK 1/2 
bind to SIRT2 and stabilise and enhance its activity resulting in modulation of apoptosis, cell cycle, 
DNA repair and genomic stability. Acetylation of SIRT2 by p300/CBP and phosphorylation by CDKs 
inhibits the enzymatic activity of SIRT2 and 26S ubiquitinates SIRT2 at the end of the cell cycle.  
 
 
1.1.4.2 Functions of SIRT2 
SIRT2 and microtubules 
Microtubules (MTs) are one of the principle components of the cytoskeleton responsible for 
the maintenance of cell structure, motility and transportation (reviewed by (Etienne-
Manneville, 2004)). MTs are composed predominantly of tubulin consisting of two 
polypeptides alpha (α) tubulin and beta (β) tubulin.  MTs are highly dynamic structures and 
the acetylation of lysine 40 of α-tubulin is associated with stable MTs. SIRT2 and HDAC6 
associate together in microtubule network and deacetylates α-tubulin regulating microtubule 
structure and cellular activities (North et al., 2003). 
SIRT2 and cell cycle regulation 
SIRT2 is one of the key regulators of cell cycle. SIRT2 acts as a novel cell cycle check point 
at early metaphase stages and prevents chromosomal instability (Dryden et al., 2003). SIRT2 
is translocated to the nucleus during the cell cycle and is associated with the centrosome in 
prophase, the mitotic spindle in metaphase and the midbody during cytokinesis (North and 
Verdin, 2007a). SIRT2 is phosphorylated during G2/M transition and its dephosphorylation 
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by CDC14B promotes down-regulation of SIRT2 and mitotic exit (Dryden et al., 2003). Cell 
cycle regulation by SIRT2 is also mediated through establishment of facultative 
heterochromatin during mitosis. SIRT2 specifically deacetylate histone H4 K16 during 
mitosis (Vaquero et al., 2006). During stress, SIRT2 promotes the chromatin condensation 
and functions as a part of mitotic check point preventing uncontrolled cellular growth 
(Serrano et al., 2013).   
Genomic integrity/stability and SIRT2 
SIRT2 is a key mitotic check point protein, controls the cell division associated separation of 
recently replicated chromosomes and thus ensures chromosomal stability (McGuinness et al., 
2011). Under mitotic stress, SIRT2 blocks the entry to chromosome condensation and the 
formation of hyperploid cells (Inoue et al., 2007). SIRT2 enhances the response towards 
replicative stress by deacetylating CDK9 kinase, thus activating the proteins involved in the 
replication stress response (Zhang et al., 2013). SIRT2 also deacetylates and activates ataxia 
telangiectasia-mutated and Rad3-related (ATR)-interacting protein (ATRIP), and promotes 
the accumulation of ATRIP to DNA damage sites and facilitates recovery form the replication 
stress (Zhang et al., 2016a).  
SIRT2 and cell survival 
SIRT2 also plays an important role in maintenance and proliferation of cells. Under mild 
oxidative stress, SIRT2 deacetylates FOXO3a resulting in transactivation of the genes 
involved in antioxidant defences mainly SOD2 and catalase (Wang et al., 2007). SIRT2 also 
enhances cell survival by deacetylating and deactivating p53 leading to inhibition of p53 
induced activation of pro-apoptotic genes namely, BAX and PUMA (p53 upregulated 
modulator of apoptosis) resulting in apoptotic cell death (Macip et al., 2003; van Leeuwen et 
al., 2013).  
SIRT2 and cancer 
The expression of SIRT2 has been shown to be down-regulated in human gliomas and it’s 
been suggested that SIRT2 may act as a tumour suppressor gene in gliomas possibly through 
the regulation of microtubule network (Hiratsuka et al., 2003). Lower levels of SIRT2 were 
also observed in gastric carcinomas (Peters et al., 2010). SIRT2 has also been shown to 
inhibit the formation and proliferation of non-small cell lung cancer by targeting JMJD2A 
(Xu et al., 2015). Contrary to these findings, higher levels of SIRT2 were associated with 
hepatocellular carcinoma (Chen et al., 2013), and acute myeloid leukaemia (Deng et al., 
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2016) and therefore function of SIRT2 as a tumour suppressor or a tumour promoter maybe 
tissue dependent. 
 
1.1.5 Sirtuin 3 (SIRT3) 
SIRT3 is a major mitochondrial deacetylase where it regulates the acetylation of several 
mitochondrial proteins such as acetyl coenzyme A synthetase 2 (AceCS2) (Hallows et al., 
2006; Schwer et al., 2006), glutamate dehydrogenase (GDH) (Schlicker et al., 2008), 
isocitrate dehydrogenase 2 (IDH2) (Schlicker et al., 2008), NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 9 (NDUFA9) (Ahn et al., 2008), SOD2 (Qiu et al., 
2010; Chen et al., 2011b), Ku70 (Sundaresan et al., 2008)  and mitochondrial ribosomal 
protein L10 (MRPL10) (Yang et al., 2010) regulating several mitochondrial processes 
including respiration, antioxidant defence mechanisms and apoptosis.  
SIRT3 is located in the mitochondrial matrix where the N-terminus 25 amino acid residue is 
necessary for mitochondrial import (Onyango et al., 2002). The Sirt3 gene is located at 
chromosome 11p15.5 and has nine exons (PubMed entry; Gene ID: 23410). Human SIRT3 
has two isoforms annotated in Uniprot (Q9NTG7) referred to as isoform 1 (43kDa) and 
isoform 2 (28kDa, mitochondrial SIRT3). Isoform 1 is synthesised in the nucleus and is the 
canonical sequence; it is translocated to mitochondria and proteolytically processed to the 
28kDa form by mitochondrial matrix processing peptidase (MPP) with the two arginine 
residues, Arg99 and Arg100, essential for cleavage (Schwer et al., 2002). Full length (FL) 
SIRT3 in the nucleus deacetylases histone H3 (K9Ac) and H4 (K16Ac) and also modulates 
the expression of stress-related and nuclear-encoded mitochondrial genes (Iwahara et al., 
2012).  
Single nucleotide polymorphisms (SNP) of SIRT 3 have been linked with lifespan extension 
in humans. The first SNP found in males, a G477T transversion in exon 3, is linked with 
healthy lifespan; interestingly the transition is silent and the exact mechanism behind the SNP 
and healthy lifespan is still not clear (Rose et al., 2003). A second SNP, a variable number 
tandem repeat (VNTR; 72bp) present in the intron 5 of SIRT3 which acts as enhancer of 
SIRT3 was associated with better survival in older age (Bellizzi et al., 2005). Hirschey et al., 
also reported another SNP in the human Sirt3 gene associated with metabolic syndrome. The 
SNP encoded a point mutation in SIRT3 protein leading to reduced enzymatic activity of 
SIRT3 suggesting that reduced activity of SIRT3 and hyperacetylation of mitochondrial 
protein is associated with metabolic syndrome (Hirschey et al., 2011).  
 24 
1.1.5.1 Regulation of SIRT3 
The activity of SIRT3 is modulated by NAD
+
/NADH, where a decrease in the ratio results in 
lower SIRT3 activity. NAM produced from the cleavage of NAD
+
 in the enzymatic reaction, 
is an endogenous inhibitor of SIRT3, thus SIRT3 self regulates its activity as with other 
sirtuins. CR and exercise have been shown to enhance the expression of SIRT3 which was 
associated with upregulation of PGC-1α and CREB phosphorylation (Palacios et al., 2009). 
PGG-1α has also been reported to increase the expression of SIRT3 by activating the Sirt3 
promoter mediated by an oestrogen-related receptor (ERR) binding element (ERRE).  The 
association of ERRE with the Sirt3 promoter results in enhanced expression of SIRT3 which 
leads to activation of several mitochondrial proteins involved in biological pathways through 
deacetylation by SIRT3 (Figure 1.5) (Kong et al., 2010; Giralt et al., 2011). 
 
 
Figure 1.5 Regulation of SIRT3 and its activity. SIRT3 is positively regulated by NAD+, CR 
and PGC1-α/ERRE. Deacetylation of mitochondrial and nuclear proteins by SIRT3 activates the target 
and modulates key physiological processes such as ATP production, ROS production, apoptosis, 
metabolism, DNA repair, fatty acid oxidation and mitochondrial dynamics. 
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1.1.5.2 Functions of SIRT3 
Role of SIRT3 in energy metabolism and ATP production 
AceCS2 is a mitochondrial protein which utilises acetate for energy production and 
thermogenesis under ketogenic conditions (Fujino et al., 2001) and was the first discovered 
target of SIRT3 (Hallows et al., 2006).  SIRT3 deacetylates AceCS2 at K642 (human) or 
K643 (mouse) and activates the activity of AceCS2. Thus by activating AceCS2, SIRT3 
controls the production of acetyl-CoA and its entry to tricarboxylic acid (TCA cycle), where it 
is used for energy production thereby promoting thermogenesis.  
Another target of SIRT3 is GDH and by deacetylating GDH, SIRT3 activates GDH and 
promotes glucose and ATP synthesis by using amino acids as a fuel for the citric acid cycle 
and gluconeogenesis (Schlicker et al., 2008). In the same study, it was reported that SIRT3 
targets and activates IDH2, an important regulation point for flux throughout the citric acid 
cycle. IDH2 forms NADPH instead of NADH and plays a critical role in NADPH-dependent 
regeneration of antioxidants (Schlicker et al., 2008). 
SIRT3 modulates ATP production by interacting with a number of proteins involved in 
electron transport chain (ETC) and improves mitochondrial function. SIRT3 directly interacts 
with NDUF9, a subunit of complex I, and enhances ATP production and the loss of SIRT3 
leads to selective inhibition of complex I activity in mitochondria (Ahn et al., 2008). SIRT3 
has also been shown to deacetylate ATP synthase F1 proteins alpha, gamma, and oligomycin 
sentivity-conferring protein (OSCP) (Vassilopoulos et al., 2014). SIRT3 deacetylates OSCP 
at K139 and mice lacking SIRT3 showed decreased ATP levels (Vassilopoulos et al., 2014).  
SIRT3 also regulates fatty acid oxidation by deacetylating long-chain acyl coenzyme A 
dehydrogenase (LCAD) which catalyses the mitochondrial β oxidation of long-chain fatty 
acids. Acetylation of LCAD causes deactivation resulting in decreased levels of fatty acid 
oxidation, and the deacetylation of LCAD by SIRT3 during fasting promotes fatty acid usage 
causing fat breakdowns in periods of CR (Hirschey et al., 2010). 
SIRT3 and PGC1-α 
PGC-1α regulates mitochondrial biogenesis, metabolism, ROS and stress repsonse. SIRT3 in 
a positive feedback loop regulates PGC-1α. PGC-1α enhances the expression of SIRT3 
through ERRE and knock down of SIRT3 results in reduced expression of PGC-1α suggesting 
that SIRT3 plays some role in regulating the expression of PGC-1α (Palacios et al., 2009; 
Kong et al., 2010). The loss of SIRT3 has been shown to induce mitochondrial dysfunction 
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and contractile heart function in SIRT3 knock out mice (Koentges et al., 2015). SIRT3 and 
PGC-1α intearct with each other and control the ROS production and promote cell survival.   
SIRT3, ROS and cell survival 
SIRT3 promotes cell survival by modulating oxidative stress via enhanced antioxidant 
defence mechanisms. Under oxidative stress, SIRT3 indirectly inhibits Bax-mediated 
apoptosis by deacetylaing and activating Ku70 (Sundaresan et al., 2008). Activated Ku70 
interacts with Bax and sequesters Bax away from mitochondria thus inhibiting Bax induced 
apoptosis (Sundaresan et al., 2008).  
SIRT3 also deacetylates IDH2 leading to increased amounts of NADPH thus protecting cell 
from oxidative stress (Someya et al., 2010). SIRT3 enhances antioxidant defences by directly 
deacetylaing and enhacing the dismutase activity of  SOD2 (Qiu et al., 2010).  
Another mechanism by which SIRT3 promotes cell survival is through regulation of 
mitochondrial unfolded protein responses (mtUPR). It is well known that oxidative stress 
causes  irreversible protein damage that leads to misfolding of proteins, mitochondrial stress 
and eventually apoptosis. Papa and Germain reported that SIRT3 modulates the mtUPR and 
ensures mitochondrial quality under proteotoxic stress (Papa and Germain, 2014). The exact 
mechanism by which SIRT3 coordinates the selective degradation of irreversibly damaged 
mitochondria is still unclear.  
SIRT3 in cancer 
Cancerous cells show a dysregulation in mitochondrial function and produce energy by a high 
rate of glycolysis and aberrant metabolism, a phenomenon known as “The Warburg Effect” 
(reviewed in (Vander Heiden et al., 2009)). Loss of SIRT3 triggers metabolic reprogramming 
thus leading to  development and proliferation of tumorigenesis (Finley and Haigis, 2012). A 
tumour suppressor role for SIRT3 has been reported in prostate cancer (Quan et al., 2015), 
hepatocellular carcinoma (Zhang and Zhou, 2012) and gastric cancer (Huang et al., 2014). 
Similarily, expression of SIRT3 was down-regulated in ovarian carcinoma (Dong et al., 
2016), B-cell malignancies (Yu et al., 2016) and SIRT3 knock-out mice developed 
spontaneous tumours (Kim et al., 2010). SIRT3 has also been shown to repress “the Warburg 
effect” in a human breast cancer cell line by destabilising HIF-1α (Finley et al., 2011). 
However, some cancers including oral cancer (Alhazzazi et al., 2011), lymph node positive 
breast cancer (Ashraf et al., 2006), bladder cancer (Li et al., 2010) and human melanoma 
(George et al., 2016) have shown elevated levels of SIRT3, where SIRT3 overexpression 
potentially demonstrates a pro-survival role in these cancers. These findings suggest that 
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SIRT3 can function as tumour suppressor or tumour promoter depending upon the cell and 
tumour type and depending on the presence of different stresses in the cell. 
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1.2 Parkinson’s disease 
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s 
disease and the most common neurodegenerative movement disorder. The characteristic 
pathological feature of the disease is progressive loss of dopaminergic (DA) neurones in the 
substantia nigra (SN) (Figure 1.6) and accumulation of α-synuclein in brain stem, spinal cord 
and cortical regions (reviewed in (Beitz, 2014)). It is clinically characterised by tremor, 
rigidity, bradykinesia, postural instability and other accompanying symptoms (Jankovic, 
2008).  
 
Figure 1.6 Progressive neuronal loss in the Substantia nigra (SN) in PD. PD is 
characterised by substantial loss of dopaminergic neurone loss in the substantia nigra. 
 
The development of PD is a multifactorial process that is associated with both genetic and 
environmental components. The risk factors that are associated with PD are advancing age, 
family history and occupational exposure to toxins including pesticides and heavy metals. 
Studies of epidemiological risk factors for the disease have shown that long term exposure to 
heavy metals such as copper, manganese, lead and iron; exposure to herbicides and pesticides 
such as rotenone, and paraquat and compounds such as MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) confer  significant risk of  PD (Noyce et al., 2012).  
 
1.2.1 Clinical features of PD 
PD commonly presents with motor symptoms of bradykinesia in association with tremor, 
rigidity or postural instability (Jankovic, 2008). PD patients also present with non-motor 
symptoms which include cognitive/neurobehavioral disorders, autonomic dysfunction, 
depression, anxiety, sensory and sleep abnormalities and oculomotor abnormalities 
(Chaudhuri et al., 2006). In 1988, United Kingdom Parkinson’s Disease Society Brain Bank 
developed the diagnostic criteria for PD (Table 1.3) (Gibb and Lees, 1988) which was further 
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revised by the Motor disorder Society (MDS) as the Unified Parkinson’s disease rating scale 
(MDS-UPDRS) (Goetz et al., 2007). 
UK Parkinson’s Disease Society Brain Bank’s clinical criteria for the diagnosis of 
Parkinson’s disease 
Step 1 
1. Bradykinesia 
2. At least one of the following criteria: 
a. Rigidity 
b. 4–6 Hz rest tremor 
c. Postural instability not caused by primary visual, vestibular, cerebellar or    
proprioceptive  dysfunction 
Step 2 
Exclusion criteria for idiopathic Parkinson’s disease 
Step 3 
At least three of the following supportive (prospective) criteria: 
1. Unilateral onset 
2. Rest tremor 
3. Progressive disorder 
4. Persistent asymmetry primarily affecting side of onset 
5. Excellent response (70–100%) to levodopa 
6. Severe levodopa induced chorea (dyskinesia) 
7. Levodopa response for 5 years or more 
8. Clinical course of 10 years or more 
Table 1.3 Clinical criteria for the diagnosis of Parkinson's disease set by UK Parkinson's 
Disease Society Brain Bank  
*Taken from Gibb, W. R. and Lees, A. J. (1988) 'The relevance of the Lewy body to the pathogenesis 
of idiopathic Parkinson's disease', J Neurol Neurosurg Psychiatry, 51, (6), pp. 745-52. (Gibb and 
Lees, 1988) 
 
MDS-UPDRS is divided into four parts as stated below 
 Part I : Non-motor Experiences of Daily Living (13 items) 
 Part II: Motor Experiences of Daily Living (13 items) 
 Part III: Motor Examination (33 scores based on 18 items, several with right, left, etc.) 
 Part IV:  Motor Complications (6 items). 
All items have five response options with the scale ranging from 0 = normal, 1 = slight, 2 = 
mild, 3 = moderate, and 4 = severe (Goetz et al., 2007). 
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1.2.2 Pathogenesis of PD 
1.2.2.1 Neurone Loss 
The main pathological feature of PD is loss of DA neurones from the SN. In the early stages 
of PD, this loss of dopamine is found to be greatest in the sensory-motor area of dorsal 
striatum and this extends to ventral part of the striatum as the disease progresses (Kish et al., 
1988). Degeneration of DA neurones is seen in normal ageing but the loss is markedly less 
than in PD. Although DA neurone loss is a characteristic feature of PD, neuronal loss also 
exist in locus coeruleus (LC) norepinephrine (NE) neurones (Zarow et al., 2003), dorsal 
nuclei of the vagus, nucleus basalis of Meynert (NBM), the raphe nuclei, and it also affects 
many other neuronal systems (Nakano and Hirano, 1984; Lees et al., 2009). 
The cause of cell death in the SN is still not well defined. Age, genetic and environmental 
factors are associated with disease risk. Apart from these, the physiological phenotype of the 
DA neurones including the size of DA neurones and the large number of connections present 
makes the neurones vulnerable to death. DA neurones are vulnerable because of the higher 
metabolic rate which may be caused by opening of L-type calcium channels during 
autonomous pacemaking activity which results in sustained entry of calcium (Ca
2+
) in 
neurones; this leads to an altered Ca
2+
 metabolism and cellular redox imbalance which makes 
the neurone susceptible to toxins (Surmeier et al., 2010). Oxidative stress caused by toxins or 
altered metabolism of dopamine, dysfunction of mitochondria, impaired ubiquitin-proteasome 
system, increased glutamergic input from the subthalamic nucleus to SN or increased gliosis 
around DA neurones may also lead to cell death. 
 
1.2.2.2 Lewy body in PD 
The second major pathological feature of PD is the presence of the Lewy body (LB), a 
distinctive filamentous neuronal inclusion in the cell body of neurones which, along with the 
presence of Lewy neurites (LNs) within dendrites and axons, is present in the SN and other 
specific regions of the brain affected in PD (Gibb and Lees, 1988; Spillantini et al., 1998). 
Lewy bodies are present in two morphological types- the classic Lewy bodies (brain stem 
Lewy body) seen in idiopathic PD and the cortical Lewy bodies observed in dementia with 
Lewy bodies (DLB) and PDD (Figure 1.7) (Mackenzie, 2001). Classical Lewy bodies are 
spherical eosinophilic neuronal inclusions that consist of dense core and pale halo (Spillantini 
et al., 1998; Mackenzie, 2001), whereas cortical Lewy bodies tend to be less well defined 
compared to classical LBs and lack distinctive core and halo (Spillantini et al., 1998). The 
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classical LBs are present in DA neurones of the SN and noradrenergic neurones of the locus 
coeruleus, whereas cortical Lewy bodies are located in the limbic areas of the brain, such as 
the amygdala, entorhinal, insular and cingulate cortices (Spillantini et al., 1998; McKeith et 
al., 2005). Lewy bodies are composed of abnormally folded α-synuclein protein and 
abnormally phosphorylated and partially degraded neurofilaments along with other proteins 
(Spillantini et al., 1997).  
 
 
Figure 1.7 α-synuclein immunohistochemistry in PD. The figure shows A) typical brainstem 
type Lewy body with halo on the SN section counter-stained with haematoxylin, B) a diffuse “cortical 
type” Lewy body in insula counter-stained with haematoxylin and C) Lewy neurites in the SN section 
counter-stained with haematoxylin  
 
1.2.3 Development and management of Parkinson’s disease 
1.2.3.1 Development 
In 2004, Braak et al., assessed post-mortem brain tissue and developed a neuropathological 
staging scheme based on the distribution of α-synuclein/LBs throughout the brain (Braak et 
al., 2004). The staging is based upon the involvement of brain regions, presence of LB/Ns or 
Lewy pathology that originates in the dorsal motor nucleus of the vagus and progresses to the 
other brain regions in the brainstem, mid and forebrain and finally throughout the cortex 
(Figure 1.8). Patients with PD were categorised into presymptomatic and symptomatic phases 
which are subdivided into six stages. The presymptomatic phase includes stages 1-3 and the 
symptomatic phase includes stages 4-6 and the areas involved and severity of the disease is 
summarised in Table 1.4.   
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Figure 1.8 Progression of PD related pathology.  A) The presymptomatic phase is marked by 
the appearance of Lewy neurites/bodies in the brains of asymptomatic persons. In the symptomatic 
phase, the individual neuropathological threshold is exceeded (black arrow). The increasing slope and 
intensity of the coloured areas below the diagonal indicate the growing severity of the pathology in 
vulnerable brain regions (right). The severity of the pathology is indicated by darker degrees of 
shading in the coloured arrow left. B) Diagram showing the ascending pathological process (white 
arrows).  
*Taken from Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. and Del Tredici, K. (2004) 
'Stages in the development of Parkinson's disease-related pathology', Cell Tissue Res, 318(1), 
pp. 121-34. (Braak et al., 2004) 
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Stage 1 
Initial development of LNs somewhere in ENS, PNS or CNS 
LNs and LBs in olfactory bulb and anterior olfactory nucleus 
LNs and LBs in dorsal motor nucleus of the vagal nerve, intermediate reticular zone 
Absence of symptoms; then a phase of prodromal symptoms, for example hyposmia, autonomic dysfunction 
Stage 2 
LNs in ENS, in peripheral parasympathetic and sympathetic nerves, and in peripheral autonomic ganglia 
LNs and LBs in medullary nuclei of the level setting system, for example lower raphe nuclei, locus coeruleus 
Hyposmia, autonomic dysfunction, for example gastrointestinal, urinary symptoms 
Disturbed sleep, parasomnias, mood changes 
Stage 3 
LNs and LBs in tegmental pedunculopontine nucleus and substantia nigra, pars compacta 
LNs in spinal cord centres reached by descending projections of level setting nuclei 
LNs and LBs in upper raphe nuclei, magnocellular nuclei of the basal forebrain, hypothalamic tuberomammillary nucleus 
LNs and LBs in central subnucleus of the amygdala 
Disturbed sleep and possible early phase motor dysfunction: asymmetric tremor, rigidity, hypokinesia 
Stage 4 
LNs and LBs in midline and intralaminar nuclei of the thalamus 
LNs and LBs in anteromedial temporal cortex (transentorhinal and entorhinal regions, hippocampal formation, plexus of LNs in the 
second sector of the Ammon's horn) 
Early phase motor dysfunction: tremor, rigidity, hypokinesia 
Stage 5 
LNs and LBs in superordinate cortical areas for regulation of autonomic functions 
LNs and LBs in high-order sensory association areas and prefrontal fields 
Late phase motor disability: fluctuation, falls, wheelchair bound or bedridden 
Cognitive impairment 
Stage 6 
LNs and LBs in first-order sensory association areas and premotor fields 
LNs and LBs in primary sensory and primary motor areas 
Late phase motor disability: fluctuation, wheelchair bound or bedridden 
Cognitive impairment, dementia 
Table 1.4 Distribution of Lewy pathology in sporadic Parkinson’s disease.  The table summarises the distribution of Lewy bodies across the 
enteric, peripheral, and central nervous systems along with the clinical symptoms.*Taken from Del Tredici, K. and Braak, H. (2016) 'Review: Sporadic 
Parkinson's disease: development and distribution of alpha-synuclein pathology', Neuropathol Appl Neurobiol, 42(1), pp. 33-50  (Del Tredici and Braak, 
2016)  
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1.2.3.2 Management 
Currently no cure is available for PD, although symptom management is possible and can be 
categorised as medically treatable, surgically treatable and paramedical care. The medical 
treatment of PD focusses on correcting the loss of dopamine which can be managed at several 
levels- i) increasing dopamine by administration of dopamine precursors, ii) preventing 
dopamine breakdown and iii) administrating dopamine agonists or mimics.  
Levodopa (l-dopa, l-3,4-dihydroxyphenylalanine) is the metabolic precursor of dopamine and 
is by far the most successful treatment to increase the levels of dopamine in PD patients. 
Levodopa crosses the blood-brain barrier and is metabolised into dopamine by dopa-
decarboxylase. The half-life of levodopa is 90 minutes and it is rapidly metabolised to 
dopamine by dopa-decarboxylase, therefore, levodopa is concomitantly administered with a 
dopa-decarboxylase inhibitor. Increased dopamine after treatment with levodopa helps in 
reduction of motor symptoms. Although, levodopa treatment is an efficient treatment for the 
motor symptoms of PD, chronic treatment with the drug results in adverse side effects 
including nausea, vomiting, light-headedness, orthostatic hypotension, psychosis, and 
dyskinesia (Clarke, 2002). Apart from levodopa, DA receptor agonists, catechol-O-
methyltransferase (COMT) inhibitors, monoamine oxidase-B inhibitors, anticholinergic 
agents, antiglutamatergic agents and adjunctive therapy are also used in PD treatment 
(Goldenberg, 2008). 
Apart from pharmacological treatments, surgical and rehabilitation techniques are also used to 
treat PD symptoms. Neurosurgical treatments of PD can broadly be classified into two major 
approaches- ablative procedures or lesional surgery such as thalamotomy and pallidotomy and 
deep brain stimulation. Destructive lesions including pallidotomy can provide improvement in 
dyskinesia and may provide some relief in bradykinesia and rigidity in some patients 
(Jankovic, 2001). Deep brain stimulation is a reversible procedure that involves the 
implantation of a pulse generator in the ventral intermediate nucleus of the thalamus, 
subthalamic nucleus or globus pallidus and helps to improve motor related signs as well as 
dyskinesia (Limousin et al., 1998). Neurosurgical treatments are not conventional methods to 
treat the symptoms of PD and it is reserved for patients with severe motor impairment and 
motor complications arising due to pharmacological treatments. Regular exercise regime and 
physiotherapy may also help to reduce the motor symptoms. Even though the motor 
symptoms of PD are treated through various medical, surgical and paramedical approaches, 
these treatments are still inadequate and come with certain degree of side effects. More 
studies must be conducted to understand the mechanisms of underlying pathogenesis of PD. 
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 1.2.4 Dementia with Lewy bodies 
Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease, is possibly the 
second most common diagnosis of dementia after Alzheimer’s disease and accounts for 
almost 10% of all dementia cases in the elderly population (McKeith, 2004). DLB is also 
known as diffuse Lewy body disease, the Lewy body dementia, the Lewy body variant of 
Alzheimer’s disease, senile dementia of Lewy body type and dementia associated with 
cortical Lewy bodies (McKeith, 2004). DLB shares symptoms with AD and PD, hence 
making the disease diagnosis difficult.  
 
1.2.4.1 Diagnosis and clinical features of DLB 
Clinically, DLB presents with core features including fluctuating cognitive impairment, 
recurrent visual hallucinations, and spontaneous parkinsonism. The consensus criteria for the 
diagnosis of DLB were developed in 1996 (McKeith et al., 1996) and further modified in 
2005 (Table 1.5) (McKeith et al., 2005).  
The diagnostic criteria also distinguish DLB from Parkinson’s disease with dementia (PDD), 
which also presents with similar clinical and pathological features. The guidelines regarding 
clinical diagnosis between DLB and PDD consider whether cognitive or motor symptoms are 
present first. In the case of DLB, dementia develops before or within 1 year of spontaneous 
parkinsonism whereas, in PDD, dementia develops within the context of established 
Parkinson's disease.  
The genetic influences or risk factors involved in DLB are marked between PD and AD. The 
PD risk factors that are involved in DLB are SNCA (α-synuclein), LRRK2 and GBA 
(Andersson et al., 2011; Mulugeta et al., 2011). The AD risk factors associated with DLB are 
amyloid precursor protein (APP), apolipoprotein E (APOE) ϵ4, presenilin-1 (PSEN-1) and 
PSEN2 (Andersson et al., 2011; Power et al., 2015; Spano et al., 2015).  
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Revised criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) 
Central feature (essential for a diagnosis of possible or probable DLB) 
 Dementia defined as progressive cognitive decline that interferes with normal social or occupational function. 
 Prominent or persistent memory impairment may not necessarily occur in the early stages but is usually evident with progression. 
 Deficits on tests of attention, executive function, and visuospatial ability may be especially prominent. 
 
Core features (probable DLB- two core features, possible DLB- one core feature) 
 Fluctuating cognition with pronounced variations in attention and alertness 
 Recurrent visual hallucinations that are typically well formed and detailed 
 Spontaneous features of parkinsonism 
 
Suggestive features (probable DLB – 1 or more suggestive feature with 1 or more core feature, possible DLB – 1 or more suggestive feature) 
 
 REM sleep behaviour disorder 
 Severe neuroleptic sensitivity 
 Low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET imaging 
 
Supportive features 
 Repeated falls and syncope 
 Transient, unexplained loss of consciousness 
 Severe autonomic dysfunction, e.g., orthostatic hypotension, urinary incontinence 
 Hallucinations in other modalities 
 Systematized delusions 
 Depression 
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 Relative preservation of medial temporal lobe structures on CT/MRI scan 
 Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity 
 Abnormal (low uptake) MIBG myocardial scintigraphy 
 Prominent slow wave activity on EEG with temporal lobe transient sharp waves 
 
Less likely diagnosis of DLB 
 In the presence of cerebrovascular disease evident as focal neurologic signs or on brain imaging 
 In the presence of any other physical illness or brain disorder sufficient to account in part or in total for the clinical picture 
 If parkinsonism only appears for the first time at a stage of severe dementia 
 
Table 1.5 Revised clinical criteria for the diagnosis of dementia with Lewy bodies (DLB).  
*Adapted from McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Arai, 
H., Ballard, C.G., Boeve, B., Burn, D.J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S., Goetz, C.G., Gomez-Tortosa, E., Halliday, G., Hansen, L.A., 
Hardy, J., Iwatsubo, T., Kalaria, R.N., Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees, A., Litvan, I., Londos, E., Lopez, O.L., Minoshima, S., 
Mizuno, Y., Molina, J.A., Mukaetova-Ladinska, E.B., Pasquier, F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q. and Yamada, M. (2005) 'Diagnosis and management 
of dementia with Lewy bodies: third report of the DLB Consortium', Neurology, 65(12), pp. 1863-72. (McKeith et al., 2005)  
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1.2.4.2 Neuropathology of DLB 
The pathological hallmarks of DLB are α-synuclein neuronal inclusions, Lewy bodies and 
Lewy neurites, which can be identified by staining for α-synuclein and ubiquitin (Kosaka, 
1978; McKeith et al., 2005). They are pathologically distributed in the neocortex, limbic 
systems, amygdala and brainstem (McKeith et al., 1996). DLB also shows Alzheimer’s type 
pathology, mainly in the form of amyloid-beta (Aβ) plaques. In some cases, tau-positive 
inclusions and neocortical neurofibrillary tangles (NFTs) also occur though the density of Aβ, 
tau inclusion and NFTs is lower than AD (Figure 1.9) (McKeith et al., 2005). Aβ involvement 
in DLB is more para-limbic and less hippocampal as compared to AD. DLB is also associated 
with alterations in the levels of several neurotransmitters including cholinergic, dopaminergic 
and serotoninergic (McKeith et al., 2005).  
Neuronal loss in the SN is seen in the DLB which is not as prominent as PD and usually is 
intermediate between PD and control, neuronal loss is also seen in locus coeruleus (LC), 
nucleus basalis of Meynert (NBM) and raphe nuclei  (Perry et al., 1990) and some neuronal 
loss is observed in the hippocampus though to a lesser degree than AD (Harding et al., 2002). 
In a recent study conducted by O’Brien and colleagues, it was shown that subcortical brain 
atrophy was higher in DLB as compared to AD (Watson et al., 2016).  
 
 
Figure 1.9 The neuropathology of dementia with Lewy bodies (DLB). The figure shows the 
pathological proteins in cortical regions. LBs- Lewy bodies, AD- Alzheimer’s disease.  
*Taken from McKeith, I. (2004) 'Dementia with Lewy bodies', Dialogues Clin Neurosci, 6(3), 
pp. 333-41. (McKeith, 2004) 
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1.2.4.3 Management of DLB 
In 2001, McKeith and colleagues developed a four stage management of DLB- accurate 
diagnosis, identification of target symptoms, non-pharmacological interventions, and 
pharmacological interventions (Barber et al., 2001). The target symptoms usually include 
cognitive impairment, motor symptoms, neuropsychiatric features (hallucinations, sleep 
disorder, behavioural changes and depression) and autonomic dysfunction. Assessment of 
functioning, and prioritisation of symptoms can be determined by clinicians and carers for the 
treatment. Non-pharmacological interventions are usually not systemised and should be set 
according to the presenting symptoms and can be targeted towards each of the core 
symptoms. Pharmacological interventions for DLB are very limited (Stinton et al., 2015). 
Cognitive symptoms have been treated with cholinesterase inhibitors (ChEIs), and patients 
have shown improvement in neuropsychiatric symptoms (McKeith et al., 2000; Ballard et al., 
2007). Treatment of motor symptoms is also limited and patients with DLB show a lower 
response to levodopa compared to PD and PDD patients, which possibly could be explained 
by the lower levels of DATs and DA receptors in DLB (Bonelli et al., 2004; Molloy et al., 
2005; Goldman et al., 2008). 
 
1.2.4.4 Biomarkers and cell death in DLB 
Differential diagnosis of DLB in the early stages of the disease is difficult since its pathology 
overlaps between AD and PD. Several imaging techniques including positron emission 
tomography (PET) and single-photon emission computed tomography (SPECT) have 
improved the diagnosis of DLB from other dementias. These imaging techniques can reliably 
show DATs loss, identify the marked deficits in occipital regions while sparing medial 
temporal lobe compared to AD (reviewed in (Mak et al., 2014)). Cerebrospinal fluid (CSF) 
markers are also used to differentially diagnose DLB. α-synuclein is a potential biomarker but 
the results have been controversial since PD and PDD both present similar features. A recent 
study suggested neurosin, a protease, that in vitro degrades α-synuclein, as a potential 
biomarker, where the levels of neurosin were lowest in DLB compared to other 
synucleopathies, control and AD (Wennstrom et al., 2013). Alzheimer’s biomarkers have also 
been used to differentiate between AD and DLB. Aβ42, Aβ38 and total and phosphorylated 
tau are more frequently used AD biomarkers but the worth of these markers are still limited 
due to mixed pathology (Andersson et al., 2011; Mulugeta et al., 2011).    
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Protein misfolding and aggregation is one of the common underlying pathogenic 
characteristic of most of the neurodegenerative disorders including DLB. How these 
misfolded proteins or aggregates cause neuronal death is still unclear. In one study, it was 
shown that LBs in DLB cause microtubule regression and mitochondrial disintegration 
resulting in reduced ATP levels and axonal transport which eventually leads to cell death 
(Power et al., 2015). Another study also reported the involvement of mitochondrial 
dysfunction in DLB cases, which was primarily caused by the disruption of energy production 
by α-synuclein oligomers and aggregates (Spano et al., 2015). The authors also proposed that 
α-synuclein induces the release of cytochrome C leading to activation of a caspase cascade 
suggesting that possibly apoptosis is the leading cause of cell death in DLB. 
 
1.2.5 Molecular mechanisms of PD 
The exact mechanism behind the pathogenesis and cell death in PD is still not clear but 
studies have presented evidence towards certain pathways or processes that contribute 
towards the initiation of the disease. These factors include oxidative stress, mitochondrial 
dysfunction, ubiquitin-proteasome system (UPS) impairment, dopamine metabolism, 
Ca
2+
/excitotoxicity, iron and neuroinflammation (Jenner, 2003; Shadrina et al., 2010). 
 
1.2.5.1 Oxidative Stress 
Oxidative stress, an imbalance between the levels of reactive oxygen species (ROS) and 
detoxifying agents has been implicated as one of the underlying mechanisms that leads to 
cellular dysfunction and death in PD.  The brain is susceptible to oxidative stress due to high 
oxygen consumption and high metabolism in neurones and glial cells. Several studies have 
shown that significant contributors to the higher level of ROS in the PD brain are dopamine 
metabolism, high levels of calcium and iron, and low levels of glutathione.  
Dopamine 
The neurotransmitter dopamine is highly unstable and is metabolised by monoamine oxidase 
(MAO), tyrosinase and COMT to produce toxic dopamine quinones and excess formation of 
hydrogen peroxide (H2O2), superoxide anions (O2
-
) and hydroxyl radicals (Munoz et al., 
2012). DA quinones are highly reactive and can cyclise to aminochrome which leads to 
generation of O2
- 
and depletes cellular NADPH. DA quinones also inactivate the DA 
transporter and tyrosine hydroxylase which leads to mitochondrial dysfunction (Berman and 
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Hastings, 1999; Kuhn et al., 1999; Hastings, 2009). These findings surrounding DA oxidation 
possibly explain why DA neurones are more susceptible to cell death.  
Calcium 
Ca
2+
 plays an important role in maintaining normal cellular physiology and for the correct 
function of excitable cells. In the brain, Ca
2+
 is critical for neuronal functioning, biochemical 
activity and signalling. The influx of Ca
2+
 is a highly energy dependent process resulting in 
increased mitochondrial activity and concomitant increased ROS generation. Over time, DA 
neurones become more dependent on Ca
2+ 
to maintain their autonomous activity, resulting in 
higher energy consumption and increased ROS levels making DA neurones more susceptible 
to cellular damage and death (Surmeier and Schumacker, 2013). Also, Ca
2+
 entry through L-
type channels elevates perinuclear and dendritic oxidative stress in DA neurones (Dryanovski 
et al., 2013). These studies suggest that excessive mitochondrial activity due to influx of Ca
2+
 
leads to an increase in ROS levels thereby damaging the SN DA neurones. 
Iron 
Iron is the most prevalent and utilised transition metal in the body and also serves as a redox 
metal that can facilitate the formation of free radicals, O2
- 
and H2O2. Several studies have 
shown that accumulation of iron occurs in the SN of PD patients (Mochizuki and Yasuda, 
2012). Iron accumulates in the brain with ageing with higher accumulation in the putamen, 
globus pallidus, red nucleus and SN (Bilgic et al., 2012). The earliest report that linked the 
accumulation of iron with PD was conducted by Sofic et al., where they reported an increase 
of 176% in the levels of total iron and 225% of iron (III) in the SN (post-mortem) of 
parkinsonian patients whereas no significant differences were observed in other brain regions 
(Sofic et al., 1988). Similar results were also observed by Barbosa et al., where PD patients 
showed a significant increase of iron in the SN compared to controls (Barbosa et al., 2015). 
Once iron is accumulated in the brain, it increases the level of ROS via Fenton chemistry and 
decreases the level of glutathione and results in high oxidative stress (Lan and Jiang, 1997). 
Iron has also been shown to play a role in DA oxidation  resulting in the formation of toxic 
intermediates such as quinones which form adducts with mitochondrial complexes I, III and 
V, resulting in mitochondrial dysfunction (Paris et al., 2005; Van Laar et al., 2009). 
Dysregulation of iron homeostasis in PD is a well observed phenomenon but whether the 
accumulation of iron is a cause of PD or just a consequence of other neurodegenerative 
processes remains to be elucidated. 
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1.2.5.2 Mitochondrial dysfunction 
Mitochondria have an important role in energy metabolism and are involved in other cellular 
processes including stress and cell death pathways and modulate calcium homeostasis; any 
impairment in these functions results in cellular damage. Mitochondrial dysfunction is usually 
characterised by decrease in complex I activity, ATP reduction and increased levels of ROS. 
It has been linked to PD with the observation that inhibition of Complex I by MPTP induces 
Parkinsonism (Vyas et al., 1986). Schapira et al., showed significant and specific reduction of 
mitochondrial Complex I activity in PD patients which showed the direct link between 
mitochondrial dysfunction and PD (Schapira et al., 1989). Inhibition of Complex I has been 
linked with enhanced ROS production, which in turn affects mitochondrial dynamics. 
Dysfunction of mitochondria has been linked with PD through toxin and genetic models and 
deletion of mtDNA has also been observed in the SN of ageing brain and PD brain (Bender et 
al., 2006; Kraytsberg et al., 2006). In PD patients, a decrease in mitochondrial function has 
also been observed in platelets (Parker et al., 1989; Krige et al., 1992; Haas et al., 1995), 
lymphocytes (Yoshino et al., 1992), muscle (Shoffner et al., 1991) and fibroblasts 
(Mytilineou et al., 1994). Mitochondrial dysfunction leads to increased oxidative stress and, 
as discussed earlier, oxidative stress damages DNA, cell membranes and alters proteasomal 
degradation of proteins.  
 
1.2.5.3 Ubiquitin-proteasome system (UPS) impairment 
The UPS is an intracellular protein degradation system which degrades and clears misfolded, 
damaged and short lived proteins in the cytoplasm, nucleus and endoplasmic reticulum. It is 
an important defence mechanism against toxic proteins, accumulation of which could alter 
cellular function and cell viability (Sherman and Goldberg, 2001). The UPS is a multi-step 
process that uses a series of enzymes to covalently link ubiquitin polypeptide chains to 
proteins, marking those proteins as substrates for the proteasome and resulting in the 
degradation of targeted proteins. Two of the enzymes involved with the UPS, parkin and 
UCH-L1, are linked with familial PD. Also, α- synuclein is a substrate of the UPS and any 
dysfunction of the UPS may relate to accumulation of α-synuclein. McNaught and colleagues 
observed reduced levels of α-subunit of 20S proteasome in the SN DA neurones and its 
activity was impaired in the SN of sporadic PD (McNaught et al., 2003). They also found 
very low levels of the PA28 proteasome activator in the SN in PD (McNaught et al., 2003).  
Furthermore, in laboratory animals, inhibition of proteasomal function leads to degeneration 
of DA neurones and the inhibition of proteasomal function is also associated with LB 
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formation (Rideout et al., 2005; McNaught et al., 2006). All these findings suggest that 
impairment in the UPS may lead to DA neuronal death in SN.  
 
1.2.5.4 Neuroinflammation 
Neuroinflammation has been associated with PD and is thought to be one of the mechanisms 
involved in the pathogenies of PD. Neuroinflammation in PD could either be microglial 
mediated or astrocyte mediated inflammation (Hirsch et al., 2012). The first evidence of 
involvement of microglial mediated inflammation in the SN of PD was reported by McGreer 
et al., in 1988, where they found significant activation of microglial cells in PD, PDD and AD 
(McGeer et al., 1988). Since then it has been shown that over-activation of microglial cells 
results in activation of pro-inflammatory cytokines including tumour necrosis factor- alpha 
(TNF-α), interleukin beta (IL-1β), interleukin-6 (IL-6) and interferon gamma (IFN-γ), which 
lead to DA neurone degeneration (Mogi et al., 1994a; Mogi et al., 1994b; Hunot et al., 1999). 
Astrocytes also play a role in the inflammatory processes in PD with astrocytic response 
being slower than microglial. Nonetheless, both cell types increase the levels of pro-
inflammatory cytokines in PD and result in neuronal cell death (Hirsch and Hunot, 2009).  
 
1.2.6 Genetic factors linked to Parkinson’s disease 
It is thought that in the majority of individuals with PD the occurrence is sporadic, and only 
10% of patients present familial history (Thomas and Beal, 2007). Recently, several loci 
linked with PD have been identified and approximately 5% of patients suffer with this kind of 
PD i.e., familial PD. These include SNCA (PARK1 and PARK4) (Polymeropoulos et al., 
1997), UCH-L1 (PARK5), LRRK2 (PARK8), GIGFY2 (PARK11), PLA2G6 (PARK14), FBX07 
(PARK15), VPS35 (PARK17) (Vilarino-Guell et al., 2011) and EIF4G1 which account for 
autosomal dominant inheritance. Parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7), and 
ATP13A2 (PARK9) show autosomal recessive inheritance. Other risk factors that are 
associated with PD are GBA, PARK10, PARK12, HTRA2 (PARK13) and PARK16 (Table 1.5). 
 
1.2.6.1 α-synuclein (SNCA, PARK1/4) 
The first gene discovered, and the most studied, is PARK1 which encodes α-synuclein protein 
that is present within LBs and LNs, is located at chromosome 4q21-23 (Polymeropoulos et 
al., 1997). The first reported mutation was an A53T point mutation in SNCA; it is a reversion 
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of the human alanine to the ancestral threonine found in rodents and other species 
(Polymeropoulos et al., 1997). The other reported mutations are A30P missense mutation 
(Kruger et al., 1998), E46K missense mutation (Zarranz et al., 2004), and α-synuclein gene 
triplication is observed in early onset PD (Singleton et al., 2003). 
 
1.2.6.2 Parkin (PARK2) 
Parkin was the second gene linked to Parkinsonism and the first identified gene for 
Autosomal Recessive Juvenile Parkinsonism (AR-JP) and is located at chromosome 6q25.2-
q27 (PARK2 locus) (Matsumine et al., 1997; Matsumine et al., 1998). Parkin is an ubiquitin-
E3 ligase that ubiquitinates several candidate substrate proteins and thereby targets them for 
proteasomal degradation. Further studies revealed different mutations in parkin that were 
linked with PD including  an internal deletion (Kitada et al., 1998), multiplications, small 
insertion/deletion and missense mutations (Mata et al., 2004).  
 
1.2.6.3 UCH-L1 (PARK5) 
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is an abundant neuronal specific protein 
and is a member of a family of deubiquitinating enzymes responsible for hydrolysing 
polymeric ubiquitin chains into monomers (Wilkinson et al., 1989). UCH-L1 was first linked 
to familial PD when a heterozygous mutation Ile93Met was identified in a German family 
with PD (Leroy et al., 1998). No other pathogenic mutations linked to UCH-L1 have been 
reported so far, although, an S18Y polymorphism in PD has been reported, which is 
associated with decreased risk of idiopathic PD (Maraganore et al., 1999). 
 
 1.2.6.4 PINK1 (PARK6) 
The second gene linked with autosomal recessive inheritance of PD was PARK6 which was 
found by Valente et al., in an Italian pedigree and later PINK1 was mapped on the same locus 
(1p35-36) and was associated with PD (Valente et al., 2001; Valente et al., 2002; Valente et 
al., 2004).  PTEN-Induced Putative Kinase 1 (PINK1) is a 581 amino acid protein which has 
a highly conserved kinase domain and is localised to mitochondria. Two homozygous 
mutations were identified in the kinase domain (a truncating nonsense mutation and a 
missense mutation), which abrogated the protective effect of PINK1 (Valente et al., 2004). It 
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has been suggested that PINK1 phosphorylates mitochondrial proteins under stress and 
prevents mitochondrial dysfunction (Valente et al., 2004).  
 
1.2.6.5 DJ-1(PARK7) 
DJ-1 is a 189 amino acid protein that is highly expressed in neurones and glial cells (Bader et 
al., 2005). DJ-1 mutations are associated with PARK7 (1p36) in two consanguineous families 
with young-onset PD (van Duijn et al., 2001; Bonifati et al., 2003) and loss of function of DJ-
1 leads to neurodegeneration (Bonifati et al., 2003). DJ-1 is a ubiquitous highly conserved 
protein and its function is still unclear but is believed to be involved in oxidative stress 
response, and mutations in this gene impairs the neuroprotective function of the protein 
(Bonifati et al., 2003). A recent study also showed that DJ-1 regulates 20S proteasome under 
oxidative stress where it upregulates and inhibits the 20S proteasome resulting in elimination 
of oxidatively damaged proteins but at the same time sparing proteins which are unaffected by 
oxidative damage (Moscovitz et al., 2015). These findings suggest that DJ-1 is essential for 
cell survival and any loss of function of the gene leads to neurodegeneration. 
 
1.2.6.6 LRRK2 (PARK8) 
Leucine-rich repeat kinase 2 (LRRK2) is an unusually large protein (2527 amino acids) with 
protein kinase activity that possesses two domains- the kinase domain catalysing 
phosphorylation and the ROC-GTPase domain that is involved in GTP-GDP hydrolysis 
(Gilsbach and Kortholt, 2014). Mutations at the PARK8 (locus: 12p11.2-q13.1) was 
associated with familial PD in a Japanese family (Funayama et al., 2002) and LRRK2 was 
later mapped to this locus (Zimprich et al., 2004). Five missense mutations and a single 
putative splice mutation were found, these mutations cause autosomal dominant PD 
(Zimprich et al., 2004). A frequent low penetrance mutation, Gly2019Ser, is linked with both 
sporadic and familial PD (Bonifati, 2007). The pathogenic mutations in LRRK2 are distributed 
throughout the functional domains, and which domain is relevant to neurodegeneration is still 
unclear with the pathogenic mechanism said be a toxic gain-of-function of kinase activity 
(West et al., 2005). 
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1.2.6.7 Other genetic factors linked with PD 
ATP13A2 belongs to the P- type superfamily of ATPases that transport inorganic compounds 
and other substrates across the cell membrane. ATP13A2 gene encodes a lysosomal P5-type 
ATPase, and is linked with Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of 
early-onset Parkinsonism with pyramidal degeneration and dementia (Ramirez et al., 2006). 
Mutations in ATP13A2 cause proteasomal dysfunction which leads to retention of protein in 
the endoplasmic reticulum (ER) and their enhanced proteasomal degradation. Loss of function 
of ATP13A2 may cause insufficient lysosomal protein degradation, accumulation of α- 
synuclein aggregates and mitochondrial dysfunction (Ramirez et al., 2006).  
High-temperature-regulated A2 (HTRA2), also called Omi is a mitochondrial serine protease 
that belongs to oligomeric HTRA protease family and is linked with neurodegeneration (Jones 
et al., 2003; Martins et al., 2004). Strauss et al., reported a loss of function mutation in the 
HTRA2 gene in German PD patients and found a G399S mutation, which was absent in the 
controls (Strauss et al., 2005), although, some studies did not find any association between 
HTRA2 variation and PD (Ross et al., 2008; Kruger et al., 2011). HTRA2 has been associated 
with PINK1 which is known to promote cell survival under oxidative stress (Plun-Favreau et 
al., 2007). 
F-box only protein 7 (FBXO7) belongs to F-box family proteins that are involved in the UPS 
protein degradation pathway. Mutations in FBXO7 cause progressive neurodegeneration and 
result in autosomal recessive Parkinsonism (Di Fonzo et al., 2009). FBXO7 has been shown 
to maintain the quality of mitochondria and it interacts with Parkin and PINK1 and mediates 
mitophagy, with mutations in FBXO7 causing mitochondrial dysfunction (Burchell et al., 
2013). These findings suggest that FBXO7 plays an important role in maintenance of 
mitochondrial dynamics and cell survival.  
Vacuolar protein sorting 35(VPS35) is a central component of the retromer cargo-recognition 
complex which is critical for endosome to golgi and endosome to plasma membrane 
trafficking (Burd and Cullen, 2014). VPS35 has also shown to shuttle cargo from 
mitochondria to peroxisomes or lysosomes (Braschi et al., 2010; Soubannier et al., 2012).  
Mutation in VPS35 leads to autosomal dominant Parkinsonism and disrupts retromer 
mediated protein sorting and recycling, inhibits autophagy, and also causes mitochondrial 
dysfunction by recycling DLP1 complexes (Vilarino-Guell et al., 2011; Zavodszky et al., 
2014; Wang et al., 2016).  
Genetic mutations/risk factors associated with PD are summarised in Table 1.5.  
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Gene Localisation Locus Inheritance Mutations Effects of Mutations 
SNCA (α-
synuclein) 
4q21-q23 PARK1/P
ARK4 
AD A30P, E46K, A53T, Genomic triplication 
and duplication,  
Mutations lead to accumulation of α-synuclein 
monomer and promote oligomerisation and toxicity.  
Parkin 6q25.2-q27 PARK2 AR Multiplications, small deletions/insertions 
and missense mutations 
Parkin is ubiquitin-E3 ligase and mutations tend to 
impair proteasomal degradation. 
Unknown 2p13 PARK3 AD - Linked to early onset of PD. (DeStefano et al., 2002) 
UCH-L1 4p14 PARK5 AD Heterozygous mutation Ile93Met, S18Y 
polymorphism 
Mutation disrupts UPS. S18Y polymorphism is 
associated with decreased risk of early onset of PD 
PINK1 1p35-p36 PARK6 AR Missense and exon-deletion mutations Mutation in PINK1 abrogates the protective effect of 
the protein 
DJ-1 1p36 PARK7 AR Missense (Leu166Pro), deletion (delExl-5) 
mutations 
DJ-1 is thought to be involved in oxidative stress 
response and mutations may alter its anti-oxidative 
properties 
LRRK2 12p11.2-
q13.1 
PARK8 AD Missense mutations, splice mutation , 
dominant substitutions and the most 
frequent Gly2019Ser mutation 
LRRK2 encodes protein kinase and mutation in the 
gene may lead to impaired cell signalling 
ATP13A2 1p36 PARK9 AR Several mutations: deletions (3057delC), 
transitions (1306+5G    A) and duplications  
(1632_1653dup22)  
Mutations cause proteasomal dysfunction 
Unknown 1p32 PARK10 Risk factor - - 
GIGYF2 2q37.1 PARK11 AD - - 
Unknown Xq21-q25 PARK12 X-linked, 
Risk factor 
- - 
HTRA2 2p12 PARK13 AD or risk 
factor 
G399S mutation? May lead to proteasome dysfunction.  
PLA2G6 22q13.1 PARK14 AR Pro860Arg?, Arg741Gln?, Arg747Trp May lead to accumulation of iron in the brain and 
hence the increased rate of oxidative stress.(Paisan-
Ruiz et al., 2009; Tomiyama et al., 2011)  
FBXO7 22q12–q13 PARK15 AR Arg498Stop, Thr22Met, Arg378Gly Mutations lead to progressive neurodegeneration.  
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Unknown 1q32 PARK16 Risk factor Single-nucleotide variants (rs947211, 
rs823128 and rs823156) 
Impaired endolysosomal and golgi pathways. 
(MacLeod et al., 2013) 
VPS35 16q11.2 PARK17 AD Missense variants, Asp620Asn, Pro316Ser Mutations may lead to disruption of endoplasmic 
trafficking and autophagy. (Vilarino-Guell et al., 
2011) 
EIF4G1 3q27.1 PARK18 AD Ala502Val,  and Arg1205His Mutations result in impairment of EIF4G1 controlled 
translational initiation of mRNAs encoding 
mitochondrial and cell survival genes resulting in 
vulnerability of cells to oxidative stress. (Chartier-
Harlin et al., 2011)  
GBA 1q21 GBA AR for 
Gaucher’s 
disease, Risk 
factor 
Several mutations including N370S, L444P, 
K198T, and R329C. 
Mutations in GBA may lead to improper lysosomal 
degradation resulting in α-synuclein aggregate 
formation. (Sidransky and Lopez, 2012)  
Table 1.6 Genetic mutations and risk factors in Parkinson’s disease.  The table summarises the genetic mutation and risk factors associated with 
Parkinson’s and their possible effect in pathogenesis of PD. 
Abbreviations: AD, Autosomal dominant; AR, Autosomal recessive; GIGYF2, Grb10-Interacting GYF Protein-2; PLA2G6, phospholipase A2 group 6; 
EIF4G1, eukaryotic translation initiation factor 4-gamma 1; GBA, glucocerebrosidase  
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1.2.7 Environmental factors associated with PD 
Apart from genetic factors, numerous environmental risk factors are thought to induce PD. 
These include history of anxiety or depression, head injury, rural life, beta block use, farming 
occupation, well water use, and exposure to pesticides, herbicides, heavy metals and industrial 
chemicals, and a lack of history of smoking and negative significant associations with coffee 
consumption, hypertension, use of NSAIDs, calcium channel blockers, and alcohol 
(Priyadarshi et al., 2001; Noyce et al., 2012). Some neurotoxins that have been linked with 
pathogenesis of PD are, MPTP (Davis et al., 1979; Langston et al., 1983), rotenone (Betarbet 
et al., 2000), paraquat (Brooks et al., 1999)  and diquat (Sechi et al., 1992). 
 
1.2.7.1 MPTP 
MPTP is a neurotoxin and its active metabolite, MPP
+
 is a mitochondrial complex I inhibitor 
that is known to damage the nigrostriatal dopaminergic pathway in PD (Figure 1.10A) 
(Ramsay and Singer, 1986). MPTP is produced as a by-product of the synthesis of a 
meperidine analogue with heroin-like properties and was identified when it was found that 
young acute onset PD patients had been exposed to this compound (Langston et al., 1983). 
MPTP crosses the blood-brain barrier and is metabolised to highly reactive MPP
+
, mainly in 
glial and serotonergic cells by MAO-B (Chiba et al., 1984; Przedborski et al., 2004). MPP
+
 
then accumulates in the DA neurones through DA transporters and once inside the neurone, 
MPP
+
 enters mitochondria via passive transport due to the large mitochondrial transmembrane 
gradient where it inhibits mitochondrial Complex I (Nicklas et al., 1985; Watanabe et al., 
2005). The inhibition of Complex I results in reduced ATP and high ROS levels which leads 
to cell death (Figure 1.10B). Accumulated MPP
+
 in the DA neurones triggers oxidative stress 
by generating ROS, nitric oxide (NO), O2
- 
 (Zang and Misra, 1993) and also stimulates the 
release of DA (Obata et al., 2001). The oxidation of excessive DA released by MPP
+
 results 
in generation of highly active and toxic quinones and free radicals leading to degeneration of 
the DA neurones. 
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A 
 
B 
 
Figure 1.10 MPTP metabolism and its action on dopaminergic neurones.  A) Metabolism 
of MPTP to MPP
+
. B) MPTP can cross the blood–brain barrier and is metabolized to MPP+ with the 
assistance of the enzyme monoamine oxidase B (MAO-B) in glial cells. MPP
+
 is then taken up by into 
neuronal cells via dopamine transporter. Once inside neurones, MPP
+
 impairs mitochondrial oxidative 
phosphorylation by inhibiting complex I of the respiratory chain and enhances the oxidative stress 
resulting in degeneration of DA neurones. 
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1.2.7.2 6-OHDA 
6-hydroxydopamine (6-OHDA) is a specific catecholaminergic neurotoxin, structurally 
analogous to dopamine (Figure 1.11A) which is toxic to monoamine neurones (Ungerstedt, 
1968) and has been used as Parkinson’s model for more than 40 years. 6-OHDA damages 
both noradrenergic and DA neurones as it exhibits higher affinity for dopamine (DAT) and 
norepinephrine (NET) transporters (Sachs and Jonsson, 1975). 6-OHDA cannot cross the 
blood-brain barrier hence, in the models, it is directly injected into the SNpc or striatum. 
Unilateral injection of 6-OHDA in the SNpc induces DA neurone degeneration and produces 
motor symptoms in rodent models (Perese et al., 1989; Betarbet et al., 2002; Thiele et al., 
2012). The mechanism by which 6-OHDA destroys neurones is thought to be via inhibition of 
the mitochondrial respiratory chain complexes I and IV and free radical formation leading to 
oxidative stress and cell death (Figure 1.11B) (Glinka et al., 1997). 6-OHDA is also oxidised 
by MAO-B and generates H2O2 which also results in oxidative stress and eventually cell death 
(Figure 1.11B) (Salonen et al., 1996). 
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Figure 1.11 Structure of 6-OHDA and its action on dopaminergic neurones.  A) Structure 
similarities between dopamine and 6-OHDA. B) 6-OHDA gets entry into neurone via DAT and 
inhibits the Complex I resulting in ATP depletion, high ROS/NOS levels leading to high oxidative 
stress and eventually cell death. MAO-B can oxidise 6-OHDA generating H2O2 leading to oxidative 
stress and cell death. 
 
Even though 6-OHDA leads to DA neurones degeneration, it does not mimic all the 
pathological and clinical features of PD. It does produce the motor symptoms; however it fails 
to produce LB/Ns and also parkinsonian tremors are absent. In general, 6-OHDA is a good 
model to study the DA degeneration however it is not a reliable model for the clinical and 
pathological features of PD. 
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1.2.7.3 Rotenone 
Rotenone is a natural toxin produced by several tropical plants and has been used for centuries 
as a selective fish poison and more recently as a commercial insecticide (Figure 1.12A) 
(Betarbet et al., 2000). Rotenone is highly lipophilic and is able to easily cross the blood-brain 
barrier and enter neuronal cells and intracellular organelles, such as mitochondria, without the 
aid of transporters. As with MPTP, rotenone has been reported to selectively target DA 
neurones (Figure 1.11B). Rotenone is a good model of PD as it reproduces most of the 
features of PD including motor symptoms and LBs (Betarbet et al., 2002) and similar to 
MPP
+
 it inhibits mitochondrial processes (Priyadarshi et al., 2001).  
Studies have reported that although rotenone caused uniform Complex I inhibition throughout 
the brain, rotenone-treated rats demonstrate many characteristics of PD, including selective 
nigrostriatal dopaminergic degeneration, formation of ubiquitin and α-synuclein-positive 
nigral inclusions, and motor deficits (Figure 1.12B) (Betarbet et al., 2000; Alam and Schmidt, 
2002; Sherer et al., 2003). It has also been shown that rotenone induces more O2
- 
in the 
presence of endogenous dopamine (Sakka et al., 2003) and also increases the aggregation of 
α-synuclein in the DA neurones (Feng et al., 2006) which explains the relatively selective 
neuronal death caused by rotenone. 
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Figure 1.12 Structure of rotenone and its action on dopaminergic neurones.  A) Structure 
of rotenone. B) Rotenone easily crosses the cellular membrane, enters the mitochondria and inhibits 
the Complex I resulting in ATP depletion, high ROS/NOS levels leading to high oxidative stress and 
eventually cell death. 
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1.2.7.4 Paraquat 
Paraquat (1,1-dimethyl-4,4-bipyridinium), a quaternary nitrogen herbicide, undergoes one-
electron reduction chemistry in cells that can sequester it, causing a widespread 
oxidative/nitrosative stress. Paraquat structurally resembles MPP
+ 
(Figure 1.13) but its mode 
of function and toxicity is different. In animal studies, repeated exposure of paraquat has been 
shown to cause loss of DA neurones and aggregation of α-synuclein, and producing 
parkinsonian symptoms (McCormack et al., 2002). The mechanism of paraquat involves 
generation of O2
-
, which leads to the formation of more toxic reactive oxygen species. 
Paraquat reduces glutathione and induces microsomal lipid peroxidation which eventually 
leads to cell death (Di Monte et al., 1986).  
 
 
Figure 1.13 Structure similarities between Paraquat and MPP
+
.   
 
1.2.7.5 Diquat 
Diquat (1, 1’-ethylene, 2, 2’-dipyridylium) is a non-selective bipyridyl herbicide, structurally 
related to paraquat (Figure 1.14A). Diquat is a potent redox cycler and is converted to a free 
radical that reacts with molecular oxygen and generates ROS (Lopes and Manso, 1989). 
Diquat undergoes a single electron reduction and in the presence of NADPH forms diquat 
radical, O2
-  
which results in higher H2O2 and oxidative stress (Lopes and Manso, 1989). ROS 
can induce lipid peroxidation in cell membranes and potentially cause cell death (Figure 
1.14B). One study has shown that diquat does not exert major deleterious effects on DA 
neurones, although, it exacerbates motor impairment (Karuppagounder et al., 2012).  
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Figure 1.14 Structure of diquat and its action on neurones.  A) Structure of diquat. B) Diquat 
enters the cytoplasm via protein uptake system (PUS) and through redox cycling it depletes the 
NADPH levels and also generates O2
-
. Increase in oxidative stress leads to damage of nucleic acids, 
lipids and proteins and eventually leads to cell death. 
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1.2.8 Cell death in PD 
Cells have numerous mechanisms by which they fight against stress or trigger cell death 
depending upon the amount of damage. The processes that have been suggested to trigger 
early death of neurones include protein accumulation, particularly of α-synuclein, altered 
protein degradation via multiple pathways, mitochondrial dysfunction, oxidative stress, 
neuroinflammation and dysregulated kinase signalling. Different mechanisms are involved in 
neuronal death, their mode of action may be different but their pathways may be 
interconnected. 
 
1.2.8.1 Apoptosis 
Apoptosis is an evolutionary conserved cell death pathway and is the most common 
programmed cell death (PCD) (Kerr et al., 1972). It is a gene directed PCD, characterised by 
morphological changes including cell shrinkage, DNA fragmentation, chromatin 
condensation, membrane blebbing and compartmentalisation. There are two main families of 
proteins involved in apoptosis- caspases (a group of proteases) (reviewed in (McIlwain et al., 
2013)) and Bcl2 family (reviewed in (Youle and Strasser, 2008)). The Bcl-2 family regulates 
mitochondrial dynamics during apoptosis and may function as pro or anti-apoptotic protein. 
The biochemical features of apoptosis include caspase activation (caspases 3, 6 and 7), DNA 
fragmentation, degradation of chromosomal DNA, cleavage of a specific subset of cellular 
polypeptides by caspases (8, 9 and 10), and expression of cell surface markers (Reed, 2000). 
The major advantage of apoptosis is that during cell death, membrane integrity remains intact 
and the cell contents are confined within apoptotic bodies and do not get released to the 
extracellular space.  
Apoptosis can be triggered by several factors including ROS/RNS, deprivation of growth 
factors, by the stimulation of cytokines, disruption in Ca
2+
 homeostasis and by dopamine, in 
relation to PD. In PD patients, several cytokines have been shown to be increased including 
IL-β, IL-2, IL-4, IL-6, EGF and TGF-α and an increase in glia expressing IFN-γ, TNF-α and 
IL-β have been observed in the SN. An increase in cytokines induces different apoptotic 
pathways involved in dopaminergic neuronal death (Mogi et al., 1994a; Mogi et al., 1994b). 
Neurotrophic factors are essential for development and continued maintenance of the CNS 
and a lack of these factors such as NGF, BDNF, neurotrophin- 3,4 and 5 has been shown to 
cause initiation of apoptosis in vitro (Kim et al., 2002). Other factors that have been shown to 
initiate apoptosis in PD are over-activation of glutamate (Glazner and Mattson, 2000) which 
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increases the influx of Ca
2+
 leading to degeneration of DA neurones (Surmeier and 
Schumacker, 2013)  and oxidative stress (Dias et al., 2013). 
There are two main apoptotic pathways: the extrinsic (mediated by simulation of death 
receptors) and the intrinsic (non-receptor-mediated mitochondrial pathway). Both the 
pathways are linked and the factors in one pathway can influence the other (Figure 1.15) 
(reviewed in (Venderova and Park, 2012)). 
The intrinsic pathway is non-receptor mediated and directly acts on targets within the cell and 
is mitochondrial initiated. It is activated by cellular stress such as a change in mitochondrial 
transmembrane potential, increased ROS production and DNA damage. It involves alteration 
in pro and anti-apoptotic proteins, cytochrome-c release and finally execution of apoptosis via 
caspase activation. These mitochondrial apoptotic events are regulated by the Bcl-2 family of 
proteins, which in turn are modulated by p53  (reviewed in (Wu and Bratton, 2013)). 
Apoptosis initiated by the extrinsic pathway involves transmembrane receptor-mediated 
interactions. Cells that express Fas or TNF receptors lead to apoptosis via ligand binding and 
protein cross-linking. Upon ligand binding, cytoplasmic adapter proteins are recruited, which 
then associate with procaspase-8 and this leads to activation of caspase-8 via death-inducing 
signalling complex (DISC) where caspase-8 triggers an execution pathway (Kischkel et al., 
1995). 
Both the pathways converge on the same execution pathway by initiating the activation of 
caspase 3 leading to DNA fragmentation, degradation of proteins, formation of apoptotic 
bodies, expression of ligands for phagocytic cell receptors and finally uptake by phagocytic 
cells (Figure 1.15) (reviewed in (McIlwain et al., 2013)). 
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Figure 1.15 Schematic illustration of mechanism of apoptosis, showing both extrinsic 
and intrinsic pathways.  Apoptosis can be induced by two pathways- the extrinsic (mediated by 
simulation of death receptors) and the intrinsic (non-receptor-mediated mitochondrial 
pathway). Both pathways converge into the same execution pathway where the process of cell 
death is initiated by activation of caspase 3.   
 
1.2.8.2 Autophagy 
Autophagy is an essential cellular homeostatic process which mainly is responsible for 
degradation of cellular organelles, long-lived proteins and proteins aggregates (Yorimitsu and 
Klionsky, 2005). Autophagy can be induced by several factors including decreased ATP 
levels, low oxygen, oxidative stress and limited nutrient availability. Based on the different 
pathways by which cargo is delivered to the lysosomes, autophagy can be divided into three 
main types: macroautophagy, microautophagy and chaperone-mediated autophagy (CMA), all 
of which sequester cell contents for proteolytic degradation by lysosomes (Figure 1.16). In 
microautophagy, targets are taken up directly into the lysosome by invagination of the 
lysosome membrane (Glick et al., 2010). In CMA, targeted proteins are translocated across 
the lysosomal membrane by a molecular chaperone which binds to lysosome-associated 
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membrane protein (lamp) type 2a, resulting in their unfolding and degradation (Agarraberes 
and Dice, 2001). 
 
 
Figure 1.16 Schematic illustrations of autophagy and its types. There are three types of 
autophagy- macroautophagy, microautophagy and chaperone mediated autophagy, all of which 
involves the breakdown of the cellular contents by lysosomes.  
*Taken from Lynch-Day, M.A., Mao, K., Wang, K., Zhao, M. and Klionsky, D.J. (2012) 'The role of 
autophagy in Parkinson's disease', Cold Spring Harb Perspect Med, 2(4), p. a009357 (Lynch-Day et 
al., 2012) 
Macroautophagy is by far the best studied among all three types and will hereafter be referred 
to as autophagy. Autophagy delivers the targets to lysosomes through intermediary of a 
double membrane-bound vesicle called autophagosomes. The autophagosome then fuses with 
the lysosome promoting the degradation of the protein cargo by lysosomal enzymes with the 
export of degraded products to the cytoplasm for re-use (Glick et al., 2010). Autophagy is 
controlled by a number of different “autophagy-specific genes” (ATGs) and so far 
approximately thirty ATGs have been identified in yeast, which are conserved in most phyla 
including mammals (reviewed in (Xie and Klionsky, 2007)). Autophagy can be categorised 
by the following five steps (i) phagophore formation or nucleation, (ii) Atg5–Atg12 
conjugation, interaction with Atg16L and multi-merization at the phagophore, (iii) LC3 
processing and insertion into the extending phagophore membrane, (iv) capture of targets for 
degradation, and (v) fusion of the autophagosome with the lysosome, followed by proteolytic 
degradation by lysosomal proteases (Glick et al., 2010). Autophagy is essential for neuronal 
survival as it degrades any protein aggregates that are toxic to neurones and any impairment 
in this process leads to neuronal death (Lee et al., 2011). 
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1.2.8.3 ER stress and PD 
The endoplasmic reticulum (ER) modulates protein synthesis, protein glycosylation, protein 
folding and trafficking, cellular responses to stress and intracellular Ca
2+
 levels. ER stress is 
caused by glucose starvation, hypoxia or oxidative stress, which leads to the accumulation of 
misfolded proteins and alterations in Ca
2+
 homeostasis. ER stress induces cellular protective 
signalling pathways collectively called the unfolded protein responses (UPR), the role of 
which is to compensate for any cellular damage and damage to proteins (Schroder and 
Kaufman, 2005). The UPR includes protein translational attenuation, induction of ER resident 
chaperones, and degradation of misfolded proteins through ER-associated degradation 
(ERAD). In the case of prolonged ER stress, unfolded proteins may trigger cellular death 
pathways through the transcription factor C/EBP homologous protein (CHOP) (Marciniak et 
al., 2004) and caspases (Nakagawa et al., 2000; Morishima et al., 2002; Hitomi et al., 2004). 
PD mimetics 6-OHDA, MPP
+
 and rotenone induce the ER stress and UPR which show the 
association between the ER stress and PD (Ryu et al., 2002). α-synuclein aggregates have 
been localised to several compartments of ER and have found to induce ER stress (Bellucci et 
al., 2011). Over-expression of UPR targeted genes promotes neuronal survival in MPTP 
treated mice (Hashida et al., 2012). ER stress markers have also been reported in the SNpc of 
post-mortem tissue from sporadic PD cases (Hoozemans et al., 2007).  
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1.3 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia, which is characterised by 
progressive cognitive deterioration, dementia and functional decline. Pathologically, AD is 
characterised by the accumulation of Aβ plaques and neurofibrillary tangles, which are 
associated with neuronal dysfunction and cell death.  
 
1.3.1 Diagnosis and Clinical features of AD 
Clinically, AD is characterised as either probable or possible AD (McKhann et al., 1984). The 
criteria for the diagnosis of AD were revised in 2011 (McKhann et al., 2011). 
Patients are categorised as probable AD when they present the following symptoms 
 Insidious onset: symptoms have a gradual onset over months to years, not sudden as in 
over hours or days 
 Clear-cut history of worsening of cognition by report or observation; and  
 The initial and most prominent cognitive deficits are evident upon history and 
examination in one of the following categories: 
 Amnestic presentation: The deficits should include impairment in learning and 
recall of recently learned information. There should also be evidence of 
cognitive dysfunction in at least one other cognitive domain. 
 Non-amnestic presentations: Language presentation: the most prominent 
deficits are in word-finding, but deficits in other cognitive domains should be 
present; Visuospatial presentation: the most prominent deficits are in spatial 
cognition, including object agnosia, impaired face recognition, 
simultanagnosia, and alexia. Deficits in other cognitive domains should be 
present; Executive dysfunction: the most prominent deficits are impaired 
reasoning, judgment, and problem solving.  
Patients are categorised as possible AD when they meet following criteria 
 Atypical course 
Atypical course meets the core clinical criteria in terms of the nature of the cognitive 
deficits for AD dementia, but either has a sudden onset of cognitive impairment or 
demonstrates insufficient historical detail or objective cognitive documentation of 
progressive decline  
Or   
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 Etiologically mixed presentation. 
Etiologically mixed presentation meets all core clinical criteria for AD dementia but 
has evidence of: a) concomitant cerebrovascular disease, defined by a history of stroke 
temporally related to the onset or worsening of cognitive impairment; or the presence 
of multiple or extensive infarctions or severe white matter hyperintensity burden; b) 
features of dementia with Lewy bodies other than the dementia itself; or c) evidence 
for another neurological disease or a non-neurological medical comorbidity or 
medication use that could have a substantial effect on cognition. 
 
Though most of the AD cases are sporadic, familial cases of AD have been reported (Bertram 
and Tanzi, 2008). The most common genetic mutation observed in early onset AD are APP, 
PSEN1 and PSEN2 which have autosomal dominant inheritance and  mutations in these genes 
lead to an overproduction of Aβ (St George-Hyslop et al., 1987; Levy-Lahad et al., 1995; 
Rogaev et al., 1995; Sherrington et al., 1995). The most common risk factor associated with 
late-onset of AD is APOE (Strittmatter et al., 1993). Mutations in APOE decrease the onset 
age of AD. Genome wide association studies have associated 18 gene loci with AD (reviewed 
in (Tanzi, 2012; Singleton and Hardy, 2016)). 
 
1.3.2 Neuropathology of AD 
The main pathological features of AD are extracellular amyloid plaques and intra-neuronal 
neurofibrillary tangles (NFTs) and neuropil threads (NTs), which are highly insoluble, 
densely packed filaments (Figure 1.18). The building blocks of amyloid plaques and 
NFTs/NTs are Aβ and tau, respectively. Macroscopically AD brain presents with 
characteristic brain atrophy, thinning of gyri and deepening of sulci, especially in the temporal 
lobe (Halliday et al., 2003).  
 
 64 
 
Figure 1.17 The neuropathology of Alzheimer’s disease. The figure shows the pathological 
proteins in cortical regions. A) Aβ Plaque evident on haematoxylin counter-stained section of insula; 
B) Neurofibrillary tangle in an insular pyramidal neurone on haematoxylin counter-stained section; C) 
Neuropil thread evident on haematoxylin counter-stained section of insula 
 
Based upon the topographical distribution of NFTs, Braak and Braak categorised the six 
stages of spread of NFTs. In stage I, NFTs appear in the transentorhinal (perirhinal) region 
along with the entorhinal cortex proper, in stage II they spread to the CA1 of hippocampus, 
followed by their accumulation in the limbic structures such as subiculum of the hippocampus 
in stage III, stage IV shows the accumulation of NFTs in the amygdala, anterior thalamus and 
claustrum. In stage V, NFTs accumulate in the isocortical regions and in stage VI remaining 
isocortical regions are severely affected (Figure 1.19) (Braak and Braak, 1991).    
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Figure 1.18 The Braak staging in Alzheimer’s disease- the progression of NFTs. The 
figure shows the beginning of NFT accumulation in the transentorhinal cortex, its progression into the 
limbic areas in stages III and IV, and its culmination in the neocortical and primary sensory areas in 
stages V and VI. 
*Taken from Kretzschmar, H. (2009) 'Brain banking: opportunities, challenges and meaning for the 
future', Nat Rev Neurosci, 10(1), pp. 70-8 (Kretzschmar, 2009) 
 
In addition to Braak staging, neuropathological changes in AD can also be categorised on the 
basis of Aβ immunohistochemistry or by neuritic plaques as recommended by the Consortium 
to Establish a Registry for Alzheimer's disease (CERAD) (Table 1.7). 
 
Other features of AD are loss of synapses (Terry et al., 1991; Scheff and Price, 1998), 
activated microglia (Alzheimer et al., 1995; Hamelin et al., 2016), cerebral amyloid 
angiopathy (Greenberg and Vonsattel, 1997), granulovacuolar degeneration (Xu et al., 1992), 
Hirano bodies (Gibson and Tomlinson, 1977) and neuronal loss in cortical regions 
(Giannakopoulos et al., 1996; Padurariu et al., 2012). Neuronal loss usually follows the 
pattern of NFTs but within the same region, neuronal loss exceeds the number of NFTs 
(Gomez-Isla et al., 1997).  
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Aβ plaque score  NFT/Braak stage Neuritic plaque/CERAD 
score 
A0: no Aβ or amyloid 
plaques 
B0: no NFTs C0: no neuritic plaques 
A1: Thal phase 1 or 2 B1: Braak stage I or II C1: CERAD score sparse 
A2: Thal phase 3 B2: Braak stage III or IV C2: CERAD score 
moderate 
A3: Thal phase 4 or 5 B3: Braak stage V or VI C3: CERAD score 
frequent 
Table 1.7 Neuropathological changes in AD ranked along Aβ plaques, NFTs and neuritic 
plaques.  
*Adapted from Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., 
Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., 
Thal, D.R., Thies, B., Trojanowski, J.Q., Vinters, H.V. and Montine, T.J. (2012) 'National Institute on 
Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease', 
Alzheimers Dement, 8(1), pp. 1-13.  (Hyman et al., 2012) 
 
1.3.3 Management of AD 
The current treatment of AD is targeted towards cognitive impairment. The most widely use 
pharmacological treatment is with cholinesterase inhibitors (ChEIs) which improves cognitive 
function and activities of daily living (O'Brien and Ballard, 2001). The most challenging 
aspect in the management of AD is the treatment of behavioural and psychological signs and 
symptoms. Psychotropic medications are used to treat depression, psychotic symptoms, and 
anxiety symptoms. Non-pharmacological interventions including counselling should be made 
available to patients. Better care giving facilities and well informed care givers can improve 
the daily living of the patients.  
 
1.3.4 Biomarkers and cell death in AD 
Diagnosis of AD at early stages and its differential diagnosis from other types of dementia are 
essential. Imaging biomarkers including MRI, PET, FDG-PET are used to assess structural 
atrophy in cortical regions, cortical thickness, functional connectivity and the cortical 
hypometabolism in AD (Kantarci and Jack, 2003; Mosconi, 2005; Magnin et al., 2009; 
Bateman et al., 2012; Dickerson and Wolk, 2012). CSF biomarkers of AD include, Aβ1-42, 
which inversely shows the CNS amyloid content, tau reflects the level of neurodegeneration, 
and phosphorylated tau reflects NFT pathology (reviewed in (Blennow et al., 2010)). 
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AD is caused by several neuropathogenic pathways that all lead to neuronal death. Aβ 
plaques, NFTs and NTs are caused due to impairment in their removal from the neurones 
which lead to toxicity and cell death. Abnormal autophagy has been reported in AD which 
results in accumulation of these protein aggregates (Nixon et al., 2005). Neuroinflammation 
in AD caused by over activity of microglial cells also leads to cell death (Spangenberg and 
Green, 2016). Excessive oxidative stress has also been shown to trigger the cell death 
pathways in AD (Hadjigeorgiou, 2008). Aβ toxicity has shown to induce the caspase cascade 
leading to apoptosis suggesting that apoptosis is a common death pathway in AD (Garwood et 
al., 2011). 
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1.4 SIRTs in PD 
Sirtuins have broad physiological effects on cells and are linked with longevity in lower 
organisms, which makes them attractive targets for several diseases including 
neurodegenerative disorders. PD is well characterised by the loss of DA neurones in the SN 
and the underlying mechanisms of the neuronal loss are believed to be oxidative stress, 
mitochondrial dysfunction, UPS impairment and neuroinflammation (details in Section 1.2.4). 
SIRTs have been shown to alleviate oxidative stress, maintain mitochondrial dynamics and, 
under cellular stress, SIRTs enhance cell survival.  
SIRT1 has been shown to exert neuroprotection against oxidative stress. In models of PD, 
rotenone and  MPP
+
 are known to reduce SIRT1 in primary cultures which may imply that 
due to reduction of SIRT1, neurones lose their ability to protect themselves from oxidative 
stress and mitochondrial dysfunction (Pallas et al., 2008). SIRT1 deacetylates and activates 
PGC-1α and maintains mitochondrial homeostasis and elevates antioxidant defences against 
MPTP and protects DA neurones from the toxicity induced by MPTP (Mudo et al., 2012).  
SIRT2, on the other hand, has been reported to promote neuronal death. Inhibition of SIRT2 
decreases α-synuclein-mediated toxicity. Sirtuin inhibitors (AGK2 and sirtinol) or genetic 
inhibition of SIRT2 increases the size of α-synuclein aggregates in cellular model of PD 
leading to inhibition of interaction of aggregates with other proteins (Outeiro et al., 2007). 
As with SIRT1, SIRT3 has been shown to promote neuronal survival. In SIRT3 null mice, 
MPTP treatment enhanced DA neurones degeneration. These mice on exposure to MPTP 
showed remarkably reduced expression of SOD2 and glutathione peroxidase, resulting in high 
ROS levels and eventual cell death (Liu et al., 2015). This finding implies that SIRT3 protects 
DA neurones from MPTP toxicity by preserving antioxidant defence mechanisms.  
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1.5 Research structure 
The research presented in this study aims to evaluate the role of SIRT1, SIRT2 and SIRT3 in 
oxidative stress mediated cell death and also the possible mechanism behind their actions. The 
study also intends to assess the expression of SIRTs in the post-mortem brain of patients with 
PD, PDD, DLB and AD. In this research study, the following hypotheses will be tested. 
1. SIRT1 protects cells from oxidative stress and is a pro-survival protein that protects 
neurones from stress induced degeneration (Chapter 3). 
2. SIRT2 enhances cell death under oxidative stress and acts as a pro-apoptotic protein 
that enhances degeneration of neurones (Chapter 4). 
3. SIRT3 acts as a stress induced protein that enhances antioxidant defence mechanisms 
and reduces oxidative stress mediated cell death (Chapter5).  
 
1.5.1 Aims 
 To assess the effects of SIRTs and their deacetylase activity on the cytotoxicity 
induced by diquat or rotenone.  
 To evaluate the mechanism behind the actions of SIRTs on oxidative stress induced by 
diquat or rotenone. 
 To determine if SIRTs play a role in α-synuclein aggregate formation and also to 
assess any possible interaction between SIRTs and α-synuclein. 
 To measure the expression of SIRTs in post-mortem brain tissue of PD, PDD, DLB 
and AD patients and determine if the levels of  SIRTs are altered in these disorders 
with a view to them having a role in the disease states. 
 To assess the enzymatic activity of SIRTs and their cellular localisation in post-
mortem brain tissue of PD, PDD, DLB and AD patients. 
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Chapter 2 
Materials and Methods 
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Chapter 2 Materials and methods 
2.1 Post-mortem human brain tissue of patients with PD, DLB, PDD and 
AD 
The brain samples used in this study were obtained from Newcastle Brain Tissue Resource, a 
Human Tissue Authority licensed tissue bank, at the Institute for Ageing and Health, 
Newcastle upon Tyne. All aspects of the study were approved by the National Research 
Ethics Service. 
Tissue was obtained at post-mortem as soon as possible after death. The brain was hemisected 
and coronal slabs of tissue, approximately 1cm thick, from the left hemisphere were sealed in 
plastic bags and frozen at -120
o
C and stored at -80
o
C. The right hemisphere was fixed in 
neutral formalin for at least 4 weeks and then regionally sampled and embedded in paraffin 
wax prior to neuropathological assessment. Cases were confirmed as having the 
neuropathological diagnosis of their clinical disorder according to established criteria. 
Frozen tissue of the relevant region was brought to -20
o
C and samples removed according to 
Brodmann areas. 
 
2.1.1 Analysis of Sirtuin levels 
2.1.1.1 Protein extraction 
Protein homogenates of post-mortem brain tissue from PD, DLB, PDD, AD and controls as 
shown in Table 2.1 were prepared by homogenising approximately 250 mg of freshly thawed 
grey matter in 2.5ml of 0.2M triethylammonium bicarbonate (TEAB) containing 1X protease 
inhibitor cocktail (Roche, UK). After the addition of 10µl of 10% SDS to an aliquot of 500µl 
homogenate, samples were vortexed and then sonicated using a sonic probe for 15 secs, 
followed by sonication on ice in a sonic bath for 40 mins. The concentration of protein was 
determined by Bradford assay. 
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Groups FCX TCX Cb Pu Hp Age 
(years) 
pH PMD 
(hours) 
Gender 
M 
(%) 
F 
(%) 
Control 11 12 12 12 8 77.5 ±  
6.98 
6.17 ± 
0.34 
19.9 ±  
6.42 
53.3 46.7 
PD 12 12 12 12 - 77.44 ± 
7.03 
5.85 ± 
0.06 
23.44 ± 
9.72 
66.7 33.3 
PDD 8 9 12 8 - 75.93 ± 
5.38 
6.19 ± 
0.32 
24.69 ± 
11.38 
71.4 28.6 
DLB 12 12 12 12 6 77.00 ± 
5.35 
6.32 ± 
0.29 
18.0 ± 
8.58 
77.8 22.2 
AD 12 12 12 - 9 80.37 ± 
5.25 
6.19 ± 
0.33 
19.84 ± 
9.30 
47.4 52.6 
 
Table 2.1 Details of brain samples used for Western blot. The table summarises the case 
details of brain samples used in Western blot analysis. FCX: Frontal cortex; TCX: Temporal Cortex; 
Cb: Cerebellum; Pu: Putamen; Hp: Hippocampus; PMD: Post-mortem delay; M: Male: F: Female 
 
2.1.1.2 Protein extraction from the Cerebellum  
An aliquot of 100µl each from homogenised cerebellar samples (Control, PD, DLB, PDD and 
AD; 12 each) were taken and to these were added 2µl 10% SDS and 4µl Benzonase nuclease 
(Merck Millipore, UK; 1U/µl). The samples were incubated at room temperature for half an 
hour and were then subjected to sonication using a sonic probe for 15 seconds and then 
sonicated on ice for 40 minutes prior to protein determination using Bradford assay. 
 
2.1.1.3 Protein quantification by Bradford assay 
A protein standard curve of bovine serum albumin (1mg, 500µg, 250µg, 125µg, 62.5µg, 
31.25µg, 15.625µg and blank; BSA; Sigma-Aldrich, UK) was prepared in diluted 
homogenising buffer (1:4 in MilliQ water). Sonicated samples were diluted in ddH2O in 1:20 
ratio. The BSA standards were added as triplicates to a 96-well plate along with triplicate 
brain samples. Bradford reagent (Sigma-Aldrich, UK) was added to each well and left to 
incubate for 15 minutes at room temperature (modified from (Bradford, 1976)). Absorbance 
was measured at 595nm in a plate reader (BioTek, UK) and protein concentration was 
calculated by linear regression from the BSA standard curve. 
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2.1.1.4 Western blotting 
Ten micrograms of protein in brain samples containing NuPAGE Sample Reducing Agent 
(one-tenth of total volume; Invitrogen, UK) and NuPAGE LDS Sample Buffer (one- fourth of 
total volume; Invitrogen, UK) were heated to 70
o
C for 10 minutes on a heated block followed 
by brief spinning and were then loaded into wells of NuPAGE 4-12% Bis-Tris Gel 
(Invitrogen) along with SeaBlue (Invitrogen) and biotinylated protein molecular weight 
marker (New England Biolabs). The gel was electrophoresed in NuPAGE MOPS SDS 
running buffer containing antioxidant (Invitrogen) at 120V for 20 minutes and then at 160V 
for an hour. The proteins were then transferred to nitrocellulose membrane using iBlot Gel 
Transfer Stacks (Invitrogen) at 20V for 10 minutes in an iBlot device (Invitrogen). 
Membranes were blocked in 5% non-fat dry milk (Marvel) in 1X Tris buffer saline (TBS) 
with 0.2% Tween (Sigma-Aldrich) (TBS-T) for 1 hour to block non- specific antibody 
binding. Blocked membranes were then incubated with primary antibodies (Table 2.2) in 5% 
Marvel in TBS-T overnight at 4
o
C. The following day the membranes were washed twice 
with TBS-T (2x 5mins) and then incubated with appropriate horseradish peroxidase (HRP) - 
conjugated secondary antibodies (Table 2.2) for 30 minutes at room temperature. Membranes 
were then washed in TBS-T for approximately 1 hour at room temperature. The membranes 
were incubated with ECL2 Western blotting substrate (Thermo Scientific, UK) for two 
minutes and exposed to Super RX Medical X-ray Film (FujiFilm, UK) to detect chemi-
luminescent signal in a dark room using Kodak Processing for Audioradiography Films 
Solution (P7042) and Kodak GBX Fixer and Replenisher (P7167) (both Sigma-Aldrich) at 
various time points to optimise resolution. The blots were scanned and band intensities were 
analysed using ImageJ software (NIH, USA).  
GAPDH was used to normalise the results and the ratios of mean protein of interest/GAPDH 
were calculated for all samples. Protein levels were analysed by comparing each group with 
control and the change in protein level was evaluated. The primary and secondary antibodies 
used in the study are listed in Table 2.2.  
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 Dilution Incubation Supplier Secondary 
antibody 
Primary Antibodies 
SIRT1 1:4,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
SIRT2 1:5,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
SIRT3 1:5,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
GAPDH-HRP 1:4,000 1 hour at 
RT 
SantaCruz 
Biotechnology 
- 
Acetylated p53 
(K382) 
1:20 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
p53 1:50 ON at 4
o
C Abcam Mouse IgG-HRP 
Acetylated α-
tubulin (K40) 
1:500,000 ON at 4
o
C Abcam Mouse IgG-HRP 
α-tubulin 1:500,000 ON at 4oC Abcam Rabbit IgG-HRP 
Acetylated H3 
(K9) 
1:5,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
Histone H3 1:10,000 ON at 4
o
C Abcam Mouse IgG-HRP 
Secondary Antibodies 
Rabbit 
VeriBlot 
1:2,000 30 minutes 
at RT 
Abcam - 
Mouse 
VeriBlot 
1:2,000 30 minutes 
at RT 
Abcam - 
Anti-biotin 
IgG 
1:4,000 30 minutes 
at RT 
Cell Signaling - 
 Table 2.2 Details of antibodies used in Western blot analysis of proteins in brain 
samples.  ON- Over night; RT- Room temperature 
 
Nitrocellulose membranes in some cases were re-probed for additional proteins or for non-
acetylated proteins. After the initial antibody probe, membranes were washed with TBS-T 
three times for five minutes (3X5 mins) at room temperature. Antibodies were then stripped 
off the membranes by incubating the membrane in stripping buffer (60mM Tris pH 6.8, 0.2% 
SDS and β-mercaptoethanol (6µl/ml prior to use)) at 50oC for an hour on a shaker. The 
membranes were then washed three times with TBS-T for five minutes (3X5 mins) followed 
by blocking and probing as before. 
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2.1.2 Determination of Sirtuins localisation  
2.1.2.1 Sample preparation and immunohistochemistry 
The right hemisphere of the brain was fixed in 10% formalin at the time of autopsy. 
Following fixation, the hemisphere was cut into 7mm coronal sections and paraffin 
embedded. For immunohistochemistry, 10µm coronal sections were sampled from the frontal 
cortex, temporal cortex and cerebellum. They were stained with SIRT1, SIRT2, and SIRT3 
for the analysis of SIRT expression using the Menarini X-Cell-Plus HRP Detection Kit 
(Menarini, Berkshire, UK) and general nuclei by haematoxylin staining using the following 
protocol. 
 Dewaxing: Heated the section at 60oC for 10 minutes followed by 2x10 minutes 
washes in xylene (Fisher Scientific) 
 Rehydration: decreasing ethanol solutions (2 x 100%, 95%, 70%, 50% and 0% ethanol 
in ddH2O). 
 Antigen retrieval: Boiled the sections in heated citrate buffer (pH 6) in microwave at 
high power heat for 10 mins before allowing to cool for 20 minutes and then 
immediately washed in running tap water. 
 Quenching: in 30% H2O2 in tap water for 20 minutes followed by 3x3 minutes washes 
in TBS-T. 
 Primary antibody: Rabbit monoclonal antibody to SIRT1, SIRT2, SIRT3 dissolved 
(Table 2.3) in TBS-T were applied on the sections for an hour at room temperature 
followed by 3x3 minutes washes  in TBS-T. 
 Universal probe: Yellow reagent was added to the sections for 30 minutes at room 
temperature followed by 3x3 minute washes in TBS-T. 
 HRP- Polymer reagent: Orange reagent was added to the sections for 30 minutes 
followed by 3x3 minutes washes in TBS-T. 
 Detection: DAB reagent (1 drop of ready mix DAB solution in 1ml DAB buffer) was 
pipetted over the sections for 3-4 minutes followed by washing in running tap water 
for 10 minutes. 
 Haematoxylin counterstaining: Sections were counterstained with haematoxylin for 
less than a minute followed by washing in running tap water. Sections were then 
dipped in acid alcohol, washed in water and dipped in ammonia water followed by 
washing in water. 
 Coverslip: Sections were dehydrated by taking them through graded alcohols to 
xylene with 1 minute in 95% ethanol and 2 minutes in 100% ethanol, and then 2 
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minute washes in xylene, before coverslips were mounted with DPX (Fisher 
Scientific). 
Primary 
antibodies 
Dilution Incubation Supplier 
SIRT1 1:20 1 hour at RT SantaCruz Biotechnology 
SIRT2 1:200 1 hour at RT SantaCruz Biotechnology 
SIRT3 1:50 1 hour at RT SantaCruz Biotechnology 
Table 2.3 Details of antibodies used in IHC. RT- Room temperature 
 
2.1.2.2 Semi-qualitative analysis of sections 
Images of the sections were acquired in sampled sections using a Zeiss Axioplan 2 
microscope (Zeiss, Oberkochen, Germany) with 10X and 63X magnifying objective and 3-
chip CCD true colour camera (JVC, Yokohama, Japan) coupled to a PC. 
 
2.1.3 Evaluation of Sirtuin activity 
2.1.3.1 Protein extraction 
Protein homogenates of post-mortem brain tissue from PD, DLB, PDD, AD and controls were 
prepared by homogenising approximately 250 mg of grey matter in 2.5ml of 0.2M TEAB. 
Samples were vortexed and then sonicated for 15 seconds with the sonicator probe followed 
by sonication on ice in a sonicating bath for 40 minutes. Samples were spun down at 100g at 
4
o
C for 5 minutes and the supernatant was collected for further assessment. The concentration 
of proteins in supernatant was determined by Bradford assay (2.1.1). 
 
2.1.3.2 Samples and buffer preparation 
 SIRT Assay Buffer (Stock ): Five millilitres of 500mM Tris-HCl, pH 8.0, containing 
1.37M sodium chloride, 27mM KCl, and 10mM MgCl2. Diluted 1.5ml of stock in 
13.5ml ddH2O. Final concentration 50mM Tris-HCl, pH 8.0, containing 137mM 
sodium chloride, 2.7mM KCl, and  1mM MgCl2 and was used in the assay and for 
diluting the reagents. 
 NAD+ Solution: Fifty millimolar solution of NAD+ was prepared in ddH2O (49.75mg 
in 1.5ml) 
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 Nicotinamide (NAM) Solution: Fifty millimolar solution of NAM was prepared in 
ddH2O (6.106mg in 1ml). 
 Peptide: Fluorescent SIRT substrate p53 (379-382) Ac-RHKK(Ac)-AMC was 
synthesised by Cambridge Research Biolabs, UK. The stock was prepared as a 5mM 
solution in diluted SIRT Assay buffer i.e., 5.4mg in 1.37ml of SIRT assay buffer and 
was stored at -70°C.  
 Inhibitors: TSA (HDAC inhibitor) 10µM (0.1mM stock diluted in assay buffer), 
EX527 (SIRT1 inhibitor) 100µM (1mM stock diluted in assay buffer), AGK2 (SIRT2 
inhibitor) 200µM (2mM stock diluted in assay buffer) and sirtinol 2mM (20mM stock 
diluted in assay buffer). 
 
2.1.3.3 SIRT fluorometric activity assay 
 
Figure 2.1 Outline of the SIRT activity assay 
 78 
The flow chart as shown in Figure 2.1 shows the stepped protocol that was followed to 
perform the SIRT activity assay. 
 Substrate preparation: To 100µl of peptide 240µl of NAD+ and 850µl of diluted 
assay buffer were added. Ten microlitres per well of substrate solution was used to 
give a final concentration of 41.6µM peptide and 1mM NAD
+
. 
 Background wells: Seventy microlitres of assay buffer and 20µl of solvent (DMSO in 
assay buffer) were added to three wells of a 96 well plate. 
 Total SIRT Activity: Thirty micrograms of brain sample, 10µl of solvent, 10µl TSA 
(at a final concentration of 100nM) were added and the total volume was made up to 
90µl using assay buffer in three wells. 
 Inhibitor wells: Thirty micrograms of brain sample, 10µl TSA (at a final 
concentration of 100nM) and 10µl of inhibitors were added and the total volume was 
made up to 90µl using assay buffer in three wells. 
 The reaction was initiated by addition of 10µl of substrate solution to all the wells in 
use. 
 The plate was covered and incubated on a shaker for 2 hours at room temperature. 
 After 2 hours 2.5μg/ml trypsin in 50mM nicotinamide was added to stop further 
deacetylation and to also cleave the deacetylated product. 
 The fluorescence was recorded for each well after one hour of incubation of the 
trypsin-NAM solution in the plate reader on excitation wavelength of 350-360nm and 
emission wavelength of 450-460nm. 
RFU/mg= (Total SIRT activity- sample)/0.03 
 Final concentration  
per well 
Substrate 41.6µM 
NAD
+
 1mM 
TSA 100nM 
EX527 10µM 
AGK2 20µM 
Sirtinol 200µM 
Table 2.4 Summary of concentration of substrate, NAD
+
 and inhibitors in well in SIRT 
activity assay 
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2.2 Cloning and plasmid constructs 
2.2.1 RNA extraction 
Fifty milligrams of brain sample (frontal cortex) was directly homogenised in 1ml TRI-
Reagent (Ribopure kit, Ambion, UK) and the RNA was extracted following the supplier’s 
instruction. One hundred microlitres of bromochloropropane (BCP) was added to 1ml of 
homogenate, vortexed at full speed for 15 seconds and then incubated at the room temperature 
for 5 minutes. The mix was then centrifuged at 12,000g for 10 minutes at 4°C to promote the 
formation of the aqueous phase, interphase and organic phase. RNA partitions into the 
aqueous phase while DNA and proteins are in the interphase and organic phase. Two hundred 
microlitres of 100% ethanol was added to 400µl of the aqueous phase in a fresh tube and the 
mix was immediately vortexed at full speed for 5 seconds to avoid RNA precipitation.  The 
sample was transferred to a filter cartridge collection tube and was centrifuged at 12,000g for 
30 seconds at room temperature; at this stage the RNA was bound to the filter in the filter 
cartridge. The flow-through was discarded and the cartridge was washed with wash solution 
(wash solution concentrate and 48ml 100% ethanol) and spun at 12,000g for 30 seconds 
following which the flow-through was discarded and the cartridge was washed again. To 
remove any residual wash solution the filter cartridge collection tube was spun at 12,000g for 
30 seconds. The filter cartridge was transferred to a fresh RNAse free Eppendorf tube and 
100μl of RNAse free water was applied directly to the membrane to elute the RNA. This was 
left to stand for 2 minutes and then centrifuged for 1 minute at 12,000g to elute the RNA.  
 
2.2.2 RNA quantification 
RNA was quantified by measuring its absorbance at 260nm using a NanoDrop 2000 
spectrophotometer (Thermo Scientific) using RNAse free water as blank. The quality of the 
sample was determined by calculating Optical Density (OD)260/OD280 ratio. Values within the 
range of 1.8-2.1 were considered apt for pure nucleic acid samples, lower ratios suggest 
protein contamination. 
 
2.2.3 Reverse transcription (RT) of RNA 
Reverse transcription was carried out according to supplier’s guidelines using SuperScript III 
Reverse Transcriptase (Invitrogen), an engineered version of Moloney Murine Leukemia 
Virus Reverse Transcriptase with reduced RNase H activity and increased thermal stability. 
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One microgram of RNA was transferred to 0.5ml sterile thin walled microcentrifuge tube then 
1µl of Oligo dT-T7 (Invitrogen) was added to the tube along with 1µl SuperRNAsin (RNase 
inhibitor; Ambion, UK). The reaction was flicked to mix and briefly spun down then 
incubated at 70
o
C for 10mins followed by 4
o
C for 2mins in a thermal cycler with the heated 
lid on. Heating the reaction mix at 70
o
C ensured the denaturation of any secondary structures 
in the RNA that could interfere with reverse transcription and cooling down the mix to 4
o
C 
allowed the annealing of oligo dT-T7 to the RNA. 
After first strand synthesis, the reaction tube was placed on the ice then centrifuged briefly 
and the remaining RT components (Table 2.5) were added to the mix. 
 
Components Amount 
First strand buffer (Invitrogen) 2µl 
10mM dNTP mix (Invitrogen) 1µl 
SuperRNAsin (Ambion) 1µl 
SuperScript III Reverse Transcriptase 
(Invitrogen) 
2µl 
Table 2.5 RT PCR reaction mix 
 
Reaction was flicked to mix and spun down and then incubated at 50
o
C in a thermal cycler for 
120 minutes with the heated lid on. cDNA from the reaction mix was used as the template for 
SIRT PCR. 
 
2.2.4 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) is a technique developed by Kari Mullis in 1980s that 
relies on thermal cycling and thermostable DNA polymerases to rapidly and selectively 
amplify target DNA segments (Mullis and Faloona, 1987). PCR uses thermal cycling through 
a defined series of temperature steps. The first step is denaturation where at a temperature of 
approximately 95
o
C, the double stranded DNA melts and gets separated and then in the 
second step, the short 5’-3’ oligonucleotides (forward and reverse primers) anneal to 
complementary target sequence at lower temperature (~50-65
o
C). In the third and final step, 
the thermostable DNA polymerase binds and extends the strand 5’-3’ (Figure 2.2). Repeating 
the steps leads to exponential amplification of target DNA sequence.  
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Figure 2.2 The basic events of Polymerase chain reaction (PCR).  
 
Q5® High-Fidelity DNA polymerase (New England Biolabs, UK), a high fidelity 
thermostable DNA polymerase with 3’5’ exonuclease activity was used for the PCR for 
cloning work. The PCR reaction mix (Table 2.6) was assembled on ice as follows: 
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Table 2.6 PCR reaction mix 
 
The samples were mixed gently, spun briefly and then quickly transferred into the preheated 
thermal cycler (98
o
C). The PCR was carried out using the following programme: 
Initial denaturation-  98
o
C    30 seconds 
Number of cycles  40 
Denaturation   98
o
C    10 seconds 
Annealing   X (primer dependent)  30 seconds 
Extension   72
o
C    1 minute 
Final extension  72
o
C    5 minutes 
Annealing temperature was optimised for individual primers. The PCR products were stored 
at 4
o
C. 
 
2.2.5 Fusion Polymerase chain reaction 
Fusion PCR was carried out to amplify SIRTs with few insertions in forward primer namely 
BamHI and Kozak sequence and SalI in reverse primer. Two halves of the sequence were 
amplified in separate tubes then fused in a third reaction (Figure 2.3). The primers were so 
designed such that few base pairs overlapped between primers B and C. Amplifications were 
performed in two separate tubes, A+B and C+D, respectively, using Q5 HF polymerase. The 
PCR products were analysed by agarose gel electrophoresis (Section 2.2.6) and correct size 
bands were excised and extracted using QIAGEN gel extraction kit (Section 2.2.7). Equal 
amount of purified PCR products were used for the fusion PCR and the reaction mixture was 
Components Amount (µl) 
Nuclease free water (dH2O) 20 
5XQ5Reaction Buffer 10.0 
dNTPs mix (25mM) 0.5 
DNA template (50-100ng) 5.0 
Forward Primer (300ng/µl) 2.0 
Reverse Primer (300ng/µl) 2.0 
Q5 HF DNA polymerase (0.02 U/µl) 0.5 
5XQ5 High GC Enhancer 10.0 
Total reaction volume 50 
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assembled on ice as mentioned in Section 2.2.4 and the primers used were forward primer 
from PCR1 and reverse primer form PCR2. After the amplification, the PCR products were 
analysed on 1% agarose gel.  
 
 
Figure 2.3 Illustration of Fusion PCR. The PCR was carried out in two steps- first the two 
halves (A+B; C+D) were amplified in separate reactions and were purified on agarose gel. The 
purified amplicons were fused in the next reaction with primers A and D and complete sequence was 
produced. 
 
2.2.6 Agarose gel electrophoresis 
The PCR products were visualised on agarose gel electrophoresis where DNA was separated 
based upon the size under the electric field. PCR samples were routinely separated on 1% 
agarose gel with 5µg/ml ethidium bromide (EtBr; Invitrogen, UK) dissolved in 1X TAE (tris-
acetate-EDTA) buffer. One gram of agarose (Invitrogen, UK) was dissolved in 100ml TAE 
buffer on a hot plate until clear and then left to cool. Once the gel was cool enough to hold, 
EtBr was added and the gel was then cast in a casting stand with a comb to form wells. The 
samples were mixed with 6X Gel loading dye (New England Biolabs, UK). Ten microlitres of 
prepared samples were loaded into the wells alongside the DNA marker and separated under 
the electric field at 80V for an hour. Once the samples were resolved, they were visualised in 
a GBOX transilluminator (Syngene, UK) under the UV lamp and the image was captured 
using the Nikon camera connected to a PC. 
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2.2.7 DNA extraction from agarose gel 
The amplified samples were separated on agarose gel then visualised under the UV lamp and 
the bands of interest were excised using a sterile scalpel blade and were transferred to 
nuclease free tubes and weighed. The DNA was extracted using QIAquick Gel Extraction Kit 
(QIAGEN, UK) following the manufacturer’s instructions. The excised gel was suspended in 
3 gel volumes of QG buffer and was then heated to 50
o
C for 10 minutes with regular 
vortexing every 2-3 minutes. One volume of isopropanol was added to the gel and mixed. The 
solution was transferred to a QIAquick spin column and centrifuged for 1 minute to bind the 
DNA to the filter of the column and the flow-through was discarded. The column was washed 
with 750µl buffer PE at 13,000rpm for a minute and the wash was repeated as before. To 
remove the residual wash buffer the column was centrifuged at 13,000rpm for a minute. To 
elute the DNA, the column was placed on a fresh nuclease free tube and 30µl of nuclease free 
water was added to the middle of the membrane. The column was left to stand for one minute 
and was then centrifuged at maximum speed for one minute. The eluted DNA was quantified 
using a NanoDrop as described in section 2.2.2. 
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2.2.8 Vectors used in cloning 
2.2.8.1 pCR2.1 
 
Figure 2.4 Map and features of pCR2.1 vector. *Taken from Addgene’s website. 
 
pCR2.1 (Invitrogen) is a vector used in TOPO cloning that facilitates the ligation of PCR 
product without any use of a DNA ligase (Figure 2.4). The vector is linearized with 
topoisomearse I covalently attached to vector and has single 3’-thymidine (T) overhangs. The 
adenine (A) overhangs were attached to the PCR product before the separation on agarose gel 
by carrying out extension at 70
o
C for 10 minutes using Taq polymerase.  
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2.2.8.2 pcDNA3.1 (+) 
pcDNA3.1 (Invitrogen) is a vector that is designed for high-level stable and transient 
expression in various mammalian cell lines. The vector has cytomegalovirus (CMV) 
enhancer- promoter that promotes high levels of expression (Figure 2.5). 
 
 
Figure 2.5 Features of pcDNA3.1 vector*Taken from Addgene’s website. 
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2.2.8.3 pLenti CMV Blast empty (w263-1) 
pLenti CMV blast empty ((Plasmid #17486, deposited by Eric Campeau; Addgene) is a third 
generation lentiviral empty destination vector designed for constitutive expression in various 
mammalian cell lines (Figure 2.6) (Campeau et al., 2009).  
 
Figure 2.6 Features of pLenti CMV blast empty vector. *Taken from Addgene’s website. 
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2.2.9 Ligation into pcR2.1 Topo vector 
The target DNA sequence was amplified and modified by adding poly A overhangs at 3’ end 
as mentioned in section 2.2.8. DNA was mixed with vector in 1:1 ratio (1µl DNA/1µl vector). 
One microlitre of salt solution (1.2M NaCl and 0.06MgCl2) was added to the mix followed by 
nuclease free water to a final volume of 6µl (TOPO cloning mix). The reaction was flicked 
gently and was incubated at the room temperature for 30 minutes. 
 
2.2.10 Transformation of chemically competent E. coli cells 
The TOPO cloning mix was centrifuged briefly and was incubated on ice prior to 
transformation of TOP10 E.coli cells. One vial of frozen TOP10 cells for each ligation was 
thawed on ice and 2µl of TOPO cloning mix was added to the vial and mixed gently by 
tapping. The cell vial was incubated on ice for 30 minutes followed by heat shock treatment in 
a water bath, equilibrated at 42
o
C, for 30 seconds without shaking. The cells were then placed 
on ice and 250µl of pre-warmed SOC medium (2% Tryptone, 0.5% Yeast Extract ,10mM 
NaCl, 2.5mM KCl ,10mM MgCl2 ,10mM MgSO4 and 20mM glucose) was added to each tube. 
The tubes were then placed in an incubator at 37
o
C, shaking horizontally at 220rpm. The 
transformed cells were spread onto two LB agar plates, each containing 50µg/ml kanamycin 
and 40mg/ml X- Gal; one plate was spread with 50µl of cells while the other with 200µl cells. 
The cells were spread on to the plates till the medium was absorbed and were then inverted 
and incubated overnight at 37
o
C. 
 
2.2.11 Plasmid DNA extraction using Miniprep kit 
White colonies on agar plates were picked and grown in 5ml LB broth containing kanamycin 
overnight at 37
o
C at 200rpm. The plasmid DNA was isolated using QIAprep Spin miniprep 
kit (QIAGEN) according to the manufacturer’s instructions. The cells were centrifuged at 
4000rpm at 4
o
C for 15 minutes. The supernatant was discarded and pellet was re-suspended in 
250µl buffer P1 (containing RNase) following which 250µl of buffer P2 was added then 
mixed thoroughly to produce a clear solution. Three hundred and fifty microliters of buffer 
N3 was added and thoroughly mixed. The suspension was centrifuged at 13,000rpm for 10 
minutes and the supernatant was transferred to QIAspin column then centrifuged at 
13,000rpm for one minute. The flow-through was discarded and 500µl of PB buffer was 
added and then centrifuged as previously. The column was washed with 750µl buffer PE 
which was centrifuged as previously. The flow-through was discarded and the column was 
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centrifuged again to remove any PE residue. The column was transferred to clean nuclease 
free tube and 50µl of nuclease free water was added to the centre of the column. The column 
was left to stand for one minute then centrifuged at 13,000rpm for one minute. The eluted 
plasmid DNA was quantified as in section 2.2.2.  
 
2.2.12 Restriction digestion of plasmid DNA 
The extracted plasmids were screened by digestion with restriction enzymes. The restriction 
digestion was usually performed in 20µl reaction volume following the manufacturer’s (New 
England Biolabs) guidelines. The reaction contained 1X buffer, up to 1µg plasmid DNA, 
0.5µl restriction enzyme and nuclease free water up to 20µl. The reaction was incubated for 1-
3 hours at 37
o
C. The samples were then mixed with 6X DNA loading buffer and ran on 
agarose gels as described in section 2.2.6. 
 
2.2.13 DNA sequencing 
The extracted plasmid DNA samples were sent to Genevision, Geneius (Newcastle upon Tyne, 
UK) and were sequenced using M13 for-21 and M13 rev-24 primers. The plasmid sequences 
were aligned with the coding sequence on Clustal Omega (EMBL-EBI; 
http://www.ebi.ac.uk/Tools/msa/clustalo/) to ascertain the insert of the plasmids. 
 
2.2.14 Glycerol stock of transformed E. coli cells 
A single colony of transformed cells with correct sequence was picked and grown in 1ml of 
LB broth overnight at 37
o
C. Sixty per cent by volume of sterile glycerol was added to 
cultured cells and the content was mixed thoroughly and transferred to a cryovial and stored at 
-80
o
C for long term.  
The sequenced plasmids were used as template for the fusion PCR (section 2.2.5). The 
complete sequence was cloned into pcR2.1 and the TOP10 cells were transformed as 
mentioned in sections 2.2.9 and 2.2.10. The white colonies were screened and the plasmid 
DNA was extracted, screened and sent for sequencing as described in sections 2.2.11-13. 
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2.2.15 Ligation of plasmid DNA into pcDNA 3.1 
The plasmids obtained from pcR2.1 TOPO cloning and pcDNA 3.1(+) were digested with 
BamHI-XbaI (New England Biolabs). The digested plasmids and vector were separated in 1% 
agarose gel and the bands of interest were excised followed by DNA extraction using 
QIAquick Gel Extraction Kit (QIAGEN) as described in section 2.2.7. The vector was treated 
with Antarctic phosphatase (New England Biolabs) at 37
o
C for 30 minutes to remove the 
5´ phosphate from DNA in order to prevent self-ligation, the enzyme was heat inactivated at 
80
o
C for 2 minutes.  
The ligation reaction was set on ice and was carried out with T4 DNA ligase (New England 
Biolabs) as follow 
Components Volume (µl) 
Digested plasmid 6.5 
Digested vector  0.5 
5X T4 DNA Ligase Reaction Buffer 2.0 
T4 DNA Ligase (5 units) 1.0 
Total volume 10 
Table 2.7 Reaction set up for the ligation with T4 DNA ligase. The reaction is set up for a 
ligation using a molar ratio of 3:1 between insert and vector. 
 
The contents were mixed gently and were incubated at 16
o
C overnight. The ligation was 
usually carried out in two different molar ratios usually 3:1 and 5:1 and the amount of insert 
to be used was calculated using the following formula 
Amount of insert (ng) = (amount of vector X kb size of insert/kb size of vector) x molar ratio 
of insert: vector. 
Two microlitres of ligation reaction was used to transform TOP10 E.coli cells and the 
transformation was carried out as described in section 2.2.10. The transformed cells were 
spread on LB agar plate containing ampicillin 100µg/ml. 
 
2.2.16 Plasmid DNA extraction using Maxiprep kit 
A HiSpeed Plasmid Maxi Kit (QIAGEN, UK) was used to extract larger quantities of DNA. 
Five hundred millilitres of an overnight culture was transferred to 50ml tubes and the pellets 
were collected at 4000rpm at 4
o
C for 20 minutes. The pellets were re-suspended in 10ml 
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buffer P1 (containing RNase) and was mixed thoroughly until the cells were dissolved. Ten 
millilitres of Buffer P2 was added, mixed thoroughly by inverting tubes and left to stand for 5 
minutes at room temperature following which 10ml chilled buffer P3 was added and mixed by 
inversion. The lysate was poured into QIAfilter cartridge and incubated at room temperature 
for 10 minutes. The lysate was then filtered into a pre-calibrated HiSpeed tip. The lysate was 
run through the tip and subsequently washed twice with QC buffer and the flow-through was 
discarded. The plasmid DNA was eluted with 15ml QF buffer to which 10.5ml of isopropanol 
was added. The sample was mixed and incubated at the room temperature for 5 minutes. The 
sample was poured into a 30ml syringe fitted with QIAprecipitator, and then the plunger was 
inserted and the sample was filtered by applying constant pressure. The precipitator was 
removed and the plunger was pulled out. The precipitator was re-attached and 2ml of 70% 
ethanol was added to the syringe. The DNA was washed by inserting the plunger and the 
ethanol was pressed out through the precipitator. The precipitator was removed and the 
plunger was pulled out. The precipitator was re-attached to the syringe and plunger was 
inserted again and the membrane was dried by pressing air through the precipitator. This step 
was repeated several times. The nozzle of precipitator was dried out and the DNA was eluted 
in nuclease free tube with 750µl of nuclease free water. Eluted DNA was quantified as in 
section 2.2.2 and was then sequenced (Section 2.2.13). Glycerol stocks of transformed cells 
were prepared and the cells were stored at -80
o
C (Section 2.2.14). 
 
2.2.17 SIRTs Plasmids from Addgene 
SIRT1 plasmid Flag-SIRT (Plasmid #1791, deposited by Michael Greenberg) (Brunet et al., 
2004), SIRT1-H363Y (Plasmid #1792, deposited by Michael Greenberg) (Brunet et al., 2004), 
SIRT2-Flag (Plasmid #13813, deposited by Eric Verdin) (North et al., 2003), SIRT3 (Plasmid 
#24924, deposited by Toren Finkel) and SIRT3-H248Y (Plasmid #24917, deposited by Toren 
Finkel) (Ahn et al., 2008) were ordered from Addgene and were cloned into pLenti CMV 
blast (For details please refer Section 2.2.15). 
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2.2.17.1 SIRT1 Wild Type/Mutant (H363Y) 
 
Figure 2.7 SIRT1 (WT/Mutant) insert in vector pECE. SIRT1pECE is a mammalian 
expression plasmid of SIRT1WT or mutant. Plasmid number 1791 deposited by Michael Greenberg 
lab.   *Taken from Addgene’s website. 
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2.2.17.2 SIRT2 Wild type 
 
 
Figure 2.8 SIRT2 insert in vector pcDNA3.1(+). SIRT2Flag is a mammalian expression 
plasmid of SIRT2WT with Flag tag. Plasmid number 13813 deposited by Eric Verdin lab. *Adapted 
from Addgene’s website. 
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2.2.17.3 SIRT3 Wild type 
 
Figure 2.9 SIRT3 (WT) in vector pCDNA4-myc-hisA vector. pCDNA4-Myc-HisA- -SIRT3 
is a mammalian expression plasmid of SIRT3WT. Plasmid number 24924 deposited by Toren Finkel 
lab.    
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2.2.17.4 SIRT3 Mutant (H248Y) 
 
Figure 2.10 SIRT3 H248Y insert in pCDNA4-myc-hisA vector. pCDNA4-Myc-HisA-
H248Y-SIRT3 is a mammalian expression plasmid of SIRT3 mutant. Plasmid number 24917 
deposited by Toren Finkel lab.    
 
2.2.18 Ligation of plasmid DNA into pLenti CMV blast 
The SIRTs plasmids obtained from Addgene and pLenti CMV blast were digested with 
BamHI-XbaI and the ligation of the plasmids into pLenti CMV blast was carried out as 
mentioned in section 2.2.15. Plasmid DNA was extracted from the transformed cells using 
HiSpeed Plasmid Maxi Kit (QIAGEN, UK; 2.2.16). Eluted DNA was quantified (2.2.2) and 
sent for sequencing (2.2.13) and the glycerol stock of transformed cells was prepared and the 
cells were stored in a 80
o
C freezer (2.2.14). 
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2.2.19 SIRTs’ Viral production 
2.2.19.1 HEK293T cells 
HEK293T cells are a highly transfectable variant of human embryonic kidney (HEK) 293cell 
line that contains the SV40 large T antigen. HEK293T cell line is usually used for the 
production of retroviruses used for viral transduction. 
HEK293T cells were obtained from Dharmacon (GE Healthcare, UK), thawed in a warm 
water bath at 37
o
C and added slowly in pre-warmed 10% growth medium (10% GM) 
containing DMEM (high glucose, sodium pyruvate (110mg/L), no L-glutamine), L-glutamine 
(200mM), 10% foetal bovine serum, 20units/ml penicillin, 100μg/ml streptomycin, 1% MEM 
non-essential amino acids and 5μg/ml fungizone (Invitrogen Ltd. Paisley, UK).  All other 
chemicals were from Sigma-Aldrich Chemical Co. (Dorset, UK). Cells were spun down at 
1000rpm for 5 minutes and the supernatant was removed. Five millilitres of 10% GM was 
added to the cells and they were transferred to a T25 flask and the cells were placed in a 
humidified incubator at 37
o
C with 5% CO2. After 24 hours the older medium was replaced 
with fresh pre-warmed 10% GM. Cells were split in a T75 flask after 2-3 days. 
 
2.2.19.2 Plasmids used for viral constructs 
Lentiviral vectors are derived from human immunodeficiency virus (HIV) and are able to 
mediate effective transduction and long-term gene expression in dividing and non-dividing 
cells. In order to increase the safety of lentiviral vectors, the components necessary for virus 
production are split across plasmids.  
A. Expression/transfer vector 
B. Packaging vector/s 
C. Envelope vector 
A third generation viral system was used to produce the virus, mainly because it is much safer 
than the second generation in a few key ways. First, two packaging plasmids were used 
instead of one- one encoding Gag and Pol and the other Rev. Second, Tat is deleted from the 
third generation expression/transfer vector making the virus safer to use. 
A. pLenti CMV Blast (Plasmid #17486, deposited by Eric Campeau) was used as the 
expression vector (Map and features in 2.2.8) 
B. Two packaging vectors were used, pMDLg/pRRE- encoding Gag, Pol and RRE 
(Plasmid #12251, deposited by Didier Trono; Addgene) and pRSV-Rev encodes Rev 
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under RSV u3 promoter (Plasmid #12253, deposited by Didier Trono; Addgene) 
(Dull et al., 1998). 
C. pMD2.G encoding VSV-G was used as an envelope vector (Plasmid #12259, 
deposited by Didier Trono; Addgene) (Figure 2.11). 
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Figure 2.11 Map of packaging and envelope vectors used for virus production. *Taken 
from Addgene’s website. 
 
 
2.2.19.3 Viral production 
HEK293T cells were used for the viral production (Figure 2.12). The cells were grown until 
70% confluent then split at a 1:3 ratio into a T75 flask. The following day the cells were 
transfected with the lentiviral vectors using PEI (polyethyleneimine, 20µl/ml; Invitrogen) as a 
transfection reagent by following the protocol outlined below. 
 SIRT expression vector: 15µg 
 pMDLg/pRRE (Packaging, Gag/Pol):15µg  
 pRSV-Rev (Packaging, Rev): 6µg  
 pMD2.G (VSV-G envelope): 3µg 
 
 
i. Two and a half millilitres of serum-free DMEM medium was added to a 15ml tube.  
ii. DNA (amount noted above) was added to the medium and mixed by gentle tapping 
and incubated at room temperature for 5 minutes. 
iii. One percent PEI was added to the reaction mix and mixed by vortexing at maximum 
speed for 10 seconds and left to incubate for 20 minutes at room temperature. 
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iv.  The older medium was removed and the cells were replenished with fresh pre-
warmed 10% GM. 
v.  The DNA-PEI mix was added drop by drop into the flask while swirling it gently and 
allowed to grow at 37
o
C overnight with 5% CO2. 
vi.  The medium was changed the following day. 
vii. After 48 hours of transfection, the medium was aspirated into a 15mL conical tube and 
centrifuged for 5 minutes at 3000rpm to pellet the cell debris. The supernatant was 
filtered through a 0.2μm low protein binding filter. The supernatant was aliquoted and 
stored at -80
o
C.  The cells were replenished with fresh 12ml medium (warm) and left 
to grow overnight in the humidified incubator at 37ºC with 5% CO2. 
viii. The medium was aspirated the following day; it was spun down at 3000rpm for 5 
minutes. The supernatant was filtered through a 0.2μm low protein binding filter 
followed by aliquoting the supernatant and storing it at -80
o
C.   
 
 
Figure 2.12 Schematic representation of viral production. 
 
2.2.20 Viral transduction 
2.2.20.1 HEK293 cells 
Human Embryonic Kidney 293 cell or HEK293 cells were derived from human kidney cells 
grown in tissue culture. HEK293 cells can be easily grown and transfected and thus are used 
as base model for any transfection/transduction experiments. 
HEK293 cells were obtained from ATCC (American Type Culture Collection) and were 
revived, grown and maintained as mentioned in Section 2.2.19.  
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2.2.20.2 Viral transduction 
HEK293 cells were grown in 6-well plates at a density of 200,000 cells per well in 2ml of 
10% GM and incubated overnight. The cells were transduced with SIRT virus by diluting the 
viral supernatant in 1ml serum-free DMEM and 2µl polybrene (stock of 4µg/µl; Sigma) and 
the volume was made up to 2ml with warm 10% GM. The older medium was aspirated from 
the well and cells were washed with 1XPBS and the medium containing the virus was applied 
to the cells. After the incubation at 37
o
C in humidified incubator with 5%CO2 for 24 hours, 
the viral medium was removed and the cells were washed with 1XPBS and 2ml fresh 10% 
GM was added to each well and the cells were incubated at 37
o
C in humidified incubator with 
5%CO2 for 5-7 days. After 7 days, transduced cells were screened by adding 10% GM 
containing Blasticidin (1.5µg/ml). 
 
2.3 SH-SY5Y  
2.3.1 General Cell culture 
SH-SY5Y neuroblastoma cells were obtained from the European Collection of Cell Cultures 
(ECACC, Salisbury, UK). SH-SY5Y is a sub-line of SK-N-SH isolated from bone-marrow of 
a four year old female with neuroblastoma. Cells were grown and maintained in growth 
medium (10% GM). Cells were grown at 37
o
C in a humidified atmosphere of 95% air/5% 
CO2. When the cells reached 75-90% confluence, the cells were split in a ratio of 1:3 into 
14ml fresh medium in T75 flask.  
 
2.3.1.1 Cell viability assays and toxin treatment 
Cells were split into 48 well plates at a density of 100,000 cells per well in 350µl 10% GM 
and incubated overnight. Rotenone (Sigma-Aldrich, Dorset, UK) was dissolved in DMSO 
(dimethyl sulphoxide, Sigma-Aldrich) and then 350µl 10% GM was added to give a final 
concentration of 0.2% DMSO. Diquat (Sigma-Aldrich, Dorset, UK) was dissolved in PBS 
(Phosphate buffer saline; Sigma-Aldrich). Three hundred and fifty microliters of 10% GM 
containing either toxin, positive or negative control was added to each well of the 48 well 
plate (4 wells per treatment) and incubated overnight for 18-20 hours. An initial dose range of 
1000µM-1µM and 500µM–0.5µM was used for diquat and rotenone, respectively. A 10% 
Alamar Blue solution (0.01% resazurin; Sigma Aldrich) in PBS (Sigma-Aldrich)) by volume 
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was added to each well and incubated for a further 4 hours before duplicates of 100µl media 
from each well were transferred to a 96 well plate. Alamar Blue reduction was measured at 
excitation wavelength of 530nm and emission wavelength of 590nm. The dose of 20μM and 
10μM and 20μM and 0.5μM, for diquat and rotenone, respectively were used in rest of the 
study (please refer Figures A.1 and A.2 for toxicity curve of diquat and rotenone). 
 
2.3.2 Comparison between transfection with SIRTs in pLenti CMV blast and 
pcDNA3.1 
2.3.2.1 Transfection of cells 
Cells were split into two 6-well plates at a density of 200,000 cells per well in 2ml 10%GM 
and were grown overnight. SIRTs in pLenti CMV and SIRT in pcDNA3.1 were used in the 
experiment. Seven and a half micrograms of plasmid DNA was added to 1ml serum free 
medium in a clean 1.5ml tube and vortexed at full speed for 5 seconds, 20µl of 1% PEI was 
added to the tube and the mix was vortexed at full speed for 10 seconds and incubated at room 
temperature for 20 minutes. The medium of the cells was replaced with fresh warm medium 
prior to transfection. Two hundred microlitres of PEI-DNA mix was added to each well and 
plates were gently swirled and incubated at 37
o
C for 48 hours. 
 
2.3.2.2 Cell lysate preparation 
Cells were washed in cold PBS twice and then were extracted by scraping the cells in chilled 
native lysis buffer (1% 10X TBS, 0.27M sucrose, 1% triton X-100, 1X protease inhibitor 
cocktail). Samples were then sonicated for 20 seconds using a sonic probe.  
 
2.3.2.3 Protein quantification using Bradford assay 
The BSA standards were prepared in diluted Native lysis buffer and the amount of protein 
was measured by Bradford assay (Section 2.1.1). 
 
2.3.2.4 Western blotting 
Samples for Western blotting were analysed as detailed in section 2.1.1. Protein levels were 
analysed by comparing each group with control and the change in protein level was evaluated 
(Table 2.8). 
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 Dilution Incubation Supplier Secondary 
antibody 
Primary Antibodies 
SIRT1 1:4,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
SIRT2 1:5,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
SIRT3 1:5,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
GAPDH-HRP 1:4,000 1 hour at RT SantaCruz 
Biotechnology 
- 
Secondary Antibodies 
Rabbit 
VeriBlot 
1:2,000 30 minutes at 
RT 
Abcam - 
Mouse 
VeriBlot 
1:2,000 30 minutes at 
RT 
Abcam - 
Anti-biotin 
IgG 
1:4,000 30 minutes at 
RT 
Cell Signaling - 
Table 2.8 Details of antibodies used in Western blotting of SIRT transfected SH-SY5Y 
cells. ON- Over night; RT- Room temperature 
 
2.3.3 SIRTs overexpression in SH-SY5Y cells 
In SIRT1 transfection, SIRT1WT or SIRT1H363Y cloned in pLenti CMV blast were used in 
the experiment and empty pLenti CMV blast was used as a control. SIRT2 transfection was 
carried out with SIRT2WT (pcDNA3.1) and empty pcDNA 3.1 was used as a control. As with 
SIRT1, in SIRT3 transfections, SIRT3WT or SIRT3H248Y cloned in pLenti CMV blast were 
used and empty pLenti CMV blast served as a control. Seven and a half micrograms of 
plasmid DNA was added to 1ml serum free medium and vortexed at full speed for 5 seconds, 
20µl of 1% PEI was added to DNA and the PEI-DNA mix was vortexed at full speed for 10 
seconds and incubated at room temperature for 20 minutes. SH-SY5Y cells were plated in 6-
well plates and incubated overnight prior to plasmid transfection. The medium was replaced 
by the fresh warm medium (2ml per well) and 200µl of PEI-DNA mix was added to each well 
and incubated at 37
o
C for 48 hours. 
 
2.3.4 Toxin treatment of SIRTs transfected cells 
SIRT1 and SIRT3 transfected cells were treated with diquat and rotenone. Two millilitres of 
10% GM containing toxins (diquat- 20µM or 10µM; rotenone- 20µM or 0.5µM) and positive 
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control (diquat- PBS and rotenone- DMSO) was added to wells and incubated overnight for 
20 hours. Cell viability was determined by Alamar Blue reduction assay. 
Cells from viable wells were extracted in native lysis buffer and protein expression of SIRTs 
and their targets were measured by Western blotting (Table 2.9). 
 
 Dilution Incubation Supplier Secondary 
antibody 
Primary Antibodies 
SIRT1 1:4,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
SIRT2 1:5,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
SIRT3 1:5,000 ON at 4
o
C Cell Signaling Rabbit IgG-HRP 
GAPDH-HRP 1:4,000  SantaCruz 
Biotechnology 
- 
NF-кB 1:2,000 ON at 4oC Cell Signaling Rabbit IgG-HRP 
Acetylated α-
tubulin (K40) 
1:100,000 ON at 4
o
C Abcam Mouse IgG- HRP 
α-tubulin 1:100,000 ON at 4oC Abcam Rabbit IgG-HRP 
SOD2 1:10,000 ON at 4
o
C Abcam Mouse IgG- HRP 
Secondary Antibodies 
Rabbit 
VeriBlot 
1:2, 000 30 minutes at 
RT 
Abcam - 
Mouse 
VeriBlot 
1:2, 000 30 minutes at 
RT 
Abcam - 
Anti-biotin 
IgG 
1:4,000 30 minutes at 
RT 
Cell Signaling - 
Table 2.9 Details of antibodies used in Western blotting of SIRTs transfected and toxin 
treated SH-SY5Y cells. ON- Over night; RT- Room temperature 
 
2.3.5 Fluorescence immunocytochemistry 
SH-SY5Y cells were grown in four well chamber slides (BD Falcon, UK) and were 
transfected with SIRT plasmids (Section 2.3.3) and treated with toxin.  
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2.3.5.1 Cell fixation 
The cells were washed with PBS x3 and the sections were covered with 4% formaldehyde 
(Sigma- Aldrich) diluted in warm 1X PBS and the cells were fixed for 15 minutes. The slides 
were washed with the PBS and cells were stored in 10% glycerol (Sigma-Aldrich, UK) at 
4
o
C. 
2.3.5.2 Immunostaining 
Glycerol was removed and the sections were washed with PBS x3. The cells were blocked in 
a blocking buffer (1X PBS/5% normal serum/0.3% triton™ X-100) for an hour. The cells 
were incubated in primary antibodies overnight (Table 2.10) at 4
o
C with gentle agitation. 
Following day, sections were washed with PBS x3 and incubated with secondary antibodies 
(Table 2.10) for 60 minutes, protected from light and subsequently washed with PBS x3. The 
excess PBS was removed by tapping and a drop of ProLong Gold Antifade Mountant with 
DAPI (Thermo Fisher) was applied for mounting and counterstaining. The slide-mounted 
specimens were covered with a clean coverslip without trapping any air bubble. The mountant 
was cured for 24 hours and the slides were stored at 4
o
C until visualisation.  
 
 Dilution Incubation Supplier Secondary 
Antibodies 
Primary Antibodies 
SIRT1 1:500 ON at 4
o
C SantaCruz 
Biotechnology 
Goat anti-rabbit 
Alexa Fluor® 594 
SIRT2 1:500 ON at 4
o
C SantaCruz 
Biotechnology 
Goat anti-rabbit 
Alexa Fluor® 594 
SIRT3 1:500 ON at 4
o
C SantaCruz 
Biotechnology 
Goat anti-rabbit 
Alexa Fluor® 594 
Phospho-α-
synuclein 
1:500 ON at 4
o
C Wako Goat anti-mouse 
Alexa Fluor® 488 
Secondary Antibodies 
Goat anti-rabbit 
Alexa Fluor® 594 
1:500 1 hour at 
RT in dark 
Thermo Fisher 
Scientific 
- 
Goat anti-mouse 
Alexa Fluor® 488 
1:500 1 hour at 
RT in dark 
Thermo Fisher 
Scientific 
- 
Table 2.10 Details of antibodies used in fluorescence immunocytochemistry of SIRTs 
transfected SH-SY5Y cells. ON- Over night; RT- Room temperature 
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2.3.5.3 Confocal Microscopy 
Images of the stained sections were acquired using a Zeiss Axioplan 2 microscope (Zeiss, 
Oberkochen, Germany). Cells were observed with a 40X objective using the following 
instrument configuration: DAPI, DNA (405nm excitation and 450nm emission filter); Alexa 
Fluor® 488, α-synuclein (488nm excitation and 525nm emission filter) and Alexa Fluor® 594, 
SIRTs (594nm excitation and 617nm emission filter). The images were captured at 1024 x 
1024 pixel resolution for analysis. 
 
2.3.5.4 Image analysis 
Stained sections were quantified using ImageJ (NIH, Bethesda, USA) analysis of confocal 
images. The total immunostaining was analysed by importing the image to ImageJ and 
binarisation of the image (converted to 8-bit grey scale) and highlighted cell area was 
quantified by analysing particles. α-synuclein aggregates immunoreactivity was also 
determined by using a standardised custom histogram based coloured thresholding technique 
and then subjected to analyse particles. The parameters recorded were total area and 
percentage area of staining. α-synuclein aggregate percentage was calculated as the total area 
of α-synuclein divided by the total area of immunostaining times 100.  
 
2.4 Forebrain neural stem cells  
2.4.1 Propagation of Stem cell  
Human neural stem cells (NSC; N1997 forebrain) were sourced from MRC/Wellcome Trust 
Human Developmental Brain Resource, Newcastle. Cells were grown in proliferation medium 
(MAGICK): advanced DMEM (Sigma) supplemented with N-2 (1:100; Life Technologies), 
B27 (1:100; Life Technologies), epidermal growth factor (EGF, 20ng/ml; R&D Systems), 1% 
penicillin-streptomycin-L-glutamine (PSG; Gibco Invitrogen), fungizone (5μg/ml; 
Invitrogen), 1% MEM non-essential amino acids (Invitrogen), sodium bicarbonate (Sigma), 
D-glucose (Sigma), ascorbic acid (Sigma), ITS liquid supplement (Invitrogen), basic 
fibroblast growth factor (FGF2; 20ng/ml; R&D Systems), leukaemia inhibitor factor (LIF; 
10ng/ml) and heparin (5μg/ml; Sigma).  
Cells were grown in T75 flasks coated with Geltrex™ (Gibco, Invitrogen) in a humidified 
incubator at 37
o
C in an environment containing 95% air and 5% CO2. The proliferation 
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medium was replenished at 2-3 day intervals by replacing 60-70% of the existing medium 
with fresh medium. On formation of neurospheres, they were triturated to smaller 
neurospheres.   
 
2.4.2 Differentiation of Stem cells 
NSCs were seeded into 6-well plates coated with 0.5% gelatine (Sigma) in DMEM and grown 
for 7 days replenishing the medium (MAGICK) every second day. The growth medium was 
replaced with differentiating medium (NOGF) containing advanced DMEM supplemented 
with 10% heat inactivated FBS (Sigma), N-2 (1:100; Life Technologies), B27 (1:100; Life 
Technologies), 1% penicillin-streptomycin-L-glutamine (PSG; Gibco Invitrogen),  fungizone 
(5μg/ml; Invitrogen), 1% MEM non-essential amino acids (Invitrogen), sodium bicarbonate 
(Sigma), D-glucose (Sigma), ascorbic acid (Sigma), Insulin-Transferrin-Selenium-G 
Supplement (ITS; Life technologies ) and heparin (5μg/ml; Sigma). The conversion of NSC 
into cells resembling a neural morphology took from between two to three days. Cells were 
allowed to grow for 14 days to develop neuritic outgrowths before use. 
 
2.4.3 Analysis of SIRT expression in stem cells and differentiated stem cells 
For analysis of SIRT expression, the cells were grown in 6-well plates. Cell lysates were 
prepared in native lysis buffer at different stages- stem cells, 48 hours of differentiation, 6 
days of differentiation, 10 days of differentiation, and neurones after 14 days of differentiation.  
Protein quantification was done using Bradford assay (2.3.2) and Western blot analysis for the 
expression of SIRT1-3 was performed as described in Section 2.3.2.  
 
2.5 Midbrain neural stem cells 
2.5.1 Propagation of stem cells 
Midbrain neural stem cells were obtained from MRC/Wellcome Trust Human Developmental 
Brain Resource, Newcastle. Cells were grown and propagated as described in Section 2.4.1. 
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2.5.2 Differentiation of stem cells 
Cells were grown in 12 well plate coated with 0.5% gelatine (Sigma) in DMEM and were 
differentiated into midbrain neurones over 18 days as summarised in Table 2.11. 
 
Days TREATMENT 
0 MAGICK 
3 MAGICK 
5 75% MAGICK + 25% N2 + 20ng/ml SHH + 100ng/ml FGF8 
7 50% MAGICK + 50% N2 + 20ng/ml SHH + 100ng/ml FGF8 
9 25% MAGICK + 75% N2 + 20ng/ml SHH + 100ng/ml FGF8 + 20ng/ml  
BDNF + 200µM AA 
11 100% N2 + 20ng/ml SHH + 100ng/ml FGF8 + 20ng/ml BDNF + 200µM 
AA 
12 100% N2 + 20ng/ml BDNF + 200µM AA + 500µM cAMP + 20ng/ml 
GDNF + 1ng/ml TGFβ3 
14 100% N2 + 20ng/ml BDNF + 200µM AA + 500µM cAMP + 20ng/ml 
GDNF + 1ng/ml TGFβ3 
16 100% N2 + 20ng/ml BDNF + 200µM AA + 500µM cAMP + 20ng/ml 
GDNF + 1ng/ml TGFβ3 
18 100% N2 + 20ng/ml BDNF + 200µM AA + 500µM cAMP + 20ng/ml 
GDNF + 1ng/ml TGFβ3 
Table 2.11 Differentiation pathway of midbrain neurones from human neural stem cells.  
Key: N2– N2 supplemented media (Dulbecco’s Modified Eagle’s Media/F12, 2mM L-
glutamine, 20 units/ml penicillin, 1% MEM non-essential amino acids, 5μg/ml fungizone 
(amphotericin B)); SHH– sonic hedgehog homolog; FGF8– fibroblast growth factor 8; 
TGFβ3– transforming growth factor 3 (all R&D Systems); BDNF– brain derived neurotrophic 
factor; GDNF– glial cell line derived neurotrophic factor (both ProSpec Bio, Ness Ziona, 
Isreal); AA– ascorbic acid; cAMP– dibutyryl cyclic adenosine monophosphate (both Sigma 
Aldrich). 
 
2.5.3. Transfection of midbrain neurones with SIRT1 expression vector 
2.5.3.1 Transfection of cells 
SIRT1 in pLenti CMV were used in the experiment. A comparative transfection experiment 
was set between XFect (Clonetech) and PEI (Invitrogen) transfection reagents.  
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A. XFect transfection: 15µg of DNA was diluted in 300µl Xfect Reaction Buffer and the 
sample was mixed by vortexing at high speed for 5 seconds. Four and a half 
microliters of XFect reagent was added to the solution (0.3µl/1µg DNA) and vortexed 
for 10 seconds. The mix was incubated at room temperature for 10 minutes to form the 
nanoparticle complexes, and then 50µl of DNA-Xfect solution was added drop wise to 
the cells and incubated at 37
o
C overnight. The medium was replaced with fresh 
medium (100% N2 + 20ng/ml BDNF + 200µM AA + 500µM cAMP + 20ng/ml 
GDNF + 1ng/ml TGFβ3) and the cells were incubated overnight at 37oC. 
B. PEI Transfection: 15µg of plasmid DNA was added to 1ml serum free medium in a 
clean 1.5ml tube and vortexed at full speed for 5 seconds, 20µl of 1% PEI was added 
to the tube and the mix was vortexed at full speed for 10 seconds and incubated at 
room temperature for 20 minutes. The cell medium was replaced with fresh warm 
medium prior to transfection. Two hundred microlitres of PEI-DNA mix was added to 
each well and plates were gently swirled and incubated at 37
o
C for 24 hours. The 
medium was replaced with fresh warm medium. 
Cells were extracted in native lysis buffer and SIRT expression was measured by Western 
blotting. 
 
2.6 Statistical Analyses 
Each experiment was repeated at least three times. Statistical analysis in the case of Western 
blotting was performed in GraphPad Prism using a t-test: two samples assuming unequal 
variances. Statistical significance was considered when p two tail was <0.05. The results are 
presented as mean and error bar represented standard deviation (+SD). In case of SIRT 
activity assays, statistical analysis was performed using two-way ANOVA (analysis of 
variance) within the groups using SPSS21 (IBM) and the results are presented as mean and 
error bar represented standard deviation (+SD). p<0.05 was considered statistically 
significant. 
In case of SH-SY5Y and stem cells studies, statistical analysis was performed using one-way 
ANOVA within the group and two-way ANOVA within two groups using SPSS21 (IBM) 
followed by appropriate post-hoc (Bonferroni) non- parametric testing. Error bars represent 
standard deviation (+SD). p <0.05 was considered statistically significant.  
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Chapter 3 SIRT1- Role in Oxidative stress mediated cell death 
and Neurodegenerative disorders 
3.1 Introduction 
SIRT1 is a NAD
+
 dependent lysine deacetylase that shares the most homology with yeast 
SIR2. SIRT1 is primarily a nuclear protein that shuttles to the cytoplasm depending upon the 
cell type and stress (Tanno et al., 2007). SIRT1 targets histones and non-histones proteins that 
are involved in the regulation of several physiological processes including mitochondrial 
biogenesis, antioxidant defence mechanisms, DNA repair, apoptosis and genomic stability 
(reviewed in (Guarente, 2013)).  
The founding member of Sirtuin family, SIR2 promotes lifespan extension in yeast (Lin et al., 
2000) and brain specific overexpression of its mammalian homologue, SIRT1 has been 
reported to delay ageing in SIRT1 overexpressing female and male transgenic mice (Satoh et 
al., 2013). Supporting Satoh et al., two mores studies reported that SIRT1 is needed for life 
span extension in mice that are either calorie restricted (Mercken et al., 2014) or on standard 
diet (Mitchell et al., 2014). These studies show that SIRT1 if activated or overexpressed in a 
tissue-specific manner can slow down ageing and enhance life span. 
SIRT1 has also been extensively studied to evaluate its role in neurodegenerative disorders. In 
cell culture and murine models of AD, SIRT1 was shown to protect cells from Aβ induced 
neurotoxicity. These studies showed that SIRT1 reduces Aβ induced toxicity by i) inhibiting 
NF-κB signalling (Chen et al., 2005a), ii) decreasing the levels of serine/threonine Rho kinase 
(ROCK1) leading to increased α-secretase activity and thus promoting non-amyliodgenic 
processing of APP (Qin et al., 2006), and iii) deacetylating tau protein and thus enhancing the 
degradation of pathogenic forms of tau (Min et al., 2010). In cellular models of PD, 
resveratrol (RSV), a known SIRT1 activator, protected cells from rotenone induced apoptosis 
and reduced α-synuclein aggregates via an AMPK-SIRT1 mediated autophagy pathway (Wu 
et al., 2011). In dopaminergic SN4741 cells, SIRT1 protected DA neurones from MPTP 
toxicity by deacetylating and activating peroxisome PGC-1α (Mudo et al., 2012). SIRT1 has 
shown to be neuroprotective in HD (Jeong et al., 2012; Jiang et al., 2012) and it has been 
proven beneficial in models of ALS (Song et al., 2014). The findings of these studies suggest 
that upregulation or activation of SIRT1 could possibly be used as a therapeutic intervention 
in neurodegenerative disorders. 
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3.2 Aim 
The aim of this study is to determine the role of SIRT1 in oxidative stress mediated cell death 
by determining the effect of SIRT1 and its enzymatic activity on cell viability in diquat or 
rotenone treated SH-SY5Y cells. Further objective is to assess the possible interaction 
between SIRT1 and α-synuclein. This study also aims to evaluate the role of SIRT1 in 
neurodegenerative disorders by determining the protein levels and enzymatic activity of 
SIRT1 in post-mortem human brain samples from PD, PDD, DLB and AD patients.  
 
3.3 Materials and methods 
3.3.1 SH-SY5Y cells 
Please refer to Materials and Methods sections 2.3.1 to 2.3.5 
 
3.3.2 Brain tissue 
Please refer to Materials and Methods sections 2.1.1, 2.1.2 and 2.1.3. 
 
3.4 Results 
3.4.1 SH-SY5Y cells 
3.4.1.1 Over-expression of SIRT1 in SH-SY5Y cells 
To test the most efficient method of SIRT1 expression, SH-SY5Y cells were transfected with 
SIRT1 wild type (WT) or SIRT1H363Y, a catalytically inactive mutant, cloned in pLenti 
CMV lentiviral vector and were compared with the insert cloned in pECE. After 48 hours of 
transfection, the cells were harvested, quantified and were probed for SIRT1 levels by 
Western blot analysis. The levels of SIRT1 were elevated by ~4 fold in both SIRT1WT 
pLenti CMV and SIRT1H363Y pLenti CMV transfected cells (p<0.001; Figure 3.1). In 
SIRT1pECE and SIRT1H363YpECE transfected cells, the levels of SIRT1 were elevated by 
1.4 and 1.3 fold, respectively (p<0.01; Figure 3.1). SIRT1 inserts cloned in pLenti CMV blast 
showed an efficient and better transfection of SH-SY5Y cells than SIRT1 cloned in pECE.  
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Figure 3.1 Transfection of SH-SY5Y cells with two different SIRT1 plasmids. SH-SY5Y 
cells were transfected with SIRT1 plasmids, in either pLenti CMV vector or pECE. Data is presented 
as fold- untreated (+SD) from three independent assays (n=3). ***p<0.001 and **p<0.01, when 
compared to mock transfection and ###p<0.001 when compared to SIRT1 insert in pLenti CMV, two-
way ANOVA (Bonferroni corrected). Image is a representative blot of SIRT1 and GAPDH. 
 
3.4.1.2 SIRT1 and effects of its deacetylase activity in toxin treated SH-SY5Y cells 
SIRT1 is the most evolutionary conserved of the mammalian sirtuins and inhibits oxidative 
stress and promotes cell survival (reviewed in (Salminen et al., 2013)). Given the function of 
SIRT1 as an oxidative stress regulator, the role of SIRT1 and its deacetylase activity was 
studied in diquat or rotenone induced oxidative stress in SH-SY5Y cells, a cellular model of 
PD. 
SH-SY5Y cells were transfected with SIRT1WT, SIRT1H363Y (mutant) and the control 
group with empty pLenti CMV vector. After 48 hours of transfection, cells were treated with 
diquat (20µM or 10µM) for 20 hours and cell viability was assessed by Alamar Blue 
reduction assay. SIRT1WT transfected cells showed increased rate of cell survival compared 
to control cells (20µM or 10µM diquat: p<0.001) and SIRT1H363Y cells (20µM diquat: 
p<0.01; 10µM diquat: p<0.001; Figure 3.2). Interestingly, increased cell viability was 
observed in SIRT1H363Y transfected cell compared to control cells (20µM or 10µM diquat: 
p<0.001; Figure 3.2).  
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Figure 3.2 Effect of deacetylase activity of SIRT1 on diquat treated SH-SY5Y cells. 
SIRT1WT and SIRT1H363Y were over-expressed in SH-SY5Y cells and control cells were 
transfected with empty vector following which cells were treated with diquat (20μM or 10μM) for 20 
hours and viability was measured by reduction of Alamar Blue. Data are presented as mean % control 
+ SD from three independent assays (n=3). ***p<0.001, **p<0.01 and *p<0.05 when compared to 
0.2% PBS, one-way ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector 
treatment and ~~~p<0.001 when compared to SIRT1WT, two-way ANOVA (Bonferroni corrected).   
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The effect of SIRT1 was also evaluated in SH-SY5Y cells that were treated with rotenone. 
Similar to diquat, SIRT1WT and SIRT1H363Y overexpression enhanced cell viability in 
rotenone (20μM or 0.5μM rotenone: p<0.001) compared to control cells where SIRT1WT 
overexpression was more potent in combating oxidative stress (Figure 3.3). 
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Figure 3.3 Effect of deacetylase activity of SIRT1 on rotenone treated SH-SY5Y cells. 
SIRT1WT and SIRT1H363Y were over-expressed in SH-SY5Y cells and control cells were 
transfected with empty vector following which cells were treated with rotenone (20μM or 0.5μM) for 
20 hours and viability was measured by reduction of Alamar Blue. Data are presented as mean % 
control + SD from three independent assays (n=3). ***p<0.001 when compared to 0.2% DMSO, one-
way ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector treatment and 
~~~p<0.001 when compared to SIRT1WT, two-way ANOVA (Bonferroni corrected).   
 
These results suggest that SIRT1 is an important survival factor under oxidative stress. 
Although, the enzymatic activity of SIRT1 is important for cell survival, the protection 
conferred against the oxidative stress is independent of its enzymatic activity to a certain 
degree. 
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3.4.1.3 Expression of SIRT1 and its possible targets in toxin treated SH-SY5Y cells 
Overexpression of SIRT1 in diquat or rotenone treated SH-SY5Y cells, rescued cells from 
oxidative stress. To test the possible mechanism behind this protection, the cells were 
subjected to Western blot analysis after Alamar Blue fluorescence. SH-SY5Y cells were 
washed with PBS, harvested, quantified, and subsequently subjected to Western blot analysis 
(detailed in Section 2.3.4). 
SIRT1 levels were measured to test the effects of oxidative stress. In 0.2% PBS treated cells, 
levels of SIRT1 were increased by ~3.0-3.5 fold in SIRT1WT (p<0.001) and SIRT1H363Y 
(p<0.001) cells compared to pLenti CMV transfected cells (Figure 3.4). In diquat (20µM or 
10µM) treated cells, the levels of SIRT1 were reduced by ~25%-35% in pLenti CMV 
transfected cells (20µM diquat: p<0.001; 10µM diquat: p<0.01). Similar reductions of ~25%- 
30% were also observed in SIRT1WT (20µM or 10µM diquat, p<0.001) and SIRT1H363Y 
transfected cells (20µM or 10µM diquat, p<0.001) when compared to respective 0.2% PBS 
treatment (Figure 3.4).  
To test the possible mechanism of protection provided by SIRT1 against oxidative stress, the 
levels of NF-κB were measured in diquat treated cells. The levels of NF-κB were reduced by 
32-35% in SIRT1WT (p<0.001) and by 23-24% in SIRT1H363Y (p<0.001) cells treated with 
0.2% PBS compared with pLenti CMV transfected cells (Figure 3.5). In diquat treated cells, 
the levels of NF-κB were reduced by 50-55% in SIRT1WT (20µM or 10µM diquat, p<0.001) 
cells and by 35-40% in SIRT1H363Y (20µM or 10µM diquat, p<0.001) when compared to 
0.2% PBS treated control cells. On the other hand, in pLenti CMV transfected cells, diquat 
treatment enhanced the level of NF-κB by ~50% (20µM or 10µM diquat, p<0.001) compared 
to 0.2% PBS treatment (Figure 3.5). 
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Figure 3.4 Expression of SIRT1 in diquat treated SH-SY5Y. SIRT1WT and SIRT1H363Y 
were over-expressed in SH-SY5Y cells and control cells were transfected with empty vector following 
which cells were treated with diquat (20μM or 10μM) for 20 hours. Cells were harvested and the 
samples were probed for SIRT1. A) represents expression of SIRT1 in 20μM diquat treated cells and 
B) represents expression of SIRT1 in 10μM diquat treated cells. Data are presented as fold- untreated 
(+SD) from three independent assays (n=3). ***p<0.001 and **p<0.01 when compared to 0.2% PBS, 
one-way ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector treatment, 
~~~p<0.001 when compared to SIRT1WT cells, two-way ANOVA (Bonferroni corrected). Images are 
representative blot of SIRT1 and GAPDH. 
 
 
 117 
A 
 
B 
 
Figure 3.5 Expression of NF-κB in diquat treated SH-SY5Y. SIRT1WT and SIRT1H363Y 
were over-expressed in SH-SY5Y cells and control cells were transfected with empty vector following 
which cells were treated with 10μM diquat for 20 hours. Cells were harvested and the samples were 
probed for NF-κB. A) represents expression of NF-κB in 20μM diquat treated cells and B) represents 
expression of NF-κB in 10μM diquat treated cells. Data are presented as fold- untreated (+SD) from 
three independent assays (n=3). ***p<0.001 when compared to 0.2% PBS, one-way ANOVA 
(Bonferroni corrected), ###p<0.001 when compared to empty vector treatment, ~~~p<0.001, 
~~p<0.01 and ~p<0.05 when compared to SIRT1WT cells, two-way ANOVA (Bonferroni corrected). 
Images are representative blot of NF-κB and GAPDH. 
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Furthermore, the levels of SIRT1 and NF-κB were measured in rotenone treated SH-SY5Y 
cells. In 0.2% DMSO treated cells, SIRT1 levels were elevated by ~3.5-4 fold in SIRT1WT 
cells (p<0.001) and by ~3.0-3.5 fold in SIRT1H363Y (p<0.001) cells when compared to 
pLenti CMV transfected cells (Figure 3.6). The levels of SIRT1 were reduced by 35-40% in 
rotenone treated pLenti CMV transfected cells when compared to 0.2% DMSO treated cells 
(20μM or 0.5μM rotenone: p<0.001: Figure 3.6). Similarly, the levels were reduced by ~25% 
in SIRT1WT (20µM or 0.5µM rotenone, p<0.001) and SIRT1H363Y transfected cells (20µM 
or 0.5µM rotenone, p<0.001) when compared to respective 0.2% DMSO treatment (Figure 
3.6). 
In 0.2% DMSO treated cells, the levels of NF-κB were reduced by ~34% and ~25% in 
SIRT1WT (p<0.001) and SIRT1H363Y (p<0.001) transfected cells, respectively, compared to 
pLenti CMV transfected cells (Figure 3.7). Following rotenone treatment, the levels of NF- 
κB were reduced by ~55% in SIRT1WT cells (20µM or 0.5µM rotenone, p<0.001) and by 
~37% in SIRT1H363Y (20µM or 0.5µM rotenone, p<0.001), whilst in pLenti CMV 
transfected cells, the levels were elevated by 55-60% in rotenone treated cells (20µM or 
0.5µM rotenone, p<0.001; Figure 3.7).   
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Figure 3.6 Expression of SIRT1 in rotenone treated SH-SY5Y. SIRT1WT and SIRT1H363Y 
were over-expressed in SH-SY5Y cells and control cells were transfected with empty vector following 
which cells were treated with rotenone (20μM or 0.5μM) for 20 hours. Cells were harvested and the 
samples were probed for SIRT1. A) represents expression of SIRT1 in 20μM rotenone treated cells 
and B) represents expression of SIRT1 in 0.5μM rotenone treated cells. Data are presented as fold- 
untreated (+SD) from three independent assays (n=3). ***p<0.001 and **p<0.01 when compared to 
0.2% DMSO, one-way ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector 
treatment, ~~~p<0.001 when compared to SIRT1WT cells, two-way ANOVA (Bonferroni corrected). 
Images are representative blot of SIRT1 and GAPDH. 
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Figure 3.7 Expression of NF-κB in rotenone treated SH-SY5Y. SIRT1WT and SIRT1H363Y 
were over-expressed in SH-SY5Y cells and control cells were transfected with empty vector following 
which cells were treated with 0.5μM rotenone for 20 hours. Cells were harvested and the samples were 
probed for NF-κB. . A) represents expression of NF-κB in 20μM rotenone treated cells and B) 
represents expression of NF-κB in 0.5μM rotenone treated cells. Data are presented as fold- untreated 
(+SD) from three independent assays (n=3).  ***p<0.001 when compared to 0.2% DMSO, one-way 
ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector treatment, ~~~p<0.001, 
~~p<0.01 and ~p<0.05 when compared to SIRT1WT cells, two-way ANOVA (Bonferroni corrected). 
Images are representative blot of NF-κB and GAPDH. 
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These findings suggest that SIRT1 confers protection against oxidative stress by inhibiting the 
expression of NF-κB. Further, the inhibition is independent of deacetylase activity. SIRT1WT 
showed higher percentage of cell survival so possibly there could be other mechanisms 
involved in combatting oxidative stress that are dependent on SIRT1 deacetylase activity. 
 
3.4.1.4 Location of SIRT1 at cellular level in toxin treated SH-SY5Y cells 
SIRT1 is generally localised in the nucleus and depending upon the environmental cues and 
cell types can translocate to the cytoplasm (Tanno et al., 2007) and possibly to mitochondria 
(Aquilano et al., 2010). Nuclear SIRT1 targets the proteins involved in DNA repair, 
antioxidant defence, genomic stability and apoptosis (Poulose and Raju, 2015), whereas 
localisation of SIRT1 in the cytoplasm augments cells sensitivity to apoptosis (Jin et al., 
2007).  In this study, oxidative stress was induced using diquat or rotenone and the cellular 
localisation of SIRT1 was determined by immunocytochemistry and fluorescent microscopy. 
SH-SY5Y cells were immunostained for SIRT1 and phospho-α-synuclein and the images 
were captured using a confocal fluorescence microscope.  
In diquat treated cells, SIRT1 was predominantly localised to the nucleus with trace amounts 
of protein observed in the cytoplasm in pLenti CMV, SIRT1WT or SIRT1H363Y transfected 
SH-SY5Y cells (Figure 3.8). Nuclear localisation of SIRT1 relates with its pro-survival 
activity under oxidative stress. In the nucleus, SIRT1 targets FOXO family members and 
promotes the expression of proteins involved in antioxidant defence mechanisms and 
simultaneously inhibits the expression of targets involved in promotion of apoptosis (Brunet 
et al., 2004) and also enhances DNA repair (Oberdoerffer et al., 2008).   
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Figure 3.8 Localisation of SIRT1 and α-synuclein in diquat treated SH-SY5Y cells. Cellular distribution of SIRT1 and phospho- α -synuclein was 
determined using fluorescent immunocytochemistry. Images show α-synuclein staining, SIRT1 staining and all staining merged including DAPI. A represents 0.2% 
PBS treated SH-SY5Y cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 3.8 Localisation of SIRT1 and α-synuclein in diquat treated SH-SY5Y cells (continued). B represents 20μM diquat treated SH-SY5Y cells. 
Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 3.8 Localisation of SIRT1 and α-synuclein in diquat treated SH-SY5Y cells (continued). C represents 10μM diquat treated SH-SY5Y cells. 
Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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In rotenone treated cells, SIRT1 was observed to be localised in the nucleus in pLenti CMV, 
SIRT1WT or SIRT1H363Y transfected cells (Figure 3.9). Nuclear localisation of SIRT1 in 
rotenone treated cells further substantiates its protective role against oxidative stress.     
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Figure 3.9 Localisation of SIRT1 and α-synuclein in rotenone treated SH-SY5Y cells. Cellular distribution of SIRT1 and phospho-α -synuclein was 
determined using fluorescent immunocytochemistry. Images show α-synuclein staining, SIRT1 staining and all staining merged including DAPI. A represents 0.2% 
DMSO treated SH-SY5Y cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 3.9 Localisation of SIRT1 and α-synuclein in rotenone treated SH-SY5Y cells (continued). B represents 20μM rotenone treated SH-SY5Y 
cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM: 50μm; Magnification: 40X  
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Figure 3.9 Localisation of SIRT1 and α-synuclein in rotenone treated SH-SY5Y cells (continued). C represents 0.5μM rotenone treated SH-SY5Y 
cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X
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3.4.1.5 Effect of SIRT1 on α-synuclein aggregate formation 
α-synuclein is a 140 amino acids long protein located in presynaptic nerve terminal 
(Maroteaux et al., 1988) that plays a role in synaptic plasticity and neurotransmitter release 
(Liu et al., 2004). As with other proteins, α-synuclein undergoes post-translational 
modifications (PTM) such as phosphorylation, nitration and ubiquitination (reviewed in 
(Schmid et al., 2013)). Phosphorylation of α-synuclein has shown to promote α-synuclein 
oligomers and aggregates (Anderson et al., 2006) and these are the basic components of 
LB/Ns, the characteristics hallmarks of PD, DLB and other Lewy body disorders (Spillantini 
et al., 1998). Oxidative stress is one of the root causes of development and progression of 
neurodegenerative disorders and has been reported to induce PTMs in proteins which leads 
protein ageing and altered physiological functions (reviewed in (Jaisson and Gillery, 2010)). 
Oxidative stress has also been implicated in promotion of α-synuclein aggregation by 
inducing PTM that leads to increased toxicity induced by α-synuclein (Xiang et al., 2013). In 
the present study, diquat or rotenone was used to induce oxidative stress and its effect on α-
synuclein aggregation is illustrated in Figure 3.10, where the cells were treated with rotenone. 
The arrows indicate the α-synuclein aggregates that vary from intermediate to large inclusions 
in rotenone treated SH-SY5Y cells. 
 
 
Figure 3.10 α-synuclein aggregate formation in SH-SY5Y cells. SH-SY5Y cells were treated 
with toxins and were stained with phospho-α-synuclein. The slides were visualised through GFP filter 
(63X magnification) for α-synuclein staining. Aggregates are highlighted with white arrows. Scale 
bar: 20μM 
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To study the role of SIRT1 in α-synuclein aggregate formation, SH-SY5Y cells were seeded 
in four-well chamber slides and the cells were transfected with SIRT1WT or SIRT1H363Y 
and the control cells were transfected with pLenti CMV for 48 hours. Following transfection, 
cells were treated either with diquat or rotenone for 20 hours then cells were fixed and were 
probed for SIRT1 and phospho-α-synuclein (please refer Section 2.3.5). The images captured 
using a confocal microscope were quantified using ImageJ software (NIH, USA).  
On treatment with diquat, a significant reduction in the number of α- synuclein aggregates 
was observed in both SIRT1WT and SIRT1H363Y transfected cells compared to pLenti 
CMV transfected cells (p<0.001; Figure 3.11). SIRT1 did not co-localise with α-synuclein 
hence its effect on the aggregate formation could possibly be through its positive action in 
ROS scavenging. Compared to SIRT1WT transfected cells, α-synuclein aggregation was 
higher in SIRT1H363Y transfected cells (p<0.001; Figure 3.11).  
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Figure 3.11 α-synuclein aggregate formation and quantification in diquat treated SH-
SY5Y cells. SIRT1WT and SIRT1H363Y overexpressing SH-SY5Y cells were treated with diquat 
(20μM or 10μM) and 0.2% PBS; cells transfected with empty vector were used as a control. Cells 
were immunostained with phospho-α-synuclein. Images were captured through GFP filter under 63X 
magnification. A) shows the captured images for α-synuclein staining and B) represents the aggregate 
quantification. Each bar represents % α-synuclein aggregates from three independent assays (n=3). 
***p<0.01 when compared to 0.2% PBS, one-way ANOVA (Bonferroni corrected), ###p<0.001 and 
##p<0.01 when compared to empty vector treatment, ~~~p<0.001when compared to SIRT1WT 
overexpressing cells, two-way ANOVA (Bonferroni corrected).  Scale bar: 20μM 
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In rotenone treated cells, overexpression of SIRT1WT and SIRT1H363Y reduced α-synuclein 
aggregate formation compared to pLenti CMV transfected cells (p<0.001; Figure 3.12). 
Rotenone is shown to induce parkinsonian symptoms in animal model of PD, where it inhibits 
Complex I, causes dopaminergic neuronal loss and also enhances the accumulation of  α- 
synuclein aggregates (Betarbet et al., 2000). The result of this study shows the similar effect 
of rotenone on α-synuclein inclusions. Similar to diquat, aggregate formation was higher in 
SIRT1H363Y transfected cells compared to SIRT1WT cells (p<0.001; Figure 3.12). 
The results obtained from this study show that diquat and rotenone both enhance α-synuclein 
aggregation and SIRT1 reduces the aggregation without directly interacting with α-synuclein.  
Even though the enzymatic activity mostly reduced the formation of aggregates, SIRT1 
mutant also reduced the inclusions suggesting that SIRT1 also acts through mechanisms 
which are independent of its deacetylase activity.    
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Figure 3.12 α-synuclein aggregate formation and quantification in rotenone treated SH-
SY5Y cells. SIRT1WT and SIRT1H363Y overexpressing SH-SY5Y cells were treated with rotenone 
(20μM or 0.5μM) and 0.2% DMSO; cells transfected with empty vector were used as a control. Cells 
were immunostained with phospho-α-synuclein. Images were captured through GFP filter under 63X 
magnification. A) shows the captured images for α-synuclein staining and B) represents the aggregate 
quantification. Each bar represents % α-synuclein aggregates from three independent assays (n=3). 
***p<0.01 when compared to 0.2% DMSO, one-way ANOVA (Bonferroni corrected), ###p<0.001 
and ##p<0.01 when compared to empty vector treatment, ~~~p<0.001 when compared to SIRT1WT 
overexpressing cells, two-way ANOVA (Bonferroni corrected).  Scale bar: 20μM 
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3.4.2 Post-mortem human brain tissue 
Among all sirtuins, SIRT1 is the most studied and has been implicated to enhance cell life by 
enhancing DNA repair, mitochondrial biogenesis and by inhibiting apoptosis and 
inflammatory responses. As discussed earlier, many studies have reported protective role of 
SIRT1 in AD, PD, HD and ALS. To further study the role of SIRT1 in neurodegenerative 
disorders, the levels of SIRT1 protein were measured in different regions of brain of PD, PDD, 
DLB and AD and were compared to a cohort-control group. 
 
3.4.2.1 SIRT1 levels in PD 
The levels of SIRT1 in PD cases were determined in four different brain regions namely, 
frontal cortex, temporal cortex, putamen and cerebellum. 
Frontal Cortex 
There are two isoforms of SIRT1 protein annotated in the UniProt database (Q96EB6 
(SIRT1_HUMAN))- SIRT1FL (predicted molecular weight 80kDa but the observed 
molecular weight on Western blot is ~120kDa possibly due to post translational modifications 
(Lynch et al., 2010)) and isoform 2 (~75kDa).  
In the frontal cortex samples of PD, 120kDaSIRT1 and SIRT1FL (80kDa) were observed on 
Western blot analysis and the level of 120kDaSIRT1 were reduced by 28% compared to 
controls (p<0.05, Figure 3.13 A) whereas, no significant difference was observed in the levels 
of SIRT1FL (Figure 3.13 A).  
Being a nuclear protein, SIRT1 targets numerous proteins residing in the nucleus and histone 
H3 acetylated at the Lys residue 9 (H3K9) is one of them, though this substrate is shared by 
another two SIRTs, SIRT3 and SIRT6. Acetylated p53 is another substrate of SIRT1 but on 
Western blot analysis its level could not be detected, hence AcH3K9 was used for Western 
blot analysis. The levels of total Histone H3 did not show any change between PD and control 
but the levels of AcH3K9 were reduced by ~25% in PD when compared to controls (p<0.05; 
Figure 3.13 B). 
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Figure 3.13 Expression of SIRT1 and its substrate H3 in the frontal cortex of PD and 
controls. The levels of SIRT1 and total and acetylated histone H3 were determined in the frontal 
cortex of PD patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised 
with GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. *p<0.05 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a representative blot of 
GAPDH, total H3 and acetylated H3.  
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Temporal Cortex 
In the temporal cortex, SIRT1FL (80kDa) and isoform 2 (75kDa) were observed and 
120kDaSIRT1 could not be detected. The levels of SIRT1FL were elevated by 15% (p<0.01; 
Figure 3.14 A) and isoform 2 were elevated by 36% (p<0.0001; Figure 3.14 A) compared to 
controls. Compared to controls, no significant difference was observed in the levels of 
acetylated or total histone H3, in the temporal cortex of PD cases (Figure 3.14 B). 
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Figure 3.14 Expression of SIRT1 and H3 in the temporal cortex of PD and controls. The 
levels of SIRT1 and total and acetylated histone H3 were determined in the temporal cortex region of 
PD patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. ***p<0.001 
and **p<0.01 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a 
representative blot of GAPDH, total H3 and acetylated H3. 
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Putamen 
In the putamen, only SIRT1FL could be observed on the blot and no significant difference 
was observed between PD and control (Figure 3.15 A). Similar to SIRT1, the levels of 
acetylated or total histone H3 were not altered in PD when compared to control (Figure 3.15 
B).  
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Figure 3.15 Expression of SIRT1 and H3 in the putamen of PD and controls. The levels of 
SIRT1 and total and acetylated histone H3 were determined in the putamen of PD patients and were 
compared to a cohort-control. A) SIRT1 band intensity was normalised with GAPDH and B) 
Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are presented as fold 
change (+SD) with respect to control from three independent replicates. No significant differences 
were observed between PD and control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a 
representative blot of GAPDH, total H3 and acetylated H3. 
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Cerebellum 
As with the putamen, only SIRT1FL could be detected in Western blot of the cerebellum and 
no significant difference was observed between PD and control (Figure 3.16 A). The levels of 
acetylated H3 in the cerebellum in PD were increased by 47%  and a significant increase of 
66% (p<0.05; Figure 3.16B) was also observed in the level of total H3 in PD compared to 
controls on normalisation with GAPDH. No significant difference in the level of AcH3K9 
was observed when it was normalised with total H3 level (Figure 3.16 B). 
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Figure 3.16 Expression of SIRT1 and H3 in the cerebellum of PD and controls. The levels 
of SIRT1 and total and acetylated histone H3 were determined in the cerebellum of PD patients and 
were compared to a cohort-control. A) SIRT1 band intensity was normalised with GAPDH and B) 
Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are presented as fold 
change (+SD) with respect to control from three independent replicates. **p<0.01 and *p<0.05 when 
compared to control, statistical analysis was done through t-test performed on GraphPad prism. A) 
Image is a representative blot of SIRT1 and GAPDH and B) Image is a representative blot of GAPDH, 
total H3 and acetylated H3.   
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 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Putamen 
(%) 
Cerebellum 
(%) 
SIRT1 
SIRT1 120kDa 
SIRT1 80kDa 
SIRT1 75kDa 
 
28  (p<0.05) 
11↓ (p>0.05) 
- 
 
- 
15 (p<0.01) 
36 (p<0.001) 
 
- 
NS 
- 
 
- 
NS 
- 
H3 
H3 
Acetylated (K9) 
Ac Vs Total 
 
NS 
24 (p<0.05) 
25 (p<0.01) 
 
NS 
NS 
NS 
 
NS 
NS 
NS 
 
66 (p<0.01) 
47 (p<0.05) 
16↓ (p>0.05) 
Table 3.1 Summary table presenting protein expression of SIRT1 and its substrate H3 in 
PD compared to controls. The alterations are expressed as percentage change. The text in green 
indicates elevation and in red indicates reduction in the protein expression. NS- No significant 
difference (any difference under 10% with p>0.05). 
 
In PD,  the expression of SIRT1 was down-regulated in the frontal cortex whereas SIRT1 was 
up-regulated in the temporal cortex. No significant alterations were observed in the putamen 
or cerebellum when compared to control (Table 3.1).  
 
3.4.2.2 Expression of SIRT1 in PDD 
In PDD, the levels of SIRT1 and histone H3 were determined in the frontal cortex, temporal 
cortex, putamen and cerebellum and were compared to a cohort-control group. 
 
Frontal Cortex 
In the frontal cortex of PDD, no significant differences were observed in the levels of 
SIRT1FL and 120kDaSIRT1 compared to control (Figure 3.17 A).  Similar to the levels of 
SIRT1, no significant differences were observed in the expression of acetylated or total H3 on 
normalisation with GAPDH (Figure 3.17 B). A small reduction of 10% (p<0.05) was 
observed in the level of acetylated H3 when normalised with total H3, this small difference 
can be attributed to the background of the blots (Figure 3.17 B). 
 
  
 143 
A 
 
B 
 
Figure 3.17 Expression of SIRT1 and H3 in the frontal cortex of PDD and controls. The 
levels of SIRT1 and total and acetylated histone H3 were determined in the frontal cortex of PDD 
patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. *p<0.05 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a representative blot of 
GAPDH, total H3 and acetylated H3. 
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Temporal Cortex 
In the temporal cortex of PDD, no significant difference was observed in the level of 
SIRT1FL (Figure 3.18 A) but the level of isoform 2 was reduced by 26% compared to control 
(p<0.01; Figure 3.18 A). The levels of acetylated H3 in the temporal cortex of PDD were 
reduced by 21% (p<0.05; Figure 3.18 B) and total H3 expression was not altered compared to 
control when normalised with GAPDH. No significant difference was observed in expression 
of acetylated H3 when it was normalised with total H3 (Figure 3.18 B). 
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Figure 3.18 Expression of SIRT1 and H3 in the temporal cortex of PDD and controls. 
The levels of SIRT1 and total and acetylated histone H3 were determined in the temporal cortex of 
PDD patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. **p<0.01 
and *p<0.05 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a 
representative blot of GAPDH, total H3 and acetylated H3. 
 146 
Putamen 
In the putamen, no significant difference was observed in the levels of SIRT1 between PDD 
and controls (Figure 3.19 A). Similarly, the levels of acetylated H3 or total H3 did not show 
any significant change between the two groups (Figure 3.19 B). 
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Figure 3.19 Expression of SIRT1 and H3 in the putamen of PDD and controls. The levels 
of SIRT1 and total and acetylated histone H3 were determined in the putamen of PDD patients and 
were compared to a cohort-control. A) SIRT1 band intensity was normalised with GAPDH and B) 
Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are presented as fold 
change (+SD) with respect to control from three independent replicates. No significant differences 
were observed between PDD and control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a 
representative blot of GAPDH, total H3 and acetylated H3. 
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Cerebellum 
No significant differences were observed in the expression of SIRT1 in the cerebellum of 
PDD when compared with control (Figure 3.20 A). The expression of total H3 or acetylated 
H3 in the cerebellum remained unaltered between the groups (Figure 3.20 B). 
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Figure 3.20 Expression of SIRT1 and H3 in the cerebellum of PDD and controls. The 
levels of SIRT1 and total and acetylated histone H3 were determined in the cerebellum of PDD 
patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. No 
significant differences were observed between PDD and control, statistical analysis was done through 
t-test performed on GraphPad prism. A) Image is a representative blot of SIRT1 and GAPDH and B) 
Image is a representative blot of GAPDH, total H3 and acetylated H3.   
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 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Putamen 
(%) 
Cerebellum 
(%) 
SIRT1 
SIRT1 120kDa 
SIRT1 80kDa 
SIRT1 75kDa 
 
19↑ (p>0.05) 
17↓ (p>0.05) 
- 
 
- 
NS 
26 (p<0.01) 
 
- 
NS 
- 
 
- 
NS 
- 
H3 
H3 
Acetylated (K9) 
Ac Vs Total 
 
NS 
NS 
10 (p<0.05) 
 
12↓ (p>0.05) 
22 (p<0.05) 
15↓ (p>0.05) 
 
12↓ (p>0.05) 
20↓ (p>0.05) 
NS 
 
14↑ (p>0.05) 
17↑(p>0.05) 
NS 
Table 3.2 Summary table presenting protein expression of SIRT1 and H3 in PDD 
compared to controls. The alterations are expressed as percentage change. The text in green 
indicates elevation and in red indicates reduction in the protein expression. NS: No significant 
difference (any difference under 10% with p>0.05). 
 
As summarised in Table 3.2, no major changes were observed in the expression of SIRT1 in 
PDD compared to control except in the temporal cortex, where, SIRT1 was down regulated 
by 26%. 
 
3.4.2.3 SIRT1 levels in DLB 
In the DLB cases, the levels of SIRT1 and histone H3 were determined in five brain regions- 
frontal cortex, temporal cortex, putamen, hippocampus and cerebellum. 
 
Frontal Cortex 
In the frontal cortex of DLB, no changes were observed in the levels of 120kDaSIRT1 (Figure 
3.21 A) whereas, SIRT1FL was up-regulated by 22% (p<0.05; Figure 3.21 A). No significant 
changes were observed in the levels of total H3 or acetylated H3 in DLB as compared to 
control (Figure 3.21 B). 
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Figure 3.21 Expression of SIRT1 and H3 in the frontal cortex of DLB and controls. The 
levels of SIRT1 and total and acetylated histone H3 were determined in the frontal cortex of DLB 
patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. *p<0.05 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a representative blot of 
GAPDH, total H3 and acetylated H3. 
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Temporal Cortex 
In the temporal cortex of DLB, SIRT1FL was up-regulated by 38% (p<0.0001; Figure 3.22 
A) whilst, no changes were observed in the levels of isoform 2 (Figure 3.22 A) when 
compared to control. The levels of acetylated H3 in the temporal cortex, showed a reduction 
of 14% (p<0.05; Figure 3.22 B) in DLB when normalised with GAPDH but no significant 
change was seen in the level of total H3. On normalisation with total H3, the levels of 
acetylated H3 did not show any significant difference between DLB and control groups 
(Figure 3.22 B). 
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Figure 3.22 Expression of SIRT1 and H3 in the temporal cortex of DLB and controls. 
The levels of SIRT1 and total and acetylated histone H3 were determined in the temporal cortex of 
DLB patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. ***p<0.001 
and *p<0.05 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a 
representative blot of GAPDH, total H3 and acetylated H3. 
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Putamen 
In the putamen, no significant differences were observed in the levels of SIRT1 between DLB 
and controls (Figure 3.23 A). The levels of acetylated and total H3 were reduced by 30% 
(p<0.001) and 34% (p<0.001), respectively, in the DLB cases (Figure 3.23 B). Since total H3 
levels were reduced, no change was observed when the levels of acetylated H3 were 
normalised with total H3 (Figure 3.23 B). 
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Figure 3.23 Expression of SIRT1 and H3 in the putamen of DLB and controls. The levels 
of SIRT1 and total and acetylated histone H3 were determined in the putamen of DLB patients and 
were compared to a cohort-control. A) SIRT1 band intensity was normalised with GAPDH and B) 
Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are presented as fold 
change (+SD) with respect to control from three independent replicates. ***p<0.001 when compared 
to control, statistical analysis was done through t-test performed on GraphPad prism. A) Image is a 
representative blot of SIRT1 and GAPDH and B) Image is a representative blot of GAPDH, total H3 
and acetylated H3.  
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Hippocampus 
The levels of SIRT1 and H3 were analysed in hippocampal samples of DLB and were 
compared with AD and controls. On the Western blot analysis, no significant difference was 
observed in the expression of SIRT1 between DLB and control (Figure 3.24 A). Compared to 
AD, the levels of SIRT1 were up-regulated in DLB by 30% (p<0.05; Figure 3.24 A). No 
significant difference was observed in the level of acetylated H3 when normalised either with 
GAPDH or total H3 but a reduction of 30% was observed in the level of total H3 in DLB 
when compared with controls (p<0.05). On comparison with AD, the level of total H3 were 
reduced by 40% and levels of acetylated H3 were upregulated by 20% when normalised with 
total H3 (p<0.05; Figure 3.24 B). 
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Figure 3.24 Expression of SIRT1 and H3 in the hippocampus of DLB, AD and controls. 
The levels of SIRT1 and total and acetylated histone H3 were determined in the hippocampus of DLB 
and AD patients and compared to a cohort-control and each other. A) SIRT1 band intensity was 
normalised with GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or 
H3. Data are presented as fold change (+SD) with respect to control from three independent replicates. 
**p<0.01 when compared to control and ##p<0.01 and #p<0.05 when compared to AD, statistical 
analysis was done through two-way ANOVA and post hoc t-test (Bonferroni corrected) on SPSS. A) 
Image is a representative blot of SIRT1 and GAPDH and B) Image is a representative blot of GAPDH, 
total H3 and acetylated H3. 
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Cerebellum 
The expression of SIRT1 was up-regulated by 21% (p<0.05; Figure 3.25 A) in the cerebellum 
of DLB patients compared to control. No significant difference was observed in the levels of 
acetylated or total H3 between DLB and control (Figure 3.25 B). 
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Figure 3.25 Expression of SIRT1 and H3 in the cerebellum of DLB and controls. The 
levels of SIRT1 and total and acetylated histone H3 were determined in the cerebellum of DLB 
patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. *p<0.05 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a representative blot of 
GAPDH, total H3 and acetylated H3. 
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 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Putamen 
(%) 
Hippocampus 
(%) 
Cerebellu
m (%) 
SIRT1 
SIRT1 120kDa 
SIRT1 80kDa 
SIRT1 75kDa 
 
14↓ (p>0.05) 
22 (p<0.05) 
- 
 
- 
38 (p<0.001) 
NS 
 
- 
11↓ (p>0.05) 
- 
 
- 
12↓ (p>0.05) 
- 
 
- 
21 (p<0.05) 
- 
H3 
H3 
Acetylated  (K9) 
Ac Vs Total 
 
NS 
NS 
NS 
 
NS 
21 (p<0.05) 
16↓ (p>0.05) 
 
34 (p<0.001) 
30 (p<0.001) 
NS 
 
34 (p<0.01) 
13↓ (p>0.05) 
27↑ (p>0.05) 
 
13↑ (p>0.05) 
24↑ (p>0.05) 
NS 
Table 3.3 Summary table presenting protein expression of SIRT1 and H3 in DLB 
compared to controls. The alterations are expressed as percentage change. The text in green 
indicates elevation and in red indicates reduction in the protein expression. NS: No significant 
difference (any difference under 10% with p>0.05). 
 
Western blot analysis of SIRT1 in DLB showed upregulation of the protein in three regions of 
brain- frontal cortex, temporal cortex and cerebellum, whereas no changes were observed in 
the putamen or hippocampus when compared to control (Table 3.3). 
 
3.4.2.4 Levels of SIRT1 in AD 
In AD cases, the expression of SIRT1 and H3 were determined in four different brain regions- 
frontal cortex, temporal cortex, hippocampus and cerebellum. 
 
Frontal Cortex 
In the frontal cortex of AD, the levels of 120kDaSIRT1 and SIRT1FL were reduced by 30% 
(p<0.01) and 26% (p<0.01), respectively, when compared to control (Figure 3.26 A). The 
levels of total H3 or acetylated H3 remained unaltered between AD and control (Figure 3.26 
B). 
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Figure 3.26 Expression of SIRT1 and H3 in the frontal cortex of AD and controls. The 
levels of SIRT1 and total and acetylated histone H3 were determined in the frontal cortex of AD 
patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. **p<0.01 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a representative blot of 
GAPDH, total H3 and acetylated H3. 
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Temporal Cortex 
In the temporal cortex of AD, the levels of SIRT1FL were reduced by 25% (p<0.01; Figure 
3.27 A), whereas, no significant change was observed in the level of isoform 2 (Figure 3.27 
A). No significant changes were observed in the levels of total H3 or acetylated H3 between 
AD and control (Figure 3.27 B). 
 
  
 163 
A 
 
B 
 
Figure 3.27 Expression of SIRT1 and H3 in the temporal cortex of AD and controls. The 
levels of SIRT1 and total and acetylated histone H3 were determined in the temporal cortex of AD 
patients and were compared to a cohort-control. A) SIRT1 band intensity was normalised with 
GAPDH and B) Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. **p<0.01 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT1 and GAPDH and B) Image is a representative blot of 
GAPDH, total H3 and acetylated H3. 
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Hippocampus 
The levels of SIRT1 and H3 were measured in the hippocampal samples of AD which were 
then compared with control and DLB. The levels of SIRT1 were down-regulated in AD by 
36% (p<0.01) and 30% (p<0.05) when compared to control and DLB, respectively (Figure 
3.24 A). No significant differences were observed in the levels of total or acetylated H3 
between AD and control. On comparison with DLB, the level of total H3 were elevated by 
40% (p<0.01) and levels of acetylated H3 were reduced by 20% when normalised with total 
H3 (p<0.05; Figure 3.24 B). 
 
Cerebellum 
The analysis of SIRT1 in the cerebellum showed a reduction of 30% in AD compared to 
control (p<0.001; Figure 3.26 A). No changes were observed in the levels of total or 
acetylated H3 among the groups (Figure 3.26 B). 
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Figure 3.28 Expression of SIRT1 and H3 in the cerebellum of AD and controls. The levels 
of SIRT1 and total and acetylated histone H3 were determined in the cerebellum of AD patients and 
were compared to a cohort-control. A) SIRT1 band intensity was normalised with GAPDH and B) 
Acetylated/total H3 band intensity was normalised with GAPDH or H3. Data are presented as fold 
change (+SD) with respect to control from three independent replicates. ***p<0.001 when compared 
to control, statistical analysis was done through t-test performed on GraphPad prism. A) Image is a 
representative blot of SIRT1 and GAPDH and B) Image is a representative blot of GAPDH, total H3 
and acetylated H3. 
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 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Hippocampus 
(%) 
Cerebellum 
(%) 
SIRT1 
SIRT1 120kDa 
SIRT1 80kDa 
SIRT1 75kDa 
 
30 (p<0.01) 
26 (p<0.01) 
- 
 
- 
25 (p<0.01) 
13↑ (p>0.05) 
 
- 
36 (p<0.01) 
- 
 
- 
30 (p<0.001) 
- 
H3 
H3 
Acetylated (K9) 
Ac Vs Total 
 
13↑ (p>0.05) 
16↑ (p>0.05) 
NS 
 
NS 
NS 
NS 
 
12↑ (p>0.05) 
NS 
12↓ (p>0.05) 
 
48↑ (p>0.05) 
43↑ (p>0.05) 
NS 
 
Table 3.4 Summary table presenting protein expression of SIRT1 and H3 in AD 
compared to controls. The alterations are expressed as percentage change. The text in green 
indicates elevation and in red indicates reduction in the protein expression. NS: No significant 
difference (any difference under 10% with p>0.05). 
 
Western blot analysis of SIRT1 in AD showed significant reduction in the levels of the 
protein in all brain regions (Table 3.4). 
 
3.4.2.5 Measurement of SIRT1 activity in the frontal and temporal cortices 
Western blot analysis of SIRT1 showed significant changes in the frontal and temporal 
cortices across the disease groups, hence, the enzymatic activity of SIRT1 was measured in 
these two regions. 
 
SIRT1 activity in the Frontal Cortex 
In the frontal cortex, total SIRT activity did not show any significant change between the 
disease groups and controls (p>0.05; Figure 3.30 A). Compared to AD, the total SIRT activity 
was reduced in PD and DLB by 22% (p<0.01), PDD did not show any significant difference 
(Figure 3.29 A). SIRT1 activity was down-regulated in PD (43%; p<0.001), PDD (39%; 
p<0.001), DLB (32%; p<0.001) and AD (31%; p<0.001) compared to controls (F=20.457, 
p<0.001; Figure 3.29 B).  
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Figure 3.29 Total SIRT and SIRT1 activities in the frontal cortex of PD, PDD, DLB, AD 
and controls. Total SIRT and SIRT1 activities were measured through a fluorometric enzymatic 
activity assay in the frontal cortex of PD, PDD, DLB and AD patients and were compared to a cohort-
control. A) shows total SIRT activity and B) represents SIRT1 activity in these groups. ***p<0.001 
when compared to control, one-way ANOVA (Bonferroni corrected). 
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SIRT1 activity in the Temporal Cortex 
In the temporal cortex, there was no significant difference in total SIRT activity between the 
disease groups and control (p>0.05). However, compared to AD there was a significant 
reduction of 33% in total SIRT activity in PDD (p<0.05) whereas PD and DLB did not show 
any significant change (Figure 3.30 A). SIRT1 activity was down-regulated in PD (25%; 
p<0.01), PDD (23%; p<0.05), DLB (30%; p<0.001) and AD (22%; p<0.05) compared to 
controls (F: 6.265, p<0.001) whereas no significant difference was seen among the disease 
groups (Figure 3.30 B).  
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Figure 3.30 Total SIRT and SIRT1 activities in the temporal cortex of PD, PDD, DLB, 
AD and controls. Total SIRT and SIRT1 activities were measured through a fluorometric enzymatic 
activity assay in the temporal cortex of PD, PDD, DLB and AD patients and were compared to a 
cohort-control. A) shows total SIRT activity and B) represents SIRT1 activity in these groups. 
***p<0.001, **p<0.01 and *p<0.05 when compared to control, one-way ANOVA (Bonferroni 
corrected). 
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3.5 Discussion 
3.5.1 SIRT1- an anti-apoptotic factor under oxidative stress 
Oxidative stress is an imbalance between the production of free radicals and antioxidant 
defence which leads to DNA, protein and lipid damage which eventually may lead to cell 
death. Oxidative stress has been implicated to play a role in the development and progression 
of neurodegenerative disorders (Giasson et al., 2000). Exposure to environmental factors, 
such as rotenone, MPTP, paraquat and diquat has been shown to lead to oxidative damage in 
DA neurones leading to parkinsonian symptoms in animal and cellular models (reviewed in 
(Di Monte et al., 2002)). SIRT1, a NAD
+
 dependent deacetylase, is a redox sensor and has 
been shown to regulate key cellular processes including antioxidant defence, DNA repair and 
genomic stability (Guarente, 2013).  
In this context, the present study was designed to determine the role of SIRT1 in cell survival 
under oxidative stress. Diquat and rotenone were used as oxidative stress inducer in 
SIRT1WT, SIRT1H363Y (catalytically inactive) and pLenti CMV (empty vector, control 
group) transfected SH-SY5Ycells. The results obtained from Alamar Blue fluorescence assay 
showed increased fluorescence in SIRT1WT and SIRT1H363Y transfected cells compared to 
the control group, nonetheless, SIRT1WT showed the highest fluorescence (Figures 3.2 and 
3.3). In SN4741 DA neurones, Mudo et al., reported the protective effect of SIRT1 in MPTP 
treated cells which was mediated through activation of PGC-1α leading to enhanced 
expression of mitochondrial antioxidants SOD2 and Thioredoxin-2 (TRx2) (Mudo et al., 
2012). This finding supports the results obtained from the present study and establishes the 
pro-survival role of SIRT1 against oxidative stress induced by diquat or rotenone in SH-
SY5Y cells. 
 
3.5.2 Oxidative stress and SIRT1- Role of deacetylase activity 
SIRT1 modulates several cellular processes that are involved in improved cell survival and 
has been shown to delay the process of ageing. Several studies have shown a protective role 
of SIRT1 against the damage caused by oxidative stress by regulating the activity of histones 
including H1, H3  and H4 (Vaquero et al., 2004) and transcription factors including FOXO 
family (Brunet et al., 2004), PGC-1α (Nemoto et al., 2005), NF-кB (Yeung et al., 2004) and 
p53 (Brooks and Gu, 2011). The regulation of histones and non-histone target proteins is 
dependent on it deacetylase activity where SIRT1 removes the acetyl group from the lysine 
residue of the protein and in turn activates or inhibits the activity of the protein. SIRT1 has 
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been shown to confer protection to cells under stress by deacetylating most of the targets. By 
deacetylating p53, SIRT1 inhibits the pro-apoptotic activity of p53 (Brooks and Gu, 2011) 
and the deacetylation of FOXO family members by SIRT1 leads to enhanced antioxidant 
proteins, GADD-45 expression and  inhibition of targets involved in cell death (Brunet et al., 
2004). The findings of the present study showed that overexpression of SIRT1WT protein 
promoted cell survival after treatment with diquat or rotenone in SH-SY5Y cells under 
enhanced oxidative stress (Figures 3.2 and 3.3). Surprisingly, SIRT1H363Y, a deacetylase 
deficient mutant conferred similar protection to cells against diquat or rotenone but not up to 
the same extent as SIRT1WT (Figures 3.2 and 3.3). Similar to the findings of this study, 
Pfister et al., showed that SIRT1WT and its mutant forms lacking deacetylase activity 
(H363Y and H355A) protected cerebellar granule neurones (CGN) from low-potassium 
induced toxicity, though in their study the extent of protection by mutant forms was same as 
SIRT1WT (Pfister et al., 2008). The difference between their and this study can be attributed 
to the type of cell used and also trigger causing cellular stress.  
In the current study, it was also observed that the expression of SIRT1 was down-regulated 
upon treatment with diquat or rotenone (Figures 3.4 and 3.6). de Kreutzenberg et al., observed 
the similar effect in human monocytes (THP-1) cells; enhanced oxidative stress in these cells 
led to reduced SIRT1 and NAMPT expressions (de Kreutzenberg et al., 2010). Reduced 
SIRT1 level possibly corresponds to elevated cell death under oxidative stress and highlights 
the important role of SIRT1 in cell survival.   
Future investigations should be conducted to look into the physical interactions of SIRT1 as a 
binding protein in complexes that are involved in defence and repair mechanisms that do not 
require the deacetylase activity of SIRT1.  
 
3.5.3 Mechanisms through which SIRT1 modulates oxidative stress 
As discussed previously, SIRT1 over-expression rescued SH-SY5Y cells from oxidative 
stress and the effect was not entirely dependent on the deacetylase activity. Pfister et al., did 
report that SIRT1 protected the CGNs from toxicity and the effect was independent of SIRT1 
deacetylase activity but could not establish a possible mechanism behind SIRT1 protection 
(Pfister et al., 2008). Ghosh et al., reported that SIRT1 and SIRT1H363Y repressed NF-кB 
activity (Ghosh et al., 2007).  In the current study, treatment with diquat or rotenone showed a 
significant reduction in the levels of NF-кB in SIRT1WT and SIRT1H363Y transfected cells. 
However, in pLenti CMV transfected cells, the levels of NF-кB were elevated (Figures 3.5 
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and 3.7). NF-кB is a family of transcription factors that regulates inflammation and immunity 
processes (Vallabhapurapu and Karin, 2009) and also plays important role in cell growth and 
development, and apoptosis (Morgan and Liu, 2011). ROS in cells trigger cell death and are 
known to activate NF-кB leading to transactivation of targets involved in protection against 
ROS (Schmitz et al., 2004) and under high oxidative stress, activation of NF-кB enhances cell 
death (Ryan et al., 2000). The results from the current study show that SIRT1 protects cells 
from oxidative stress by repressing the expression of NF-кB suggesting that possibly NF-кB 
enhances cell death on treatment with diquat or rotenone. 
SIRT1WT overexpression in SH-SY5Y cells enhanced the cell survival which indicates that 
even though the deacetylase activity is not entirely responsible for the protection conferred by 
SIRT1, it definitely does play role in cell survival. Under stress, SIRT1 has been shown to 
enhance cell survival by targeting p53, FOXO family and Ku70.  SIRT1 directly deacetylates 
p53 and inhibits the pro-apoptotic activity of p53 (Luo et al., 2001). Inhibition of p53 by 
SIRT1 leads to reduced expression of p21 and PUMA, the targets of p53 that regulate 
apoptosis (Yamakuchi et al., 2008). Apart from inhibiting p53-dependent apoptosis, SIRT1 
also inhibits Bax-mediated apoptosis via Ku70. SIRT1 deacetylates and activates DNA repair 
factor Ku70, which sequestrates Bax away from mitochondria to the cytoplasm and attenuates 
apoptotic signals (Cohen et al., 2004). These studies suggest that under stress SIRT1protects 
cells from stress-induced damage and inhibits cell death. 
One of the major targets of SIRT1 are FOXO family proteins and deacetylation of these 
factors leads to the activation of proteins involved in antioxidant defence and simultaneously 
inhibits pro-apoptotic targets (Brunet et al., 2004). SIRT1 deacetylates FOXO1 and enhances 
the expression of its targets especially SOD2 and p27
kip1
 resulting in low ROS levels and 
increased genomic stability (Daitoku et al., 2004). Under stress, FOXO3a is translocated to 
the nucleus from the cytoplasm and associates with SIRT1 and enhances SOD2 and catalase 
expression (Brunet et al., 2004). SIRT1 also promotes DNA repair via GADD45 by 
deacetylating FOXO4 (van der Horst et al., 2004) but inhibits the apoptotic pathways 
triggered by FOXO members.  In this study it was observed that under oxidative stress SIRT1 
was localised in the nucleus suggesting that SIRT1 may interact with FOXO family members 
and enhance their protective actions against stress.   
These findings suggest that SIRT1 indeed is a pro-survival protein that enhances antioxidant 
defence mechanisms, increases DNA repair, maintains genomic stability and inhibits cell 
death under oxidative stress. The results from the present study also showed the protective 
effect of SIRT1 on treatment with diquat or rotenone. Nevertheless, future studies should 
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concentrate on the role of SIRT1 as a binding factor or possibly a transcriptional factor/co-
factor that regulates cell survival. 
 
3.5.4 Possible role of SIRT1 in α-synuclein aggregate formation 
Lewy bodies (LB), composed of abnormally folded and aggregated α-synuclein proteins,  are 
a characteristic feature of PD and other Lewy bodies disorders  (Spillantini et al., 1998). α-
synuclein is a small soluble pre-synaptic protein that undergoes oligomerisation and 
aggregation resulting in fibrillation and formation of LBs. Several factors trigger 
oligomerisation of α-synuclein and oxidative stress is one of them. In this study, 
oligomerisation of α-synuclein proteins was initiated by inducing oxidative stress on 
treatment with diquat or rotenone, following which, the percentage of α-synuclein aggregates 
were measured in SH-SY5Y cells. Over-expression of SIRT1WT reduced the formation of α-
synuclein aggregates (Figures 3.11 and 3.12) and SIRT1H363Y a showed similar effect when 
compared to the control group (Figures 3.11-3.12). Interestingly, SIRT1 was not seen to co-
localise with α-synuclein suggesting that the effect of SIRT1 on the aggregate formation is 
maybe indirect and possibly through reduction of oxidative stress.  
Guo et al., reported that resveratrol (RSV) treatment in the mouse alleviated MPTP-induced 
parkinsonian symptoms and triggered the degradation of α-synuclein oligomers via SIRT1 
(Guo et al., 2016). They also showed that inhibition of SIRT1 by EX527 antagonized the 
protective effect of RSV, suggesting that protection exerted by RSV is SIRT1 dependent to a 
certain extent. However, Kitao et al., showed that on histological analysis, genetic over-
expression of SIRT1 could not protect DA neurones of SIRT1 transgenic mice from acute 
MPTP toxicity (Kitao et al., 2015). The difference between the two studies can possibly be 
explained by the course of MPTP treatment; while Kitao et al., studied the role of SIRT1 in 
acute MPTP toxicity, Guo et al., studied the role of SIRT1 in chronic MPTP treatment. Based 
on these findings, it is possible to say that RSV protects DA neurones against MPTP toxicity 
through its own antioxidant properties and at least a part of its protection is SIRT1 dependent.  
The results obtained from Alamar Blue fluorescence and fluorescence immunocytochemistry 
suggest that SIRT1 protects SH-SY5Y cells from oxidative stress and reduces aggregate 
formation of α-synuclein. In future investigations, the role of SIRT1 should be studied in 
prolonged oxidative stress with more focus on its actions that are not dependent on its 
deacetylase activity. 
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3.5.5 SIRT1- neurodegenerative disorder related expression 
Neurodegenerative disorders typically present pathologically with loss of neurones in the 
CNS. The causes of neurodegenerative disorders are still unknown, although environmental 
and known genetic risk factors are suggested to initiate these disorders. Ageing is believed to 
be the largest risk factor for the development and progression of neurodegeneration by 
affecting a number of cellular processes. At the molecular level, apoptosis, oxidative stress 
and mitochondrial dysfunction have been shown to promote these disorders. As discussed 
earlier, SIRT1 has shown to inhibit apoptosis by regulating p53, combat oxidative stress by 
regulating antioxidant defences via FOXO family members, regulates mitochondrial 
biogenesis mediated by PGC-1α, and maintains genomic stability by modulating histones. 
Stress affects the expressions, functions and localisation of the proteins (Welch, 1992). SIRT1 
modulates oxidative stress and represses the damages caused by it.  
In this context, this study investigated the expression of SIRT1 in post-mortem brain regions 
of PD, PDD, DLB and AD patients. On Western blot analysis, SIRT1FL (80kDa) was 
observed in all brain regions whereas 120kDaSIRT1 was undetectable except in the frontal 
cortex and SIRT1 isoform 2 was detectable only in the temporal cortex. In general, no major 
alterations were observed in the levels of SIRT1 in PD and PDD, whilst the levels of SIRT1 
showed a trend of elevation in DLB. However, in AD, the levels of SIRT1 were reduced in all 
brain regions (Table 3.5). Pallas et al., analysed the expression of SIRT1 in PD (n=3), DLB 
(n=4) in the frontal cortex and compared to controls (n= 4) and observed no changes between 
the groups (Pallas et al., 2008). In this study, no significant difference was seen in expression 
of SIRT1 in PD but elevated levels of the protein were observed in DLB. The inconsistencies 
between the studies could possibly be explained by the group size, in this study, the number 
of cases was larger. SIRT1 expression was not altered significantly in Lewy body disorders 
(PD, PDD and DLB) but a major reduction in the level of SIRT1 was observed in AD and this 
could possibly be explained by the greater degree of cortical atrophy seen in AD (Li et al., 
2016). Further research should be conducted to look into cellular distribution of SIRT1 in 
human brain and also its interaction with biomarkers of these diseases should be assessed.   
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 Frontal 
Cortex 
Temporal 
Cortex 
Putamen Hippocampus Cerebellum 
PD ↓ ↑ No significant 
changes 
- No significant 
changes 
PDD No significant 
changes 
No significant 
changes 
No significant 
changes 
- No significant 
changes 
DLB ↑ ↑ No significant 
changes 
No significant 
changes 
↑ 
AD ↓ ↓ - ↓ ↓ 
Table 3.5 Summary of expression of SIRT1 in neurodegenerative disorders compared to 
a control group. ↑ indicates elevation; ↓ indicates reduction and – indicates that the expression of 
SIRT1 was not studied in that particular brain region. 
 
To further assess the role of SIRT1, its activity was measured in the frontal and temporal 
cortices of disease groups and was compared to a cohort control group. Compared to control, 
SIRT1 activity was reduced in disease groups although no significant difference was seen 
among the disease groups. Oxidative stress has also been shown to play a negative role in 
neurodegenerative disorders (Owen et al., 1997; Halliwell, 2006) and this possibly explains 
the reduced activity of SIRT1. Combined results from in vitro and human brain suggest that 
SIRT1 expression and its activity are down-regulated under stress which possibly hinders the 
protective effect of SIRT1 towards cell survival. 
 
3.5.6 Conclusions 
In the current study, it was shown that over-expression of SIRT1 protected SH-SY5Y cells 
from diquat or rotenone by down-regulating NF-кB. The observed protection exerted by 
SIRT1 is not entirely dependent on its deacetylase activity as the inactive mutant of SIRT1 
also conferred a degree of protection to cells.  In post-mortem human brain tissue, expression 
of SIRT1 did not differ in Lewy body disorders whilst reduction in SIRT1 expression was 
observed in AD, though the enzymatic activity was down-regulated in all groups compared to 
controls. Based upon these findings it can be concluded that SIRT1 is a pro-survival protein 
which is down-regulated under stress.  
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Chapter 4 SIRT2- Association with oxidative stress mediated cell 
death and its characterisation in neurodegenerative disorders 
4.1 Introduction 
The mammalian Sirtuin, SIRT2, is a NAD
+
 dependent cytoplasmic protein and is an 
orthologue to yeast Hst2p (Perrod et al., 2001). SIRT2 though predominantly a cytoplasmic 
protein, SIRT2 shuttles between the cytoplasm and nucleus depending upon the cell cycle 
stage (North and Verdin, 2007a).  Human SIRT2 deacetylates a number of cytoplasmic and 
nuclear proteins and thus is a key modulator of many cellular processes including cell cycle, 
cell motility, autophagy, metabolic homeostasis, myelination, antioxidant defence 
mechanisms and tumorigenesis. 
Although all SIRTs are expressed in the brain, SIRT2 is the most abundant (Maxwell et al., 
2011) and is expressed in nearly all brain regions with particularly high levels in myelin- 
producing oligodendrocytes (OL) (Li et al., 2007a; Zhu et al., 2012). In a mouse model, 
isoform 2 of SIRT2, SIRT2.2 is highly expressed in the adult CNS and age related 
accumulation of SIRT2.2 and SIRT2.3 was observed in mouse and human cortical region 
(Maxwell et al., 2011). SIRT2 regulates myelin formation by deacetylating α-tubulin (K40) in 
OL (Li et al., 2007a) and deacetylating Par-3 (protease activated receptor) in Schwann’s cells 
(Beirowski et al., 2011). Whilst being a modulator of OL differentiation, SIRT2 is also 
suggested to have a role in regulation of neurite growth and neuronal motility in hippocampal 
neurones (Pandithage et al., 2008). These findings indicate that SIRT2 influences axonal 
plasticity and plays an important role in maintenance of neuronal network in the CNS and 
hence may be involved in age related neurodegenerative disorders.  
Neurodegenerative disorders affect mostly older people and the ageing process involves 
oxidative stress, DNA damage and weakened cellular repair and compensatory mechanisms. 
SIRT2 has been shown to play a role in regulation of these processes; hence, regulation of 
SIRT2 could provide therapeutic targets concerned with age-related neurodegenerative 
disorders.  
In few studies, SIRT2 has been reported to play a role in PD. In cellular and drosophila 
models of PD, inhibition of SIRT2 has been shown to rescue from α-synuclein mediated 
toxicity (Outeiro et al., 2007). Inhibition of SIRT2 decreases α-synuclein-mediated toxicity. 
Sirtuin inhibitors (AGK2 and sirtinol) and genetic inhibition of SIRT2 increased the size of α-
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synuclein aggregates in a cellular model of PD, which assists in the reduction of protein 
aggregates (Outeiro et al., 2007). 
4.2 Aims 
Given the role of SIRT2 in the CNS and PD, the aims of this study were to investigate the role 
of SIRT2 in oxidative stress mediated cell death and to characterise its role in PD: 
i) Study the effect of SIRT2 over-expression and its inhibition on cell viability in SH-
SY5Y cells. 
ii) Evaluate the effects of SIRT2 on α-synuclein aggregation in toxin treated SH-SY5Y 
cells. 
iii) Determine the levels of SIRT2 and its substrate in PD, PDD, DLB and AD brain 
samples. 
iv) Study the expression of SIRT2 at cellular level in PD, PDD, DLB and AD brain 
samples. 
v) Measure the SIRT2 enzymatic activity in PD, PDD, DLB and AD brain samples. 
 
4.3 Materials and methods 
4.3.1 SH-SY5Y cells 
Please refer to Materials and Methods sections 2.3.1 to 2.3.5 
 
4.3.1.2 SIRT2 transfection and AGK2 treatment 
SH-SY5Y cells were seeded in 12 well-plates and the cells were transfected with 
SIRT2pcDNA3.1 and the control group was transfected with empty pcDNA3.1 plasmid. To 
study the effect of SIRT2 inhibition, one set of cells transfected with SIRT2 and pcDNA3.1 
were treated with toxin alone and second set with toxin and AGK2 (25µM, SIRT2 inhibitor; 
Tocris, UK). AGK2 was added to cells 2 hours prior to diquat or rotenone treatment and the 
cells were incubated overnight for 20 hours. 
 
4.3.2 Brain tissue 
Please refer to Materials and Methods sections 2.1.1, 2.1.2 and 2.1.3. 
 179 
4.4 Results 
4.4.1 SH-SY5Y cells 
4.4.1.2 SIRT2 inhibition by AGK2 
To determine the toxicity of the SIRT2 inhibitor, AGK2, SH-SY5Y cells were treated with 
different concentrations of AGK2 ranging from 50µM-5µM and assessed for toxicity after 20 
hours. Viability was assessed by Alamar Blue reduction assay. No significant toxicity was 
observed in the cells after the Alamar Blue assay (Figure 4.1) and no morphological changes 
were observed in the cells. For further studies, a dosage of 25µM of AGK2 was selected as it 
was above the IC50 for SIRT2 (3.5µM) and below the IC50 for other SIRTs (>50µM).  
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Figure 4.1 Effect of AGK2 on viability of SH-SY5Y cells. SH-SY5Y cells were treated with 
various concentration of AGK2. Data is presented as mean (+SD) from three independent assays 
(n=3). No significant difference, One-way ANOVA (Bonferroni corrected). 
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SH-SY5Y cells were treated with SIRT inhibitors, EX527 (10µM; SIRT1 inhibitor), CHIC-35 
(0.5µM; SIRT1 inhibitor) and AGK2 (25µM; SIRT2 inhibitor). The cells were treated in 12 
well plates and after 20 hours of incubation, cell lysates were prepared and the levels of 
acetylated α-tubulin (a substrate of SIRT2) were determined using Western blotting (Section 
2.3.2). As shown in Figure 4.2, the level of acetylated α-tubulin was elevated by 72% in 
AGK2 treated cells compared to 0.2% DMSO treated cells (p<0.05, One-Way ANOVA) 
whereas no significant changes were observed in SIRT1 inhibitor treated cells. Levels of 
acetylated α-tubulin were also normalised with total α-tubulin levels and a remarkable 
increase of 1.7 fold was observed in AGK2 treated cells (p<0.01) whilst no significant 
changes were observed in SIRT1 inhibitors treated cells. This suggests that AGK2 is a potent 
inhibitor of SIRT2 and SIRT1 inhibitors do not inhibit SIRT2. 
 
 
Figure 4.2 Efficiency of AGK2 on SIRT2 inhibition. SH-SY5Y cells were treated with AGK2 
and SIRT1 inhibitors- EX527 and CHIC-35 for 20 hours and cell lysates were subjected to Western 
blot to probe acetylated α-tubulin (SIRT2 substrate) and total α-tubulin. Data presented as fold- 
untreated (+SD) from three independent assays (n=3). ***p<0.001, One-way ANOVA (Bonferroni-
corrected). Image is a representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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4.4.1.3 Over-expression of SIRT2 in SH-SY5Y cells 
SH-SY5Y cells were transfected with SIRT2pcDNA3.1 and SIRT2pLenti CMV plasmids and 
the efficiency of transfection was determined by analysing the levels of SIRT2 in the 
transfected cells. In SIRT2pcDNA3.1 transfected cells, the level of SIRT2 was increased by 
9.5 fold (Figure 4.3, p<0.001, One-Way ANOVA) whereas no change was observed in the 
cells transfected with SIRT2pLenti CMV plasmid (Figure 4.3, p>0.05, One-way ANOVA). 
This result shows that SIRT2pcDNA3.1 transfects the cells efficiently and SIRT2pLentiCMV 
fails to transfect the cells. 
 
Figure 4.3 Transfection of SH-SY5Y cells with different SIRT2 plasmids. SH-SY5Y cells 
were transfected with SIRT2 plasmids, in either pLenti CMV vector or pcDNA3.1. Data is presented 
as fold- untreated (+SD) from three independent assays (n=3). ***p<0.001 and ###p<0.001, when 
compared to mock and pLenti CMV, respectively, one-way ANOVA (Bonferroni-corrected). Image is 
a representative blot of SIRT2 and GAPDH. 
 
4.4.1.4 Effect of SIRT2 expression and inhibition on cell viability in toxin treated cells 
SIRT2 is a ubiquitously expressed lysine deacetylase and is abundantly present in human 
brain. The role of SIRT2 was studied in various neurodegenerative disorders and it was 
reported that inhibition of SIRT2 rescued the cells from α-synuclein toxicity (Outeiro et al., 
2007). Based upon this finding, the role of SIRT2 was studied in SH-SY5Y cells that were 
subjected to oxidative stress induced either by diquat or rotenone. 
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To investigate the role of SIRT2 in oxidative stress mediated cell death by diquat, SH-SY5Y 
cells were treated 20µM or 10µM diquat. SH-SY5Y cells were transfected with SIRT2 and 
control group was transfected with empty pcDNA3.1. After 48 hours of transfection one set of 
cells (SIRT2 cells and pcDNA3.1 cells) was treated with diquat alone and the other set of 
cells was first incubated with AGK2 (25µm) for two hours followed by diquat treatment for 
20 hours. Viability of cells was determined by the Alamar Blue assay. Cells transfected with 
SIRT2 were more viable with significant increase in Alamar Blue fluorescence compared to 
empty vector transfected cells (p<0.001, two-way ANOVA; Figure 4.4). Interestingly, 
significant elevation in cytotoxicity was observed in empty vector transfected cells co-
incubated with diquat and AGK2, than in cells treated with diquat alone (20µM diquat: 
p<0.001  and 10µM diquat p<0. 001; two- way ANOVA, Figure 4.4). 
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Figure 4.4 Effects of SIRT2 overexpression and inhibition on diquat treated SH-SY5Y 
cells. SIRT2 was over-expressed in SH-SY5Y cells and control cells were transfected with empty 
vector following which one set of cells was treated with diquat (20 or 10μM) alone and another with 
SIRT2 inhibitor AGK2 and diquat (20 or 10μM) for 20 hours and viability measured by reduction of 
Alamar Blue. Data are presented as fold- untreated (+SD) from three independent assays (n=3). 
***p<0.001 when compared to 0.2% PBS, one-way ANOVA (Bonferroni corrected), 
###p<0.001and ##p<0.01 when compared to empty vector treatment, ~~~p<0.001 when 
compared to empty vector+AGK2 treatment and $$p<0.01 and $p<0.05 when compared to 
SIRT2 overexpressing cells, two-way ANOVA (Bonferroni-corrected). 
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Similarly, the role of SIRT2 was investigated in rotenone treated SH-SY5Y cells. In cells 
treated with 0.5µM rotenone, no significant effect was seen by overexpression or inhibition of 
SIRT2 (p>0.05; Figure 4.5) but in cells treated with 20µM rotenone, reduction in toxicity was 
observed in SIRT2 over expressing cells compared to control cells and control cells treated 
with AGK2 (p<0.001; Figure 4.5). 
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Figure 4.5 Effects of SIRT2 overexpression and inhibition on rotenone treated SH-SY5Y 
cells. SIRT2 was over-expressed in SH-SY5Y cells and control cells were transfected with empty 
vector following which one set of cells was treated with rotenone (20 or 0.5μM) alone and another 
with SIRT2 inhibitor AGK2 and rotenone (20 or 0.5μM) for 20 hours and viability measured by 
reduction of Alamar Blue. Data are presented as fold- untreated (+SD) from three independent 
assays (n=3). ***p<0.001 when compared to 0.2% DMSO, one-way ANOVA (Bonferroni 
corrected), ###p<0.001and ##p<0.01 when compared to empty vector treatment, ~~~p<0.001 
when compared to empty vector+AGK2 treatment, two-way ANOVA (Bonferroni-corrected).    
 
The above observations indicate that SIRT2 overexpression rescued cells from diquat and 
rotenone induced cell death and inhibition of SIRT2 was deleterious to cells.  
  
  
 184 
4.4.1.5 Determination of expression of SIRT2 and its targets in toxin treated cells 
Following the viability assay after toxins treatment, SH-SY5Y cells were analysed using 
Western blot analysis for SIRT2 and its possible targets. After the Alamar Blue assay, cells 
were washed with PBS and harvested and were subjected to Western blot analysis (please 
refer Section 2.3.4 for details). 
Western blot analysis of diquat treated SH-SY5Y cells showed a significant increase in 
SIRT2 levels in SIRT2 transfected cells with a 3-3.5 fold increase in vehicle (0.2% PBS) 
treated cells compared to the empty vector transfected cells (p<0.001 compared to both empty 
vector and empty vector+AGK2, Figure 4.6). Similar increase was seen in 10μM diquat  
treated cells, interestingly a small increase of 12% in SIRT2 levels was observed in SIRT2 
transfected cells compared to SIRT2 transfected cells treated with AGK2 (p<0.01). 
In order to test the efficiency of SIRT2 inhibition by AGK2, levels of acetylated α-tubulin 
(K40), a known substrate of SIRT2 (North et al., 2003), was measured in the samples. As 
shown in Figures 4.7, the levels of acetylated α-tubulin were elevated by 1.2-1.6 fold in cells 
co-incubated with AGK2 and diquat (p<0.001 in empty vector+AGK2 cells and p<0.01 in 
SIRT2+AGK2 cells) compared to empty vector transfected cells. The levels of acetylated α-
tubulin were reduced by 50% in SIRT2 transfected cells (p<0.01; Figure 4.7) compared to 
empty vector transfected cells. These findings suggest that AGK2 is a potent SIRT2 inhibitor.  
SIRT2 has been shown to increase antioxidant defence mechanism by deacetylating FOXO3a 
and elevating FOXO3a DNA binding, resulting in an increased expression of SOD2 (Wang et 
al., 2007).  To test the mechanism by which SIRT2 may increase cell viability, the levels of 
SOD2 were measured in toxin treated SH-SY5Y cells. SOD2 levels were measured in diquat 
(20μM or 10μM) treated cells. In 20μM diquat treated cells, SOD2 levels were elevated in 
pcDNA3.1 (~1.5 fold, p<0.001; Figure 4.8), SIRT2 (~2 fold, p<0.001; Figure 4.8) and 
SIRT2+AGK2 cells (~1.6 fold; p<0.001; Figure 4.8) compared to 0.2% PBS treated 
pcDNA3.1 cells. The levels of SOD2 were reduced by 28% in pcDNA3.1+AGK2 cells 
(p<0.001; Figure 4.8) compared to 0.2% PBS treated pcDNA3.1 cells. In 10μM diquat treated 
cells, SOD2 levels were elevated in pcDNA3.1 (~1.5 fold, p<0.001; Figure 4.8), SIRT2 (~1.7 
fold, p<0.001; Figure 4.8) and SIRT2+AGK2 cells (~1.4 fold; p<0.01; Figure 4.7 B) 
compared to 0.2% PBS treated pcDNA3.1 cells. The levels of SOD2 were reduced by 12% in 
pcDNA3.1+AGK2 cells (p<0.05; Figure 4.8) compared to 0.2% PBS treated pcDNA3.1 cells. 
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Figure 4.6 Expression of SIRT2 in diquat treated SH-SY5Y cells. SIRT2 was over-expressed 
in SH-SY5Y cells and control cells were transfected with empty vector following which one set of 
cells was treated with diquat alone and another with SIRT2 inhibitor AGK2 and diquat.  Cells were 
harvested and the samples were probed for A) SIRT2 expression in 20μM diquat treated cells and B) 
SIRT2 expression in 10μM diquat treated cells. Data are presented as fold- untreated (+SD) from three 
independent assays (n=3). *p<0.05 when compared to 0.2% PBS, one-way ANOVA (Bonferroni 
corrected), ###p<0.001and ##p<0.01 when compared to empty vector treatment, ~~~p<0.001 and 
~p<0.05 when compared to empty vector+AGK2 treatment and $$$p<0.001 and $$p<0.01 when 
compared to SIRT2 overexpressing cells, two-way ANOVA (Bonferroni-corrected). Images are 
representative blot of SIRT2 and GAPDH. 
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Figure 4.7 Expression of α-tubulin in diquat treated SH-SY5Ycells. SIRT2 was over-
expressed in SH-SY5Y cells and control cells were transfected with empty vector following which one 
set of cells was treated with diquat alone and another with SIRT2 inhibitor AGK2 and diquat.  Cells 
were harvested and the samples were probed for A) α-tubulin expression in 20μM diquat treated cells 
and B) α-tubulin expression in 10μM diquat treated cells. Data are presented as fold- untreated (+SD) 
from three independent assays (n=3). *p<0.05 when compared to 0.2% PBS, one-way ANOVA 
(Bonferroni corrected), ###p<0.001, ##p<0.01 and #p<0.05 when compared to empty vector 
treatment, ~~~p<0.001 when compared to empty vector+AGK2 treatment and $$$p<0.001 when 
compared to SIRT2 overexpressing cells, two-way ANOVA (Bonferroni-corrected). Images are 
representative blot of α-tubulin and GAPDH. 
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Figure 4.7 Expression of α-tubulin in diquat treated SH-SY5Y cells (continued).  
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Figure 4.8 Expression of SOD2 in diquat treated SH-SY5Ycells. SIRT2 was over-expressed 
in SH-SY5Y cells and control cells were transfected with empty vector following which one set of 
cells was treated with diquat alone and another with SIRT2 inhibitor AGK2 and diquat.  Cells were 
harvested and the samples were probed for A) SOD2 expression in 20μM diquat treated cells and B) 
SOD2 expression in 10μM diquat treated cells. Data are presented as fold- untreated (+SD) from three 
independent assays (n=3). ***p<0.001, **p<0.01 and *p<0.05 when compared to 0.2% PBS, one-way 
ANOVA and (Bonferroni corrected), ###p<0.001and ##p<0.01 when compared to empty vector 
treatment, ~~~p<0.001 when compared to empty vector+AGK2 treatment and $$$p<0.001 when 
compared to SIRT2 overexpressing cells, two-way ANOVA (Bonferroni-corrected). Images are 
representative blot of SOD2 and GAPDH. 
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The levels of SIRT2 and α-tubulin were also determined in rotenone treated cells. Similar to 
diquat treated cells, the levels of SIRT2 increased by 2.5-2.75 fold in 20μM rotenone treated 
cells and by 4-4.5 fold in 0.5μM rotenone treated cells (Figure 4.9; p<0.001) compared to 
empty vector transfected cells. The levels of acetylated α-tubulin were significantly higher in 
AGK2 treated cells in both rotenone treatments (20μM or 0.5μM rotenone: p<0.001) and the 
levels were reduced in SIRT2 transfected cells (20μM or 0.5μM rotenone: p<0.001; Figure 
4.10).  
The expression of SOD2 was tested only in 20μM rotenone treated cells as 0.5μM rotenone 
cells did not show significant difference in cell viability between the groups. The levels of 
SOD2 were elevated in pcDNA3.1 (~1.3 fold, p<0.01; Figure 4.11), SIRT2 (~1.6 fold, 
p<0.001; Figure 4.11) and SIRT2+AGK2 cells (~1.4 fold; p<0.001; Figure 4.11) compared to 
0.2% PBS treated pcDNA3.1 cells. The levels of SOD2 were reduced by 17% in 
pcDNA3.1+AGK2 cells (p<0.05; Figure 4.11) compared to 0.2% DMSO treated pcDNA3.1 
cells. 
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Figure 4.9 Expression of SIRT2 in rotenone treated SH-SY5Ycells. SIRT2 was over-
expressed in SH-SY5Y cells and control cells were transfected with empty vector following which one 
set of cells was treated with rotenone alone and another with SIRT2 inhibitor AGK2 and  rotenone. 
Cells were harvested and the samples were probed for A) SIRT2 expression in 20μM rotenone treated 
cells and B) SIRT2 expression in 0.5μM rotenone treated cells. Data are presented as fold- untreated 
(+SD) from three independent assays (n=3). **p<0.01 and *p<0.05 when compared to 0.2% DMSO, 
one-way ANOVA (Bonferroni corrected), ###p<0.001and ##p<0.01 when compared to empty vector 
treatment, ~~~p<0.001 and ~p<0.05 when compared to empty vector+AGK2 treatment, two-way 
ANOVA (Bonferroni-corrected). Images are representative blot of SIRT2 and GAPDH. 
 
 
 
 
 191 
A 
 
Figure 4.10 Expression of α-tubulin in rotenone treated SH-SY5Ycells. SIRT2 was over-
expressed in SH-SY5Y cells and control cells were transfected with empty vector following which one 
set of cells was treated with rotenone alone and another with SIRT2 inhibitor AGK2 and  rotenone. 
Cells were harvested and the samples were probed for A) α-tubulin expression in 20μM rotenone 
treated cells and B) α-tubulin expression in 0.5μM rotenone treated cells. Data are presented as fold- 
untreated (+SD) from three independent assays (n=3). ###p<0.001, ##p<0.01 and #p<0.05 when 
compared to empty vector treatment, ~~~p<0.001 when compared to empty vector+AGK2 treatment 
and $$$p<0.001 when compared to SIRT2 overexpressing cells, two-way ANOVA (Bonferroni-
corrected). Images are representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Figure 4.10 Expression of α-tubulin in rotenone treated SH-SY5Ycells (continued).   
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Figure 4.11 Expression of SOD2 in rotenone treated SH-SY5Ycells. SIRT2 was over-
expressed in SH-SY5Y cells and control cells were transfected with empty vector following which one 
set of cells was treated with rotenone alone and another with SIRT2 inhibitor AGK2 and  rotenone. 
Cells were harvested and the samples were probed for SOD2 expression in 20μM rotenone treated 
cells. Data are presented as fold- untreated (+SD) from three independent assays (n=3). ***p<0.001, 
**p<0.01 and *p<0.05 when compared to 0.2% DMSO, one-way ANOVA (Bonferroni corrected), 
###p<0.001 when compared to empty vector treatment, ~~~p<0.001 when compared to empty 
vector+AGK2 treatment, and $$p<0.01 when compared to SIRT2 over-expressing cells, two-way 
ANOVA (Bonferroni-corrected). Images are representative blot of GAPDH and SOD2. 
 
All these findings in diquat or rotenone treated cells suggest that SIRT2 protects the cells 
from toxicity and the effect is possibly SOD2 dependent. 
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4.4.1.6 Cellular distribution of SIRT2 in toxin treated cell 
Cells respond to stress by synthesising stress proteins and/or by re-localising the proteins to 
different cellular compartments. To study the effect of cellular stress on localisation of SIRT2, 
SH-SY5Y cells were treated with diquat or rotenone to induce the stress and the localisation 
of SIRT2 was measured through immunocytochemistry and confocal microscopy. SH-SY5Y 
cells were immunostained for SIRT2 and phospho-α-synuclein and the images were captured 
using confocal fluorescence microscope.  
On treatment with diquat, SIRT2 was localised both in the nucleus and the cytoplasm but was 
present prominently in the nucleus (Figure 4.12). The localisation of SIRT2 in the nucleus 
under diquat induced oxidative stress could be attributed to the role played by SIRT2 in DNA 
damage repair and cell cycle regulation under regular circumstances and as well as under 
genotoxic stress (Vaquero et al., 2006; Vempati et al., 2010). SIRT2 showed some co-
localisation with α-synuclein but co-localisation was not 100% suggesting that SIRT2 may 
not physically interact with α-synuclein. The proportion of co-localisation may potentially be 
attributed to the interaction of both SIRT2 and α-synuclein with α-tubulin (Alim et al., 2002; 
North et al., 2003).  
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Figure 4.12 Localisation of SIRT2 and α-synuclein in diquat treated SH-SY5Y cells. Cellular distribution of SIRT2 and phospho-α-synuclein was 
determined using fluorescent immunocytochemistry. Images show α-synuclein immunostaining, SIRT2 immunostaining and all staining merged including DAPI. A 
represents 0.2% PBS treated SH-SY5Y cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 4.12 Localisation of SIRT2 and α-synuclein in diquat treated SH-SY5Y cells (continued). B represents 20μM diquat treated SH-SY5Y cells. 
Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
 197 
C 
 
Figure 4.12 Localisation of SIRT2 and α-synuclein in diquat treated SH-SY5Y cells (continued). C represents 10μM diquat treatedSH-SY5Y cells. 
Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Cellular localisation of SIRT2 was also determined in rotenone treated SH-SY5Y cells. As in 
diquat treated cells, SIRT2 was observed to be localised both in the nucleus and cytoplasm 
and was co-localised with α-synuclein to a minimal extent (Figure 4.13). 
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Figure 4.13 Localisation of SIRT2 and α-synuclein in rotenone treated SH-SY5Y cells. Cellular distribution of SIRT2 and phospho-α-synuclein was 
determined using fluorescent immunocytochemistry. Images show α-synuclein immunostaining, SIRT2 immunostaining and all staining merged including DAPI. A 
represents 0.2% DMSO treated SH-SY5Y cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 4.13 Localisation of SIRT2 and α-synuclein in rotenone treated SH-SY5Y cells (continued). B represents 20μM rotenone treated SH-SY5Y 
cells. Scale bar: 50μm 
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Figure 4.13 Localisation of SIRT2 and α-synuclein in rotenone treated SH-SY5Y cells (continued). C represents 0.5μM rotenone treated SH-SY5Y 
cells. Scale bar: 50μm 
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4.4.1.7 Effects of SIRT2 overexpression and inhibition on α-synuclein aggregates 
PD involves the progressive loss of DA neurones in the SN and the characteristic feature of 
the disease is the presence of cytosolic inclusions called Lewy bodies that are rich in α-
synuclein. α-synuclein has no apparent ordered structure under normal physiological 
conditions (Weinreb et al., 1996; Uversky et al., 2001).  The α-synuclein aggregates present 
in LBs are generally formed because of the association of misfolded α-synuclein proteins and 
the levels of misfolded proteins can increase under several conditions such as oxidative stress 
(Norris et al., 2003), inhibition of protein degradation (McNaught et al., 2002) and 
mitochondrial dysfunction (Mullin and Schapira, 2013). Figure 4.14 illustrates the formation 
of α-synuclein aggregates under the oxidative stress induced by rotenone. The arrows indicate 
the α-synuclein aggregates that vary from intermediate to large inclusions and are more in 
number in rotenone treated SH-SY5Y cells.  
 
 
Figure 4.14 α-synuclein aggregate formation in SH-SY5Y cells. SH-SY5Y cells were treated 
with toxins and were stained phospho-α-synuclein. The slides were visualised through GFP filter (63X 
magnification) for α-synuclein staining. Aggregates are highlighted with white arrows. Scale bar: 
20μM 
 
To test the effect of SIRT2 on α-synuclein aggregate formation, SH-SY5Y cells were seeded 
in four-chambered slides and the cells were transfected with SIRT2 and the control cells were 
transfected with pcDNA3.1 for 48 hours. As described in section 4.3.1.2, one set of slides 
were treated with toxin (diquat or rotenone) alone and another set was co-incubated with 
AGK2 and toxin. After 20 hours of incubation, cells were fixed and were probed for SIRT2 
and α-synuclein staining (please refer Section 2.3.5). The images captured using a confocal 
microscope were quantified using ImageJ software (NIH, USA).  
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In diquat treated cells, a significant increase of 80-95% in aggregate formation was seen in 
AGK2 treated pcDNA3.1 transfected cells when compared to 0.2% PBS treated pcDNA3.1 
transfected cells (Figure 4.15; p<0.001). In SIRT2+AGK2 cells, aggregate formation was 
higher than pcDNA3.1 cells (p<0.01) and SIRT2 cells (p<0.001) but was significantly lower 
than pcDNA3.1+AGK2 (p<0.001) cells when treated with 20μM diquat (Figure 4.15).  Over-
expression of SIRT2 inhibited α-synuclein aggregate formation in 20μM diquat treated cells 
compared to pcDNA3.1 transfected cells (p<0.001; <23%).  
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Figure 4.15 α-synuclein aggregate formation and quantification in diquat treated SH-
SY5Y cells. SIRT2 overexpressing SH-SY5Y cells were treated with diquat (20μM or 10μM) and 
0.2% PBS; cells transfected with empty vector were used as a control and another set of SIRT2 and 
empty vector cells was co-incubated with AGK2 and diquat. Cells were immunostained with phospho-
α-synuclein. Images were captured through GFP filter under 63X magnification. A) shows the 
captured images for α-synuclein staining and B) represents the aggregate quantification. Each bar 
represents % α-synuclein aggregates from three independent assays (n=3). ***p<0.001, **p<0.01 and 
*p<0.05 when compared to 0.2% PBS, one-way ANOVA (Bonferroni corrected), ###p<0.001and 
##p<0.01 when compared to empty vector treatment, ~~~p<0.001when compared to empty 
vector+AGK2 treatment and $$$p<0.001 and $p<0.05 when compared to SIRT2 overexpressing cells, 
two-way ANOVA (Bonferroni corrected).  Scale bar: 20μM 
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Rotenone has been shown to induce α-synuclein aggregate formation in the SN of rats 
following chronic treatment (Betarbet et al., 2000) and a recent study showed rotenone 
increased α-synuclein aggregation by phosphorylation of α-synuclein and also by impairing 
the process of degradation of the aggregates through autophagy (Yuan et al., 2015). Based 
upon these findings, the effect of SIRT2 on α-synuclein aggregation was evaluated in 
rotenone treated cells.  
AGK2 treated pcDNA3.1 (p<0.001) and SIRT2 SH-SY5Y (p<0.001) cells showed increased 
amount of aggregates in all treatments- 0.2% DMSO, 20μM or 0.5μM rotenone when 
compared to 0.2% DMSO treatment of the control cells. SIRT2 overexpression on the other 
hand reduced the aggregate formation (p<0.001; Figure 4.16).  
These results suggest that SIRT2 impairs α-synuclein aggregate formation and possibly 
reduces the aggregate induced toxicity, thus promoting cell survival in toxin treated cells.  
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Figure 4.16 α-synuclein aggregate formation and quantification in rotenone treated SH-
SY5Y cells. SIRT2 overexpressing SH-SY5Y cells were treated with rotenone (20μM or 0.5μM) and 
0.2% DMSO; cells transfected with empty vector were used as a control and another set of SIRT2 and 
empty vector cells was co-incubated with AGK2 and rotenone. Cells were immunostained with 
phospho-α-synuclein. Images were captured through GFP filter under 63X magnification. A) shows 
the captured images for α-synuclein staining and B) represents the aggregate quantification. Each bar 
represents % α-synuclein aggregates from three independent assays (n=3). ***p<0.001, **p<0.01 and 
*p<0.05 when compared to 0.2% DMSO, one-way ANOVA (Bonferroni corrected), ###p<0.001, 
##p<0.01 and #p<0.05 when compared to empty vector treatment, ~~~p<0.001when compared to 
empty vector+AGK2 treatment and $$$p<0.001 when compared to SIRT2 overexpressing cells, two-
way ANOVA (Bonferroni corrected). Scale bar: 20μM 
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4.4.2 Post-mortem Human Brain tissue 
4.4.2.1 Measurement of SIRT2 levels in PD 
As discussed, SIRT2 accumulates in the ageing brain and also in certain models of PD, SIRT2 
inhibition has been shown to protect cells from α-synuclein mediated toxicity (Outeiro et al., 
2007). The levels of SIRT2 in PD cases were therefore determined in four different brain 
regions namely, frontal cortex, temporal cortex, putamen and cerebellum. 
Frontal Cortex 
There are four reported isoforms of SIRT2 and isoforms 2 and 3 have been reported to be the 
most abundant in the human brain. In Western blot analysis of the frontal cortex, isoforms- 
SIRT2.3 and SIRT2.2 were detected but not isoforms 1 and 4. As shown in Figure 4.17 A, the 
levels of SIRT2 were found to be significantly increased with SIRT2.3 increased by 25% 
(p<0.05) and SIRT2.2 increased by 30% (p<0.01) in PD cases. 
α-tubulin acetylated at K40 is a known substrate of SIRT2 and is an integral part of MTs that 
form the cytoskeleton responsible for cellular division, intracellular transport, structure and 
motility. Through deacetylation of α-tubulin SIRT2 modulates protein transport and 
myelination in the CNS.  The levels of acetylated α-tubulin and total tubulin were determined 
in the frontal cortex and reduced levels of acetylated α-tubulin were observed in PD cases 
(19%, p<0.001; Figure 4.17B) whereas the levels of total α-tubulin did not show any change. 
On normalisation with total α-tubulin, the levels of acetylated α-tubulin were reduced by 15% 
(p<0.01; Figure 4.17B).   
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Figure 4.17 Expression of SIRT2 and α-tubulin in the frontal cortex of PD and controls. 
The levels of SIRT2 and total and acetylated α-tubulin were determined in the frontal cortex of PD 
patients and were compared to a control-cohort. A) SIRT2 band intensity was normalised with 
GAPDH and B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  
Data are presented as fold change (+SD) with respect to control from three independent replicates. 
***p<0.001, **p<0.01 and *p<0.05 when compared to control, statistical analysis was done through t-
test performed on GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH and B) 
Image is a representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Temporal Cortex  
The levels of SIRT2 and α-tubulin were also measured in the temporal cortex. No significant 
difference was observed in the expression of either isoforms of SIRT2 among controls and PD 
cases (p>0.05; Figure 4.18A). As with SIRT2, there was no significant difference in 
acetylated or total α-tubulin levels in PD compared to controls (p>0.05; Figure 4.18B). 
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Figure 4.18 Expression of SIRT2 and α-tubulin in the temporal cortex of PD and 
controls. The expression of SIRT2 and total and acetylated α-tubulin were determined in the 
temporal cortex of PD patients and compared to a cohort-control. A) SIRT2 band intensity was 
normalised with GAPDH and B) Acetylated/total α-tubulin band intensity was normalised with 
GAPDH or α-tubulin.  Data are presented as fold change (+SD) with respect to control from three 
independent replicates. No significant differences were observed between PD and control, statistical 
analysis was done through t-test performed on GraphPad prism. A) Image is a representative blot of 
SIRT2 and GAPDH and B) Image is a representative blot of α-tubulin, acetylated α-tubulin and 
GAPDH. 
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Putamen 
In the putamen, there was no observable difference in the level of SIRT2.3 (Figure 4.19A) 
whereas, reduction of 23% in the expression of SIRT2.2 was observed in PD compared to 
controls but the difference was statistically insignificant (p>0.05; Figure 4.19A). The levels of 
acetylated or total α-tubulin were not changed in PD when the intensity of α-tubulin was 
normalised with GAPDH, but a significant increase of 15% was observed in acetylated α-
tubulin when the band intensity was normalised with total α-tubulin (p<0.05; Figure 4.19B).  
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Figure 4.19 Expression of SIRT2 and α-tubulin in the putamen of PD and controls. The 
levels of SIRT2 and total and acetylated α-tubulin were probed in the putamen of PD patients and 
compared to a cohort-control. A) SIRT2 band intensity was normalised with GAPDH and B) 
Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  Data are 
presented as fold change (+SD) with respect to control from three independent replicates. *p<0.05 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a representative blot of α-
tubulin, acetylated α-tubulin and GAPDH. 
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Cerebellum 
Western blot analysis of SIRT2 detected only SIRT2.2 in the cerebellum and an increase of 
57% was noticed in PD compared to controls (p<0.001; Figure 4.20 A). The levels of 
acetylated α-tubulin were elevated by 45% in the cerebellum (p<0.001; Figure 4.20 B) which 
was paralleled by increased levels of total α-tubulin (51%; p<0.001; Figure 4.20 B). 
Normalisation with total α-tubulin showed no significant difference in the level of acetylated 
α-tubulin between PD and controls (p>0.05; Figure 4.20 B). 
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Figure 4.20 Expression of SIRT2 and α-tubulin in the cerebellum of PD and controls. 
The levels of SIRT2 and total and acetylated α-tubulin were probed in the cerebellum of PD patients 
and compared to cohort-control group. A) SIRT2 band intensity was normalised with GAPDH and B) 
Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  Data are 
presented as fold change (+SD) with respect to control from three independent replicates. ***p<0.001 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a representative blot of α-
tubulin, acetylated α-tubulin and GAPDH. 
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 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Putamen (%) Cerebellum 
(%) 
SIRT2 
Isoform3 41kDa 
Isoform 2 39.5kDa 
 
21 (p<0.05) 
30 (p<0.01) 
 
11↓ (p<0.05) 
NS 
 
NS 
22↓ (p>0.05) 
 
- 
58 (p<0.001) 
α-tubulin 
α-tubulin 
Acetylated (K40) 
Ac Vs Total 
 
NS 
19 (p<0.001) 
15 (p<0.01) 
 
NS 
NS 
NS 
 
14↑ (p<0.05) 
NS  
15 (p<0.05) 
 
51 (p<0.01) 
45 (p<0.05) 
15↑ (p>0.05) 
Table 4.1 Summary table presenting protein expression of SIRT2 and α-tubulin in PD 
compared to controls. The alterations are expressed as percentage change. The text in green 
indicates elevation and in red indicates reduction in the protein expression. NS: No significant 
difference (any difference under 10% with p>0.05). 
 
Based upon these findings it can be concluded that SIRT2 levels weren’t significantly 
different in the temporal cortex or putamen but increased levels of SIRT2 were found in the 
frontal cortex and cerebellum.  
 
4.4.2.2 Measurement of SIRT2 levels in PDD 
Along with PD cases, the levels of SIRT2 and its substrate were evaluated in PDD cases to 
determine if there were any differences between the disease groups. As in PD, in PDD, SIRT2 
and its substrate levels were determined in the frontal cortex, temporal cortex, putamen and 
cerebellum. 
Frontal Cortex 
Unlike PD, the levels of SIRT2 isoforms in the frontal cortex were not changed in PDD 
compared to controls (Figure 4.21 A). Corresponding with the levels of SIRT2, the levels of 
acetylated or total α-tubulin were not different in either group (Figure 4.21 B).  
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Figure 4.21 Expression of SIRT2 and α-tubulin in the frontal cortex of PDD and 
controls. The levels of SIRT2 and total and acetylated α-tubulin were measured in the frontal cortex 
of PDD patients and compared to a cohort control. A) SIRT2 band intensity was normalised with 
GAPDH and B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  
Data are presented as fold change (+SD) with respect to control from three independent replicates. No 
significant differences were observed in PDD when compared to control, statistical analysis was done 
through t-test performed on GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH 
and B) Image is a representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Temporal Cortex 
In the temporal cortex, the levels of SIRT2.3 were reduced by 23% (p<0.01; Figure 4.22 A) 
and a reduction of 16% was seen in SIRT2.2 levels as well but the difference was statistically 
insignificant (p>0.05; Figure 4.22 A). The levels of acetylated or total α-tubulin in the 
temporal cortex did not show any difference in PDD when compared to controls (Figure 
4.22B).  
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Figure 4.22 Expression of SIRT2 and α-tubulin in the temporal cortex of PDD and 
controls. The levels of SIRT2 total and acetylated α-tubulin were measured in the temporal cortex of 
PDD patients and compared to a cohort-control. A) SIRT2 band intensity was normalised with 
GAPDH and B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  
Data are presented as fold change (+SD) with respect to control from three independent replicates. 
**p<0.01 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a 
representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Putamen 
In the putamen, Western blot analysis did not show any significant change in the levels of 
either isoforms of SIRT2 in PDD compared to controls (p>0.05; Figure 4.23 A). The levels of 
acetylated α-tubulin did not show any change but the levels of total tubulin were higher in 
PDD cases (41%, p<0.01; Figure 4.23 B). The levels of acetylated α-tubulin were reduced 
when the band intensity was normalised with total α-tubulin (28%, p<0.001; Figure 4.23 B).   
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Figure 4.23 Expression of SIRT2 and α-tubulin in the putamen of PDD and controls. The 
levels of SIRT2 and total and acetylated α-tubulin were measured in the putamen of PDD patients and 
compared to a cohort-control. A) SIRT2 band intensity was normalised with GAPDH and B) 
Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  Data are 
presented as fold change (+SD) with respect to control from three independent replicates. ***p<0.001 
and **p<0.01 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a 
representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Cerebellum 
Similar to PD, only SIRT2.2 was detected in the cerebellar samples of PDD and there was no 
significant difference in the levels between PDD and controls (p>0.05; Figure 4.24 A). The 
levels of acetylated and total α-tubulin were elevated in PDD when the band intensity was 
normalised with GAPDH (acetylated- 33%, p<0.01; total- 33%, p<0.05; Figure 4.24 B) but no 
apparent difference in the levels of acetylated tubulin was observed when the intensity was 
normalised with total α-tubulin (p>0.05; Figure 4.24 B). 
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Figure 4.24 Expression of SIRT2 and α-tubulin in the cerebellum of PDD and controls. 
The levels of SIRT2 and total and acetylated α-tubulin were measured in the cerebellum of PDD 
patients and compared to a cohort-control. A) SIRT2 band intensity was normalised with GAPDH and 
B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  Data are 
presented as fold change (+SD) with respect to control from three independent replicates. **p<0.01 
and *p<0.05 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a 
representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Putamen (%) Cerebellum 
(%) 
SIRT2 
Isoform3 41kDa 
Isoform 2 39.5kDa 
 
NS 
NS 
 
23 (p<0.01) 
16↓ (p>0.05)  
 
NS 
20↑ (p>0.05) 
 
- 
23↑ (p>0.05) 
α-tubulin 
α-tubulin 
Acetylated (K40) 
Ac Vs Total 
 
NS 
NS 
NS 
 
NS 
NS 
NS 
 
42 (p<0.01) 
NS 
28 (p<0.001) 
 
34 (p<0.05) 
34 (p<0.01) 
NS 
Table 4.2 Summary table presenting protein expression of SIRT2 and α-tubulin in PDD 
compared to controls. The alterations are expressed as percentage change. The text in green 
indicates elevation and in red indicates reduction in the protein expression. NS: No significant 
difference (any difference under 10% with p>0.05). 
 
Based upon these findings, in general, the levels of SIRT2 levels were not significantly 
different from the controls except in the temporal cortex of PDD cases. 
 
4.4.2.3 Determination of levels of SIRT2 in DLB 
In DLB, the levels of SIRT2 and α-tubulin were determined in five brain regions- frontal 
cortex, temporal cortex, putamen, hippocampus and cerebellum. 
Frontal Cortex 
In the frontal cortex samples, no significant difference was found in the levels of SIRT2 
isoforms between DLB and controls (Figure 4.25 A). Similar to the expression of SIRT2, no 
significant difference was observed in the levels of acetylated or total α-tubulin in the frontal 
cortex (Figure 4.25B). 
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Figure 4.25 Expression of SIRT2 and α-tubulin in the frontal cortex of DLB and 
controls. The levels of SIRT2 and total and acetylated α-tubulin were measured in the frontal cortex 
of DLB patients and compared to a cohort-control. A) SIRT2 band intensity was normalised with 
GAPDH and B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  
Data are presented as fold change (+SD) with respect to control from three independent replicates. No 
significant differences were observed in DLB when compared to control, statistical analysis was done 
through t-test performed on GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH 
and B) Image is a representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Temporal Cortex  
In the temporal cortex of DLB patients, the levels of both the isoforms of SIRT2 were 
elevated, SIRT2.3 by 24% (p<0.05; Figure 4.26 A) and SIRT2.2 by 33% (p<0.01; Figure 4.26 
A). The levels of acetylated α-tubulin did not show any change in DLB when the intensity 
was normalised with GAPDH whereas, the levels of total α-tubulin were reduced by 40% 
(p<0.001) compared to controls (Figure 4.26 B). The levels of acetylated α-tubulin were 
elevated by 50% (p<0.001; Figure 4.26 B) when the band intensity was normalised with total 
α-tubulin, which related to the lower level of α-tubulin in DLB. 
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Figure 4.26 Expression of SIRT2 and α-tubulin in the temporal cortex of DLB and 
controls. The levels of SIRT2 and total and acetylated α-tubulin were measured in temporal cortex of 
DLB patients and compared to a cohort-control. A) SIRT2 band intensity was normalised with 
GAPDH and B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  
Data are presented as fold change (+SD) with respect to control from three independent replicates. 
***p<0.001, **p<0.01 and *p<0.05 when compared to control, statistical analysis was done through t-
test performed on GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH and B) 
Image is a representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Putamen 
The level of SIRT2.3 was reduced in the putamen of DLB by 13% (p<0.05; Figure 4.27 A) 
but no significant difference was observed in the level SIRT2.2 (Figure 4.27 A). Western blot 
analysis of acetylated α-tubulin in the putamen did not show any difference in DLB compared 
to control (Figure 4.27 B), whereas a reduction of 20% was observed in the level of total α-
tubulin in DLB (p<0.05; Figure 4.27 B). The levels of acetylated α-tubulin didn’t show any 
significant difference when the band intensity was normalised with total α-tubulin (Figure 
4.26 B). 
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Figure 4.27 Expression of SIRT2 and α-tubulin in the putamen of DLB and controls. The 
levels of SIRT2 and total and acetylated α-tubulin were measured in the putamen of DLB patients and 
compared to a cohort-control. A) SIRT2 band intensity was normalised with GAPDH and B) 
Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  Data are 
presented as fold change (+SD) with respect to control from three independent replicates. *p<0.05 
when compared to control, statistical analysis was done through t-test performed on GraphPad prism. 
A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a representative blot of α-
tubulin, acetylated α-tubulin and GAPDH. 
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Hippocampus 
The levels of SIRT2 and α-tubulin were analysed in the hippocampal samples of DLB and 
were compared with AD and controls. On the Western blot analysis, only SIRT2.2 was 
detected and no significant difference was observed in the expression of SIRT2 among the 
groups (Figure 4.28 A). Similar to the expression of SIRT2 no significant alteration was 
observed in the levels of acetylated or total α-tubulin among the groups when normalised with 
GAPDH (Figure 4.28 B). No difference was observed in the level of acetylated α-tubulin in 
DLB compared with control and AD when normalised with total α-tubulin (Figure 4.28 B). 
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Figure 4.28 Expression of SIRT2 and α-tubulin in the hippocampus of DLB, AD and 
controls. The levels of SIRT2 and total and acetylated α-tubulin were measured in hippocampus of 
DLB and AD patients and compared to a cohort-control and each other. A) SIRT2 band intensity was 
normalised with GAPDH and B) Acetylated/total α-tubulin band intensity was normalised with 
GAPDH or α-tubulin.  Data are presented as fold change (+SD) with respect to control from three 
independent replicates. *p<0.05 when compared to control, statistical analysis was done through two-
way ANOVA and post hoc test (Bonferroni corrected) on SPSS. A) Image is a representative blot of 
SIRT2 and GAPDH and B) Image is a representative blot of α-tubulin, acetylated α-tubulin and 
GAPDH. 
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Cerebellum 
The analysis of SIRT2 levels in the cerebellum of DLB showed an increase of 25% (p<0.01; 
Figure 4.29 A) in the SIRT2.2 isoform, only this isoform being detected, similar to the 
cerebellar samples from PD and PDD. The levels of acetylated or total α-tubulin in the 
cerebellum did not show any significant difference in DLB when the intensity of α-tubulin 
was normalised with GAPDH, but a significant increase of 39% (p<0.05) was observed in 
acetylated α-tubulin when the band intensity was normalised with total α-tubulin (p<0.05; 
Figure 4.29 B).  
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Figure 4.29 Expression of SIRT2 and α-tubulin in the cerebellum of DLB and controls. 
The levels of SIRT2 and total and acetylated α-tubulin were measured in the cerebellum of DLB 
patients and compared to a cohort-control. A) SIRT2 band intensity was normalised with GAPDH and 
B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin.  Data are 
presented as fold change (+SD) with respect to control from three independent replicates. **p<0.01 
and *p<0.05 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a 
representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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 Frontal 
Cortex 
(%) 
Temporal 
Cortex (%)  
Putamen 
(%) 
Cerebellum 
(%) 
Hippocampus 
(%) 
SIRT2 
Isoform3 41kDa 
Isoform2 39.5kDa 
 
NS 
NS 
 
24 (p<0.05) 
33(p<0.01) 
 
13 (p<0.05) 
NS 
 
- 
25 (p<0.01) 
 
- 
NS 
α-tubulin 
α-tubulin 
Acetylated (K40) 
Ac Vs Total 
 
NS 
NS 
NS 
 
40 (p<0.001) 
NS 
50 (p<0.001) 
 
20 (p<0.05) 
NS 
12↑ (p>0.05) 
 
19↓ (p>0.05) 
15↑ (p>0.05) 
39 (p<0.05) 
 
NS 
17↑ (p>0.05) 
20↑ (p>0.05) 
Table 4.3 Summary table presenting protein expression of SIRT2 and α-tubulin in DLB 
compared to controls. The alterations are expressed as percentage change. The text in green 
indicates elevation and in red indicates reduction in the protein expression. NS: No significant 
difference (any difference under 10% with p>0.05). 
 
Western blot analysis of SIRT2 in DLB showed some changes compared to the control group 
with prominent differences observed in the temporal cortex and cerebellum (Table 4.3).  
 
4.4.2.4 Determination of levels of SIRT2 in AD 
In AD cases, the expression of SIRT2 and its substrate α-tubulin were determined in four 
brain regions- frontal cortex, temporal cortex, hippocampus and cerebellum. 
Frontal Cortex 
In the frontal cortex of AD, no significant difference was observed in the levels of either 
isoforms of SIRT2 compared to controls (Figure 4.30 A). No significant differences were 
observed in the levels of acetylated or total α-tubulin between AD and control groups (Figure 
4.30 B). 
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Figure 4.30 Expression of SIRT2 and α-tubulin in the frontal cortex of AD and controls. 
The levels of SIRT2 and total and acetylated α-tubulin were measured in the frontal cortex of AD 
patients and compared to a cohort-control. A) SIRT2 band intensity was normalised with GAPDH and 
B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. No 
significant differences were observed in AD when compared to control, statistical analysis was done 
through t-test performed on GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH 
and B) Image is a representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Temporal Cortex 
Similar to the frontal cortex, no significant differences were observed in the levels of SIRT2 
isoforms (Figure 4.31 A) in the temporal cortex. The level of acetylated α-tubulin did not 
show any significant difference in the temporal cortex in AD when the intensity of α-tubulin 
was normalised with GAPDH whereas the levels of α-tubulin were reduced by 24% (p<0.01; 
Figure 4.31 B). Corresponding to the reduced amount of α-tubulin, a significant increase of 
29% was observed in acetylated α-tubulin when the band intensity was normalised with total 
α-tubulin (p<0.05; Figure 4.31 B).  
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Figure 4.31 Expression of SIRT2 and α-tubulin in the temporal cortex of AD and 
controls. The levels of SIRT2 and total and acetylated α-tubulin were measured in the temporal 
cortex of AD patients and compared to a cohort-control. A) SIRT2 band intensity was normalised with 
GAPDH and B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin. 
Data are presented as fold change (+SD) with respect to control from three independent replicates. 
**p<0.01 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a 
representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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Hippocampus 
The levels of SIRT2.2 were marginally reduced by 14% and 20% compared to controls and 
DLB, respectively, but the difference was statistically insignificant (p>0.05; Figure 4.28 A). 
In the case of α-tubulin, the levels of acetylated or total α-tubulin did not show any significant 
difference when normalised with GAPDH (Figure 4.28 B) but the levels of acetylated α-
tubulin were increased by 30% (p<0.05) compared to controls when the band intensity was 
normalised with total α-tubulin, whereas, no significant difference was observed between AD 
and DLB (Figure 4.28 B). 
 
Cerebellum 
An increase of 14% was seen in the levels of SIRT2.2 in the cerebellum of AD compared to 
controls (p<0.05; Figure 4.32 A). Interestingly, the levels of both acetylated and total α-
tubulin were elevated by 63% (p<0.01; Figure 4.32 B) and 53% (p<0.01; Figure 4.31 B), 
respectively, in the cerebellum. On the other hand, an increase of only 15% (p<0.05) was 
observed in the levels of acetylated α-tubulin in AD when the band intensity was normalised 
with total α-tubulin (Figure 4.32 B). 
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Figure 4.32 Expression of SIRT2 and α-tubulin in the cerebellum of AD and controls. 
The levels of SIRT2 and total and acetylated α-tubulin were measured in the cerebellum of AD 
patients and compared to a cohort-control. A) SIRT2 band intensity was normalised with GAPDH and 
B) Acetylated/total α-tubulin band intensity was normalised with GAPDH or α-tubulin. Data are 
presented as fold change (+SD) with respect to control from three independent replicates. **p<0.01 
and *p<0.05 when compared to control, statistical analysis was done through t-test performed on 
GraphPad prism. A) Image is a representative blot of SIRT2 and GAPDH and B) Image is a 
representative blot of α-tubulin, acetylated α-tubulin and GAPDH. 
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 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Hippocampus 
(%) 
Cerebellum 
(%) 
SIRT2 
Isoform3 41kDa 
Isoform2 39.5kDa 
 
16↑ (p>0.05) 
NS 
 
NS 
NS 
 
- 
NS 
 
- 
13 (p<0.05) 
α-tubulin 
α-tubulin 
Acetylated (K40) 
Ac Vs Total 
 
NS 
NS 
NS 
 
24 (p<0.01) 
NS 
29 (p<0.01) 
 
13↓ (p>0.05) 
19↑ (p>0.05) 
37 (p<0.05) 
 
53 (p<0.01) 
63 (p<0.01) 
15 (p<0.05) 
Table 4.4 Summary table presenting protein expression of SIRT2 and α-tubulin in AD 
compared to controls. The alterations are expressed as percentage change. The text in green 
indicates elevation and in red indicates reduction in the protein expression. NS: No significant 
difference (any difference under 10% with p>0.05). 
 
As summarised in Table 4.5, the levels of SIRT2 did not alter in AD with the exception of a 
marginal increase in the cerebellum.  
 
4.4.2.5 Measurement of SIRT2 activity in the frontal and temporal cortices 
The Western blot analysis of SIRT2 in different regions of brain showed significant changes 
in the frontal and temporal cortices, therefore the enzymatic activity of SIRT2 was determined 
in the brain extracts obtained from these regions.  
 
SIRT2 activity in the Frontal Cortex 
In the frontal cortex, measurement of total SIRT activity did not show any significant change 
between the disease groups and controls (p>0.05, Figure 4.33 A); however, compared to AD, 
the total SIRT activity was reduced in PD and DLB by 22% (p<0.01),  PDD did not show any 
significant difference (Figure 4.33 A). In the frontal cortex, SIRT2 activity was upregulated in 
PD (33%; p<0.001), PDD (28%; p<0.05), DLB (29%; p<0.01) and AD (31%; p<0.01) 
compared to controls (F=5.906, p<0.001; Figure 4.33 B).  
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Figure 4.33 Total SIRT and SIRT2 activities in the frontal cortex of PD, PDD, DLB, AD 
and controls. Total SIRT and SIRT2 activities were measured through a fluorometric enzymatic 
activity assay in the frontal cortex of PD, PDD, DLB and AD patients and were compared to cohort-
control group. A) shows total SIRT activity in these groups and B) represents SIRT2 activity. 
***p<0.001, **p<0.01 and *p<0.05 when compared to control, one-way ANOVA (Bonferroni 
corrected). 
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SIRT2 activity in the Temporal Cortex 
In the temporal cortex, there was no significant difference in total SIRT activity between the 
disease groups and control (p>0.05.; Figure 4.34 A), however, compared to AD there was a 
significant reduction of 33% in total SIRT activity in PDD (p<0.05), other groups did not 
show any significant change (Figure 4.34 A). In the temporal cortex, SIRT2 activity was 
upregulated in PD (19%; p<0.01), PDD (17%; p<0.05), DLB (21%; p<0.001) and AD (18%; 
p<0.01) compared to controls whereas no significant difference was seen among the disease 
groups (F= 5.593; p<0.001; Figure 4.34 B).  
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Figure 4.34 Total SIRT and SIRT2 activities in temporal cortex of PD, PDD, DLB, AD 
and controls. Total SIRT and SIRT2 activities were measured through a fluorometric enzymatic 
activity assay in the temporal cortex of PD, PDD, DLB and AD patients and compared to cohort-
control group. A) shows total SIRT activity in these groups and B) represents SIRT2 activity. 
***p<0.001, **p<0.01 and *p<0.05 when compared to control, one-way ANOVA (Bonferroni 
corrected). 
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4.4.2.6 Cellular distribution of SIRT2 in the human brain 
In SH-SY5Y cells, SIRT2 was localised more in the nucleus under stress conditions. The 
cellular localisation of SIRT2 was thus determined in the temporal cortex, hippocampus and 
cerebellum in PD, PDD, DLB, AD and elderly control group. In temporal cortex, no apparent 
difference was observed within the PD, PDD, DLB and controls. SIRT2 was localised both in 
the cytoplasm and nucleus in these groups whereas, in AD, SIRT2 was predominantly 
localised in the cytoplasm (Figures 4.35). The location of SIRT2 was determined in different 
regions of the hippocampus– CA1, CA2, CA3 and CA4. In controls, SIRT2 was localised in 
the nucleus in CA1 neurones (Figure 4.36) and CA2 neurones (Figure 4.37) and was localised 
in both the nucleus and cytoplasm in CA3 neurones (Figure 4.38) and CA4 neurones (Figure 
4.39), whereas in PD SIRT2 was present in the cytoplasm and occasionally present in the 
nucleus in CA1-4 (Figures 4.36- 4.39). As in PD, in PDD cases, SIRT2 was localised both in 
the nucleus and cytoplasm in CA1 and CA2 but was prominently in the cytoplasm in CA3 and 
CA4 (Figures 4.36- 4.39). In the DLB and AD, SIRT2 was present in the cytoplasm in CA1 
neurones and in other CA subfields occasional nuclear localisation was observed but it was 
pre-dominantly present in the cytoplasm (Figures 4.36- 4.39). Determination of SIRT2 sub-
cellular localisation of SIRT2 in the cerebellum did not show any significant difference in 
disease groups and controls. In general, nuclear staining of Purkinje cells and granular 
neurones was observed in all groups (Figure 4.40). SIRT2 did not show a staining pattern that 
could be associated to Lewy bodies. These results suggest that there was no significant effect 
of disease conditions on the location of SIRT2 within the cell. 
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Figure 4.35 Cellular distribution of SIRT2 in the Temporal Cortex of Disease and 
Control Groups. The images show the cellular localisation of SIRT2 in grey matter of 
superior temporal gyrus of temporal cortex in PD, PDD, DLB, AD and control cases. SIRT2 
was localised in both in the cytoplasm and the nucleus of the neurones in the groups, being 
pre-dominantly present in the cytoplasm in AD. The picture in inset is 63X oil immersion 
image overlaid on 10X image. Scale bars- black scale bar= 50μM and red scale bar= 20μM 
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Figure 4.36 Cellular distribution of SIRT2 in CA1 of the Hippocampus in Disease and 
Control Groups. The images show the cellular localisation of SIRT2 in CA1 of hippocampus 
in PD, PDD, DLB, AD and control cases. In control SIRT2 was observed to be localised in 
the nucleus, whilst in PD and PDD, it was localised both in the nucleus and the cytoplasm. 
DLB and AD showed the cytoplasmic location of SIRT2. The picture in inset is 63X oil 
immersion image overlaid on 10X image. Scale bars- black scale bar= 50μM and red scale bar 
= 20μM 
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Figure 4.37 Cellular distribution of SIRT2 in CA2 of the Hippocampus in Disease and 
Control Groups. The images show the cellular localisation of SIRT2 in CA2 of hippocampus 
in PD, PDD, DLB, AD and control cases. SIRT2 was localised in the nucleus in control, and 
was present pre-dominantly in the cytoplasm and occasionally in the nucleus in PD and PDD.  
SIRT2 was localised pre-dominantly in the cytoplasm in DLB and AD. The picture in inset is 
63X oil immersion image overlaid on 10X image. Scale bars- black scale bar= 50μM and red 
scale bar = 20μM 
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Figure 4.38 Cellular distribution of SIRT2 in CA3 of the Hippocampus in Disease and 
Control Groups. The images show the subcellular localisation of SIRT2 in CA3 of 
hippocampus in PD, PDD, DLB, AD and control cases. SIRT2 was pre-dominantly localised 
in the cytoplasm with occasional presence in the nucleus in all disease and control cases. The 
picture in inset is 63X oil immersion image overlaid on 10X image. Scale bars- black scale 
bar= 50μM and red scale bar = 20μM 
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Figure 4.39 Cellular distribution of SIRT2 in CA4 of the Hippocampus in Disease and 
Control Groups. The images show the cellular localisation of SIRT2 in CA4 of hippocampus 
in PD, PDD, DLB, AD and control cases. SIRT2 was pre-dominantly localised in the 
cytoplasm with occasional presence in the nucleus in all disease and control cases. The picture 
in inset is 63X oil immersion image overlaid on 10X image. Scale bars- black scale bar= 
50μM and red scale bar = 20μM 
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Figure 4.40 Cellular distribution of SIRT2 in the Cerebellum in Disease and Control 
Groups. The images show the cellular localisation of SIRT2 in Purkinje cells and granular 
layer of cerebellum in PD, PDD, DLB, AD and elderly control group. SIRT2 was localised in 
the nucleus of Purkinje cells in disease and control cases. The picture in inset is 63X oil 
immersion image overlaid on 10X image. Scale bars- black scale bar= 50μM and red scale bar 
= 20μM 
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Temporal cortex (Superior Temporal Gyrus) 
 Control PD PDD DLB AD 
General 
impression 
Nuclear and 
occasional 
cytoplasmic  
Nuclear and 
occasional 
cytoplasmic 
Nuclear and 
cytoplasmic 
Nuclear and 
cytoplasmic 
Cytoplasmic 
Hippocampus 
 Control PD PDD DLB AD 
CA1 Nuclear More 
cytoplasmic 
and 
occasional 
nuclear  
More 
cytoplasmic 
and 
occasional 
nuclear  
Cytoplasmic Cytoplasmic 
CA2 Nuclear More 
cytoplasmic 
and 
occasional 
nuclear  
More 
cytoplasmic 
and 
occasional 
nuclear  
Cytoplasmic More 
cytoplasmic 
and bit 
nuclear 
CA3 Nuclear and 
cytoplasmic 
More 
cytoplasmic 
and 
occasional 
nuclear  
Cytoplasmic Cytoplasmic More 
cytoplasmic 
and 
occasional 
nuclear  
CA4 Nuclear and 
cytoplasmic 
More 
cytoplasmic 
and 
occasional 
nuclear  
Cytoplasmic More 
cytoplasmic 
and 
occasional 
nuclear  
More 
cytoplasmic 
and 
occasional 
nuclear  
Cerebellum 
 Control PD PDD DLB AD 
General 
impression 
Nuclear in 
PCs, not so 
prominent 
glial cells or 
ASCs 
Nuclear and 
cytoplasmic 
in PCs and 
granular 
layer 
Cytoplasmic 
and nuclear 
both  
Cytoplasmic 
PCs, nuclear 
granular 
Nuclear in 
both 
Table 4.5 Summary table presenting localisation of SIRT2 in different brain regions of 
PD, PDD, DLB, AD and control groups.   
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4.5 Discussion 
4.5.1 SIRT2 inhibition and general toxicity of AGK2 
AGK2 is a reversible SIRT2 inhibitor that shows 15-fold more affinity towards SIRT2 than 
SIRT1 and SIRT3 (Outeiro et al., 2007). Inhibition of SIRT2 by AGK2 has been reported to 
confer neuroprotection in PD (Outeiro et al., 2007) and HD models (Luthi-Carter et al., 
2010). Based upon these reports, a cell viability assay was performed to test the toxicity of 
AGK2 in SH-SY5Y cells under normal conditions. AGK2 did not show any significant 
toxicity in SH-SY5Y cells when treated with different concentrations of AGK2 ranging from 
50-5µM (Figure 4.1).  Among other SIRT inhibitors used (EX527 and CHIC- 35), AGK2 was 
able to inhibit SIRT2 (Figure 4.2) since the acetylation of α-tubulin was increased by 72% in 
AGK2 treated cells and no significant alterations were observed using other SIRT inhibitors 
in agreement with other studies (Outeiro et al., 2007) which found that AGK2 is a more 
potent and specific inhibitor of SIRT2. These results show that inhibition of SIRT2 was not 
toxic to cells under normal conditions which allowed the evaluation of the role of SIRT2 in 
toxin induced oxidative stress in SH-SY5Y cells using a dose of 25µM AGK2. 
 
4.5.2 Effect of SIRT2 inhibition on oxidative stress mediated cell death 
Oxidative stress indicates an imbalance between ROS (free radicals) and cellular antioxidant 
defence mechanisms wherein the former accumulate and lead to irreversible cellular damage 
leading to impaired cell viability and enhanced cell death (review in (Betteridge, 2000)). 
Oxidative stress has also been implicated in the initiation and progression of PD (review in 
(Olanow, 1990)).  
Pesticides including diquat and rotenone have been reported to induce oxidative stress and 
rotenone has been shown to induce Parkinsonian symptoms in a rat model (Betarbet et al., 
2000). Diquat is a potent redox cycler (Rawlings et al., 1994) that upon entry into cells 
utilises molecular oxygen to generate O2
-
 and these O2
-
 can lead to lipid peroxidation in cell 
membranes resulting in cell death (Jones and Vale, 2000). Based upon the roles of diquat and 
rotenone in ROS generation, these two toxins were used in this study and the expression and 
activity of SIRT2 was manipulated in SH-SY5Y cells to study its role in regulation of ROS. 
Some studies have reported that inhibition of SIRT2 reduces α-synuclein mediated toxicity in 
PD models and SIRT2 inhibition also rescued cells from mutant HTT in HD models (Outeiro 
et al., 2007; Luthi-Carter et al., 2010). Contrary to these studies, the findings from this study 
suggest that SIRT2 inhibition increased cell death in diquat or rotenone treated cells (Figures 
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4.4 and 4.5). In diquat or rotenone treated cells, SIRT2 overexpressing SH-SY5Y cells 
showed increased viability and cells co-incubated with diquat or rotenone and AGK2 showed 
elevated cell death. As with other SIRTs, SIRT2 is NAD
+ 
dependent and is a potential redox 
sensor and thus could be implicated in regulation of oxidative stress in cells.  
Based upon SIRT2’s dependency on NAD+, several studies were conducted to evaluate the 
role of SIRT2 in oxidative stress mediated cellular damage and death. These studies showed 
that SIRT2 enhanced cell viability under oxidative stress and inhibition or knock down of 
SIRT2 decreased intracellular ATP levels and enhanced cell death. Wang et al., reported that 
SIRT2 regulates oxidative stress by deacetylating FOXO3a and enhances the expression of 
FOXO3a targets namely p27
Kip1
 and SOD2, and under severe oxidative stress it enhances the 
expression of the pro-apoptotic protein Bim (Wang et al., 2007). Consequently, through 
p27
Kip1
, SIRT2 promotes cell cycle arrest and reduces the amount of ROS via SOD2 (Wang et 
al., 2007). In PC12 cells, silencing or inhibition of SIRT2 by AGK2 led to decreased ATP 
levels and enhanced cell death via necrosis (Nie et al., 2011). In contrast, Nie et al., in a 
further study showed that inhibition of SIRT2 rescued differentiated PC12 cells from H2O2 
induced toxicity and silencing of SIRT2 reduced the levels of ROS following H2O2 treatment 
(Nie et al., 2014).  
These findings corroborate with results from this study and suggest that possibly via 
upregulation of SOD2 and deacetylation of p53, SIRT2 regulates cell viability and combats 
oxidative stress and necrosis. The other studies that have shown deleterious effect of SIRT2 
under oxidative stress could be a result of different cell lines and toxins used to trigger 
oxidative stress.  
 
4.5.3 Different mechanisms through which SIRT2 modulates Oxidative stress 
ROS at high levels in cells leads to irreversible damage to proteins, lipids and DNA and 
further impair antioxidant defence mechanisms which eventually results in cell death. Cells 
defend themselves against oxidative stress by producing antioxidant proteins such as SOD2 
and catalase. In this study, it was found that under oxidative stress, inhibition of SIRT2 
increased cell death and over-expression of SIRT2 enhanced cell survival. Under oxidative 
stress, SIRT2 deacetylates FOXO3a and enhances the expression of its target SOD2. SOD2 
itself combats oxidative stress and elevates cell survival rate (Wang et al., 2007). Based upon 
this finding, the expression of SOD2 was measured in diquat or rotenone treated cells. 
Western blot analysis showed that under oxidative stress induced by diquat or rotenone 
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inhibition of SIRT2 reduced the levels of SOD2 and the over-expression of SIRT2 led to 
elevated levels of SOD2 (Figures 4.8 and 4.11). This suggests that protection conferred by 
SIRT2 in toxin treated SH-SY5Y cells is mediated in part by SOD2.  
SOD2 mediated cell protection is one mechanism by which SIRT2 reduces ROS levels. 
Earlier studies have highlighted other possible mechanisms by which SIRT2 combats 
oxidative stress. Apart from SOD2, SIRT2 has also been shown to elevate the expression of 
catalase and glutathione peroxidase. Kim et al., showed the protective role of SIRT2 in 
murine macrophages against H2O2 induced oxidative stress (Kim et al., 2013). They 
transduced murine macrophages with PEP1-SIRT2 protein which inhibited inflammation and 
oxidative stress by reducing the levels of cytokines and ROS levels, and promoted cell 
survival by enhancing the expression of antioxidants namely SOD2, catalase and glutathione 
peroxidase (Kim et al., 2013) (PEP1 is used in transduction since it enhances transduction and 
ensures high stability and without toxicity to cells).  
Additional targets of SIRT2 implicated in ROS level modulation are glucose-6-phosphate 
dehydrogenase (G6PD) and phosphoglycerate mutase (PGAM2). Wang et al., showed that in 
menadione treated HEK293T and mouse erythrocytes, SIRT2 rescued cells from ROS 
production and cell death by deacetylating and activating G6PD. Upon deacetylation by 
SIRT2, active G6PD stimulates the pentose phosphate pathway (PPP) to release NADPH to 
protect HEK293T and mouse erythrocytes from oxidative damage (Wang et al., 2014). Under 
oxidative stress, SIRT2 deacetylates PGAM2 and activates the glycolytic enzyme and 
combats oxidative stress (Xu et al., 2014). PGAM2 plays a crucial role in energy homeostasis 
and also contribute to the biosynthesis of amino acids and nucleotide precursors (Xu et al., 
2014). These studies have shown that SIRT2 modulates ROS levels and promotes cell 
survival through an antioxidant pathway mechanism.  
SIRT2 has also been shown to modulate the activity and expression of p53, a transcription 
factor, tumour suppressor and apoptosis inducer. p53 is acetylated at the C-terminal lysine 
residues, most importantly at K382, which stabilises p53 and also enhances its activity 
(Poyurovsky et al., 2010; Brooks and Gu, 2011). SIRT1 has been shown to deacetylate p53 at 
K382 within the nucleus and few studies have shown that SIRT2 also deacetylates 
p53K382Ac (Peck et al., 2010; van Leeuwen et al., 2013; Hoffmann et al., 2014). High levels 
of ROS trigger p53 pro-oxidative activity which leads to activation of specific genes 
including proline oxidase, which leads to enhanced oxidative stress (Polyak et al., 1997; 
Donald et al., 2001). Along with activation of pro-oxidant genes, p53 induces the expression 
of pro-apoptotic genes namely, BAX and PUMA (p53 upregulated modulator of apoptosis) and 
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activation of both results in apoptotic cell death (Macip et al., 2003). Thus deacetylation of 
p53 by SIRT1 and/or by SIRT2 impairs the activity of p53 and inhibits p53 mediated cell 
apoptosis and enhances cell survival under high oxidative stress.  
Apart from modulating antioxidant defence mechanisms and p53-mediated apoptosis, SIRT2 
has been shown to play an important role in genomic stability, DNA repair mechanisms and 
cell-cycle progression. SIRT2 is translocated to the nucleus during G2/M transition, where it 
controls genomic stability by deacetylating H4K16 and modulates chromatin condensation 
(Vaquero et al., 2006). It also modulates chromatin condensation through regulation of 
deposition of H4K20me1. SIRT2 deacetylates histone methyl transferase, PR-SET7 and 
enhances its stability in chromatin and its catalytic activity towards H4K20, thus ensuring 
correct chromatin packing (Serrano et al., 2013). SIRT2 maintains genomic integrity through 
regulation of centrosome replication and modulation of Anaphase Promoting 
Complex/Cyclosome (APC/C) activity (Kim et al., 2011a). Upon DNA damage, SIRT2 has 
been observed to regulate double strand break repair probably through deacetylation of 
H4K16. Deacetylation of H4K16 at DNA damage sites enhances the recruitment of 53BP1 to 
DSBs and promotes DNA repair by non-homologous end joining (Hsiao and Mizzen, 2013).  
The findings of this research are in keeping with several other studies and it can be concluded 
that SIRT2 improves cell survival by activation of SOD2 and other antioxidant pathways, by 
potentially enhancing DNA damage repair and by inhibiting p53 mediated apoptosis. 
 
4.5.4 SIRT2 and α-synuclein aggregate formation 
α-synuclein is a major component of LBs and LNs (Spillantini et al., 1998) and aggregation 
of α-synuclein is enhanced by several modifications and conditions including oxidative stress 
(Hashimoto et al., 1999), phosphorylation (Fujiwara et al., 2002) and C- terminal truncation 
(Li et al., 2005). Given the role of α-synuclein aggregation in PD, in this study the percentage 
of α-synuclein aggregates was measured in diquat or rotenone treated cells and it was found 
that SIRT2 inhibition in pcDNA3.1 transfected cells enhanced aggregate formation in diquat 
as well as rotenone treated cells (Figures 4.15 and 4.16).  However, over-expression of SIRT2 
diminished α-synuclein aggregate formation in diquat or rotenone treated cells (Figures 4.15 
and 4.16). These results suggest that SIRT2 inhibits α-synuclein aggregate formation and 
possibly reduces the toxicity caused by α-synuclein intermediates and aggregates.  
Contrary to findings of this research, Outeiro et al., reported that SIRT2 inhibition rescues 
from α-synuclein mediated toxicity (Outeiro et al., 2007). This rather contradictory result 
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could be attributed to different style of treatments and over-expression of proteins. In their 
study, A53T (mutant α-synuclein) was over-expressed in cellular and fly models and these 
models were then subjected to SIRT2 inhibition whereas, in this study α-synuclein aggregate 
formation was induced by diquat or rotenone treatment in SIRT2 transfected cells or AGK2- 
treated SIRT2pcDNA3.1 cells. The results obtained from SIRT2 over-expressing cells and 
SIRT2 inhibited cells show that SIRT2 does not enhance α-synuclein aggregate formation 
rather SIRT2 impairs aggregate formation. Alamar Blue assays of diquat or rotenone 
treatment (Figures 4.4 and 4.5) also corroborate the finding that SIRT2 inhibition enhances 
cellular death and SIRT2 over-expression promotes cell survival under oxidative stress. All 
these findings suggest that SIRT2 acts as a pro-survival factor under oxidative stress.  
 
4.5.5 Expression of SIRT2 in neurodegenerative disorders 
The ageing brain is characterised by several molecular, structural and functional changes 
which enhance the chances of development and progression of diseases. The ageing brain 
shows gene expression changes specifically in the levels of stress response genes, 
mitochondrial genes and genes involved in synaptic function (review in (Yankner et al., 
2008)). SIRT2 plays a crucial role in antioxidant defence mechanisms (Wang et al., 2007) and 
in DNA damage repair (Hsiao and Mizzen, 2013). These higher levels of oxidative stress and 
DNA damage are implicated in neurodegenerative disorders such as PD and AD.  
In this study, the levels of SIRT2 were measured in several brain regions in PD, PDD, DLB 
and AD and compared to a control group. In general, the levels of SIRT2 did not change 
between the disease groups and controls but a tendency of elevation in the levels of SIRT2 
was observed in all disease groups. The higher levels of SIRT2 were observed in the frontal 
cortex and the cerebellum of PD, temporal cortex and the cerebellum of DLB and the 
cerebellum of AD (Table 4.6). Maxwell et al., showed that SIRT2 accumulates in the ageing 
brain (Maxwell et al., 2011) and this may possibly explain why major changes were not 
observed in SIRT2 levels in disease groups. Very few studies have been conducted on SIRT2 
expression in human brain; more robust studies are needed to elucidate the expression, 
localisation and the role of SIRT2 in these disorders using post-mortem human brain tissue. 
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 Frontal 
Cortex 
Temporal 
Cortex 
Putamen Hippocampus Cerebellum 
PD ↑ No significant 
changes 
No significant 
changes 
- ↑ 
PDD No significant 
changes 
↓ No significant 
changes 
- No significant 
changes 
DLB No significant 
changes 
↑ ↓ No significant 
changes 
↑ 
AD No significant 
changes 
No significant 
changes 
- No significant 
changes 
↑ 
Table 4.6 Summary of expression of SIRT2 in neurodegenerative disorders compared to 
a control group. ↑ indicates elevation; ↓ indicates reduction and – indicates that the expression of 
SIRT2 was not studied in that particular brain region. 
 
4.5.6 Cellular localisation of SIRT2 under stress 
Cellular stress subjects proteins to a variety of modifications which affect the stability, 
activity and even the localisation of proteins (Welch, 1992). In this study it was observed that 
under oxidative stress induced by diquat or rotenone, SIRT2 was localised to the nucleus and 
the cytoplasm but was predominantly present in the nucleus (Figures 4.12 and 4.13).  SIRT2 
is predominantly a cytoplasmic protein but may shuttle to the nucleus based upon the cell 
cycle stage and cellular stress (North and Verdin, 2007a; Serrano et al., 2013).  Under 
oxidative stress, the known target of SIRT2, FOXO3a shuttles to the nucleus (Huang and 
Tindall, 2007) and induces the expression of its target SOD2 to antagonise the effect of ROS 
(Kops et al., 2002). FOXO3a has been shown to save cells from oxidative stress through 
direct activation of SOD2 (Kops et al., 2002). SIRT2 activates FOXO3a mediated 
transcription of SOD2 and similar results were seen in this study (Figures 4.8 and 4.11). The 
results from this study are consistent with earlier studies which reported that SIRT2 localises 
in the nucleus under stress.  
The cellular localisation of SIRT2 was also determined in the temporal cortex, hippocampus 
and cerebellum in PD, PDD, DLB and AD a control group. Contrary to the results obtained 
from in vitro studies no significant difference was observed in the localisation of SIRT2 
within the disease groups and controls (Figures 4.35-4.40). One of the major disadvantages of 
these findings in post-mortem brain tissue was the reduced quality of staining of the cells. 
Generally the sections were palely stained hence the determination of SIRT2 location was 
difficult. In future, more specific and better antibody should be used to determine the location 
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of SIRT2 and dual-immunostaining should be performed along with known biomarkers of 
disease groups. 
 
4.5.7 SIRT2 activity- a potential compensatory mechanism 
Several studies conducted on the role of SIRT2 in neurodegenerative disorders have 
suggested a negative role of SIRT2 and inhibition of SIRT2 has been found beneficial for 
cells (Outeiro et al., 2007; Luthi-Carter et al., 2010). While protein levels of SIRT2 were 
essentially unchanged, enzymatic activity for SIRT2 showed a different picture. SIRT2 
activity was higher in disease groups than control but no significant difference was observed 
between neurodegenerative disorders (Figures 4.33 and 4.34). The current results in toxin 
induced oxidative stress in SH-SY5Y cells shows SIRT2 over-expression promotes cell 
survival and inhibits α-synuclein aggregate formation. It is possible that elevated SIRT2 
activity in disease group is a compensatory mechanism. SIRT1 has been shown to be 
neuroprotective in different neurodegenerative disorders and as discussed previously, SIRT1 
activity is remarkably reduced in disease groups although the total SIRT activity did not differ 
among the groups. It is possible that to overcome reduced SIRT1 activity, SIRT2 activity is 
increased in order to induce the activity of antioxidant proteins including SOD2 and catalase. 
Combining the in vitro work and the results obtained from post-mortem human brain tissue it 
is possible that SIRT2 is needed to fight against oxidative stress and possibly the higher 
SIRT2 activity in human brain tissue is a compensatory mechanism to combat neuronal stress. 
Further studies are needed to evaluate the role of SIRT2 and its interaction with 
neurodegenerative and inflammatory markers. Along with SIRT2, expression of these 
markers should also be evaluated in disease groups and the role of SIRT2 should be further 
investigated under chronic oxidative stress in midbrain neuronal models of PD.  
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4.5.8 Conclusions 
This study has shown that in SH-SY5Y cells, under diquat or rotenone induced oxidative 
stress, SIRT2 over-expression protected the cells from oxidative damage and reduced α-
synuclein aggregate formation. Also, the inhibition of SIRT2 by AGK2 under oxidative 
stress, elevated cell death and increased the number of α-synuclein aggregates. These findings 
suggest that SIRT2 promotes cell survival and may provide this protection through activation 
of SOD2. In post-mortem human brain tissue, SIRT2 protein expression did not differ 
between different disease groups (PD, PDD, DLB and AD) and controls but the enzymatic 
activity of SIRT2 was higher in disease groups compared to controls. Based upon the findings 
from the in vitro work and post-mortem brain tissue studies it can be concluded that SIRT2 
hyperactivity in disease groups could be a compensatory mechanism. However, a more robust 
study based upon chronic oxidative stress is needed to further investigate the role of SIRT2.   
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Chapter 5 SIRT3- Involvement in Oxidative stress and 
Neurodegenerative disorders 
5.1 Introduction 
Mitochondria play an important role in numerous cellular processes that are involved in 
energy production, cell signalling, cellular homeostasis and cell survival and mitochondrial 
dysfunction has been associated with ageing and age-related disorders including AD and PD 
(reviewed in (Lin and Beal, 2006)). Mitochondrial activities are regulated in response to 
various environmental factors and the mechanisms behind the regulation are still unclear. 
Post-translational modification of mitochondrial proteins is one of the mechanisms that play a 
role in modulation of mitochondrial activity. Reversible acetylation/acylation of proteins on 
the lysine residue affects the function of proteins and thus regulates mitochondrial activity 
(reviewed in (Baeza et al., 2016)). One protein family that regulates the acetylation/acylation 
of proteins are Sirtuins. Mitochondrial SIRTs, SIRT3, SIRT4 and SIRT5 are implicated in the 
regulation of metabolism, mitochondrial fidelity and antioxidant defence-mechanisms. 
Among these three mitochondrial SIRTs, SIRT3 is the major mitochondrial deacetylase 
(Lombard et al., 2007) and has been shown to play an important role in energy homeostasis 
(Ahn et al., 2008) and metabolic pathways (Rardin et al., 2013) and ameliorates oxidative 
stress (reviewed in (Bell and Guarente, 2011)). 
SIRT3 is the most studied mitochondrial SIRT which possesses deacetylase activity and is 
located predominantly in the mitochondrial matrix (reviewed in (Lombard and Zwaans, 
2014)). SIRT3 knock out mice show hyperacetylation of most of the mitochondrial proteome 
and the acetylation of lysine inactivates most of the proteins involved in different 
mitochondrial activities (Lombard et al., 2007; Zhao et al., 2010). Under stress, SIRT3 
deacetylates and activates SOD2, reducing oxidative stress leading to improved cell survival 
(Qiu et al., 2010). Oxidative stress has been implicated promoting neural cell death in 
neurodegenerative disorders including AD (reviewed in (Perry et al., 2002)) and PD 
(reviewed in (Jenner, 2003)). Regulation of antioxidant mechanisms, energy production and 
homeostasis and metabolic pathways by SIRT3 suggest that it has a potential neuroprotective 
role which is possibly mediated by reduction of ROS and ageing. Furthermore, SIRT3 has 
been shown to protect neurones from NMDA-induced excitotoxic injury in mouse cortical 
neuronal culture (Kim et al., 2011b). One further study has shown that over-expression of 
SIRT3 in mouse hippocampal neuronal culture can rescue neurones from augmented 
 267 
mitochondrial oxidative stress (Weir et al., 2012). These findings suggest that SIRT3 has a 
potential therapeutic role in neurodegenerative disorders. 
 
5.2 Aims 
The aim of this study is to investigate the role of SIRT3 in oxidative stress-mediated cell 
death in SH-SY5Y cells and to evaluate the possible interaction between SIRT3 and α-
synuclein. Another aim is to evaluate the role of SIRT3 in neurodegenerative disorders (PD, 
PDD, DLB and AD) by examining protein levels and cellular location in post-mortem human 
brain tissue. 
 
5.3 Materials and methods 
5.3.1 SH-SY5Y cells 
Please refer to Materials and Methods sections 2.3.1 to 2.3.5 
 
5.3.2 Brain tissue 
Please refer to Materials and Methods sections 2.1.1, 2.1.2 and 2.1.3. 
 
5.4 Results 
5.4.1 SH-SY5Y cells 
5.4.1.1 Over-expression of SIRT3 in SH-SY5Y cells 
SH-SY5Y cells were transfected with SIRT3 wild type (WT) and SIRT3H248Y, a 
catalytically inactive mutant, cloned in pLenti CMV lentiviral vector and were compared with 
SIRT3 and SIRT3H248Y insert cloned in pcDNA4. After 48 hours of transfection, the cells 
were harvested, protein quantified and probed for SIRT3 levels by Western Blot analysis. The 
levels of SIRT3 isoform 1 (37kDa) were elevated by ~7 fold in SIRT3 pLenti CMV (p<0.001; 
Figure 5.1) transfected cells and an increase of ~4 fold (p<0.001; Figure 5.1) were observed in 
SIRT3H248Y pLenti CMV transfected cells, whilst no changes were observed in SIRT3 
pcDNA4 and SIRT3H248Y pcDNA4 transfected cells when compared  to non-transfected 
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cells (Figure 5.1). Similar results were observed with the expression of SIRT3 isoform 2 
(mitochondrial SIRT3 28kDa) in SIRT3 pLenti CMV transfected cells; an increase of ~5.5 
fold was seen in SIRT3WT (p<0.001; Figure 5.1) transfected cells and ~4.5 fold increase was 
found in SIRT3H248Y transfected cells (p<0.001; Figure 5.1). SIRT3 inserts cloned in pLenti 
CMV blast showed an efficient and better transfection of SH-SY5Y cells than SIRT3 cloned 
in pCDNA4.  
 
 
Figure 5.1 Transfection of SH-SY5Y cells with different SIRT3 plasmids. SH-SY5Y cells 
were transfected with SIRT3 plasmids, in either pLenti CMV vector or pcDNA4. Data is presented as 
fold- untreated (+SD) from three independent assays (n=3). ***p<0.001, One-way ANOVA when 
compared to mock transfection (Bonferroni corrected). Image is a representative blot of SIRT3 and 
GAPDH. 
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5.4.1.2 Effect of SIRT3 wild type and SIRT3 mutant over-expression in toxin treated SH-
SY5Y cells 
SIRT3 is a nuclear coded protein that has two isoforms, isoform 1 is located in the nucleus 
and is translocated to the mitochondria where it is processed to give rise to shorter isoform 2 
(Schwer et al., 2002). Isoform 2 of SIRT3 is the major mitochondrial NAD
+
 dependent 
deacetylase and regulates the acetylation of many mitochondrial proteins involved in 
mitochondrial physiology, energy metabolism and ROS detoxification. Based upon these 
findings, the role of SIRT3 was studied in SH-SY5Y cells that were treated with diquat or 
rotenone. 
To study the role of SIRT3 in oxidative stress mediated cell death, SH-SY5Y cells were 
treated with 20µM or 10μM diquat. SH-SY5Y cells were transfected with SIRT3WT or 
SIRT3H248Y (mutant) and control group with empty pLenti CMV vector. After 48 hours of 
transfection, cells were treated with diquat for 20 hours and cell viability was measured by 
Alamar Blue reduction assay. In 20µM diquat treated SH-SY5Y cells, a significant increase in 
the cell survival was observed in SIRT3WT transfected cells when compared to control group 
(19%↑, p<0.001; Figure 5.2). SIRT3H248Y cells showed reduced cell survival when 
compared to control group (11%↓, p<0.001; Figure 5.2) and a decrease of 30% in Alamar 
Blue fluorescence was observed on comparison with SIRT3WT cells (p<0.001; Figure 5.2). 
Whereas in 10µM diquat treated cells, no significant difference in cell viability was observed 
between SIRT3WT and control cells (p>0.05; Figure 5.2) but a decrease in cell viability was 
observed in SIRT3H248Y cells when compared to both SIRT3WT (18%↓, p<0.001; Figure 
5.2) and control cells (11%↓, p<0.05; Figure 5.2).  
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Figure 5.2 Effects of SIRT3WT and SIRT3 enzymatic mutant overexpression on diquat 
treated SH-SY5Y cells. SIRT3WT and SIRT3H248Y were over-expressed in SH-SY5Y cells and 
control cells were transfected with empty pLenti CMV vector following which cells were treated with 
diquat (20 or 10μM) for 20 hours and viability was measured by reduction of Alamar Blue. Data are 
presented as mean % control + SD from three independent assays (n=3).  ***p<0.001 and **p<0.01 
when compared to 0.2% PBS, one-way ANOVA (Bonferroni corrected), ###p<0.001 when compared 
to empty vector treatment and ~~~p<0.001 when compared to SIRT3WT, two-way ANOVA 
(Bonferroni corrected).   
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Role of SIRT3 was also examined in rotenone treated SH-SY5Y cells. After 48 hours of 
transfection with SIRT3WT, SIRT3H248Y or pLenti CMV plasmids, SH-SY5Y cells were 
treated with 20µM or 0.5µM rotenone for 20 hours followed by measurement of fluorescence 
by Alamar Blue reduction assay. SIRT3WT cells showed an increase in cell viability in 
rotenone 20µM treated cells (12%↑, p<0.001; Figure 5.3), whereas SIRT3H248Y showed 
reduced cell growth when compared to control (13%↓, p<0.001; Figure 5.3) and SIRT3WT 
(25%↓, p<0.001; Figure 5.3). SIRT3WT cells showed improved cell survival in 0.5µM 
rotenone treated cells compared to control (13%↑, p<0.001; Figure 5.3) and SIRT3H248Y 
cells showed reduced cell viability compared to control (8%↓, p<0.01; Figure 5.3) and 
SIRT3WT cells (21%↓, p<0.001; Figure 5.3).  
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Figure 5.3 Effects of SIRT3WT and SIRT3 enzymatic mutant overexpression on 
rotenone treated SH-SY5Y cells. SIRT3WT and SIRT3H248Y were over-expressed in SH-SY5Y 
cells and control cells were transfected with empty pLenti CMV vector following which cells were 
treated with rotenone (20 or 0.5μM) for 20 hours and viability measured by reduction of Alamar Blue. 
Data are presented as mean % control + SD from three independent assays (n=3).  ***p<0.001 when 
compared to 0.2% DMSO, one-way ANOVA (Bonferroni corrected), ###p<0.01 when compared to 
empty vector treatment and ~~~p<0.001 when compared to SIRT3WT, two-way ANOVA (Bonferroni 
corrected).   
 
These findings indicate that SIRT3 acts as a pro-survival protein that enhances cell survival 
under oxidative stress induced either by diquat or rotenone. These data also indicate that the 
deacetylase activity of SIRT3 is essential to scavenge ROS. 
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5.4.1.3 Determination of expression of SIRT3 and its possible targets in toxin treated SH-
SY5Y cells 
Following cell viability assessment after toxin treatment, SH-SY5Y cells were probed for the 
levels of SIRT3 and its possible targets. After the Alamar Blue assay, cells were washed with 
PBS and harvested and were subjected to Western blot analysis (please refer Section 2.3.4 for 
details). 
To test the efficiency of transfection, the levels of SIRT3 were determined in diquat treated 
cells. In 0.2% PBS treated cells, the levels of SIRT3 isoform 1 were increased in SIRT3WT 
transfected cells by ~4.5-5.5 fold (p<0.001) and by ~2.5-3.5 fold (p<0.001) in SIRT3H248Y 
cells when compared to empty vector transfected cells (Figure 5.4). The levels of SIRT3 
isoform 2 (mitochondrial SIRT3) were also elevated by ~2.5 fold in SIRT3WT (p<0.001) 
transfected cells and by ~2 fold in SIRT3H248Y (p<0.001) transfected cells compared to 
control cells (Figure 5.4).  Interestingly, diquat treatments (20µM or10µM) elevated the levels 
of SIRT3 isoforms in control cells, isoform 1 by ~1.8-2.5 fold and isoform 2 by ~1.9- 2.2 fold 
compared to 0.2% PBS treatment (p<0.01; Figure 5.4). An increase in the levels of SIRT3 
was also observed in SIRT3WT and SIRT3H248Y transfected cells, SIRT3 isoform 1 was 
elevated by ~1.3-2 fold (p<0.001) in SIRT3WT cells and by ~1.3- 2.5 fold in SIRT3H248Y 
cells. SIRT3 isoform 2 was increased by ~1.5-1.8 fold in SIRT3WT cells (p<0.001) and ~1.5-
1.7 fold in SIRT3H248Y cells (p<0.001) compared to the respective 0.2% PBS treatment 
(Figure 5.4). Qiu et al., reported that under oxidative stress SIRT3 expression was increased 
and rescued the cells from oxidative stress by activating SOD2 (Qiu et al., 2010).  
As reported earlier SIRT3WT overexpression elevated cell survival rate, therefore to 
determine the possible mechanism behind this increased cell survival, the level of SOD2 was 
measured in diquat treated cells. Western blot analysis of diquat treated cells showed elevated 
levels of SOD2 in empty vector transfected cells and SIRT3WT cells where in SIRT3WT 
transfected cells the levels of SOD2 were higher  by ~1.5-1.9 fold compared to diquat treated 
control cells (p<0.001; Figure 5.5). Whereas, the levels of SOD2 in SIRT3H248Y transfected 
cells were reduced by ~30% in diquat treated cells (p<0.001; Figure 5.5). 
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Figure 5.4 Expression of SIRT3 in diquat treated SH-SY5Y. SIRT3WT and SIRT3H248Y 
were over-expressed in SH-SY5Y cells and control cells were transfected with empty pLenti CMV 
vector following which cells were treated with diquat (20μM or 10μM) for 20 hours. Cells were 
harvested and the samples were probed for A) SIRT3 expression in 20μM diquat treated cells and B) 
SIRT3 expression in 10μM diquat treated cells. Data presented as fold- untreated (0.2% PBS) (+SD) 
from three independent assays (n=3). ***p<0.001 and **p<0.01 when compared to 0.2% PBS, one-
way ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector treatment, 
~~~p<0.001, ~~p<0.01and ~p<0.05 when compared to SIRT3WT cells, two-way ANOVA 
(Bonferroni corrected). Images are a representative blot of SIRT3 and GAPDH.  
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Figure 5.5 Expression of SOD2 in diquat treated SH-SY5Y. SIRT3WT and SIRT3H248Y 
were over-expressed in SH-SY5Y cells and control cells were transfected with empty pLenti CMV 
vector following which cells were treated with diquat (20μM or 10μM) for 20 hours. Cells were 
harvested and the samples were probed for A) SOD2 expression in 20μM diquat treated cells and B) 
SOD2 expression in 10μM diquat treated cells.  ***p<0.001 and **p<0.01 when compared to 0.2% 
PBS, one-way ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector 
treatment, ~~~p<0.001when compared to SIRT3WT cells, two-way ANOVA (Bonferroni corrected). 
Images are a representative blot of GAPDH and SOD2. 
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The levels of SIRT3 and SOD2 were also measured in rotenone treated SH-SY5Y cells. The 
elevated levels of SIRT3 in SIRT3- transfected cells showed an effective transfection of cells. 
Oxidative stress induced by rotenone resulted in increased expression of SIRT3 isoforms in 
control cells; when compared to 0.2% DMSO treated cells, levels of isoform 1 were elevated 
by ~2.0-2.5 fold (p<0.01; Figure 5.6) and levels of isoform 2 were elevated by ~1.5-2.0 fold 
(p<0.01; Figure 5.6). The levels of SIRT3 in 0.2% DMSO treated SIRT3WT and SIRTH248Y 
cells were increased when compared to 0.2% DMSO treated pLenti CMV transfected cells, 
levels of isoform 1 increased by ~3.5- 4.5 fold in SIRT3WT cells (p<0.001; Figure 5.6) and 
by ~2.5- 4 fold in SIRT3H248Y cells (p<0.001; Figure 5.6). The levels of isoform 2 increased 
by ~3.0-3.5 fold in SIRT3WT cells (p<0.001; Figure 5.6) and by ~2.0-2.5 fold in 
SIRT3H248Y cells (p<0.001; Figure 5.6).  
The levels of SOD2 were higher in rotenone treated pLenti CMV and SIRT3WT cells where 
the increase was more prominent (~2 fold) in SIRT3WT cells (p<0.001; Figure 5.7). 
However, in SIRT3H248Y transfected cells the levels of SOD2 were reduced by 30% which 
directly correlates with reduced cell viability (p<0.001; Figure 5.7).  
 
  
 276 
A 
 
B 
 
Figure 5.6 Expression of SIRT3 in rotenone treated SH-SY5Y. SIRT3WT and SIRT3H248Y 
were over-expressed in SH-SY5Y cells and control cells were transfected with empty pLenti CMV 
vector following which cells were treated with rotenone (20μM or 10μM) for 20 hours. Cells were 
harvested and the samples were probed for A) SIRT3 expression in 20μM rotenone treated cells and 
B) SIRT3 expression in 0.5μM rotenone treated cells. Data presented as fold- untreated (+SD) from 
three independent assays (n=3). ***p<0.001 and **p<0.01 when compared to 0.2% DMSO, one-way 
ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector treatment, ~~~p<0.001, 
~~p<0.01 and ~p<0.05 when compared to SIRT3WT cells, two-way ANOVA (Bonferroni corrected). 
Images are a representative blot of SIRT3 and GAPDH.  
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Figure 5.7 Expression of SOD2 in rotenone treated SH-SY5Y. SIRT3WT and SIRT3H248Y 
were over-expressed in SH-SY5Y cells and control cells were transfected with empty pLenti CMV 
vector following which cells were treated with rotenone (20μM or 10μM) for 20 hours. Cells were 
harvested and the samples were probed for A) SOD2 expression in 20μM rotenone treated cells and B) 
SOD2 expression in 0.5μM rotenone treated cells. Data are presented as fold- untreated (+SD) from 
three independent assays (n=3). ***p<0.001 and **p<0.01 when compared to 0.2% DMSO, one-way 
ANOVA (Bonferroni corrected), ###p<0.001 when compared to empty vector treatment, 
~~~p<0.001when compared to SIRT3WT cells, two-way ANOVA (Bonferroni corrected). Images are 
a representative blot of GAPDH and SOD2. 
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These findings suggest that under oxidative stress, cells combat oxidative damage by 
elevating the expression of SIRT3 which directly activates SOD2 and rescues cells, and the 
enzymatic activity of SIRT3 is essential for conferring the protection to cells. 
 
5.4.1.4 Cellular localisation of SIRT3 in toxin treated SH-SY5Y cells 
As discussed earlier, SIRT3 is a nuclear encoded protein that is translocated to mitochondria. 
SIRT3 has two isoforms, isoform 1 and 2 and the localisation and activity of isoform 1 have 
always been under debate. Several studies have shown that isoform1 and 2 both have 
deacetylase activity and isoform 1 under stress accumulates in the nucleus and maintains 
DNA integrity by deacetylating histones (reviewed in (Kincaid and Bossy-Wetzel, 2013)).  In 
this study, diquat or rotenone was used to induce oxidative stress and the cellular localisation 
of SIRT3 was determined by immunocytochemistry and fluorescent microscopy. SH-SY5Y 
cells were immunostained for SIRT3 and phospho-α-synuclein and the images were captured 
using a confocal microscope.  
In diquat treated cells, SIRT3 was localised in both the nucleus and cytoplasm but was 
prominently present in the cytoplasm (Figure 5.8). SIRT3 has been reported to accumulate in 
the nucleus in response to stress where it deacetylates Ku70 and histone and protects the cells 
from any damage caused by stress (Sundaresan et al., 2008). This explains the nuclear 
staining of SIRT3, with the cytoplasmic staining of SIRT3 more likely to be mitochondrial 
although specific mitochondrial staining will need to be performed to confirm this. SIRT3 
was co-localised with α-synuclein and surprisingly in SIRT3H248Y transfected cells, SIRT3 
showed higher degree of co-localisation with α-synuclein (Figure 5.8).  
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Figure 5.8 Localisation of SIRT3 and α-synuclein in diquat treated SH-SY5Y cells. Cellular distribution of SIRT3 and phospho-α-synuclein was 
determined using fluorescent immunocytochemistry. Images show α-synuclein staining, SIRT3 staining and all staining merged including DAPI staining. A 
represents 0.2% PBS treated SH-SY5Y cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 5.8 Localisation of SIRT3 and α-synuclein in diquat treated SH-SY5Y cells (continued). B represents 20μM diquat treated SH-SY5Y 
cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 5.8 Localisation of SIRT3 and α-synuclein in diquat treated SH-SY5Y cells (continued). C represents 10μM diquat treated SH-SY5Y 
cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
 282 
Cellular localisation of SIRT3 was also determined in rotenone treated SH-SY5Y cells and 
similar to diquat treated cells, SIRT3 was observed to be localised both in the nucleus and 
cytoplasm. SIRT3H248Y co-localised with α-synuclein to higher extent than SIRT3WT 
(Figure 5.9).  
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Figure 5.9 Localisation of SIRT3 and α-synuclein in rotenone treated SH-SY5Y cells. Cellular distribution of SIRT3 and phospho-α-synuclein 
was determined using fluorescent immunocytochemistry. Images show α-synuclein staining, SIRT3 staining and all staining merged including DAPI satining. 
A represents 0.2% DMSO treated SH-SY5Y cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 5.9 Localisation of SIRT3 and α-synuclein in rotenone treated SH-SY5Y cells (continued). B represents 20μM rotenone treated SH-
SY5Y cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X 
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Figure 5.9 Localisation of SIRT3 and α-synuclein in rotenone treated SH-SY5Y cells (continued). C represents 0.5μM rotenone treated SH-
SY5Y cells. Scale bars- white scale bar= 50μM and red scale bar= 20μM; Magnification: 40X
 286 
5.4.1.5 Effect of SIRT3 on α-synuclein aggregate formation 
Lewy bodies are the characteristic feature of PD and other Lewy body disorders and consist of 
aggregated α-synuclein (reviewed in (Cookson, 2005)). Studies have shown that α-synuclein 
can accumulate in mitochondria, down regulate Complex I and hence enhance oxidative stress 
leading to cell death (reviewed in (Stefanis, 2012)). α-synuclein has been reported to change 
mitochondrial morphology both in vitro and in vivo and this is possibly caused by either direct 
interaction of α-synuclein with mitochondrial membranes (Nakamura et al., 2011) or through 
an indirect interaction which is mediated by increased translocation of dynamin-like protein 1 
(DLP1) to mitochondria (Gui et al., 2012); both direct or indirect interactions result in 
mitochondrial fragmentation, thus accelerating cell death .   
Figure 5.10 illustrates the formation of α-synuclein aggregates under oxidative stress induced 
by rotenone. The arrows indicate the α-synuclein aggregates that vary from intermediate to 
large inclusions and are more evident in rotenone treated SH-SY5Y cells.  
 
 
Figure 5.10 α-synuclein aggregate formation in SH-SY5Y cells. SH-SY5Y cells were treated 
with toxins and were stained with phospho-α-synuclein. The slides were visualised through GFP filter 
(63X magnification) for α-synuclein staining. Aggregates are highlighted with white arrows. Scale 
bar: 20μM 
 
SIRT3 plays an important role in maintenance of mitochondrial dynamics and α-synuclein has 
been reported to change the mitochondrial morphology. To study the effect of SIRT3 on α-
synuclein aggregation, SH-SY5Y cells were seeded in four-well chamber slides and the cells 
were transfected with SIRT3WT or SIRT3H248Y and control cells with pLenti CMV for 48 
hours. Following transfection, cells were treated either with diquat or rotenone for 20 hours 
then cells were fixed and were probed for SIRT3 and α-synuclein staining (please refer 
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Section 2.3.5). The images captured using a confocal microscope were quantified on ImageJ 
software (NIH, USA).  
In diquat treated cells, overexpression of SIRT3WT protein inhibited α-synuclein aggregate 
formation compared to pLenti CMV transfected cells (p<0.001; Figure 5.11). On the other 
hand, SIRT3H248Y transfected cells showed significant increase in α-synuclein aggregation 
in diquat treated cells (p<0.001) when compared to 0.2% PBS treated control cells (Figure 
5.11) or to control cells treated with diquat (p<0.001).  
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Figure 5.11 α-synuclein aggregate formation and quantification in diquat treated SH-
SY5Y cells. SIRT3WT and SIRT3H248Y overexpressing SH-SY5Y cells were treated with diquat 
(20μM or 10μM) and 0.2% PBS; cells transfected with empty vector were used as a control. Cells 
were immunostained with phospho-α-synuclein. Images were captured through GFP filter under 63X 
magnification. A) shows the captured images for α-synuclein staining and B) represents the aggregate 
quantification. Each bar represents % α-synuclein aggregates from three independent assays (n=3). 
***p<0.01 when compared to 0.2% PBS, one-way ANOVA (Bonferroni corrected), ###p<0.001and 
##p<0.01 when compared to empty vector treatment, ~~~p<0.001when compared to SIRT3WT 
overexpressing cells, two-way ANOVA (Bonferroni corrected).  Scale bar: 20μM 
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Rotenone has been shown to induce α-synuclein aggregate formation and parkinsonian 
symptoms in animal and cellular models of PD (Betarbet et al., 2000). Therefore, the effect of 
SIRT3 was studied in rotenone treated SH-SY5Y cells. As with diquat treated cell, 
overexpression of SIRT3WT reduced α-synuclein aggregate formation compared to 0.2% 
DMSO treated control cells (p<0.001) or to rotenone treated control cells (p<0.001; Figure 
5.12). On the other hand, the inactive mutant SIRT3H248Y transfected cells showed a 
significant increase in α-synuclein aggregation in rotenone treated cells compared to pLenti 
CMV (p<0.001) and SIRT3WT (p<0.001) transfected cells (Figure 5.12). 
The findings of these studies show that SIRT3 overexpression inhibits α-synuclein aggregate 
formation and enzymatic activity of SIRT3 is required for protection against α-synuclein 
aggregates mediated toxicity. 
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Figure 5.12 α-synuclein aggregate formation and quantification in rotenone treated SH-
SY5Y cells. SIRT3WT and SIRT3H248Y overexpressing SH-SY5Y cells were treated with rotenone 
(20μM or 0.5μM) and 0.2% DMSO; cells transfected with empty vector were used as a control. Cells 
were immunostained with phospho-α-synuclein. Images were captured through GFP filter under 63X 
magnification. A) shows the captured images for α-synuclein staining and B) represents the aggregate 
quantification. Each bar represents % α-synuclein aggregates from three independent assays (n=3). 
***p<0.01 when compared to 0.2% DMSO, one-way ANOVA (Bonferroni corrected), 
###p<0.001and ##p<0.01 when compared to empty vector treatment, ~~~p<0.001when compared to 
SIRT3WT overexpressing cells, two-way ANOVA (Bonferroni corrected).  Scale bar: 20μM 
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5.4.2 Post-mortem human brain tissue 
Oxidative stress is one of the major factors that contributes to ageing and makes individuals 
susceptible to age related disorders. SIRT3 regulates several aspects of metabolic homeostasis 
and enhances antioxidant defence mechanisms under stress. SIRT3 has been reported to be 
neuroprotective in some of the neurodegenerative disorders. The overexpression of SIRT3 has 
been shown to increase neuronal span by decreasing mitochondrial oxidative stress (Weir et 
al., 2012) and in HD model, trans-(-)-ε-viniferin enhanced neuroprotection by enhancing the 
expression of SIRT3 which in turn reduced ROS level and protected cells from oxidative 
damage (Fu et al., 2012). Based upon these findings, the expression of SIRT3 was determined 
in different brain regions of PD, PDD, DLB and AD cases and was compared to an age 
matched control group. The SIRT3 isoform 1 is localised to the nucleus where it deacetylates 
histone H3 acetylated at lysine residue 9 (K9Ac) and modulates the expression of stress-
related genes (Iwahara et al., 2012). Interestingly, Histone H3 acetylated at lysine9 is also a 
substrate of SIRT1 and SIRT6, however, since the antibodies for the acetylated substrates of 
SIRT3 such as SOD2, AceCS2 are not available and hence the levels of AcHK9 were 
determined as an alternative and have been discussed in Chapter 3. 
 
5.4.2.1 Determination of SIRT3 levels in PD 
The levels of SIRT3 in PD cases, were determined in four different brain regions namely, 
frontal cortex, temporal cortex, putamen and cerebellum.  
 
Frontal Cortex 
Western blot analysis of SIRT3 in the frontal cortex showed that isoform 1 migrated to 37kDa 
instead of 44kDa and shorter isoform migrated at its predicted size 28kDa. Compared to the 
control group no significant difference in the levels of either isoforms of SIRT3 was observed 
in PD patients (Figure 5.13).  
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Figure 5.13 Expression of SIRT3 in the frontal cortex of PD and controls. The levels of 
SIRT3 were determined in the frontal cortex of PD patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) with 
respect to control from three independent replicates. No significant differences were observed 
between PD and control, statistical analysis was done through t-test performed on GraphPad prism. 
Image is a representative blot of SIRT3 and GAPDH. 
 
Temporal Cortex 
In the temporal cortex, no significant differences were observed in the levels of either SIRT3 
isoforms between PD or the control (Figure 5.14). 
 
 
Figure 5.14 Expression of SIRT3 in the temporal cortex of PD and controls. The levels of 
SIRT3 were determined in the temporal cortex of PD patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) with 
respect to control from three independent replicates. No significant differences were observed 
between PD and control, statistical analysis was done through t-test performed on GraphPad prism. 
Image is a representative blot of SIRT3 and GAPDH. 
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Putamen 
In the putamen, no observable differences were found in the levels of isoform1 or isoform2 of 
SIRT3 in PD compared to controls (Figure 5.15).  
 
 
Figure 5.15 Expression of SIRT3 in the putamen of PD and controls. The levels of SIRT3 
were determined in the putamen of PD patients and were compared to a control-cohort. SIRT3 band 
intensity was normalised with GAPDH. Data is presented as fold change (+SD) with respect to control 
from three independent replicates. No significant differences were observed between PD and 
control, statistical analysis was done through t-test performed on GraphPad prism. Image is a 
representative blot of SIRT3 and GAPDH. 
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Cerebellum 
Western blot analysis of SIRT3 in the cerebellum of PD cases, showed elevated levels of 
SIRT3 isoforms, with the longer isoform increased by 71% (p<0.01) and the shorter isoform 
increased by 37% (p<0.05) compared to controls (Figure 5.16). 
 
 
Figure 5.16 Expression of SIRT3 in the cerebellum of PD and controls. The levels of SIRT3 
were determined in the cerebellum of PD patients and were compared to a control-cohort. SIRT3 band 
intensity was normalised with GAPDH. Data is presented as fold change (+SD) with respect to control 
from three independent replicates. **p<0.01 and *p<0.05 when compared to control, statistical 
analysis was done through t-test performed on GraphPad prism. Image is a representative blot of 
SIRT3 and GAPDH. 
 
 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Putamen (%) Cerebellum 
(%) 
SIRT3 
Isoform1 37kDa 
Isoform2 28kDa 
 
NS 
NS 
 
NS 
15↓ (p>0.05) 
 
NS 
12↓ (p>0.05) 
 
71% (p<0.01) 
38% (p<0.05) 
Table 5.1 Summary table presenting protein expression of SIRT3 in PD compared to 
controls. The alterations are expressed as percentage change. The text in green indicates elevation 
and in red indicates reduction in the protein expression. NS: No significant difference (any difference 
under 10% with p>0.05). 
 
As summarised in the Table 5.1, in general, the expression of SIRT3 isoforms did not alter 
between PD and controls but a significant increase in their levels was observed in the 
cerebellum.  
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5.4.2.2 Determination of SIRT3 levels in PDD 
In PDD, the levels of SIRT3 were determined in the frontal cortex, temporal cortex, putamen 
and cerebellum and were compared to a cohort-control group. 
Frontal Cortex 
In the frontal cortex of PDD cases, no significant differences were observed in the levels of 
either SIRT3 isoforms when compared to controls (Figure 5.17).  
 
 
Figure 5.17 Expression of SIRT3 in the frontal cortex of PDD and controls. The levels of 
SIRT3 were determined in the frontal cortex of PDD patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) with 
respect to control from three independent replicates. No significant differences were observed between 
PDD and control, statistical analysis was done through t-test performed on GraphPad prism. Image is a 
representative blot of SIRT3 and GAPDH. 
 
Temporal Cortex 
In the temporal cortex, no significant difference was observed in the level of isoform 1 but a 
significant increase of 18% (p<0.05) was observed in the level of isoform 2 in PDD compared 
to controls (Figure 5.18). 
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Figure 5.18 Expression of SIRT3 in the temporal cortex of PDD and controls. The levels 
of SIRT3 were determined in the temporal cortex of PDD patients and were compared to a control-
cohort. SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) 
with respect to control from three independent replicates. *p<0.05 when compared to control, 
statistical analysis was done through t-test performed on GraphPad prism. Image is a representative 
blot of SIRT3 and GAPDH. 
 
Putamen 
Western blot analysis of SIRT3 in the putamen of PDD cases, did not show any significant 
difference in the level of isoform 1 whereas, a significant increase of 35% was seen in the 
level of isoform 2 (p<0.001) compared to controls (Figure 5.19).  
 
 
Figure 5.19 Expression of SIRT3 in the putamen of PDD and controls. The levels of SIRT3 
were determined in the putamen of PDD patients and were compared to a control-cohort. SIRT3 band 
intensity was normalised with GAPDH. Data is presented as fold change (+SD) with respect to control 
from three independent replicates. ***p<0.001 when compared to control, statistical analysis was done 
through t-test performed on GraphPad prism. Image is a representative blot of SIRT3 and GAPDH. 
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Cerebellum 
In the cerebellum of PDD, the levels of SIRT3 isoform1 were elevated by 27% but the 
difference was statistically insignificant (p>0.05) and the levels of isoform 2 remained 
unaltered when compared to controls (Figure 5.20). 
 
 
Figure 5.20 Expression of SIRT3 in the cerebellum of PDD and controls. The levels of 
SIRT3 were determined in the cerebellum of PDD patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) with 
respect to control from three independent replicates. No significant differences were observed between 
PDD and control, statistical analysis was done through t-test performed on GraphPad prism. Image is a 
representative blot of SIRT3 and GAPDH. 
 
 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Putamen (%) Cerebellum 
(%) 
SIRT3 
Isoform1 37kDa 
Isoform2 28kDa 
 
NS 
NS 
 
NS 
18 (p<0.05) 
 
26%↑ (p>0.05) 
35 (p<0.05) 
 
27%↑ (p>0.05) 
12%↓ (p>0.05) 
Table 5.2 Summary table presenting protein expression of SIRT3 in PDD compared to 
controls. The alterations are expressed as percentage change. The text in green indicates elevation 
and in red indicates reduction in the protein expression. NS: No significant difference (any difference 
under 10% with p>0.05). 
 
Based upon the findings, it could be summarised that no significant difference in the levels of 
isoform 1 of SIRT3 were observed between PDD and controls whereas, the levels of isoform 
2 were observed to be elevated in the temporal cortex and the putamen (Table 5.2).  
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5.4.2.3 Determination of SIRT3 levels in DLB 
In DLB cases, the levels of SIRT3 proteins were determined in five brain regions- frontal 
cortex, temporal cortex, putamen, hippocampus and cerebellum. 
Frontal Cortex 
In the frontal cortex, no significant difference was observed in the levels of SIRT3 isoforms 
between DLB and controls (Figure 5.21). 
 
 
Figure 5.21Expression of SIRT3 in the frontal cortex of DLB and controls. The levels of 
SIRT3 were determined in the frontal cortex of DLB patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) with 
respect to control from three independent replicates. No significant differences were observed between 
DLB and control, statistical analysis was done through t-test performed on GraphPad prism. Image is a 
representative blot of SIRT3 and GAPDH. 
 
Temporal Cortex 
In the temporal cortex of DLB cases, the levels of SIRT3 isoforms were reduced, isoform 1 
by 22% (p<0.001) and isoform 2 by 27% (p<0.001) when compared to controls (Figure 5.22). 
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Figure 5.22 Expression of SIRT3 in the temporal cortex of DLB and controls. The levels 
of SIRT3 were determined in the temporal cortex of DLB patients and were compared to a control-
cohort. SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) 
with respect to control from three independent replicates. ***p<0.001 and **p<0.01 when compared 
to control, statistical analysis was done through t-test performed on GraphPad prism. Image is a 
representative blot of SIRT3 and GAPDH. 
 
Putamen 
The levels of isoform 1 of SIRT3 in the putamen did not show any change in DLB but a 
significant reduction of 22% was observed in the level of isoform 2 in DLB when compared 
to control (p<0.001; Figure 5.23). 
 
 
Figure 5.23 Expression of SIRT3 in the putamen of DLB and controls. The levels of SIRT3 
were determined in the putamen of DLB patients and were compared to a control-cohort. SIRT3 band 
intensity was normalised with GAPDH. Data is presented as fold change (+SD) with respect to control 
from three independent replicates. ***p<0.001 when compared to control, statistical analysis was done 
through t-test performed on GraphPad prism. Image is a representative blot of SIRT3 and GAPDH. 
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Hippocampus 
The levels of SIRT3 analysed in the hippocampal samples of DLB and were compared with 
AD and controls. The levels of isoform 1 were elevated in DLB compared to control (p<0.05) 
and AD (p<0.05) and no significant difference was observed in the expression of isoform 2 
among the groups (Figure 5.24). 
 
 
Figure 5.24 Expression of SIRT3 in the hippocampus of DLB, AD and controls. The 
levels of SIRT3 were measured in the hippocampus of DLB and AD patients and compared to a 
cohort-control and each other. SIRT3 band intensity was normalised with GAPDH. Data is presented 
as fold change (+SD) with respect to control from three independent replicates. *p<0.05 and #p<0.05 
when compared to control and AD, respectively. Statistical analysis was done through two-way 
ANOVA (Bonferroni corrected) on SPSS. Image is a representative blot of SIRT3 and GAPDH. 
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Cerebellum 
In the cerebellar samples of DLB, the levels of SIRT3 isoform1 were elevated by 34% but the 
difference was statistically insignificant (p>0.05) and the levels of isoform 2 remained 
unaltered when compared to control (Figure 5.25).  
 
 
Figure 5.25 Expression of SIRT3 in the cerebellum of DLB and controls. The levels of 
SIRT3 were determined in the cerebellum of DLB patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) with 
respect to control from three independent replicates. No significant differences were observed between 
DLB and control, statistical analysis was done through t-test performed on GraphPad prism. Image is a 
representative blot of SIRT3 and GAPDH.  
 
 Frontal 
Cortex (%) 
Temporal 
Cortex (%) 
Putamen 
(%) 
Hippocampus 
(%) 
Cerebellum 
(%) 
SIRT3 
Isoform1 37kDa 
Isoform2 28kDa 
 
13↑(p>0.05) 
NS 
 
22 (p<0.001) 
27 (p<0.001) 
 
NS 
22 (p<0.001) 
 
45 (p=0.015) 
19↑(p>0.05) 
 
34↑(p>0.05)
NS 
Table 5.4 Summary table presenting protein expression of SIRT3 in DLB compared to 
controls. The alterations are expressed as percentage change. The text in green indicates elevation 
and in red indicates reduction in the protein expression. NS: No significant difference (any difference 
under 10% with p>0.05). 
 
Western blot analysis of SIRT3 in DLB showed some changes compared to control group and 
the prominent changes were observed in the expression of isoform 1 in the temporal cortex 
and hippocampus, whereas, the levels of isoform 2 were reduced in the temporal cortex and 
putamen (Table 5.3). 
 302 
5.4.2.4 Determination of SIRT3 levels in AD 
In AD cases, the expression of SIRT3 and H3 were determined in four different brain regions- 
frontal cortex, temporal cortex, hippocampus and cerebellum. 
Frontal Cortex 
In the frontal cortex of AD cases, no significant change was observed in the level of isoform 1 
of SIRT3 (Figure 5.26) whereas, a reduction of 17% was seen in the level of isoform 2 
(p<0.01; Figure 5.26). 
 
 
Figure 5.26 Expression of SIRT3 in the frontal cortex of AD and controls. The levels of 
SIRT3 were determined in the frontal cortex of AD patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) with 
respect to control from three independent replicates. **p<0.01 when compared to control, statistical 
analysis was done through t-test performed on GraphPad prism. Image is a representative blot of 
SIRT3 and GAPDH. 
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Temporal Cortex 
The level of isoform 1 in the temporal cortex of AD was reduced by 29% (p<0.01; Figure 
5.27) whilst no change was observed in the expression of isoform 2 as compared to control 
(Figure 5.27). 
 
 
Figure 5.27 Expression of SIRT3 in the temporal cortex of AD and controls. The levels of 
SIRT3 were determined in the temporal cortex of AD patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) respect to 
control from three independent replicates. **p<0.01 when compared to control, statistical analysis was 
done through t-test performed on GraphPad prism. Image is a representative blot of SIRT3 and 
GAPDH. 
 
Hippocampus 
The levels of either SIRT3 isoforms did not alter between AD and control in the hippocampus 
(Figure 5.24). Compared to DLB, the level of isoform 1 was reduced by ~45% (p<0.05; 
Figure 5.24) whilst no change was observed in the expression of isoform 2 (Figure 5.24). 
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Cerebellum 
The analysis of SIRT3 in the cerebellum of AD did not show any significant difference in the 
levels of isoform1 and isoform 2 between AD and control (Figure 5.28). 
 
 
Figure 5.28 Expression of SIRT3 in the cerebellum of AD and controls. The levels of 
SIRT3 were determined in the cerebellum of AD patients and were compared to a control-cohort. 
SIRT3 band intensity was normalised with GAPDH. Data is presented as fold change (+SD) with 
respect to control from three independent replicates. No significant differences were observed between 
AD and control, statistical analysis was done through t-test performed on GraphPad prism. Image is a 
representative blot of SIRT3 and GAPDH. 
 
 Frontal 
Cortex 
Temporal 
Cortex 
Hippocampus Cerebellum 
SIRT3 
Isoform1 37kDa 
Isoform2 28kDa 
 
NS 
17 (p<0.01) 
 
29 (p<0.01) 
NS 
 
NS 
22↑ (p>0.05) 
 
14↑ (p>0.05) 
NS 
Table 5.4 Summary table presenting protein expression of SIRT3 in AD compared to 
controls. The alterations are expressed as percentage change. The text in green indicates elevation 
and in red indicates reduction in the protein expression. NS: No significant difference (any difference 
under 10% with p>0.05). 
 
As summarised in Table 5.4, the expression of SIRT3 isoforms did not differ greatly between 
AD and control groups apart from reduced levels of isoform 1 in the temporal cortex and 
isoform 2 in the frontal cortex.  
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5.4.2.5 Cellular distribution of SIRT3 in the temporal cortex and hippocampus of human 
brain 
In SH-SY5Y, under oxidative stress SIRT3 was localised to both the nucleus and the 
cytoplasm (Section 5.4.1.4) thus the localisation of SIRT3 was determined in the temporal 
cortex and hippocampus of PD, PDD, DLB, AD and a control group. Staining of SIRT3 in 
tissue sections was, in general, weak.  
In grey matter of the superior temporal gyrus, SIRT3 was localised in the cytoplasm of 
neurones in control group whereas in the neurones of PD, PDD, DLB and AD, SIRT3 was 
located in the cytoplasm but the localisation was more perinuclear (Figure 5.29). In all the 
groups, staining of microglial cells were observed but with intense staining in disease groups. 
No plaques or tangles were observed in SIRT3 staining of disease groups and SIRT3 did not 
show a staining pattern that could be associated to Lewy bodies.  
In the hippocampus, cellular location of SIRT3 was determined in the different regions (CA1, 
CA2, CA3 and CA4). In the neurones of CA1, SIRT3 was localised in the cytoplasm and 
showed increased levels of stains around the nucleus (perinuclear) in all groups and microglial 
cells were also stained (Figure 5.30). Similar to CA1, SIRT3 in neurones of CA2 was 
localised within the cytoplasm and was again more concentrated around the nucleus with 
strong staining of microglial cells (Figure 5.31). In CA3 and CA4, SIRT3 showed 
cytoplasmic staining with a more perinuclear localisation in neurones (Figures 5.32 and 5.33). 
Microglial cells in CA3 and CA4 were also stained in all groups (Figures 5.32 and 5.33). 
Compared to the temporal cortex, hippocampal neurones were intensely stained and SIRT3 
staining was most intense in DLB among all the disease groups. Microglial staining was more 
intense in disease groups compared to controls.  
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Figure 5.29 Cellular distribution of SIRT3 in the Temporal Cortex of Disease and 
Control Groups. The images show the cellular localisation of SIRT3 in the grey matter of 
superior temporal gyrus of the temporal cortex in PD, PDD, DLB, AD and control cases. In 
control cases, SIRT3 was localised in the cytoplasm and in the disease groups SIRT3 showed 
more perinuclear localisation in neurones. Microglial cells were stained in all groups with 
intense staining in disease groups. The picture in inset is 63X oil immersion image overlaid 
on 10X image. Scale bars- black scale bar= 50μM and red scale bar= 20μM 
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Figure 5.30 Cellular distribution of SIRT3 in CA1 of the Hippocampus in Disease and 
Control Groups. The images show the cellular localisation of SIRT3 in CA1 of the 
hippocampus in PD, PDD, DLB, AD and control cases. In all groups, SIRT3 was observed to 
be localised in the cytoplasm with a more perinuclear localisation in neurones and microglial 
cells were stained in all groups with intense staining in disease groups. The picture in inset is 
63X oil immersion image overlaid on 10X image. Scale bars- black scale bar= 50μM and red 
scale bar= 20μM 
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Figure 5.31 Cellular distribution of SIRT3 in CA2 of the Hippocampus in Disease and 
Control Groups. The images show the cellular localisation of SIRT3 in CA2 of the 
hippocampus in PD, PDD, DLB, AD and control cases. SIRT3 was observed to be localised 
in the cytoplasm with a more perinuclear localisation in neurones in all groups. Microglial 
cells were stained in all groups with intense staining in disease groups. The picture in inset is 
63X oil immersion image overlaid on 10X image. Scale bars- black scale bar= 50μM and red 
scale bar= 20μM 
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Figure 5.32 Cellular distribution of SIRT3 in CA3 of the Hippocampus in Disease and 
Control Groups. The images show the cellular localisation of SIRT3 in CA3 of the 
hippocampus in PD, PDD, DLB, AD and control cases. In all groups, SIRT3 was observed to 
be localised in the cytoplasm with a more perinuclear localisation in neurones and microglial 
cells were stained in all groups with intense staining in disease groups. The picture in inset is 
63X oil immersion image overlaid on 10X image. Scale bars- black scale bar= 50μM and red 
scale bar= 20μM 
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Figure 5.33 Cellular distribution of SIRT3 in CA4 of the Hippocampus in Disease and 
Control Groups. The images show the cellular localisation of SIRT3 in CA4 of the 
hippocampus in PD, PDD, DLB, AD and control cases. In all groups, SIRT3 was observed to 
be localised in the cytoplasm with a more perinuclear localisation in neurones and microglial 
cells were stained in all groups with intense staining in disease groups. The picture in inset is 
63X oil immersion image overlaid on 10X image. Scale bars- black scale bar= 50μM and red 
scale bar= 20μM 
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5.5 Discussion 
5.5.1 Role of SIRT3 in oxidative stress mediated cell death 
Most cellular ROS are produced by mitochondria in the ETC generally at complex I and 
complex III (reviewed in (Turrens, 1997)). Endogenous ROS within certain limits are 
essential to maintain cellular homeostasis and are usually under check by the antioxidant 
defence mechanism which restricts the production and release of free radicals or superoxide. 
Any disruption in the balance of ROS production and antioxidant defence mechanisms results 
in oxidative stress, which leads to damage of cellular components which may eventually lead 
to cell death (reviewed in (Finkel and Holbrook, 2000)). Oxidative stress and mitochondrial 
dysfunction have been implicated in the pathogenesis of PD (reviewed in (Hauser and 
Hastings, 2013)).  
Given the role of oxidative stress in the development and progression of PD, in this study 
diquat and rotenone were used as oxidative stress inducers, diquat, a redox cycler that leads to 
lipid peroxidation in cell membrane resulting in cell death (Jones and Vale, 2000) and 
rotenone, a potent mitochondrial complex I inhibitor that reproduces the features of PD 
(Betarbet et al., 2000). To study the role of SIRT3 in oxidative stress induced damage, SH-
SY5Y cells were transfected with SIRT3WT plasmid and with an enzymatically inactive 
mutant SIRT3H248Y and the cells transfected with empty pLenti CMV vector, served as a 
control group. Overexpression of SIRT3WT promoted cell survival in diquat or rotenone 
treated cells (Figures 5.2 and 5.3) whereas the enzymatic inactive mutant enhanced cell death 
(Figures 5.2 and 5.3).  
SIRT3 has been reported to be neuroprotective in AD and HD models. SH-SY5Y a human 
neuroblastoma cell line that is frequently used as an in vitro model of PD (reviewed in (Xie et 
al., 2010)) and this study has shown that SIRT3 overexpression rescues SH-SY5Y cells from 
oxidative stress caused either by diquat or rotenone and promotes cell survival, establishing a 
neuroprotective role of SIRT3 in a cellular model of PD. 
 
5.5.2 Deacetylase activity of SIRT3 and oxidative stress 
Acetylation of lysine residue of proteins is one of the post-translational modifications that 
may activate or inhibit a target protein. In mitochondria, acetylation is widespread and 
generally is associated with inhibition of mitochondrial proteins (reviewed in (Baeza et al., 
2016)). SIRT3 is the major mitochondrial deacetylase and regulates mitochondrial processes 
including energy homeostasis, metabolism and ROS scavenging. SIRT3 has been shown to 
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protect the cells from oxidative damage and SIRT3 knockout (KO) mice, though 
phenotypically asymptomatic, show higher levels of hyperacetylated mitochondrial proteins 
and higher levels of ROS leading to obesity, insulin resistance and cardiohypertrophy 
(Hirschey et al., 2011).  
In this study, SIRT3WT transfected cells showed an improved survival compared control 
cells and the inactive mutant SIRT3H248Y reduced the cell viability compared to SIRT3WT 
and control cells (Figures 5.2 and 5.3). These results indicate that deacetylase activity is 
required for protection conferred by SIRT3. The findings of this study corroborate recent 
studies that have shown that SIRT3 deacetylase activity is essential for enhanced antioxidant 
mechanisms. Qui et al., showed that SIRT3 enhances ROS resistance by deacetylating SOD2 
(Qiu et al., 2010). Furthermore, SIRT3 rescues neurones from MPTP toxicity by 
deacetylating SOD2 and ATP synthase β whereas SIRT3H248Y diminished the 
neuroprotective effect of SIRT3 (Zhang et al., 2016c). The results obtained from this study 
indicate that deacetylase activity of SIRT3 is required to confer the protection to cells against 
oxidative stress. 
 
5.5.3 Possible mechanisms behind SIRT3 pro-survival activity 
ROS are the by-products of normal cellular metabolism which are subsequently processed by 
antioxidant defence mechanisms. Antioxidants that scavenge free radicals and defend the cell 
from oxidative stress are mainly SODs, catalase and glutathione peroxidases (GPX). As 
discussed in the previous section, SIRT3 enhances cell survival under oxidative stress by 
directly deacetylating and activating SOD2. In this study it was found that overexpression of 
SIRT3 rescued cells from oxidative stress induced by either diquat or rotenone and to study 
the mechanism behind this the levels of SOD2 were determined in diquat or rotenone treated 
cells. Western blot analysis showed that under oxidative stress the levels of SOD2 were 
elevated in diquat or rotenone treated control cells and the levels of SOD2 were 1.5-2 fold 
higher in SIRT3WT transfected cells (Figures 5.5 and 5.7). However, the levels of SOD2 
were reduced in SIRT3H248Y transfected cells. Surprisingly, the levels of SIRT3 were 
elevated in control cells after treatment with diquat or rotenone (Figures 5.4 and 5.6). These 
findings suggest that SIRT3 possibly is a stress induced gene that activates SOD2 and 
potentially increases its expression leading to enhanced cell survival and this action of SIRT3 
is dependent on its enzymatic activity.  
 318 
Several studies have shown mechanisms other than SOD2, by which SIRT3 could reduce 
oxidative damage caused by ROS. The TCA cycle enzyme, IDH2 is another substrate of 
SIRT3, which produces NADPH in mitochondria. NADPH is necessary for the reduction of 
glutathione, a cofactor used by GPX to reduce ROS. Thus by deacetylating and activating 
IDH2 SIRT3 regulates mitochondrial ROS levels (Someya et al., 2010; Yu et al., 2012). 
SIRT3 enhances the antioxidant pathway by interacting with FOXO3a and enhancing the 
expression of its target SOD2 (Jacobs et al., 2008). Similarly, Sundaresan et al., showed that 
SIRT3 deacetylates FOXO3a and reduces the ROS levels in cardiomyocytes by elevating the 
expression of FOXO3a dependent genes SOD2 and catalase (Sundaresan et al., 2009). Under 
CR, FOXO3a is translocated to mitochondria in an AMPK-dependent manner. In 
mitochondria, SIRT3 interacts with FOXO3a and SIRT3-FOXO3a forms a complex with 
mitochondrial RNA polymerase that leads to the activation of mitochondrial genes involved 
in respiration and thereby maintaining the necessary energy levels to ensure sustained cellular 
growth (Peserico et al., 2013). In addition, under CR, SIRT3 deacetylates CypD and blocks 
its association with adenine nucleotide translocator (ANT) thereby inhibiting the formation of 
mitochondrial permeability transition pore (mPTP) (Hafner et al., 2010). mPTP formation is a 
hallmark of mitochondrial dysfunction that causes leakage of NAD
+
 and ATP to the 
cytoplasm and thus initiating apoptosis (reviewed in (Kim et al., 2007b)). Inhibition of mPTP 
formation by SIRT3 ensures improved mitochondrial dynamics and cell survival. 
Apart from regulating antioxidants, SIRT3 regulates DNA damage control under stress by 
deacetylating and activating a base excision repair enzyme, 8-oxoguanine-DNA glycosylase 1 
(OGG1) which is localised both in the nucleus and mitochondria (Cheng et al., 2013). 
Deacetylation of OGG1 by SIRT3 prevents it degradation and stabilises the protein and its 
incision activity and enhances mitochondrial DNA repair and protects the cells from apoptosis 
under oxidative stress (Cheng et al., 2013).  
Based upon the results obtained from this study and the several recent studies, it can be 
concluded that SIRT3 protects the cells from oxidative stress and the protection is mediated 
in-part by SOD2 and the deacetylase activity of SIRT3 is necessary for the protection 
conferred against oxidative damage. 
 
5.5.4 SIRT3 and its role in α-synuclein aggregate formation 
α-synuclein is a key component of LBs and LNs (Cookson, 2005), α-synuclein forms 
aggregates that have low solubility (Kahle et al., 2001) and are post translationally modified 
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and oxidative stress has been reported to enhance α-synuclein aggregate formation 
(Hashimoto et al., 1999). α-synuclein has also been shown to change mitochondrial 
morphology (reviewed in (Schapira, 2011)) and is accumulated in mitochondria where it 
dysregulates complex I resulting in enhanced oxidative stress (Devi et al., 2008).  
In this study, α-synuclein aggregate formation was initiated by oxidative stress induced by 
diquat or rotenone. Overexpression of SIRT3WT inhibited α-synuclein aggregate formation in 
diquat or rotenone treated cells (Figures 5.11 and 5.12) compared to control cells whilst the 
enzymatic mutant SIRT3H248Y elevated α-synuclein aggregate formation (Figures 5.11 and 
5.12). These results suggest that SIRT3 deacetylase activity decreases α-synuclein mediated 
toxicity which corresponds to cell viability assay. SIRT3 was also observed to co-localise 
with α-synuclein (Figures 5.8 and 5.9). This finding suggests that α-synuclein is possibly 
acetylated and acetylation may possibly play a role in α-synuclein aggregate formation. 
Corresponding with this finding, Zhang et al., showed that SIRT3 overexpression decreased 
cell apoptosis and prevented α-synuclein aggregation and SIRT3 knockdown having the 
opposite effect (Zhang et al., 2016b).  
 
5.5.5 Expression of SIRT3 in neurodegenerative disorders 
Ageing is one of the major factors that leads to development and progression of disease. The 
exact mechanism behind ageing is still not well understood but it leads to impaired 
antioxidant defence and DNA repair mechanisms, reduction in ATP levels (reviewed in 
(Hindle, 2010)) and is associated with oxidative stress and mitochondrial dysfunction 
(reviewed in (Conley et al., 2007)) which are linked with several neurodegenerative disorders 
such as AD and PD (reviewed in (Lin and Beal, 2006)). SIRT3, a major mitochondrial 
deacetylase regulates energy production, antioxidant defence mechanisms, DNA damage 
control and increases cell survival by combating ROS productions and has been reported to 
protect neurones from oxidative stress in models of AD (Weir et al., 2012) and HD (Fu et al., 
2012). 
In this study, the levels of SIRT3 were determined in post-mortem brain regions of PD, PDD, 
DLB and AD patients and were compared with an age-matched control group. In general, no 
major alterations were observed in the levels of SIRT3 between control and disease groups. In 
PD no major difference was observed in the levels of SIRT3, whereas in PDD a trend of 
elevation was observed in the levels of SIRT3. DLB showed reduced levels of SIRT3 and the 
similar trend of reduction in the levels of SIRT3 was observed in AD (Table 5.5).  
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 Frontal 
Cortex 
Temporal 
Cortex 
Putamen Hippocampus Cerebellum 
PD No significant 
changes 
No significant 
changes 
No significant 
changes 
- ↑ 
PDD No significant 
changes 
↑ ↑ - No significant 
changes 
DLB No significant 
changes 
↓ ↓ ↑ No significant 
changes 
AD ↓ ↓ - No significant 
changes 
No significant 
changes 
Table 5.5 Summary of expression of SIRT3 in neurodegenerative disorders compared to 
a control group. ↑ indicates elevation; ↓ indicates reduction and – indicates that the expression of 
SIRT3 was not studied in that particular brain region. 
 
Weir et al., determined the expression of SIRT3 in the temporal neocortex of AD and 
observed the up-regulated expression of SIRT3 (Weir et al., 2012). Their finding does not 
corroborate with the finding of this study and the difference could be explained by the regions 
examined. Weir et al., studied the expression of SIRT3 in Brodmann areas 6 and 22 and this 
study determined the levels of SIRT3 in Brodmann area 20 and 9. Even though no major 
changes were observed in the levels of SIRT3 between the groups, the activity of SIRT3 may 
differ. Since no specific inhibitor of SIRT3 is currently available hence the activity of SIRT3 
could not be determined and as mentioned in previous chapters total SIRT deacetylase activity 
did not change among the groups. Apart from this study and Weir et al., no other studies have 
evaluated the role of SIRT3 in human brain thus more detailed studies of expression of SIRT3 
need to be conducted, both at the mRNA and protein levels. 
 
5.5.6 Sub-cellular localisation of SIRT3 under stress  
Human SIRT3 is present in two forms- longer isoform (isoform 1) and shorter isoform 
(isoform 2 or mitochondrial SIRT3), and both possess deacetylase activity. Under stress, 
isoform 1 accumulates in the nucleus where it targets stress related proteins and mitochondrial 
SIRT3 activates the proteins involved in antioxidant defence mechanisms (reviewed in 
(Kincaid and Bossy-Wetzel, 2013)). When treated with diquat or rotenone, SIRT3 was 
localised both in the nucleus and the cytoplasm but with prominent expression in the 
cytoplasm which may represent a mitochondrial localisation (Figures 5.8 and 5.9). However, 
dual immunostaining of SIRT3 and a mitochondrial marker such as porin needs to be done to 
establish the exact location of SIRT3. SIRT3WT showed some percentage of co-localisation 
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with α-synuclein aggregates in SH-SY5Y cells, on the other hand SIRT3H248Y showed 
greater percentage of co-localisation with α-synuclein (Figures 5.8 and 5.9). It is possible that 
SIRT3 directly interacts with α-synuclein and inhibits its oligomerisation and thus aggregate 
formation. It will be interesting to determine the acetylation of α-synuclein and its effects on 
the structure of the protein. This would enable us to explore whether the acetylated residue of 
α-synuclein is a direct target of SIRT3.  
SIRT3 cellular location was determined in the temporal cortex and hippocampus of PD, PDD, 
DLB and AD and in general, immunostaining was not robust. In the temporal cortex, SIRT3 
was localised in the neuronal cytoplasm in controls and in the disease groups it was observed 
to be perinuclear (Figure 5. 29). In the hippocampus, no major difference was observed 
between controls and disease groups; SIRT3 was localised to the cytoplasm with additional 
prominent perinuclear localisation (Figures 5.30- 33). In both brain regions, microglial cells 
showed intense immunostaining in disease groups (Figure 5.29-33). Rangarajan et al., showed 
that post trauma SIRT3 expression is induced in microglial cells in vitro and in vivo and 
enhanced SIRT3 expression led to upregulation of SOD2 and catalase via activation of 
FOXO3a (Rangarajan et al., 2015). It is possible that intense microglial staining in the disease 
groups is an indication of oxidative stress and expression of SIRT3 is upregulated in 
microglial cells and neurones to combat the oxidative stress which is known to be higher in 
neurodegenerative disorders. In future, studies need to be conducted to determine the exact 
location of SIRT3 in neurones and microglial cells.  
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5.5.7 Conclusions 
In this study it was shown that SIRT3 overexpression rescued SH-SY5Y cells from oxidative 
stress induced by diquat or rotenone and the cytoprotection was at least in part through 
activation and higher expression of SOD2. The observed protection conferred by SIRT3 is 
through its enzymatic activity as the enzymatic mutant form of SIRT3 failed to protect the 
cells from oxidative stress.  
Expression of SIRT3 in post-mortem human brain tissue did not differ greatly between 
disease (PD, PDD, DLB and AD) and control groups. Although it was not possible to 
determine the activity of SIRT3. No specific inhibitor of SIRT3 is currently available and 
therefore, it will be interesting to identify a specific inhibitor of SIRT3 and determine its 
activity in human brain tissue. In the temporal cortex of disease groups, SIRT3 showed a 
perinuclear location and this possibly indicates a sign of cell stress since SIRT3 accumulates 
in the nucleus under stress and triggers the activation of stress related proteins including 
FOXO3a and Ku70. 
Based upon the findings from the in vitro and human brain tissue studies, it can be concluded 
that SIRT3 is a stress activated protein which rescues cells from oxidative stress and also 
reduces the aggregation of α-synuclein.  
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Chapter 6 Development of Laboratory tools for overexpression of 
SIRTs in Human Neural Stem Cells 
6.1 Introduction 
Animal models have been used successfully to study models diseases and in particular 
neurological disorders including AD, PD, and HD. Transgenic rodent models have been 
generated from the genetic mutations involved in these disorders to determine the underlying 
causes of cell death. The changes in animal models, however, do not necessarily relate to the 
changes observed in humans. To study the effect of genetic or environmental factors in human 
brain, human neural stem cells (NSCs) derived from embryos or foetal brain, provide a 
potential study model. NSCs are multipotent cells that can differentiate into multiple cell 
types via exogenous environmental stimuli. They undergo asymmetric cell division and 
primarily generate three types of cells of the CNS- neurones, astrocytes and oligodendrocytes. 
NSCs can provide information regarding the cellular changes due to genetic or environmental 
stimuli at different stages, especially at the molecular and cellular level.  
The transfection of foreign nucleic acids into cells is a crucial step for many cellular and 
molecular biology studies. The transfection of post-mitotic cells such as neurones is a greater 
challenge due to the efficiency of introduction and expression of transgenes.  Several methods 
have been developed for improved efficiency of transfection in neurones and these are listed 
below and taken together these techniques have made transfection of post-mitotic cells 
possible. 
i) Calcium-phosphate co-precipitation, a cost effective method, which usually results 
in low-efficiency in transfection (Goetze et al., 2004) 
ii) Lipofection, another cost effective method in which nucleic acids are introduced 
into cells by means of liposomes, which are often  toxic to neurones and may lead 
to changes in the morphology of neuronal cells (Washbourne and McAllister, 2002) 
iii) Viral based transfection where viral vectors are used to transfer the transgene, 
resulting in an high efficiency of transfection,  but the method is time consuming 
and requires extra safety measures (Washbourne and McAllister, 2002)  
iv) Electroporation which delivers the gene into cells by altering the properties of 
plasma membrane by subjecting the cells to electric pulses. It may result in 
toxicity after exposure to electrical pulses; relatively expensive method (Dib-Hajj 
et al., 2009) 
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v) Physical transfection methods including microinjection where nucleic acids are 
directly injected and biolistics where DNA coated metal particles are injected into 
the cells. Physical methods may prove to be extremely stressful for cells  
(Washbourne and McAllister, 2002) 
vi) Nucleofection, a modified form of electroporation where under high voltage pulses, 
nucleic acids are directly delivered to the nucleus, relatively expensive and 
transfection is efficient only in freshly derived neurones (Zeitelhofer et al., 2007). 
As discussed in previous chapters, SIRTs have been shown to be critical for cell survival 
under oxidative stress. In this chapter, SIRT expression vectors were developed for the 
introduction of SIRT genes into differentiated NSCs.  
6.2 Aims 
The aims of this study are to design SIRT expression vectors and to explore chemical 
transfection methods for incorporation of SIRT expression vectors in differentiated NSCs and 
also to determine the expression of SIRTs in forebrain NSCs at various stages of 
differentiation.  
6.3 Materials and methods 
6.3.1 PCR and cloning 
The detailed protocol of DNA synthesis from human brain tissue and replication of SIRT 
insert by PCR is provided in Section 2.2. 
 
6.3.2 Transfection of stem cells 
Neurones derived from midbrain NSCs were transfected with SIRT1 in pLenti CMV using 
transfection reagents, Xfect and PEI and their efficiency of transfection was determined by 
Western blot analysis (Section 2.5.3). 
 
6.3.4 Western blotting 
Endogenous SIRT expression was determined by Western blot analysis of samples obtained 
from forebrain NSCs (Section 2.4.3). 
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6.4 Results 
6.4.1 Cloning of SIRTs inserts in mammalian vectors 
6.4.1.1 Amplification of SIRT genes from cDNA 
In order to develop SIRT expression vector, firstly, RNA was extracted from the post-mortem 
human brain tissue. The RNA extracted was used as a template to synthesise cDNA which 
was then used for replication of SIRT inserts. SIRTs were amplified from cDNA and after 40 
cycles, the amplicons were resolved on 1% agarose gel. SIRT1 band was observed at ~2.2kb, 
SIRT2 at 1.2kb and SIRT3 at 1.2kb (Figure 6.1). The bands were excised from the gel and 
then extracted and purified using QIAGEN Gel extraction kit (details in Section 2.2.7). The 
purified amplicons were cloned into pCR2.1 vector and the ligation mix was used to 
transform Top10 E.coli cells (details in Section 2.2.10). The transformed colonies were 
picked and the plasmids were extracted using QIAGEN mini prep kit (details in Section 
2.2.11).  
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A    B     C 
    
Figure 6.1 SIRTs PCR inserts from cDNA synthesised from RNA extracted from human 
post-mortem brain samples. A represents SIRT1 (2.2kB), B represents SIRT2 (1.2kb) and C 
represents SIRT3 1.2kB. 
 
The plasmids extracted from the transformed E. coli colonies were subjected to restriction 
digestions using EcoRI. In SIRT1, plasmid extracted from colony 2 had the desired insert 
(Figure 6.2) and all the plasmids extracted from the colonies of SIRT2 and SIRT3 had the 
desired inserts (Figure 6.2). 
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A 
 
B 
 
Figure 6.2 Restriction digestion of SIRTs plasmids cloned in pCR2.1 vector. A represents 
SIRT1 and SIRT2 digests with EcoRI and C represents SIRT3 digests with EcoRI. 
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6.4.1.2 Fusion PCR 
Fusion PCR was carried out to amplify SIRT inserts with desired restriction enzymes and a 
Kozak sequence and the amplification was performed in two stages as described in Section 
2.2.5.  Fusion PCR amplified the desired bands, SIRT1 at 2.2kb, SIRT2 at 1.2kb and SIRT3 at 
1.2kb (desired bands are highlighted by arrows in Figure 6.3). These bands were excised from 
the gels and extracted and were ligated into pCR2.1 vector. Top10 E.coli cells were 
transformed with the ligation mix and the plasmids were extracted from the transformed 
colonies. 
The extracted plasmids were double digested with BamHI-SalI and all the plasmids were 
observed to have the desired inserts. To confirm the correct orientation of inserts, SIRT1 was 
digested with EcoRI and the band was observed at 2.2kb (Figure 6.4A).  SIRT2 desired band 
was observed at 1.1kb with SacI digestion (Figure 6.4B) and SIRT3 was digested with HindII 
and the band was observed at 1kb (Figure 6.4C). The single digestion with the restriction 
enzymes confirmed that the plasmids have the insert in the right orientation.  
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A       B 
     
C 
 
Figure 6.3 SIRTs fusion PCR with primers with Bam HI- Kozak sequence at 5’ and SalI 
at 3’. A represents SIRT1 (2.2kB), B represents SIRT2 (1.2kb) and C represents SIRT3 1.2kB. 
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A           B 
      
C 
 
Figure 6.4 Restriction digestion of SIRTs plasmids cloned in pCR2.1 vector. A represents 
SIRT1WT digests with BamHI-SalI and EcoRI, B represents SIRT2 digests with BamHI-SalI and SacI 
and C represents SIRT3 digests with BamHI-SalI and HindIII. 
 
The nature of the cloned SIRT inserts was checked by sequencing. The inserts were then 
digested by BamHI-XbaI and were ligated into BamHI-XbaI digested pcDNA3.1 vector. 
Ligation mix was used to transform Top10 E. coli cells and the colonies were screened for 
SIRT plasmids. But despite several attempts, E. coli cells could not be transformed with 
SIRT-pcDNA3.1 ligation mix.  
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6.4.2 Cloning of SIRTs inserts in lentiviral vector 
SIRTs plasmids were purchased from Addgene due to failure of cloning the SIRT inserts in 
mammalian expression vector pcDNA3.1. SIRT1pECE, SIRT1H363YpECE, 
SIRT2pcDNA3.1, SIRT3pcDNA4 and SIRT3H248YpcDNA4 and lentiviral vector pLenti 
CMV blast were obtained from Addgene (details in Section 2.2.8 and 2.2.16). Each of the 
plasmids was digested with BamHI-XbaI. SIRT1 digestion (WT and H363Y) with BamHI-
XbaI resulted in two bands- a band of 2.7kb and a band of 2.5kb in size. 2.5kb band was the 
insert needed and was used for cloning into pLenti CMV Blast vector (Figure 6.5 B and C). 
BamHI-XbaI digests of SIRT2 cut the desired insert at 1.2 kb (Figure 6.5D) and the digest of 
SIRT3 (WT and H248Y; Figure 6.5E and B) resulted in the desired bands at 1.2kb.  
 
 
A      B 
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C 
 
D       E 
   
Figure 6.5 Restriction digestion of plasmids from Addgene with BamHI-XbaI. A 
represents pLenti CMV blast digests, B represents SIRT1WT and SIRT3H248Y digests, C represents 
SIRT1H363Y digests, D represents SIRT2 digests and E represents SIRT3 digests. 
 
After the digestion with BamHI-XbaI the desired bands were excised from the gel, extracted 
and purified and were ligated into lentiviral vector pLenti CMV. Top10 E. coli cells were 
transformed with the SIRT-pLenti CMV ligation mix (detailed protocol in Section 2.2). The 
transformed colonies were picked and grown overnight and plasmids were extracted using 
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QIAGEN HiSpeed Plasmid Maxi Kit (Section 2.2.16). The extracted plasmids were digested 
with restriction enzymes for 3 hours at 37
o
C and were then analysed on 1% agarose gel to 
assess the nature of the inserts. All the plasmids were digested with BamHI-XbaI and the gel 
electrophoresis showed that all the plasmids had SIRT inserts.  
SIRT1 was also digested with EcoRI and the bands around 2.2 kb and 800bp were observed 
suggesting that plasmids had the SIRT1 insert in the correct orientation (Figure 6.6 A and B). 
SIRT2 digestion with SacI showed that inserts were present in the correct orientation and the 
cuts were observed at around 1.2kb and 1.8kb (Figure 6.6 C). SIRT3 plasmids digested with 
HindIII were also observed to have the insert in the correct orientation with cuts observed 
around 1.8kb and 1kb (Figure 6.6 C and D). The cuts observed after restriction digestion of 
SIRT plasmids with respective restrictions enzymes are summarised in Table 6.1.  
 
 
 
 
 
 
  
 335 
A SIRT1 (2244bp)     B SIRT2 (1170bp) 
EcoRI: Cuts at 2089    SacI: Cuts at 1001    
  pLenti CMV digest with 
SacI 
Bands (bp) 
7744-6575+2485 3654 
2673-2485 188 
4659-2485 2174 
6575-6412 163 
w.r.t BamHI (4816-4659) 157 
w.r.t XbaI (6412-4852) 1560 
SIRT2 digest   
157+1001 1158 
1560+169 1729 
In reverse orientation   
157+169 326 
1560+1001 2561 
C SIRT3 (1200bp)   
HindIII: Cuts at 364 and 1177 
pLenti CMV digest with 
HindIII 
Band (bp) 
7744-6615+2212 3341 
2525-2212 313 
3078-2525 553 
3661-3078 583 
4136-3661 475 
w.r.t BamHI (4816-4136) 680 
w.r.t XbaI (6615-4852) 1763 
SIRT3 digest   
680+364 1044 
1763+23 1786 
In reverse orientation   
680+23 703 
1763+364 2127 
Table 6.1 Summary table of SIRT cuts with restriction enzymes. A summarises the cuts 
observed after digestion of SIRT1 plasmids with EcoRI, B summarises the cuts observed after 
digestion of SIRT2 with SacI and C summarises the cuts observed after digestion of SIRT3 with 
HindIII.  
pLenti CMV digest 
with EcoRI 
Bands 
(bp) 
7744-5504+4747 6987 
w.r.t BamHI (4816-
4747) 
69 
w.r.t XbaI (5504-4852) 652 
SIRT1 Digest   
69+2089 2158 
676+155 831 
In reverse orientation   
69+155 224 
676+2089 2765 
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A          B 
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C            D        E 
        
 
Figure 6.6 Restriction digestion of SIRT inserts cloned in pLenti CMV Blast. A represents SIRT1WT double digests with BamHI-XbaI, single digest 
with EcoRI and single digest with BamHI, B represents SIRT1H363Y double digests with BamHI-XbaI and single digest with EcoRI, C represents SIRT2 double 
digests with BamHI-XbaI, single digest with SacI and single digest with BamHI, D represents SIRT3WT double digests with BamHI-XbaI, single digest with 
HindIII and single digest with BamHI and E represents SIRT3H248Y double digests with BamHI-XbaI and single digest with HindIII. 
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6.4.3 Transfection efficiency of plasmids generated 
SIRTs plasmids in pLenti CMV were used to transfect HEK293 cells to validate the 
efficiency of plasmids.  After transfection with SIRT pLenti CMV plasmids, HEK cells were 
washed with PBS and were harvested, quantified and probed for SIRT1, SIRT2 and SIRT3 
levels by Western Blot analysis. The levels of SIRTs were elevated in transfected HEK293 
cells compared to medium and empty vector transfected cells suggesting that SIRTs cloned in 
pLenti CMV vector are capable of transfecting the cells (Figure 6.7).  
 
 
Figure 6.7 SIRT pLenti CMV transfection of HEK293 cells using PEI as a transfection 
reagent.  HEK293 cells were transfected with SIRT pLenti CMV plasmids at different concentration 
for 48 hours and then cells were subjected to Western blot analysis to probe for SIRT1, SIRT2 and 
SIRT3 levels. Image is a representative blot of SIRT1, SIRT2 and SIRT3. 
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6.4.4 SIRT Viral production 
Lentiviral vectors are type of retrovirus that have ability to mediate potent transduction and 
stable expression in dividing and non-dividing cells. SIRT inserts were cloned into pLenti 
CMV blast, a lentiviral expression vector and the efficiency of the transfection of these 
vectors was tested in HEK293 cells (Section 6.4.3). HEK293T cells were used for viral 
production and the components needed for virus production were spread across four plasmids, 
and these were, pLenti CMV (expression vector), pMDLg/pRRE & pRSV-Rev (packaging 
vectors) and pMD2.G (envelope vector) (details in Section 2.2.19). HEK293T cells were 
transfected with lentiviral vectors using PEI as a transfection reagent. The lentiviral 
transfection was carried out overnight and after 48hours of transfection the medium was 
collected and centrifuged at 3000rpm to remove the cell debris. The supernatant was collected 
and was filtered through 0.2μM low protein binding filter, then aliquoted and stored at -80oC. 
To test if SIRT viruses were produced, HEK293 cells were transduced with filtered viral 
supernatant (details in Section 2.20.2.2). After 5-7 days of transduction, HEK293 cells were 
screened with Blasticidin S.  Cell death after Blasticidin S screening suggested that the SIRT 
lentiviruses were not produced. Several attempts with optimisation of the ratio between 
expression, packaging, envelope plasmid and polybrene concentration did not result in 
successful SIRT lentivirus production. 
 
6.4.5 Transfection efficiency of SIRT1pLenti CMV in midbrain neural stem cells 
using Xfect and PEI 
After the successful transfection of HEK293 cells with SIRTpLenti CMV plasmids, midbrain 
neurones derived from human NSC were transfected with SIRT1 pLenti CMV plasmid. Two 
transfection reagents, PEI and XFect were used to carry out the transfection. As shown in 
Figure 6.8, cells transfected with XFect showed a significant increase of 3 fold in the levels of 
SIRT1 as compared to non-transfected cells (medium; p<0.001) and PEI  transfected cells 
(p<0.001). Transfection carried out using PEI failed to show any increase in the levels of 
SIRT1. This result suggests that XFect is capable of transfecting post-mitotic cells lines and 
in this case midbrain neurones derived from human NSCs.  
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Figure 6.8 SIRT1 transfection of midbrain neurones using transfection reagents, PEI 
and XFect.  Midbrain neurones differentiated from human midbrain neural stem cells were 
transfected with PEI and XFect transfecting reagents overnight. Cells were harvested after 48 hours of 
transfection and were probed for SIRT1.  Data presented as fold- untreated (+SD) from three 
independent assays (n=3). ***p<0.001 when compared to medium, ###p<0.001 when compared to 
PEI, two-way ANOVA (Bonferroni corrected). Image is a representative blot of SIRT1 and GAPDH. 
 
6.4.6 SIRTs expression during differentiation of forebrain neural stem cells 
SIRTs have shown to play a role in differentiation and development of cells. Endogenous 
levels of SIRT1, SIRT2 and SIRT3 were measured in differentiating human forebrain NSCs. 
Cells were harvested at different time intervals- stem cells, 2 days of differentiation, 6 days of 
differentiation, 10 days of differentiation, and neurones after 14 days of differentiation. All 
the samples were probed for SIRTs expression. 
The levels of 120kDaSIRT1  were observed to increase as differentiation of stem cells 
progressed and the levels of the protein were highest once the stem cells were differentiated 
into neurones at 14 days (Figure 6.9). No significant differences were observed between stem 
cells and the cells that were differentiated for 2 days. SIRT1FL analysis did not show 
significant differences between stem cell stages, cells after two days and six days of 
differentiation. The levels of SIRT1FL were reduced in the cells that were harvested after 10 
days of differentiation. The levels of SIRT1 were highest in neurones (Figure 6.9).   
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Figure 6.9 Expression of SIRT1 in stem cells, differentiating stem cells and forebrain 
neurones.  Forebrain neural stem cells were harvested in native lysis buffer at different stages- stem 
cells (0 day), 2 days of differentiation, 6 days of differentiation, 10 days of differentiation, and as 
neurones after 14 days of differentiation.  Cells were probed for SIRT1 by Western blot analysis. Data 
presented as fold- untreated (+SD) from three independent assays (n=1). ***p<0.001 and *p<0.05 
when compared to 0 day, ###p<0.001 and #p<0.05 when compared to 2 days, ~~~p<0.001, ~~p<0.01 
and ~p<0.05 when compared to 6 days and $$$p<0.001 when compared to 10 days, one-way ANOVA 
and post hoc test (Bonferroni corrected). Image is representative blot of SIRT1 and GAPDH. 
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On Western blot analysis, three isoforms of SIRT2 were observed on the blot, isoform 2 
(39.5kDa), isoform 3 (41kDa) and isoform 4 (30kDa). The levels of SIRT2.3 (41kDa) did not 
show any alteration between 0 and 2 days and the levels were elevated by 1.2 fold in 6 days 
samples. The levels dropped to 1 in 10 day samples which were then elevated by 1.4 fold in 
14 days neurones (Figure 6.10). The levels of SIRT2.2 (39.5kDa) were reduced as 
differentiation progressed with the lowest level on 6
th
 day and a gradual increase was 
observed as differentiation progressed and the levels reached 0.6 fold in neurones at 14 days 
(Figure 6.10). The levels of SIRT2.4 showed no significant differences between stem cells 
and the cells that were differentiated for 2 days. The levels of SIRT2.4 were lowest on 6
th
 day 
(0.8 fold) and the levels returned to normal levels on the 10
th
 day. The levels of SIRT2.4 were 
highest in 14 days neurones (Figure 6.10).   
 
 
Figure 6.10 Expression of SIRT2 in stem cells, differentiating stem cells and forebrain 
neurones.  Forebrain neural stem cells were harvested in native lysis buffer at different stages- stem 
cells (0day), 2 days of differentiation, 6 days of differentiation, 10 days of differentiation, and 
neurones after 14 days of differentiation.  Cells were probed for SIRT2 by Western blot analysis. Data 
presented as fold- untreated (+SD) from three indepedent assays (n=1). ***p<0.001 and **p<0.01 
when compared to 0 day, ###p<0.001, ##p<0.01 and #p<0.05 when compared to 2 days, ~~~p<0.001, 
~~p<0.01 and ~p<0.05 when compared to 6 days and $$$p<0.001 when compared to 10 days, one-
way ANOVA (Bonferroni corrected). Image is a representative blot of SIRT2 and GAPDH. 
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On Western blot analysis, only isoform 2 of SIRT3 (28kDa) was observed and isoform 1  
(37kDa) remained undetectable on the blot. The levels of isoform 2 (28kDa) did not show any 
alteration between 0 and 2 days and the levels dropped to 0.7 fold at 6
th
 day and 10
th
 day 
samples. The levels of SIRT3 returned to basal levels in neurones at 14 days (Figure 6.11).  
 
 
Figure 6.11 Expression of SIRT3 in stem cells, differentiating stem cells and forebrain 
neurones.  Forebrain neural stem cells were harvested in native lysis buffer at different stages- stem 
cells (0day), 2 days of differentiation, 6 days of differentiation, 10 days of differentiation, and 
neurones after 14 days of differentiation.  Cells were probed for SIRT3 by Western blot analysis. Data 
presented as fold- untreated (+SD) from three independnt assays (n=1). ***p<0.001 and *p<0.05 
when compared to 0 day, ###p<0.001 and #p<0.05 when compared to 2 days, ~~~p<0.001, ~~p<0.01 
and ~p<0.05 when compared to 6 days and $$$p<0.001 when compared to 10 days, one-way ANOVA 
and post hoc test (Bonferroni corrected). Image is a representative blot of SIRT3 and GAPDH. 
 
These findings suggest that SIRTs are down-regulated during differentiation most likely due 
to their negative role in neuronal differentiation, but are retained to basal levels or higher 
suggesting the crucial role they play in cell maintenance and survival.  
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6.5 Discussion 
Stem cells have become a key cellular model to study and understand the molecular and 
cellular aspects of numerous diseases. NSCs can be genetically manipulated and their ability 
to differentiate into mature human neurones makes them a remarkable model to study and 
understand the different molecular mechanisms of a neurological disorder. Given that NSCs 
can be used as a cellular model for neurodegenerative disorders, this study intended to design 
SIRT vectors that could possibly be used for efficient transfection of differentiated stem cells 
and thus study their role in maintenance of neuronal function and cell death.  RNA extracted 
from the post-mortem human brain was used as a template to synthesise cDNA. Using the 
respective primers for SIRTs the gene of interest (GOI) was cloned from the cDNA (Figure 
6.1) and by using fusion PCR the required insertions (BamHI and Kozak sequence in the 
sense primer and SalI in the antisense primer) were added to the GOIs to ensure the stable 
transfection in mammalian cell lines (Figure 6.3). GOIs were successfully cloned in pCR2.1 
vector and were tested by restriction digestion (Figure 6.4) and sequencing. Cloning the GOIs 
into pcDNA3.1 was not successful even though the restriction enzyme sites matched and the 
inserts were in frame with respect to the vector. Even after the several attempts of 
optimisation of ligation ratio and the ligation time the GOIs could not be cloned into pcDNA 
3.1 and eventually the plasmids were bought from Addgene. The restriction enzymes used for 
digestion to cut the insert out were BamHI-XbaI as the inserts did not have these sites in their 
reading frame. The most possible reason for the ligation of insert to not work could be the 
close proximity of the restriction enzymes in pcDNA3.1.  
The plasmids purchased from Addgene were used in further experiments of this study. To 
obtain SIRT inserts in lentiviral vectors, the inserts were cut from the plasmids using BamHI-
XbaI (Figure 6.5) and were cloned into pLenti CMV blast vector that was digested with 
BamHI-XbaI. The inserts were successfully cloned into the lentiviral vectors and were 
efficient in transfecting HEK293 cells (Figure 6.7). The inserts in pLenti viral vectors and the 
packaging and envelope plasmids (details in Section 2.2.19) were used to transfect HEK293T 
cells to produce SIRT lentiviruses. Even though SIRT pLenti CMV plasmids were able to 
transfect the cells efficiently, SIRT viral production was not successful. Viral production was 
unsuccessful possibly because of the cell line used. HEK293T cells are frequently used for 
viral production it might be possible that particular batch used in this study was not 
compatible. Another possible explanation is that viruses were produced but were present in 
low numbers.  In future, ELISA should be performed on the viral VSV-G protein to ensure 
the viral production. The efficiency of transfection of SIRT pLenti vectors were assessed in 
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midbrain neurones derived from the NSCs and the transfection with XFect showed an 
increase of  3 fold in the expression of SIRT1 (Figure 6.8). This shows that non-dividing 
midbrain neurones can efficiently be transfected with SIRT pLenti CMV vectors using XFect 
as a transfection reagent and this could possibly provide an alternative method of gene 
expression in post-mitotic cells.  
In this study the expression of SIRTs was measured during the differentiation of forebrain 
NSCs into forebrain neurones. The expression of SIRT was normalised to stem cells and the 
different stages of differentiation were compared. Western blot analysis showed that during 
the process of differentiation the levels of SIRT1FL, SIRT2 and SIRT3 were reduced but 
returned to basal or higher levels once NSCs were differentiated into neurones (Figures 6.9-
6.11). Few studies have evaluated the role of SIRT1 in differentiation of rat and human 
embryonic stem cells. Calvanese et al, showed that SIRT1 is down-regulated both at mRNA 
and protein levels and its downregulation leads to activation of key developmental genes 
(Calvanese et al., 2010). Similar results were observed by Liu et al., where they showed that 
repression of SIRT1 was necessary for differentiation and maturation of embryonic cortical 
neurones (Liu et al., 2014a). Even though the levels of SIRT1FL were reduced during 
differentiation it wasn’t completely absent and the levels were higher in differentiated 
neurones suggesting that SIRT1 is required for optimal survival, maintenance and 
proliferation of stem cells and neurones. SIRT2 is abundantly expressed in human brain 
where it regulates the differentiation of myelin sheath producing oligodendrocytes. In this 
study, low levels of SIRT2 proteins were observed during the early stages of differentiation 
which were elevated once the stem cells were differentiated into neurones. A study conducted 
by Sidorova-Darmos et al., in a rat model reported low or undetectable levels of SIRT2 in 
embryonic and early post-natal brain whereas in adult and developing brain the levels of 
SIRT2 were ubiquitously high throughout the different brain regions (Sidorova-Darmos et al., 
2014). In the same study, SIRT3 levels were measured and in contrast to the result of this 
study, they found elevated expressions of SIRT3 both at mRNA and protein levels in different 
regions of brain but the levels were lower in the cerebellum. The inconsistencies in the levels 
of SIRT3 between the two studies could possibly be attributed to the different study models. 
The findings of this study show that SIRTs are present during the maintenance and 
proliferation of NCSs but during the process of differentiation their levels are reduced 
possibly to enhance the correct differentiation of neurones and other brain cells. 
Based upon the findings of this study it thus can be concluded that post-mitotic cells such as 
neurones can be efficiently transfected with lentiviral vectors using XFect transfection 
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reagent. The measurement of SIRT expression during the process of differentiation suggests 
that the expression of SIRTs is controlled during differentiation, possibly to ensure the 
optimal differentiation of brain cells. SIRTs were restored to basal or higher levels in 
differentiated neurones suggesting the vital role they play in survival and maintenance of 
neurones.  
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Chapter 7 Concluding Discussion 
7.1 Introduction 
Neurodegenerative disorders involve progressive loss of neurones in key areas and primarily 
affect the elderly population. Along with neuronal loss, the presence of protein aggregates in 
the brain is a common hallmark. In cellular and animal models of neurodegeneration, SIRTs 
have been shown to modulate neuronal loss and toxicity incurred by different cytotoxic 
proteins and processes, and in particular responses to α-synuclein, Aβ, and HTT (Chen et al., 
2005a; Outeiro et al., 2007; Pallas et al., 2008; Fu et al., 2012).  
The aim of this research study was to assess the role of SIRTs- SIRT1 (nuclear), SIRT2 
(cytoplasmic) and SIRT3 (mitochondrial), under oxidative stress in a cellular model of PD, 
and to investigate their expression in neurodegenerative disorders. In this study, diquat and 
rotenone were used to induce oxidative stress in dopaminergic SH-SY5Y cells and the effects 
of over-expression and lack of enzymatic activity of SIRTs on cytotoxicity and formation of 
α-synuclein aggregates were assessed. The protein levels, enzymatic activity and cellular 
localisation of SIRTs were determined in post-mortem brain tissue of PD, PDD, DLB and AD 
patients (neurodegenerative disorders), which were compared with an age-matched control 
group. 
 
7.2 SIRT1 is a stress targeted pro-survival protein 
Following oxidative stress induced by diquat or rotenone, SIRT1 alleviated the toxic effects 
of the two toxins and enhanced cell viability in SH-SY5Y cells. The protection conferred by 
SIRT1 is partially independent of its deacetylase activity as SIRT1H363Y, an enzymatic 
mutant, also protected the cells from toxicity induced by diquat or rotenone, though not to the 
same degree as SIRT1WT. Most of the studies so far have reported that under oxidative stress, 
SIRT1 activity is required for the positive regulation of cell survival (detailed review in 
(Salminen et al., 2013)). The finding of this study implies that SIRT1 is more than a 
deacetylase and it possibly works as an interacting factor with other proteins that act either as 
pro-apoptotic or anti-apoptotic factors. Similar to the finding of this study, Pfister et al., 
reported that the protection conferred by SIRT1 to cerebellar granule neurones against low 
potassium induced toxicity was independent of its deacetylase activity (Pfister et al., 2008).  
Investigations into the protection conferred by SIRT1 showed that SIRT1 reduced the 
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expression of NF-кB and enhanced cell survival. This finding is supported by a study 
conducted by Ghosh et al., where they reported that SIRT1 and SIRT1H363Y reduce the 
transcription of NF-кB (Ghosh et al., 2007). NF-кB regulates cellular homeostasis by 
promoting antioxidant defence mechanisms and by suppressing apoptotic genes (Morgan and 
Liu, 2011). On the other hand,  under higher level of oxidative stress, NF-кB promotes cell 
death via p53 tumour suppressor, death receptor Fas and its ligand FasL and several other pro-
apoptotic factors (reviewed in (Fan et al., 2008)). This finding suggests that on treatment with 
diquat or rotenone, NF-кB possibly promotes the expression of pro-apoptotic genes and by 
repressing NF-кB, SIRT1 represses the transactivation of pro-apoptotic genes and increases 
cell survival.  
One of the interesting finding of this study revealed that on exposure to toxins, the levels of 
SIRT1 are down-regulated, which resulted in enhanced cell death in control cells. This finding 
suggests that SIRT1 is essential to protect against oxidative stress and along with its 
deacetylase activity SIRT1 can modulate cell survival as an interacting factor by repressing 
the expression of NF-кB and thus leading to the down-regulation of pro-apoptotic genes.  
The effect of SIRT1 was also studied in the formation of α-synuclein oligomer and aggregate 
formation. Fluorescent immunocytochemistry of toxin treated SH-SY5Y cells revealed that 
SIRT1 reduces the formation of α-synuclein aggregates. Albani et al., also reported that 
resveratrol, a SIRT1 activator, reduced α-synuclein induced toxicity via SIRT1 mediated 
pathways (Albani et al., 2009). Dual immunostaining of SIRT1 with phospho-α-synuclein 
revealed that SIRT1 does not co-localise with α-synuclein and hence the negative effect of 
SIRT1 on aggregate formation is possibly through its ability to reduce oxidative stress. 
Oxidative stress has been shown to accelerate α-synuclein aggregate formation by promoting 
its phosphorylation (Xiang et al., 2013). Thus by reducing oxidative stress, SIRT1 reduces α-
synuclein aggregate formation and the toxicity induced by α-synuclein aggregates. 
Fluorescent imaging of SH-SY5Y cells showed a nuclear localisation of SIRT1 which 
suggests a pro-survival role of SIRT1. In the nucleus, SIRT1 interacts with histones and 
FOXO family members and promotes genomic integrity and cell survival via enhanced 
antioxidant defence pathway activities. It is possible that apart from deacetylating its nuclear 
targets, SIRT1 also acts as a binding factor in heterochromatin complexes or in the 
transcription complexes of FOXO downstream targets.  
The levels of SIRT1 were down-regulated in differentiating neurones which were further 
elevated in differentiated neurones. This finding suggests that for the activation of key 
developmental genes SIRT1 is down-regulated but for optimal cell survival and maintenance, 
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elevated SIRT1 expression is needed. In the future, a stem cell model could be used to study 
the role of SIRT1 and its interaction with neurotrophic factors should be investigated to 
establish the exact role of SIRT1 in the development and differentiation of neurones from 
neural stem cells (NSCs).  
Finally, the expression and activity of SIRT1 was determined in post-mortem tissue of PD, 
PDD, DLB and AD patients. The protein levels of SIRT1 did not show any major changes in 
PD, PDD or DLB cases whilst in AD, the levels of SIRT1 were reduced in all the brain 
regions investigated. Another interesting finding of this study was observed in the activity of 
SIRT1 in the frontal and temporal cortices, which was down-regulated in neurodegenerative 
disorders as compared to controls. The lower SIRT1 activity in disease groups correlates with 
higher oxidative stress and neuroinflammation. Studies have reported that oxidative stress and 
inflammation are upregulated in neurodegenerative disorders (reviewed in (Glass et al., 2010; 
Gandhi and Abramov, 2012)). SIRT1 has been shown to alleviate the damage induced by 
oxidative stress and neuroinflammation. Thus, down regulation of SIRT1 in disease groups 
could be associated with neuronal loss induced by chronic oxidative stress and 
neuroinflammation.  
The findings of this study proved that SIRT1 is required for cell survival both in toxin treated 
SH-SY5Y cells and potentially in brain tissue. Down-regulation of SIRT1 in these two 
systems has shown to be associated with enhance cell death suggesting that SIRT1 can 
possibly be used as a therapeutic target in neurodegenerative disorders. 
 
7.3 SIRT2 plays a protective role under oxidative stress 
In line with the hypothesis that SIRT2 acts as a pro-apoptotic factor, the effect of SIRT2 and 
SIRT2 inhibition was assessed in diquat or rotenone treated cells. Contrary to several 
published studies, the data from the experiments of this study showed that SIRT2 does not 
enhance cell death under oxidative stress, it rather promotes cell survival. Inhibition of SIRT2, 
which so far has been associated with improved cell survival (Outeiro et al., 2007), proved to 
enhance cell death in this study. In general, inhibition of SIRT2 by AGK2 under normal 
conditions did not prove to be toxic to cells whereas, its inhibition enhanced cell death in 
diquat or rotenone treated cells. The investigation into the mechanism behind the protection 
exerted by SIRT2 showed enhanced levels of the antioxidant protein SOD2, which most 
likely was through a FOXO3a dependent mechanism. FOXO3a is a known target of SIRT2 
and under oxidative stress SIRT2 has been shown to deacetylate FOXO3a and thus activates 
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the expression of its downstream targets especially SOD2 and catalase (Wang et al., 2007). 
As with SIRT1, SIRT2 could also have enhanced cell survival by inhibiting p53 but Western 
blot analysis failed to detect significant levels of p53. In future studies, additional p53 
antibodies should be tested to determine the levels and activity of p53 protein.  
The investigation of SIRT2 on α-synuclein aggregate formation revealed that SIRT2 does not 
promote the aggregation or oligomerisation of α-synuclein. In contrast, SIRT2 inhibition 
dramatically enhanced aggregate formation and SIRT2 over-expression reduced aggregate 
formation. To date, SIRT2 has been viewed as a therapeutic target where inhibition of SIRT2 
is required for neuronal cell survival. This study however, has shed a different light on the 
actions of SIRT2 under oxidative stress. The contrasting results obtained from this study are 
possibly due to the mechanism by which aggregate formation of α-synuclein was induced. 
Further investigation showed that co-localisation of SIRT2 with α-synuclein was minimal and 
SIRT2 was localised more to the nucleus than the cytoplasm. This nuclear localisation 
suggests that SIRT2 may target the transcription factor FOXO3a and enhance the expression 
of antioxidant proteins and promote cell survival. It could also promote DNA damage repair 
to prevent cell death. Future studies should examine the levels of nuclear targets of SIRT2 in 
order to establish the exact mechanism of SIRT2 against oxidative stress and α-synuclein 
aggregate formation. 
The expression of SIRT2 was also studied in differentiating NSCs and as with SIRT1, levels 
of SIRT2 were down-regulated during differentiation. Once the NSCs were differentiated into 
neurones, the levels of SIRT2 were either restored to basal levels or were elevated suggesting 
that SIRT2 may be required for the maintenance and survival of neurones. In future, the role 
of SIRT2 in the development and differentiation of neurones from NSCs should be assessed 
in-depth by studying its interactions with different factors involved in the differentiation 
processes. 
In post-mortem brain tissues of neurodegenerative disorders, the levels of SIRT2 did not show 
any major differences between the disease groups and control group but SIRT2 enzymatic 
activity in the former, was elevated in both the frontal and temporal cortices. The increased 
activity of SIRT2 could possibly be a compensatory mechanism to alleviate oxidative stress. 
Activity of SIRT1 is down-regulated, so it is possible that SIRT2 is more active to inhibit 
inflammatory responses and oxidative stress. SIRT1 and SIRT2 have been observed to share 
some targets including p53, NF-кB, histones H3 and H4 and following down-regulation of 
SIRT1 activity it is safe to assume that SIRT2 activity is elevated to target specific proteins 
such as p53 and modulate apoptosis, neuroinflammation and genomic stability. Also, in 
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relation to the in vitro work, it is possible that SIRT2 is up-regulated to combat oxidative 
stress and to inhibit α-synuclein aggregation.  
The assessment of the cellular localisation of SIRT2 did not show any major differences 
between the disease groups and controls. One of the difficulties encountered during 
immunohistochemistry (IHC) of the sections was lack of staining of the cells using the SIRT2 
antibody, even though at least four different antibodies were tested to stain sections. In further 
studies, additional antibodies should be assessed and the IHC should be optimised by using 
possible signal enhancers.  
The experimental evidence obtained from in vitro and post-mortem brain tissue demonstrates 
that SIRT2 diminishes the damage induced by oxidative stress. In future, before inhibiting 
SIRT2 for therapeutic purposes it should be taken into consideration that SIRT2 does reduce 
oxidative stress mediated-cell death and that SIRT2 inhibition might lead to the death of 
healthy neurones and other brain cells.  
 
7.4 SIRT3 is a stress induced pro-survival protein 
Being a mitochondrial SIRT, SIRT3 modulates oxidative stress and on treatment with toxins, 
SIRT3 mitigated the damage induced by oxidative stress. The protection provided by SIRT3 
was dependent on its enzymatic activity as the enzymatic mutant failed to rescue the cells 
from the oxidative stress, the mutant rather enhanced the cell death. This finding is supported 
by recent studies that have shown that SIRT3 exerts protection under oxidative stress 
conditions (Cheng et al., 2013; Dai et al., 2014). This study also found that the protection 
exerted by SIRT3 was mediated through SOD2. Up-regulation of SOD2 by SIRT3 scavenges 
ROS and diminishes the negative effect of oxidative stress on cells. SOD2 is a target of 
SIRT3 and is deacetylated and activated by SIRT3 but the mechanism by which SIRT3 
increases the expression of SOD2 needs to be assessed. One possible mechanism is that 
SIRT3 increases the expression of SOD2 through FOXO3a. SIRT3 has been shown to 
deacetylate and activate FOXO3a and thereby enhance the expression of genes essential for 
mitochondrial homeostasis (Tseng et al., 2013). This study also found that SIRT3 is up-
regulated under stress and in turn also enhances the expression of SOD2 suggesting that 
SIRT3 combats oxidative stress by enhancing antioxidant defence pathways. In future, it will 
be interesting to assess the acetylation levels of FOXO3a in toxin treated cells and to also 
assess the interaction between SIRT3 and FOXO3a.  
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One of the major significant findings to emerge from this study is that SIRT3 co-localises 
with α-synuclein and inhibits α-synuclein aggregate formation. The inhibition of α-synuclein 
aggregation was dependent on the deacetylase activity of SIRT3 suggesting that acetylation of 
α-synuclein might possibly play a role in aggregate formation. Mutant SIRT3 showed 
elevated co-localisation with α-synuclein with greater numbers of aggregates thus supporting 
the finding that SIRT3 interacts with α-synuclein and deacetylates α-synuclein and inhibits 
the formation of toxic aggregates. In future, it will be interesting to look into the acetylation 
of lysine residues of α-synuclein and its effect on oligomerisation of the protein. 
An essential role of SIRT3 in cell survival and maintenance was also supported by the 
experiments done with differentiating NSCs. SIRT3 levels were down-regulated during the 
process of differentiation but were restored to normal levels in neurones suggesting that 
SIRT3 is required for cellular maintenance.  
The investigation of SIRT3 in post-mortem human brain tissue in neurodegenerative disorders 
revealed no major alterations between control and the disease groups. Even though the levels 
of SIRT3 protein remain unaltered the same cannot be said about the enzymatic activity of the 
protein. In future, specific SIRT3 inhibitors could be investigated to study the activity of 
SIRT3 in human brain tissue.  
The IHC of SIRT3 in the temporal cortex and hippocampus sections of neurodegenerative 
disorders showed strong microglial staining compared to control. The intense microglial 
staining in disease group possibly associates with the oxidative stress observed in 
neurodegenerative disorders. This finding is supported by a recent study that showed 
enhanced expression of SIRT3 in microglial cells of rat brains subjected to brain injury 
(Rangarajan et al., 2015). Enhanced expression of SIRT3 triggered the upregulation of 
catalase and SOD2 and activated the antioxidant pathways against cellular stress. This finding 
further substantiates the crucial role of SIRT3 in scavenging ROS and promoting cell survival.  
Taken together, the investigations into the role of SIRT3 in oxidative stress and 
neurodegenerative disorders demonstrate that SIRT3 is a stress induced protein that combats 
oxidative stress. With respect to diseases, it is safe to state that over-activation of SIRT3 
could be able to rescue neurones from protein aggregate and oxidative stress induced toxicity.  
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7.5 Study limitations 
One of the major limitations of this research is lack of in-depth study of the mechanisms of 
action of SIRTs against oxidative stress. The investigations into the effect of SIRTs on 
oxidative stress were relatively broad and did not capture the involvement of several cellular 
processes in which SIRTs are involved. The study went to look into three different SIRTs and 
their role was analysed in the same models, however, in future research, the emphasis should 
be given on one SIRT at a time and all possible mechanisms behind its actions and 
interactions should be explored. 
Another limitation of this study is the model used. SH-SY5Y cells are a basic PD cellular 
model that show a dopaminergic phenotype but fail to represent the true environment of the 
CNS or of SN neurones.  Also the effects of SIRTs were studied under acute oxidative stress 
instead of chronic oxidative stress. In future, these experiments should be replicated in stem 
cell derived neurones that are a more realistic representation of the CNS and to study the role 
of SIRTs in chronic oxidative stress in this model.  
In post-mortem human brain tissue, the major limitation was the unavailability of antibodies 
for SIRT substrates and a specific inhibitor of SIRT3. The lack of these reagents limited the 
study and the precise role of SIRTs in neurodegenerative disorders is still not clear. The exact 
location of SIRTs within the cell and their localisation in different cells could not be 
determined because of lack of time and suitable antibodies. Due to lack of time, the 
experiments to assess any interaction of SIRTs with several bio-markers of neurodegenerative 
disorders could not be performed.   
 
7.6 Future directions 
The findings from this study provide the foundations for future research.  Further research 
studies should investigate: 
 The different cell death pathways including apoptosis, necrosis and autophagy and the 
effect of SIRTs should be tested on the proteins involved with these pathways. Assays 
including fluorescence-activated cell sorting (FACS), apoptosis detecting assays, ATP 
determination could be used to explore the cellular pathways in which SIRTs might be 
involved. 
 355 
 The involvement of acetylation of α-synuclein and its effect on oligomerisation could 
be examined which will provide more insight in the mechanism behind aggregate 
formation. 
 The toxicity assays and the role of SIRTs in chronic oxidative stress could be 
modelled in neurones derived from humans NSCs. 
 Interaction of SIRTs with biomarkers including α-synuclein, Aβ, tau and TDP43 
should be assessed in post-mortem brain tissue of neurodegenerative disorders. 
 Potential activators of SIRT should be evaluated through high throughput screening as 
therapeutic targets for neurodegenerative disorders. 
 
7.7 Conclusion 
In conclusion, the results of this research study suggest that SIRTs are pro-survival factors 
that alleviate oxidative damage and α-synuclein aggregate formation and increase cell 
survival by enhancing the antioxidant defence pathways and curbing inflammatory responses.  
SIRT1 is down-regulated under oxidative stress both in vitro and in post-mortem brain tissues 
of PD, PDD, DLB and AD patients. Enhanced SIRT1 expression decreases the inflammatory 
responses and cell death pathways mediated by NF-кB.  
SIRT2 protects cells from the oxidative stress induced damage by enhancing the expression of 
SOD2 and inhibition of SIRT2 was deleterious to cells. The enhanced activity of SIRT2 in 
post-mortem brain tissues could possibly be a compensatory mechanism that helps cells to 
fight against chronic oxidative stress.  
SIRT3 is a stress induced protein that protects the cells from oxidative stress by enhancing a 
SOD2 mediated antioxidant defence mechanism and co-localises with α-synuclein and 
reduces its aggregation.  
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Appendix A - Diquat and Rotenone toxicity curves 
1. Diquat toxicity curve 
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Figure A.1 Dose–response effect of diquat on SH-SY5Y cells. Each graph is representation 
of three independent studies. Data presented as mean (±SD) from quadruplicate assays (n=3). 
*** p<0.001 when compared to 0.2% PBS, one way ANOVA and post hoc t-test (Bonferroni 
corrected). 
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2. Rotenone toxicity curve 
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Figure A.2 Dose–response effect of rotenone on SH-SY5Y cells. Each graph is 
representation of three independent studies. Data presented as mean (±SD) from quadruplicate 
assays (n=3). *** p<0.001 when compared to 0.2% DMSO, one way ANOVA and post hoc t-
test (Bonferroni corrected). 
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Appendix B- List of Primers used for PCR and the Sequences of 
cloned SIRT Plasmids 
1 List of primers 
1.1 Primers for SIRT amplification from cDNA 
SIRTs  Primers Product Size 
SIRT1 Fwd 
Rev 
ATGGCGGACGAGGCGGCCCTC  
CTATGATTTGTTTGATGGATAGTTCAT 
~2.2kb 
SIRT2 Fwd 
Rev 
ATGGCAGAGCCAGACCCC 
TCACTGGGGTTTCTCCCT 
~1.2kb 
SIRT3 Fwd 
Rev 
ATGGCGTTCTGGGGTTGG 
CTATTTGTCTGGTCCATCAAG 
~1.2kb 
 
 
1.2 Primers for Fusion PCR 
SIRTs Set Primers Product 
Size 
 
 
SIRT1 
Set 1 
SIRT1 Fwd: 
ATCGGGATCCGCCACCATGGCGGACGAG 
SIRT1 Cen Rev: ACATGAAGAGGTGTGGGTGG 
 
~1.5kb 
Set 2 
SIRT1 Cen Fwd: GCCAAACTTTGCTGTAACCC 
SIRT1 Rev: 
ATCGGTCGACCTACTTATCGTCTGATTTGTTTGATGG 
 
781bp 
SIRT2 Set 1 
SIRT2 Fwd: 
ATCGGGATCCGCCACCATGGCAGAGCCAGAC 
SIRT2 Cen Rev: GGCGCATGAAGTAGTGACAG 
 
460bp 
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SIRT2 
 
Set 2 
SIRT2 Cen Fwd: ACATCCGGAACCCTTCTTCG 
SIRT2 Rev: 
ATCGGTCGACTCACTTATCGTCCTGGGGTTT CTC 
 
781bp 
 
 
SIRT3 
Set 1 
SIRT3 Fwd: 
GGATCCGCCACCATGGCGTTCTGGGGTTGG 
SIRT3 Cen Rev: GAGGCAAAGGTTCCATGAGC 
790bp 
 
Set 2 
SIRT3 Cen Fwd: TCGATGGGCTTGAGAGAGTG  
SIRT3 Rev: GTCGACCTATTTGTCTGGTCCATCAAG 
500bp 
 
 
 
1.3 Primers for PCR using Fusion PCR products as template 
SIRTs  Primers Product 
Size 
SIRT1 Fwd 
Rev 
ATCGGGATCCGCCACCATGGCGGACGAG 
ATCGGTCGACCTACTTATCGTCTGATTTGTTTGATGG 
~2.2kb 
SIRT2 Fwd 
Rev 
ATCGGGATCCGCCACCATGGCAGAGCCAGAC 
ATCGGTCGACTCACTTATCGTCCTGGGGTTT CTC 
~1.2kb 
SIRT3 Fwd 
Rev 
GGATCCGCCACCATGGCGTTCTGGGGTTGG 
GTCGACCTATTTGTCTGGTCCATCAAG 
~1.2kb 
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2 Plasmid Sequences 
Plasmids were sequenced twice, forward and reverse and the resulting sequence was averaged 
to one sequence. The sequences were aligned against respective SIRT coding sequence (CD) 
using Clustal Omega (EMBL-EBI; http://www.ebi.ac.uk/Tools/msa/clustalo/). 
2.1 Plasmids in pCR2.1 
2.1.1 SIRT1WT plasmid  
SIRT1CD      GGCAGTTGGAAGATGGCGGACGAGGCGGCCCTCGCCCTTCAGCCCGGCGGCTCCCCCTCG 
SIRT1Pl      GGATCCGCCACCATGGCGGACGAGGCGGCCCTCGCCCTTCAGCCCGGCGGCTCCCCCTCG 
             **       *  ************************************************ 
 
SIRT1CD      GCGGCGGGGGCCGACAGGGAGGCCGCGTCGTCCCCCGCCGGGGAGCCGCTCCGCAAGAGG 
SIRT1Pl      GCGGCGGGGGCCGACAGGGAGGCCGCGTCGTCCCCCGCCGGGGAGCCGCTCCGCAAGAGG 
             ************************************************************ 
 
SIRT1CD      CCGCGGAGAGATGGTCCCGGCCTCGAGCGGAGCCCGGGCGAGCCCGGTGGGGCGGCCCCA 
SIRT1Pl      CCGCGGAGAGATGGTCCCGGCCTCGAGCGGAGCCCGGGCGAGCCCGGTGGGGCGGCCCCA 
             ************************************************************ 
 
SIRT1CD      GAGCGTGAGGTGCCGGCGGCGGCCAGGGGCTGCCCGGGTGCGGCGGCGGCGGCGCTGTGG 
SIRT1Pl      GAGCGTGAGGTGCCGGCGGCGGCCAGGGGCTGCCCGGGTGCGGCGGCGGCGGCGCTGTGG 
             ************************************************************ 
 
SIRT1CD      CGGGAGGCGGAGGCAGAGGCGGCGGCGGCAGGCGGGGAGCAAGAGGCCCAGGCGACTGCG 
SIRT1Pl      CGGGAGGCGGAGGCAGAGGCGGCGGCGGCAGGCGGGGAGCAAGAGGCCCAGGCGACTGCG 
             ************************************************************ 
 
SIRT1CD      GCGGCTGGGGAAGGAGACAATGGGCCGGGCCTGCAGGGCCCATCTCGGGAGCCACCGCTG 
SIRT1Pl      GCGGCTGGGGAAGGAGACAATGGGCCGGGCCTGCAGGGCCCATCTCGGGAGCCACCGCTG 
             ************************************************************ 
 
SIRT1CD      GCCGACAACTTGTACGACGAAGACGACGACGACGAGGGCGAGGAGGAGGAAGAGGCGGCG 
SIRT1Pl      GCCGACAACTTGTACGACGAAGACGACGACGACGAGGGCGAGGAGGAGGAAGAGGCGGCG 
             ************************************************************ 
 
SIRT1CD      GCGGCGGCGATTGGGTACCGAGATAACCTTCTGTTCGGTGATGAAATTATCACTAATGGT 
SIRT1Pl      GCGGCGGCGATTGGGTACCGAGATAACCTTCTGTTCGGTGATGAAATTATCACTAATGGT 
             ************************************************************ 
 
SIRT1CD      TTTCATTCCTGTGAAAGTGATGAGGAGGATAGAGCCTCACATGCAAGCTCTAGTGACTGG 
SIRT1Pl      TTTCATTCCTGTGAAAGTGATGAGGAGGATAGAGCCTCACATGCAAGCTCTAGTGACTGG 
             ************************************************************ 
 
SIRT1CD      ACTCCAAGGCCACGGATAGGTCCATATACTTTTGTTCAGCAACATCTTATGATTGGCACA 
SIRT1Pl      ACTCCAAGGCCACGGATAGGTCCATATACTTTTGTTCAGCAACATCTTATGATTGGCACA 
             ************************************************************ 
 
SIRT1CD      GATCCTCGAACAATTCTTAAAGATTTATTGCCGGAAACAATACCTCCACCTGAGTTGGAT 
SIRT1Pl      GATCCTCGAACAATTCTTAAAGATTTATTGCCGGAAACAATACCTCCACCTGAGTTGGAT 
             ************************************************************ 
 
SIRT1CD      GATATGACACTGTGGCAGATTGTTATTAATATCCTTTCAGAACCACCAAAAAGGAAAAAA 
SIRT1Pl      GATATGACACTGTGGCAGATTGTTATTAATATCCTTTCAGAACCACCAAAAAGGAAAAAA 
             ************************************************************ 
 
SIRT1CD      AGAAAAGATATTAATACAATTGAAGATGCTGTGAAATTACTGCAAGAGTGCAAAAAAATT 
SIRT1Pl      AGAAAAGATATTAATACAATTGAAGATGCTGTGAAATTACTGCAAGAGTGCAAAAAAATT 
             ************************************************************ 
 
SIRT1CD      ATAGTTCTAACTGGAGCTGGGGTGTCTGTTTCATGTGGAATACCTGACTTCAGGTCAAGG 
SIRT1Pl      ATAGTTCTAACTGGAGCTGGGGTGTCTGTTTCATGTGGAATACCTGACTTCAGGTCAAGG 
             ************************************************************ 
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SIRT1CD      GATGGTATTTATGCTCGCCTTGCTGTAGACTTCCCAGATCTTCCAGATCCTCAAGCGATG 
SIRT1Pl      GATGGTATTTATGCTCGCCTTGCTGTAGACTTCCCAGATCTTCCAGATCCTCAAGCGATG 
             ************************************************************ 
 
SIRT1CD      TTTGATATTGAATATTTCAGAAAAGATCCAAGACCATTCTTCAAGTTTGCAAAGGAAATA 
SIRT1Pl      TTTGATATTGAATATTTCAGAAAAGATCCAAGACCATTCTTCAAGTTTGCAAAGGAAATA 
             ************************************************************ 
 
SIRT1CD      TATCCTGGACAATTCCAGCCATCTCTCTGTCACAAATTCATAGCCTTGTCAGATAAGGAA 
SIRT1Pl      TATCCTGGACAATTCCAGCCATCTCTCTGTCACAAATTCATAGCCTTGTCAGATAAGGAA 
             ************************************************************ 
 
SIRT1CD      GGAAAACTACTTCGCAACTATACCCAGAACATAGACACGCTGGAACAGGTTGCGGGAATC 
SIRT1Pl      GGAAAACTACTTCGCAACTATACCCAGAACATAGACACGCTGGAACAGGTTGCGGGAATC 
             ************************************************************ 
 
SIRT1CD      CAAAGGATAATTCAGTGTCATGGTTCCTTTGCAACAGCATCTTGCCTGATTTGTAAATAC 
SIRT1Pl      CAAAGGATAATTCAGTGTCATGGTTCCTTTGCAACAGCATCTTGCCTGATTTGTAAATAC 
             ************************************************************ 
 
SIRT1CD      AAAGTTGACTGTGAAGCTGTACGAGGAGATATTTTTAATCAGGTAGTTCCTCGATGTCCT 
SIRT1Pl      AAAGTTGACTGTGAAGCTGTACGAGGAGATATTTTTAATCAGGTAGTTCCTCGATGTCCT 
             ************************************************************ 
 
SIRT1CD      AGGTGCCCAGCTGATGAACCGCTTGCTATCATGAAACCAGAGATTGTGTTTTTTGGTGAA 
SIRT1Pl      AGGTGCCCAGCTGATGAACCGCTTGCTATCATGAAACCAGAGATTGTGTTTTTTGGTGAA 
             ************************************************************ 
 
SIRT1CD      AATTTACCAGAACAGTTTCATAGAGCCATGAAGTATGACAAAGATGAAGTTGACCTCCTC 
SIRT1Pl      AATTTACCAGAACAGTTTCATAGAGCCATGAAGTATGACAAAGATGAAGTTGACCTCCTC 
             ************************************************************ 
 
SIRT1CD      ATTGTTATTGGGTCTTCCCTCAAAGTAAGACCAGTAGCACTAATTCCAAGTTCCATACCC 
SIRT1Pl      ATTGTTATTGGGTCTTCCCTCAAAGTAAGACCAGTAGCACTAATTCCAAGTTCCATACCC 
             ************************************************************ 
 
SIRT1CD      CATGAAGTGCCTCAGATATTAATTAATAGAGAACCTTTGCCTCATCTGCATTTTGATGTA 
SIRT1Pl      CATGAAGTGCCTCAGATATTAATTAATAGAGAACCTTTGCCTCATCTGCATTTTGATGTA 
             ************************************************************ 
 
SIRT1CD      GAGCTTCTTGGAGACTGTGATGTCATAATTAATGAATTGTGTCATAGGTTAGGTGGTGAA 
SIRT1Pl      GAGCTTCTTGGAGACTGTGATGTCATAATTAATGAATTGTGTCATAGGTTAGGTGGTGAA 
             ************************************************************ 
 
SIRT1CD      TATGCCAAACTTTGCTGTAACCCTGTAAAGCTTTCAGAAATTACTGAAAAACCTCCACGA 
SIRT1Pl      TATGCCAAACTTTGCTGTAACCCTGTAAAGCTTTCAGAAATTACTGAAAAACCTCCACGA 
             ************************************************************ 
 
SIRT1CD      ACACAAAAAGAATTGGCTTATTTGTCAGAGTTGCCACCCACACCTCTTCATGTTTCAGAA 
SIRT1Pl      ACACAAAAAGAATTGGCTTATTTGTCAGAGTTGCCACCCACACCTCTTCATGTTTCAGAA 
             ************************************************************ 
 
SIRT1CD      GACTCAAGTTCACCAGAAAGAACTTCACCACCAGATTCTTCAGTGATTGTCACACTTTTA 
SIRT1Pl      GACTCAAGTTCACCAGAAAGAACTTCACCACCAGATTCTTCAGTGATTGTCACACTTTTA 
             ************************************************************ 
 
SIRT1CD      GACCAAGCAGCTAAGAGTAATGATGATTTAGATGTGTCTGAATCAAAAGGTTGTATGGAA 
SIRT1Pl      GACCAAGCAGCTAAGAGTAATGATGATTTAGATGTGTCTGAATCAAAAGGTTGTATGGAA 
             ************************************************************ 
 
SIRT1CD      GAAAAACCACAGGAAGTACAAACTTCTAGGAATGTTGAAAGTATTGCTGAACAGATGGAA 
SIRT1Pl      GAAAAACCACAGGAAGTACAAACTTCTAGGAATGTTGAAAGTATTGCTGAACAGATGGAA 
             ************************************************************ 
 
SIRT1CD      AATCCGGATTTGAAGAATGTTGGTTCTAGTACTGGGGAGAAAAATGAAAGAACTTCAGTG 
SIRT1Pl      AATCCGGATTTGAAGAATGTTGGTTCTAGTACTGGGGAGAAAAATGAAAGAACTTCAGTG 
             ************************************************************ 
 
SIRT1CD      GCTGGAACAGTGAGAAAATGCTGGCCTAATAGAGTGGCAAAGGAGCAGATTAGTAGGCGG 
SIRT1Pl      GCTGGAACAGTGAGAAAATGCTGGCCTAATAGAGTGGCAAAGGAGCAGATTAGTAGGCGG 
             ************************************************************ 
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SIRT1CD      CTTGATGGTAATCAGTATCTGTTTTTGCCACCAAATCGTTACATTTTCCATGGCGCTGAG 
SIRT1Pl      CTTGATGGTAATCAGTATCTGTTTTTGCCACCAAATCGTTACATTTTCCATGGCGCTGAG 
             ************************************************************ 
 
SIRT1CD      GTATATTCAGACTCTGAAGATGACGTCTTATCCTCTAGTTCTTGTGGCAGTAACAGTGAT 
SIRT1Pl      GTATATTCAGACTCTGAAGATGACGTCTTATCCTCTAGTTCTTGTGGCAGTAACAGTGAT 
             ************************************************************ 
 
SIRT1CD      AGTGGGACATGCCAGAGTCCAAGTTTAGAAGAACCCATGGAGGATGAAAGTGAAATTGAA 
SIRT1Pl      AGTGGGACATGCCAGAGTCCAAGTTTAGAAGAACCCATGGAGGATGAAAGTGAAATTGAA 
             ************************************************************ 
 
SIRT1CD      GAATTCTACAATGGCTTAGAAGATGAGCCTGATGTTCCAGAGAGAGCTGGAGGAGCTGGA 
SIRT1Pl      GAATTCTACAATGGCTTAGAAGATGAGCCTGATGTTCCAGAGAGAGCTGGAGGAGCTGGA 
             ************************************************************ 
 
SIRT1CD      TTTGGGACTGATGGAGATGATCAAGAGGCAATTAATGAAGCTATATCTGTGAAACAGGAA 
SIRT1Pl      TTTGGGACTGATGGAGATGATCAAGAGGCAATTAATGAAGCTATATCTGTGAAACAGGAA 
             ************************************************************ 
 
SIRT1CD      GTAACAGACATGAACTATCCATCAAACAAATCA------------------ 
SIRT1Pl      GTAACAGACATGAACTATCCATCAAACAAATCAGACGATAAGTAGGTCGAC 
             ********************************* 
 
2.1.2 SIRT2 plasmid 
SIRT2CD      AGCACCGCGCCCATGGCAGAGCCAGACCCCTCTCACCCTCTGGAGACCCAGGCAGGGAAG 
SIRT2Pl      GGATCCGCCACCATGGCAGAGCCAGACCCCTCTCACCCTCTGGAGACCCAGGCAGGGAAG 
              *  ****  ************************************************** 
 
SIRT2CD      GTGCAGGAGGCTCAGGACTCAGATTCAGACTCTGAGGGAGGAGCCGCTGGTGGAGAAGCA 
SIRT2Pl      GTGCAGGAGGCTCAGGACTCAGATTCAGACTCTGAGGGAGGAGCCGCTGGTGGAGAAGCA 
             ************************************************************ 
 
SIRT2CD      GACATGGACTTCCTGCGGAACTTATTCTCCCAGACGCTCAGCCTGGGCAGCCAGAAGGAG 
SIRT2Pl      GACATGGACTTCCTGCGGAACTTATTCTCCCAGACGCTCAGCCTGGGCAGCCAGAAGGAG 
             ************************************************************ 
 
SIRT2CD      CGTCTGCTGGACGAGCTGACCTTGGAAGGGGTGGCCCGGTACATGCAGAGCGAACGCTGT 
SIRT2Pl      CGTCTGCTGGACGAGCTGACCTTGGAAGGGGTGGCCCGGTACATGCAGAGCGAACGCTGT 
             ************************************************************ 
 
SIRT2CD      CGCAGAGTCATCTGTTTGGTGGGAGCTGGAATCTCCACATCCGCAGGCATCCCCGACTTT 
SIRT2Pl      CGCAGAGTCATCTGTTTGGTGGGAGCTGGAATCTCCACATCCGCAGGCATCCCCGACTTT 
             ************************************************************ 
 
SIRT2CD      CGCTCTCCATCCACCGGCCTCTATGACAACCTAGAGAAGTACCATCTTCCCTACCCAGAG 
SIRT2Pl      CGCTCTCCATCCACCGGCCTCTATGACAACCTAGAGAAGTACCATCTTCCCTACCCAGAG 
             ************************************************************ 
 
SIRT2CD      GCCATCTTTGAGATCAGCTATTTCAAGAAACATCCGGAACCCTTCTTCGCCCTCGCCAAG 
SIRT2Pl      GCCATCTTTGAGATCAGCTATTTCAAGAAACATCCGGAACCCTTCTTCGCCCTCGCCAAG 
             ************************************************************ 
 
SIRT2CD      GAACTCTATCCTGGGCAGTTCAAGCCAACCATCTGTCACTACTTCATGCGCCTGCTGAAG 
SIRT2Pl      GAACTCTATCCTGGGCAGTTCAAGCCAACCATCTGTCACTACTTCATGCGCCTGCTGAAG 
             ************************************************************ 
 
SIRT2CD      GACAAGGGGCTACTCCTGCGCTGCTACACGCAGAACATAGATACCCTGGAGCGAATAGCC 
SIRT2Pl      GACAAGGGGCTACTCCTGCGCTGCTACACGCAGAACATAGATACCCTGGAGCGAATAGCC 
             ************************************************************ 
 
SIRT2CD      GGGCTGGAACAGGAGGACTTGGTGGAGGCGCACGGCACCTTCTACACATCACACTGCGTC 
SIRT2Pl      GGGCTGGAACAGGAGGACTTGGTGGAGGCGCACGGCACCTTCTACACATCACACTGCGTC 
             ************************************************************ 
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SIRT2CD      AGCGCCAGCTGCCGGCACGAATACCCGCTAAGCTGGATGAAAGAGAAGATCTTCTCTGAG 
SIRT2Pl      AGCGCCAGCTGCCGGCACGAATACCCGCTAAGCTGGATGAAAGAGAAGATCTTCTCTGAG 
             ************************************************************ 
 
SIRT2CD      GTGACGCCCAAGTGTGAAGACTGTCAGAGCCTGGTGAAGCCTGATATCGTCTTTTTTGGT 
SIRT2Pl      GTGACGCCCAAGTGTGAAGACTGTCAGAGCCTGGTGAAGCCTGATATCGTCTTTTTTGGT 
             ************************************************************ 
 
SIRT2CD      GAGAGCCTCCCAGCGCGTTTCTTCTCCTGTATGCAGTCAGACTTCCTGAAGGTGGACCTC 
SIRT2Pl      GAGAGCCTCCCAGCGCGTTTCTTCTCCTGTATGCAGTCAGACTTCCTGAAGGTGGACCTC 
             ************************************************************ 
 
SIRT2CD      CTCCTGGTCATGGGTACCTCCTTGCAGGTGCAGCCCTTTGCCTCCCTCATCAGCAAGGCA 
SIRT2Pl      CTCCTGGTCATGGGTACCTCCTTGCAGGTGCAGCCCTTTGCCTCCCTCATCAGCAAGGCA 
             ************************************************************ 
 
SIRT2CD      CCCCTCTCCACCCCTCGCCTGCTCATCAACAAGGAGAAAGCTGGCCAGTCGGACCCTTTC 
SIRT2Pl      CCCCTCTCCACCCCTCGCCTGCTCATCAACAAGGAGAAAGCTGGCCAGTCGGACCCTTTC 
             ************************************************************ 
 
SIRT2CD      CTGGGGATGATTATGGGCCTCGGAGGAGGCATGGACTTTGACTCCAAGAAGGCCTACAGG 
SIRT2Pl      CTGGGGATGATTATGGGCCTCGGAGGAGGCATGGACTTTGACTCCAAGAAGGCCTACAGG 
             ************************************************************ 
 
SIRT2CD      GACGTGGCCTGGCTGGGTGAATGCGACCAGGGCTGCCTGGCCCTTGCTGAGCTCCTTGGA 
SIRT2Pl      GACGTGGCCTGGCTGGGTGAATGCGACCAGGGCTGCCTGGCCCTTGCTGAGCTCCTTGGA 
             ************************************************************ 
 
SIRT2CD      TGGAAGAAGGAGCTGGAGGACCTTGTCCGGAGGGAGCACGCCAGCATAGATGCCCAGTCG 
SIRT2Pl      TGGAAGAAGGAGCTGGAGGACCTTGTCCGGAGGGAGCACGCCAGCATAGATGCCCAGTCG 
             ************************************************************ 
 
SIRT2CD      GGGGCGGGGGTCCCCAACCCCAGCACTTCAGCTTCCCCCAAGAAGTCCCCGCCACCTGCC 
SIRT2Pl      GGGGCGGGGGTCCCCAACCCCAGCACTTCAGCTTCCCCCAAGAAGTCCCCGCCACCTGCC 
             ************************************************************ 
 
SIRT2CD      AAGGACGAGGCCAGGACAACAGAGAGGGAGAAACCCCAG------------------ 
SIRT2Pl      AAGGACGAGGCCAGGACAACAGAGAGGGAGAAACCCCAGGGGGATAAGTGAGTCGAC 
             ***************************************                   
 
2.1.3 SIRT3WT plasmid 
SIRT3CD      GCGAGTCCGGAGGACTCCTTGGACTGCGCGGAACATGGCGTTCTGGGGTTGGCGCGCCGC 
SIRT3Pl      ----------------------GGATCCGCCACCATGGCGTTCTGGGGTTGGCGCGCCGC 
                                       *    * *************************** 
 
SIRT3CD      GGCAGCCCTCCGGCTGTGGGGCCGGGTAGTTGAACGGGTCGAGGCCGGGGGAGGCGTGGG 
SIRT3Pl      GGCAGCCCTCCGGCTGTGGGGCCGGGTAGTTGAACGGGTCGAGGCCGGGGGAGGCGTGGG 
             ************************************************************ 
 
SIRT3CD      GCCGTTTCAGGCCTGCGGCTGTCGGCTGGTGCTTGGCGGCAGGGACGATGTGAGTGCGGG 
SIRT3Pl      GCCGTTTCAGGCCTGCGGCTGTCGGCTGGTGCTTGGCGGCAGGGACGATGTGAGTGCGGG 
             ************************************************************ 
 
SIRT3CD      GCTGAGAGGCAGCCATGGGGCCCGCGGTGAGCCCTTGGACCCGGCGCGCCCCTTGCAGAG 
SIRT3Pl      GCTGAGAGGCAGCCATGGGGCCCGCGGTGAGCCCTTGGACCCGGCGCGCCCCTTGCAGAG 
             ************************************************************ 
 
SIRT3CD      GCCTCCCAGACCCGAGGTGCCCAGGGCATTCCGGAGGCAGCCGAGGGCAGCAGCTCCCAG 
SIRT3Pl      GCCTCCCAGACCCGAGGTGCCCAGGGCATTCCGGAGGCAGCCGAGGGCAGCAGCTCCCAG 
             ************************************************************ 
 
SIRT3        TTTCTTCTTTTCGAGTATTAAAGGTGGAAGAAGGTCCATATCTTTTTCTGTGGGTGCTTC 
SIRT3Pl      TTTCTTCTTTTCGAGTATTAAAGGTGGAAGAAGGTCCATATCTTTTTCTGTGGGTGCTTC 
             ************************************************************ 
 
SIRT3        AAGTGTTGTTGGAAGTGGAGGCAGCAGTGACAAGGGGAAGCTTTCCCTGCAGGATGTAGC 
SIRT3Pl      AAGTGTTGTTGGAAGTGGAGGCAGCAGTGACAAGGGGAAGCTTTCCCTGCAGGATGTAGC 
             ************************************************************ 
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SIRT3CD      TGAGCTGATTCGGGCCAGAGCCTGCCAGAGGGTGGTGGTCATGGTGGGGGCCGGCATCAG 
SIRT3Pl      TGAGCTGATTCGGGCCAGAGCCTGCCAGAGGGTGGTGGTCATGGTGGGGGCCGGCATCAG 
             ************************************************************ 
 
SIRT3CD      CACACCCAGTGGCATTCCAGACTTCAGATCGCCGGGGAGTGGCCTGTACAGCAACCTCCA 
SIRT3Pl      CACACCCAGTGGCATTCCAGACTTCAGATCGCCGGGGAGTGGCCTGTACAGCAACCTCCA 
             ************************************************************ 
 
SIRT3CD      GCAGTACGATCTCCCGTACCCCGAGGCCATTTTTGAACTCCCATTCTTCTTTCACAACCC 
SIRT3Pl      GCAGTACGATCTCCCGTACCCCGAGGCCATTTTTGAACTCCCATTCTTCTTTCACAACCC 
             ************************************************************ 
 
SIRT3CD      CAAGCCCTTTTTCACTTTGGCCAAGGAGCTGTACCCTGGAAACTACAAGCCCAACGTCAC 
SIRT3Pl      CAAGCCCTTTTTCACTTTGGCCAAGGAGCTGTACCCTGGAAACTACAAGCCCAACGTCAC 
             ************************************************************ 
 
SIRT3CD      TCACTACTTTCTCCGGCTGCTTCATGACAAGGGGCTGCTTCTGCGGCTCTACACGCAGAA 
SIRT3Pl      TCACTACTTTCTCCGGCTGCTTCATGACAAGGGGCTGCTTCTGCGGCTCTACACGCAGAA 
             ************************************************************ 
 
SIRT3CD      CATCGATGGGCTTGAGAGAGTGTCGGGCATCCCTGCCTCAAAGCTGGTTGAAGCTCATGG 
SIRT3Pl      CATCGATGGGCTTGAGAGAGTGTCGGGCATCCCTGCCTCAAAGCTGGTTGAAGCTCATGG 
             ************************************************************ 
 
SIRT3        AACCTTTGCCTCTGCCACCTGCACAGTCTGCCAAAGACCCTTCCCAGGGGAGGACATTCG 
SIRT3Pl      AACCTTTGCCTCTGCCACCTGCACAGTCTGCCAAAGACCCTTCCCAGGGGAGGACATTCG 
             ************************************************************ 
 
SIRT3CD      GGCTGACGTGATGGCAGACAGGGTTCCCCGCTGCCCGGTCTGCACCGGCGTTGTGAAGCC 
SIRT3Pl      GGCTGACGTGATGGCAGACAGGGTTCCCCGCTGCCCGGTCTGCACCGGCGTTGTGAAGCC 
             ************************************************************ 
 
SIRT3CD      CGACATTGTGTTCTTTGGGGAGCCGCTGCCCCAGAGGTTCTTGCTGCATGTGGTTGATTT 
SIRT3Pl      CGACATTGTGTTCTTTGGGGAGCCGCTGCCCCAGAGGTTCTTGCTGCATGTGGTTGATTT 
             ************************************************************ 
 
SIRT3        CCCCATGGCAGATCTGCTGCTCATCCTTGGGACCTCCCTGGAGGTGGAGCCTTTTGCCAG 
SIRT3Pl      CCCCATGGCAGATCTGCTGCTCATCCTTGGGACCTCCCTGGAGGTGGAGCCTTTTGCCAG 
             ************************************************************ 
 
SIRT3CD      CTTGACCGAGGCCGTGCGGAGCTCAGTTCCCCGACTGCTCATCAACCGGGACTTGGTGGG 
SIRT3Pl      CTTGACCGAGGCCGTGCGGAGCTCAGTTCCCCGACTGCTCATCAACCGGGACTTGGTGGG 
             ************************************************************ 
 
SIRT3CD      GCCCTTGGCTTGGCATCCTCGCAGCAGGGACGTGGCCCAGCTGGGGGACGTGGTTCACGG 
SIRT3Pl      GCCCTTGGCTTGGCATCCTCGCAGCAGGGACGTGGCCCAGCTGGGGGACGTGGTTCACGG 
             ************************************************************ 
 
SIRT3CD      CGTGGAAAGCCTAGTGGAGCTTCTGGGCTGGACAGAAGAGATGCGGGACCTTGTGCAGCG 
SIRT3Pl      CGTGGAAAGCCTAGTGGAGCTTCTGGGCTGGACAGAAGAGATGCGGGACCTTGTGCAGCG 
             ************************************************************ 
 
SIRT3CD      GGAAACTGGGAAGCTTGATGGACCAGACAAA------------------ 
SIRT3Pl      GGAAACTGGGAAGCTTGATGGACCAGACAAAGACGATAAGTAGGTCGAC 
             ******************************* 
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2.2 Plasmids cloned in pLenti CMV Blast 
2.2.1 SIRT1WT plasmid  
SIRT1CD      ------------------------GGCAGTTGGAAGATGGCGGACGAGGCGGCCCTCGCC 
SIRT1WT      ATGGACTACAAGGACGATGACGATAAACCCGGGAATTCGGCGGACGAGGCGGCCCTCGCC 
                                            ****   ********************** 
 
SIRT1CD      CTTCAGCCCGGCGGCTCCCCCTCGGCGGCGGGGGCCGACAGGGAGGCCGCGTCGTCCCCC 
SIRT1WT      CTTCAGCCCGGCGGCTCCCCCTCGGCGGCGGGGGCCGACAGGGAGGCCGCGTCGTCCCCC 
             ************************************************************ 
 
SIRT1CD      GCCGGGGAGCCGCTCCGCAAGAGGCCGCGGAGAGATGGTCCCGGCCTCGAGCGGAGCCCG 
SIRT1WT      GCCGGGGAGCCGCTCCGCAAGAGGCCGCGGAGAGATGGTCCCGGCCTCGAGCGGAGCCCG 
             ************************************************************ 
 
SIRT1CD      GGCGAGCCCGGTGGGGCGGCCCCAGAGCGTGAGGTGCCGGCGGCGGCCAGGGGCTGCCCG 
SIRT1WT      GGCGAGCCCGGTGGGGCGGCCCCAGAGCGTGAGGTGCCGGCGGCGGCCAGGGGCTGCCCG 
             ************************************************************ 
 
SIRT1CD      GGTGCGGCGGCGGCGGCGCTGTGGCGGGAGGCGGAGGCAGAGGCGGCGGCGGCAGGCGGG 
SIRT1WT      GGTGCGGCGGCGGCGGCGCTGTGGCGGGAGGCGGAGGCAGAGGCGGCGGCGGCAGGCGGG 
             ************************************************************ 
 
SIRT1CD      GAGCAAGAGGCCCAGGCGACTGCGGCGGCTGGGGAAGGAGACAATGGGCCGGGCCTGCAG 
SIRT1WT      GAGCAAGAGGCCCAGGCGACTGCGGCGGCTGGGGAAGGAGACAATGGGCCGGGCCTGCAG 
             ************************************************************ 
 
SIRT1CD      GGCCCATCTCGGGAGCCACCGCTGGCCGACAACTTGTACGACGAAGACGACGACGACGAG 
SIRT1WT      GGCCCATCTCGGGAGCCACCGCTGGCCGACAACTTGTACGACGAAGACGACGACGACGAG 
             ************************************************************ 
 
SIRT1CD      GGCGAGGAGGAGGAAGAGGCGGCGGCGGCGGCGATTGGGTACCGAGATAACCTTCTGTTC 
SIRT1WT      GGCGAGGAGGAGGAAGAGGCGGCGGCGGCGGCGATTGGGTACCGAGATAACCTTCTGTTC 
             ************************************************************ 
 
SIRT1CD      GGTGATGAAATTATCACTAATGGTTTTCATTCCTGTGAAAGTGATGAGGAGGATAGAGCC 
SIRT1WT      GGTGATGAAATTATCACTAATGGTTTTCATTCCTGTGAAAGTGATGAGGAGGATAGAGCC 
             ************************************************************ 
 
SIRT1CD      TCACATGCAAGCTCTAGTGACTGGACTCCAAGGCCACGGATAGGTCCATATACTTTTGTT 
SIRT1WT      TCACATGCAAGCTCTAGTGACTGGACTCCAAGGCCACGGATAGGTCCATATACTTTTGTT 
             ************************************************************ 
 
SIRT1CD      CAGCAACATCTTATGATTGGCACAGATCCTCGAACAATTCTTAAAGATTTATTGCCGGAA 
SIRT1WT      CAGCAACATCTTATGATTGGCACAGATCCTCGAACAATTCTTAAAGATTTATTGCCGGAA 
             ************************************************************ 
 
SIRT1CD      ACAATACCTCCACCTGAGTTGGATGATATGACACTGTGGCAGATTGTTATTAATATCCTT 
SIRT1WT      ACAATACCTCCACCTGAGTTGGATGATATGACACTGTGGCAGATTGTTATTAATATCCTT 
             ************************************************************ 
 
SIRT1CD      TCAGAACCACCAAAAAGGAAAAAAAGAAAAGATATTAATACAATTGAAGATGCTGTGAAA 
SIRT1WT      TCAGAACCACCAAAAAGGAAAAAAAGAAAAGATATTAATACAATTGAAGATGCTGTGAAA 
             ************************************************************ 
 
SIRT1CD      TTACTGCAAGAGTGCAAAAAAATTATAGTTCTAACTGGAGCTGGGGTGTCTGTTTCATGT 
SIRT1WT      TTACTGCAAGAGTGCAAAAAAATTATAGTTCTAACTGGAGCTGGGGTGTCTGTTTCATGT 
             ************************************************************ 
 
SIRT1CD      GGAATACCTGACTTCAGGTCAAGGGATGGTATTTATGCTCGCCTTGCTGTAGACTTCCCA 
SIRT1WT      GGAATACCTGACTTCAGGTCAAGGGATGGTATTTATGCTCGCCTTGCTGTAGACTTCCCA 
             ************************************************************ 
 
SIRT1CD      GATCTTCCAGATCCTCAAGCGATGTTTGATATTGAATATTTCAGAAAAGATCCAAGACCA 
SIRT1WT      GATCTTCCAGATCCTCAAGCGATGTTTGATATTGAATATTTCAGAAAAGATCCAAGACCA 
             ************************************************************ 
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SIRT1CD      TTCTTCAAGTTTGCAAAGGAAATATATCCTGGACAATTCCAGCCATCTCTCTGTCACAAA 
SIRT1WT      TTCTTCAAGTTTGCAAAGGAAATATATCCTGGACAATTCCAGCCATCTCTCTGTCACAAA 
             ************************************************************ 
 
SIRT1CD      TTCATAGCCTTGTCAGATAAGGAAGGAAAACTACTTCGCAACTATACCCAGAACATAGAC 
SIRT1WT      TTCATAGCCTTGTCAGATAAGGAAGGAAAACTACTTCGCAACTATACCCAGAACATAGAC 
             ************************************************************ 
 
SIRT1CD      ACGCTGGAACAGGTTGCGGGAATCCAAAGGATAATTCAGTGTCATGGTTCCTTTGCAACA 
SIRT1WT      ACGCTGGAACAGGTTGCGGGAATCCAAAGGATAATTCAGTGTCATGGTTCCTTTGCAACA 
             ************************************************************ 
 
SIRT1CD      GCATCTTGCCTGATTTGTAAATACAAAGTTGACTGTGAAGCTGTACGAGGAGATATTTTT 
SIRT1WT      GCATCTTGCCTGATTTGTAAATACAAAGTTGACTGTGAAGCTGTACGAGGAGATATTTTT 
             ************************************************************ 
 
SIRT1CD      AATCAGGTAGTTCCTCGATGTCCTAGGTGCCCAGCTGATGAACCGCTTGCTATCATGAAA 
SIRT1WT      AATCAGGTAGTTCCTCGATGTCCTAGGTGCCCAGCTGATGAACCGCTTGCTATCATGAAA 
             ************************************************************ 
 
SIRT1CD      CCAGAGATTGTGTTTTTTGGTGAAAATTTACCAGAACAGTTTCATAGAGCCATGAAGTAT 
SIRT1WT      CCAGAGATTGTGTTTTTTGGTGAAAATTTACCAGAACAGTTTCATAGAGCCATGAAGTAT 
             ************************************************************ 
 
SIRT1CD      GACAAAGATGAAGTTGACCTCCTCATTGTTATTGGGTCTTCCCTCAAAGTAAGACCAGTA 
SIRT1WT      GACAAAGATGAAGTTGACCTCCTCATTGTTATTGGGTCTTCCCTCAAAGTAAGACCAGTA 
             ************************************************************ 
 
SIRT1CD      GCACTAATTCCAAGTTCCATACCCCATGAAGTGCCTCAGATATTAATTAATAGAGAACCT 
SIRT1WT      GCACTAATTCCAAGTTCCATACCCCATGAAGTGCCTCAGATATTAATTAATAGAGAACCT 
             ************************************************************ 
 
SIRT1CD      TTGCCTCATCTGCATTTTGATGTAGAGCTTCTTGGAGACTGTGATGTCATAATTAATGAA 
SIRT1WT      TTGCCTCATCTGCATTTTGATGTAGAGCTTCTTGGAGACTGTGATGTCATAATTAATGAA 
             ************************************************************ 
 
SIRT1CD      TTGTGTCATAGGTTAGGTGGTGAATATGCCAAACTTTGCTGTAACCCTGTAAAGCTTTCA 
SIRT1WT      TTGTGTCATAGGTTAGGTGGTGAATATGCCAAACTTTGCTGTAACCCTGTAAAGCTTTCA 
             ************************************************************ 
 
SIRT1CD      GAAATTACTGAAAAACCTCCACGAACACAAAAAGAATTGGCTTATTTGTCAGAGTTGCCA 
SIRT1WT      GAAATTACTGAAAAACCTCCACGAACACAAAAAGAATTGGCTTATTTGTCAGAGTTGCCA 
             ************************************************************ 
 
SIRT1CD      CCCACACCTCTTCATGTTTCAGAAGACTCAAGTTCACCAGAAAGAACTTCACCACCAGAT 
SIRT1WT      CCCACACCTCTTCATGTTTCAGAAGACTCAAGTTCACCAGAAAGAACTTCACCACCAGAT 
             ************************************************************ 
 
SIRT1CD      TCTTCAGTGATTGTCACACTTTTAGACCAAGCAGCTAAGAGTAATGATGATTTAGATGTG 
SIRT1WT      TCTTCAGTGATTGTCACACTTTTAGACCAAGCAGCTAAGAGTAATGATGATTTAGATGTG 
             ************************************************************ 
 
SIRT1CD      TCTGAATCAAAAGGTTGTATGGAAGAAAAACCACAGGAAGTACAAACTTCTAGGAATGTT 
SIRT1WT      TCTGAATCAAAAGGTTGTATGGAAGAAAAACCACAGGAAGTACAAACTTCTAGGAATGTT 
             ************************************************************ 
 
SIRT1CD      GAAAGTATTGCTGAACAGATGGAAAATCCGGATTTGAAGAATGTTGGTTCTAGTACTGGG 
SIRT1WT      GAAAGTATTGCTGAACAGATGGAAAATCCGGATTTGAAGAATGTTGGTTCTAGTACTGGG 
             ************************************************************ 
 
SIRT1CD      GAGAAAAATGAAAGAACTTCAGTGGCTGGAACAGTGAGAAAATGCTGGCCTAATAGAGTG 
SIRT1WT      GAGAAAAATGAAAGAACTTCAGTGGCTGGAACAGTGAGAAAATGCTGGCCTAATAGAGTG 
             ************************************************************ 
 
SIRT1CD      GCAAAGGAGCAGATTAGTAGGCGGCTTGATGGTAATCAGTATCTGTTTTTGCCACCAAAT 
SIRT1WT      GCAAAGGAGCAGATTAGTAGGCGGCTTGATGGTAATCAGTATCTGTTTTTGCCACCAAAT 
             ************************************************************ 
 
SIRT1CD      CGTTACATTTTCCATGGCGCTGAGGTATATTCAGACTCTGAAGATGACGTCTTATCCTCT 
SIRT1WT      CGTTACATTTTCCATGGCGCTGAGGTATATTCAGACTCTGAAGATGACGTCTTATCCTCT 
             ************************************************************ 
 369 
 
SIRT1CD      AGTTCTTGTGGCAGTAACAGTGATAGTGGGACATGCCAGAGTCCAAGTTTAGAAGAACCC 
SIRT1WT      AGTTCTTGTGGCAGTAACAGTGATAGTGGGACATGCCAGAGTCCAAGTTTAGAAGAACCC 
             ************************************************************ 
 
SIRT1CD      ATGGAGGATGAAAGTGAAATTGAAGAATTCTACAATGGCTTAGAAGATGAGCCTGATGTT 
SIRT1WT      ATGGAGGATGAAAGTGAAATTGAAGAATTCTACAATGGCTTAGAAGATGAGCCTGATGTT 
             ************************************************************ 
 
SIRT1CD      CCAGAGAGAGCTGGAGGAGCTGGATTTGGGACTGATGGAGATGATCAAGAGGCAATTAAT 
SIRT1WT      CCAGAGAGAGCTGGAGGAGCTGGATTTGGGACTGATGGAGATGATCAAGAGGCAATTAAT 
             ************************************************************ 
 
SIRT1CD      GAAGCTATATCTGTGAAACAGGAAGTAACAGACATGAACTATCCATCAAACAAATCA 
SIRT1WT      GAAGCTATATCTGTGAAACAGGAAGTAACAGACATGAACTATCCATCAAACAAATCATAG 
             ********************************************************* 
 
ACTACAAGGACGATGACGATAAACCCGGGAATTCGG: DYKDDDDKPGNS sequence 
preceded by start codon 
 
2.2.2 SIRT1H363Y plasmid 
 
SIRT1CD         ------------------------GGCAGTTGGAAGATGGCGGACGAGGCGGCCCTCGCC 
SIRT1H363Y      ATGGACTACAAGGACGATGACGATAAACCCGGGAATTCGGCGGACGAGGCGGCCCTCGCC 
                                               ****   ********************** 
 
SIRT1CD         CTTCAGCCCGGCGGCTCCCCCTCGGCGGCGGGGGCCGACAGGGAGGCCGCGTCGTCCCCC 
SIRT1H363Y      CTTCAGCCCGGCGGCTCCCCCTCGGCGGCGGGGGCCGACAGGGAGGCCGCGTCGTCCCCC 
                ************************************************************ 
 
SIRT1CD         GCCGGGGAGCCGCTCCGCAAGAGGCCGCGGAGAGATGGTCCCGGCCTCGAGCGGAGCCCG 
SIRT1H363Y      GCCGGGGAGCCGCTCCGCAAGAGGCCGCGGAGAGATGGTCCCGGCCTCGAGCGGAGCCCG 
                ************************************************************ 
 
SIRT1CD         GGCGAGCCCGGTGGGGCGGCCCCAGAGCGTGAGGTGCCGGCGGCGGCCAGGGGCTGCCCG 
SIRT1H363Y      GGCGAGCCCGGTGGGGCGGCCCCAGAGCGTGAGGTGCCGGCGGCGGCCAGGGGCTGCCCG 
                ************************************************************ 
 
SIRT1CD         GGTGCGGCGGCGGCGGCGCTGTGGCGGGAGGCGGAGGCAGAGGCGGCGGCGGCAGGCGGG 
SIRT1H363Y      GGTGCGGCGGCGGCGGCGCTGTGGCGGGAGGCGGAGGCAGAGGCGGCGGCGGCAGGCGGG 
                ************************************************************ 
 
SIRT1CD         GAGCAAGAGGCCCAGGCGACTGCGGCGGCTGGGGAAGGAGACAATGGGCCGGGCCTGCAG 
SIRT1H363Y      GAGCAAGAGGCCCAGGCGACTGCGGCGGCTGGGGAAGGAGACAATGGGCCGGGCCTGCAG 
                ************************************************************ 
 
SIRT1CD         GGCCCATCTCGGGAGCCACCGCTGGCCGACAACTTGTACGACGAAGACGACGACGACGAG 
SIRT1H363Y      GGCCCATCTCGGGAGCCACCGCTGGCCGACAACTTGTACGACGAAGACGACGACGACGAG 
                ************************************************************ 
 
SIRT1CD         GGCGAGGAGGAGGAAGAGGCGGCGGCGGCGGCGATTGGGTACCGAGATAACCTTCTGTTC 
SIRT1H363Y      GGCGAGGAGGAGGAAGAGGCGGCGGCGGCGGCGATTGGGTACCGAGATAACCTTCTGTTC 
                ************************************************************ 
 
SIRT1CD         GGTGATGAAATTATCACTAATGGTTTTCATTCCTGTGAAAGTGATGAGGAGGATAGAGCC 
SIRT1H363Y      GGTGATGAAATTATCACTAATGGTTTTCATTCCTGTGAAAGTGATGAGGAGGATAGAGCC 
                ************************************************************ 
 
SIRT1CD         TCACATGCAAGCTCTAGTGACTGGACTCCAAGGCCACGGATAGGTCCATATACTTTTGTT 
SIRT1H363Y      TCACATGCAAGCTCTAGTGACTGGACTCCAAGGCCACGGATAGGTCCATATACTTTTGTT 
                ************************************************************ 
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SIRT1CD         CAGCAACATCTTATGATTGGCACAGATCCTCGAACAATTCTTAAAGATTTATTGCCGGAA 
SIRT1H363Y      CAGCAACATCTTATGATTGGCACAGATCCTCGAACAATTCTTAAAGATTTATTGCCGGAA 
                ************************************************************ 
 
SIRT1CD         ACAATACCTCCACCTGAGTTGGATGATATGACACTGTGGCAGATTGTTATTAATATCCTT 
SIRT1H363Y      ACAATACCTCCACCTGAGTTGGATGATATGACACTGTGGCAGATTGTTATTAATATCCTT 
                ************************************************************ 
 
SIRT1CD         TCAGAACCACCAAAAAGGAAAAAAAGAAAAGATATTAATACAATTGAAGATGCTGTGAAA 
SIRT1H363Y      TCAGAACCACCAAAAAGGAAAAAAAGAAAAGATATTAATACAATTGAAGATGCTGTGAAA 
                ************************************************************ 
 
SIRT1CD         TTACTGCAAGAGTGCAAAAAAATTATAGTTCTAACTGGAGCTGGGGTGTCTGTTTCATGT 
SIRT1H363Y      TTACTGCAAGAGTGCAAAAAAATTATAGTTCTAACTGGAGCTGGGGTGTCTGTTTCATGT 
                ************************************************************ 
 
SIRT1CD         GGAATACCTGACTTCAGGTCAAGGGATGGTATTTATGCTCGCCTTGCTGTAGACTTCCCA 
SIRT1H363Y      GGAATACCTGACTTCAGGTCAAGGGATGGTATTTATGCTCGCCTTGCTGTAGACTTCCCA 
                ************************************************************ 
 
SIRT1CD         GATCTTCCAGATCCTCAAGCGATGTTTGATATTGAATATTTCAGAAAAGATCCAAGACCA 
SIRT1H363Y      GATCTTCCAGATCCTCAAGCGATGTTTGATATTGAATATTTCAGAAAAGATCCAAGACCA 
                ************************************************************ 
 
SIRT1CD         TTCTTCAAGTTTGCAAAGGAAATATATCCTGGACAATTCCAGCCATCTCTCTGTCACAAA 
SIRT1H363Y      TTCTTCAAGTTTGCAAAGGAAATATATCCTGGACAATTCCAGCCATCTCTCTGTCACAAA 
                ************************************************************ 
 
SIRT1CD         TTCATAGCCTTGTCAGATAAGGAAGGAAAACTACTTCGCAACTATACCCAGAACATAGAC 
SIRT1H363Y      TTCATAGCCTTGTCAGATAAGGAAGGAAAACTACTTCGCAACTATACCCAGAACATAGAC 
                ************************************************************ 
 
SIRT1CD         ACGCTGGAACAGGTTGCGGGAATCCAAAGGATAATTCAGTGTCATGGTTCCTTTGCAACA 
SIRT1H363Y      ACGCTGGAACAGGTTGCGGGAATCCAAAGGATAATTCAGTGTTATGGTTCCTTTGCAACA 
                ****************************************** ***************** 
 
SIRT1CD         GCATCTTGCCTGATTTGTAAATACAAAGTTGACTGTGAAGCTGTACGAGGAGATATTTTT 
SIRT1H363Y      GCATCTTGCCTGATTTGTAAATACAAAGTTGACTGTGAAGCTGTACGAGGAGATATTTTT 
                ************************************************************ 
 
SIRT1CD         AATCAGGTAGTTCCTCGATGTCCTAGGTGCCCAGCTGATGAACCGCTTGCTATCATGAAA 
SIRT1H363Y      AATCAGGTAGTTCCTCGATGTCCTAGGTGCCCAGCTGATGAACCGCTTGCTATCATGAAA 
                ************************************************************ 
 
SIRT1CD         CCAGAGATTGTGTTTTTTGGTGAAAATTTACCAGAACAGTTTCATAGAGCCATGAAGTAT 
SIRT1H363Y      CCAGAGATTGTGTTTTTTGGTGAAAATTTACCAGAACAGTTTCATAGAGCCATGAAGTAT 
                ************************************************************ 
 
SIRT1CD         GACAAAGATGAAGTTGACCTCCTCATTGTTATTGGGTCTTCCCTCAAAGTAAGACCAGTA 
SIRT1H363Y      GACAAAGATGAAGTTGACCTCCTCATTGTTATTGGGTCTTCCCTCAAAGTAAGACCAGTA 
                ************************************************************ 
 
SIRT1CD         GCACTAATTCCAAGTTCCATACCCCATGAAGTGCCTCAGATATTAATTAATAGAGAACCT 
SIRT1H363Y      GCACTAATTCCAAGTTCCATACCCCATGAAGTGCCTCAGATATTAATTAATAGAGAACCT 
                ************************************************************ 
 
SIRT1CD         TTGCCTCATCTGCATTTTGATGTAGAGCTTCTTGGAGACTGTGATGTCATAATTAATGAA 
SIRT1H363Y      TTGCCTCATCTGCATTTTGATGTAGAGCTTCTTGGAGACTGTGATGTCATAATTAATGAA 
                ************************************************************ 
 
SIRT1CD         TTGTGTCATAGGTTAGGTGGTGAATATGCCAAACTTTGCTGTAACCCTGTAAAGCTTTCA 
SIRT1H363Y      TTGTGTCATAGGTTAGGTGGTGAATATGCCAAACTTTGCTGTAACCCTGTAAAGCTTTCA 
                ************************************************************ 
 
 
SIRT1CD         GAAATTACTGAAAAACCTCCACGAACACAAAAAGAATTGGCTTATTTGTCAGAGTTGCCA 
SIRT1H363Y      GAAATTACTGAAAAACCTCCACGAACACAAAAAGAATTGGCTTATTTGTCAGAGTTGCCA 
                ************************************************************ 
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SIRT1CD         CCCACACCTCTTCATGTTTCAGAAGACTCAAGTTCACCAGAAAGAACTTCACCACCAGAT 
SIRT1H363Y      CCCACACCTCTTCATGTTTCAGAAGACTCAAGTTCACCAGAAAGAACTTCACCACCAGAT 
                ************************************************************ 
 
SIRT1CD         TCTTCAGTGATTGTCACACTTTTAGACCAAGCAGCTAAGAGTAATGATGATTTAGATGTG 
SIRT1H363Y      TCTTCAGTGATTGTCACACTTTTAGACCAAGCAGCTAAGAGTAATGATGATTTAGATGTG 
                ************************************************************ 
 
SIRT1CD         TCTGAATCAAAAGGTTGTATGGAAGAAAAACCACAGGAAGTACAAACTTCTAGGAATGTT 
SIRT1H363Y      TCTGAATCAAAAGGTTGTATGGAAGAAAAACCACAGGAAGTACAAACTTCTAGGAATGTT 
                ************************************************************ 
 
SIRT1CD         GAAAGTATTGCTGAACAGATGGAAAATCCGGATTTGAAGAATGTTGGTTCTAGTACTGGG 
SIRT1H363Y      GAAAGTATTGCTGAACAGATGGAAAATCCGGATTTGAAGAATGTTGGTTCTAGTACTGGG 
                ************************************************************ 
 
 
 
SIRT1CD         GAGAAAAATGAAAGAACTTCAGTGGCTGGAACAGTGAGAAAATGCTGGCCTAATAGAGTG 
SIRT1H363Y      GAGAAAAATGAAAGAACTTCAGTGGCTGGAACAGTGAGAAAATGCTGGCCTAATAGAGTG 
                ************************************************************ 
 
SIRT1CD         GCAAAGGAGCAGATTAGTAGGCGGCTTGATGGTAATCAGTATCTGTTTTTGCCACCAAAT 
SIRT1H363Y      GCAAAGGAGCAGATTAGTAGGCGGCTTGATGGTAATCAGTATCTGTTTTTGCCACCAAAT 
                ************************************************************ 
 
SIRT1CD         CGTTACATTTTCCATGGCGCTGAGGTATATTCAGACTCTGAAGATGACGTCTTATCCTCT 
SIRT1H363Y      CGTTACATTTTCCATGGCGCTGAGGTATATTCAGACTCTGAAGATGACGTCTTATCCTCT 
                ************************************************************ 
 
SIRT1CD         AGTTCTTGTGGCAGTAACAGTGATAGTGGGACATGCCAGAGTCCAAGTTTAGAAGAACCC 
SIRT1H363Y      AGTTCTTGTGGCAGTAACAGTGATAGTGGGACATGCCAGAGTCCAAGTTTAGAAGAACCC 
                ************************************************************ 
 
SIRT1CD         ATGGAGGATGAAAGTGAAATTGAAGAATTCTACAATGGCTTAGAAGATGAGCCTGATGTT 
SIRT1H363Y      ATGGAGGATGAAAGTGAAATTGAAGAATTCTACAATGGCTTAGAAGATGAGCCTGATGTT 
                ************************************************************ 
 
SIRT1CD         CCAGAGAGAGCTGGAGGAGCTGGATTTGGGACTGATGGAGATGATCAAGAGGCAATTAAT 
SIRT1H363Y      CCAGAGAGAGCTGGAGGAGCTGGATTTGGGACTGATGGAGATGATCAAGAGGCAATTAAT 
                ************************************************************ 
 
SIRT1CD         GAAGCTATATCTGTGAAACAGGAAGTAACAGACATGAACTATCCATCAAACAAATCA 
SIRT1H363Y      GAAGCTATATCTGTGAAACAGGAAGTAACAGACATGAACTATCCATCAAACAAATCATAG 
                ********************************************************* 
ACTACAAGGACGATGACGATAAACCCGGGAATTCGG: DYKDDDDKPGNS sequence 
preceded by start codon. CAT→TAT indicates the substitution of histidine to tyrosine 
(H363Y). 
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2.2.3 SIRT3 plasmid 
SIRT3CD      ATGGCGTTCTGGGGTTGGCGCGCCGCGGCAGCCCTCCGGCTGTGGGGCCGGGTAGTTGAA 
SIRT3Pl      ATGGCGTTCTGGGGTTGGCGCGCCGCGGCAGCCCTCCGGCTGTGGGGCCGGGTAGTTGAA 
             ************************************************************ 
 
SIRT3CD      CGGGTCGAGGCCGGGGGAGGCGTGGGGCCGTTTCAGGCCTGCGGCTGTCGGCTGGTGCTT 
SIRT3Pl      CGGGTCGAGGCCGGGGGAGGCGTGGGGCCGTTTCAGGCCTGCGGCTGTCGGCTGGTGCTT 
             ************************************************************ 
 
SIRT3CD      GGCGGCAGGGACGATGTGAGTGCGGGGCTGAGAGGCAGCCATGGGGCCCGCGGTGAGCCC 
SIRT3Pl      GGCGGCAGGGACGATGTGAGTGCGGGGCTGAGAGGCAGCCATGGGGCCCGCGGTGAGCCC 
             ************************************************************ 
 
SIRT3CD      TTGGACCCGGCGCGCCCCTTGCAGAGGCCTCCCAGACCCGAGGTGCCCAGGGCATTCCGG 
SIRT3Pl      TTGGACCCGGCGCGCCCCTTGCAGAGGCCTCCCAGACCCGAGGTGCCCAGGGCATTCCGG 
             ************************************************************ 
 
SIRT3CD      AGGCAGCCGAGGGCAGCAGCTCCCAGTTTCTTCTTTTCGAGTATTAAAGGTGGAAGAAGG 
SIRT3Pl      AGGCAGCCGAGGGCAGCAGCTCCCAGTTTCTTCTTTTCGAGTATTAAAGGTGGAAGAAGG 
             ************************************************************ 
 
SIRT3CD      TCCATATCTTTTTCTGTGGGTGCTTCAAGTGTTGTTGGAAGTGGAGGCAGCAGTGACAAG 
SIRT3Pl      TCCATATCTTTTTCTGTGGGTGCTTCAAGTGTTGTTGGAAGTGGAGGCAGCAGTGACAAG 
             ************************************************************ 
 
SIRT3CD      GGGAAGCTTTCCCTGCAGGATGTAGCTGAGCTGATTCGGGCCAGAGCCTGCCAGAGGGTG 
SIRT3Pl      GGGAAGCTTTCCCTGCAGGATGTAGCTGAGCTGATTCGGGCCAGAGCCTGCCAGAGGGTG 
             ************************************************************ 
 
SIRT3CD      GTGGTCATGGTGGGGGCCGGCATCAGCACACCCAGTGGCATTCCAGACTTCAGATCGCCG 
SIRT3Pl      GTGGTCATGGTGGGGGCCGGCATCAGCACACCCAGTGGCATTCCAGACTTCAGATCGCCG 
             ************************************************************ 
 
SIRT3CD      GGGAGTGGCCTGTACAGCAACCTCCAGCAGTACGATCTCCCGTACCCCGAGGCCATTTTT 
SIRT3Pl      GGGAGTGGCCTGTACAGCAACCTCCAGCAGTACGATCTCCCGTACCCCGAGGCCATTTTT 
             ************************************************************ 
 
SIRT3CD      GAACTCCCATTCTTCTTTCACAACCCCAAGCCCTTTTTCACTTTGGCCAAGGAGCTGTAC 
SIRT3Pl      GAACTCCCATTCTTCTTTCACAACCCCAAGCCCTTTTTCACTTTGGCCAAGGAGCTGTAC 
             ************************************************************ 
 
SIRT3CD      CCTGGAAACTACAAGCCCAACGTCACTCACTACTTTCTCCGGCTGCTTCATGACAAGGGG 
SIRT3Pl      CCTGGAAACTACAAGCCCAACGTCACTCACTACTTTCTCCGGCTGCTTCATGACAAGGGG 
             ************************************************************ 
 
SIRT3CD      CTGCTTCTGCGGCTCTACACGCAGAACATCGATGGGCTTGAGAGAGTGTCGGGCATCCCT 
SIRT3Pl      CTGCTTCTGCGGCTCTACACGCAGAACATCGATGGGCTTGAGAGAGTGTCGGGCATCCCT 
             ************************************************************ 
 
SIRT3CD      GCCTCAAAGCTGGTTGAAGCTCATGGAACCTTTGCCTCTGCCACCTGCACAGTCTGCCAA 
SIRT3Pl      GCCTCAAAGCTGGTTGAAGCTCATGGAACCTTTGCCTCTGCCACCTGCACAGTCTGCCAA 
             ************************************************************ 
 
SIRT3CD      AGACCCTTCCCAGGGGAGGACATTCGGGCTGACGTGATGGCAGACAGGGTTCCCCGCTGC 
SIRT3Pl      AGACCCTTCCCAGGGGAGGACATTCGGGCTGACGTGATGGCAGACAGGGTTCCCCGCTGC 
             ************************************************************ 
 
SIRT3CD      CCGGTCTGCACCGGCGTTGTGAAGCCCGACATTGTGTTCTTTGGGGAGCCGCTGCCCCAG 
SIRT3Pl      CCGGTCTGCACCGGCGTTGTGAAGCCCGACATTGTGTTCTTTGGGGAGCCGCTGCCCCAG 
             ************************************************************ 
 
SIRT3CD      AGGTTCTTGCTGCATGTGGTTGATTTCCCCATGGCAGATCTGCTGCTCATCCTTGGGACC 
SIRT3Pl      AGGTTCTTGCTGCATGTGGTTGATTTCCCCATGGCAGATCTGCTGCTCATCCTTGGGACC 
             ************************************************************ 
 
SIRT3CD      TCCCTGGAGGTGGAGCCTTTTGCCAGCTTGACCGAGGCCGTGCGGAGCTCAGTTCCCCGA 
SIRT3Pl      TCCCTGGAGGTGGAGCCTTTTGCCAGCTTGACCGAGGCCGTGCGGAGCTCAGTTCCCCGA 
             ************************************************************ 
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SIRT3CD      CTGCTCATCAACCGGGACTTGGTGGGGCCCTTGGCTTGGCATCCTCGCAGCAGGGACGTG 
SIRT3Pl      CTGCTCATCAACCGGGACTTGGTGGGGCCCTTGGCTTGGCATCCTCGCAGCAGGGACGTG 
             ************************************************************ 
 
SIRT3CD      GCCCAGCTGGGGGACGTGGTTCACGGCGTGGAAAGCCTAGTGGAGCTTCTGGGCTGGACA 
SIRT3Pl      GCCCAGCTGGGGGACGTGGTTCACGGCGTGGAAAGCCTAGTGGAGCTTCTGGGCTGGACA 
             ************************************************************ 
 
SIRT3CD      GAAGAGATGCGGGACCTTGTGCAGCGGGAAACTGGGAAGCTTGATGGACCAGACAAA--- 
SIRT3Pl      GAAGAGATGCGGGACCTTGTGCAGCGGGAAACTGGGAAGCTTGATGGACCAGACAAACTC 
             *********************************************************    
 
SIRT3CD      ------------------------------------------------------------ 
SIRT3Pl      GAGTCTAGAGGGCCCTTCGAACAAAAACTCATCTCAGAAGAGGATCTGAATATGCATACC 
                                                                          
 
SIRT3CD      ------------------------------------------------------------ 
SIRT3Pl      GGTCATCATCACCATCACCATATACTGCAGGATGTAGCTGAGCTGATTCGGGCCAGAGCC 
                                                                          
 
SIRT3CD      ------------------------------------------------------------ 
SIRT3Pl      TGCCAGAGGGTGGTGGTCATGGTGGGGGCCGGCATCAGCACACCCAGTGGCATTCCAGAC 
                                                                          
 
SIRT3CD      ------------------------------------------------------------ 
SIRT3Pl      TTCAGATCGCCCGGGGAGTGGCCTGTACAGCAACCTCCAGCAGTACGATCTCCCGTACCC 
                                                                          
 
SIRT3CD      --------------- 
SIRT3Pl      CGAGGCCATTTTTGA 
 
GAACAAAAACTCATCTCAGAAGAGGATCTG- Myc tag, CATCATCACCATCACCAT- 
Histidine tag, TGA: Stop codon 
 
2.2.4 SIRT3H248Y plasmid 
 
 
SIRT3CD           ATGGCGTTCTGGGGTTGGCGCGCCGCGGCAGCCCTCCGGCTGTGGGGCCGGGTAGTTGAA 
SIRT3H248YPl      ATGGCGTTCTGGGGTTGGCGCGCCGCGGCAGCCCTCCGGCTGTGGGGCCGGGTAGTTGAA 
                  ************************************************************ 
 
SIRT3CD           CGGGTCGAGGCCGGGGGAGGCGTGGGGCCGTTTCAGGCCTGCGGCTGTCGGCTGGTGCTT 
SIRT3H248YPl      CGGGTCGAGGCCGGGGGAGGCGTGGGGCCGTTTCAGGCCTGCGGCTGTCGGCTGGTGCTT 
                  ************************************************************ 
 
SIRT3CD           GGCGGCAGGGACGATGTGAGTGCGGGGCTGAGAGGCAGCCATGGGGCCCGCGGTGAGCCC 
SIRT3H248YPl      GGCGGCAGGGACGATGTGAGTGCGGGGCTGAGAGGCAGCCATGGGGCCCGCGGTGAGCCC 
                  ************************************************************ 
 
SIRT3CD           TTGGACCCGGCGCGCCCCTTGCAGAGGCCTCCCAGACCCGAGGTGCCCAGGGCATTCCGG 
SIRT3H248YPl      TTGGACCCGGCGCGCCCCTTGCAGAGGCCTCCCAGACCCGAGGTGCCCAGGGCATTCCGG 
                  ************************************************************ 
 
SIRT3CD           AGGCAGCCGAGGGCAGCAGCTCCCAGTTTCTTCTTTTCGAGTATTAAAGGTGGAAGAAGG 
SIRT3H248YPl      AGGCAGCCGAGGGCAGCAGCTCCCAGTTTCTTCTTTTCGAGTATTAAAGGTGGAAGAAGG 
                  ************************************************************ 
 
SIRT3CD           TCCATATCTTTTTCTGTGGGTGCTTCAAGTGTTGTTGGAAGTGGAGGCAGCAGTGACAAG 
SIRT3H248YPl      TCCATATCTTTTTCTGTGGGTGCTTCAAGTGTTGTTGGAAGTGGAGGCAGCAGTGACAAG 
                  ************************************************************ 
 
SIRT3CD           GGGAAGCTTTCCCTGCAGGATGTAGCTGAGCTGATTCGGGCCAGAGCCTGCCAGAGGGTG 
SIRT3H248YPl      GGGAAGCTTTCCCTGCAGGATGTAGCTGAGCTGATTCGGGCCAGAGCCTGCCAGAGGGTG 
                  ************************************************************ 
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SIRT3CD           GTGGTCATGGTGGGGGCCGGCATCAGCACACCCAGTGGCATTCCAGACTTCAGATCGCCG 
SIRT3H248YPl      GTGGTCATGGTGGGGGCCGGCATCAGCACACCCAGTGGCATTCCAGACTTCAGATCGCCG 
                  ************************************************************ 
 
SIRT3CD           GGGAGTGGCCTGTACAGCAACCTCCAGCAGTACGATCTCCCGTACCCCGAGGCCATTTTT 
SIRT3H248YPl      GGGAGTGGCCTGTACAGCAACCTCCAGCAGTACGATCTCCCGTACCCCGAGGCCATTTTT 
                  ************************************************************ 
 
SIRT3CD           GAACTCCCATTCTTCTTTCACAACCCCAAGCCCTTTTTCACTTTGGCCAAGGAGCTGTAC 
SIRT3H248YPl      GAACTCCCATTCTTCTTTCACAACCCCAAGCCCTTTTTCACTTTGGCCAAGGAGCTGTAC 
                  ************************************************************ 
 
SIRT3CD           CCTGGAAACTACAAGCCCAACGTCACTCACTACTTTCTCCGGCTGCTTCATGACAAGGGG 
SIRT3H248YPl      CCTGGAAACTACAAGCCCAACGTCACTCACTACTTTCTCCGGCTGCTTCATGACAAGGGG 
                  ************************************************************ 
 
SIRT3CD           CTGCTTCTGCGGCTCTACACGCAGAACATCGATGGGCTTGAGAGAGTGTCGGGCATCCCT 
SIRT3H248YPl      CTGCTTCTGCGGCTCTACACGCAGAACATCGATGGGCTTGAGAGAGTGTCGGGCATCCCT 
                  ************************************************************ 
 
SIRT3CD           GCCTCAAAGCTGGTTGAAGCTCATGGAACCTTTGCCTCTGCCACCTGCACAGTCTGCCAA 
SIRT3H248YPl      GCCTCAAAGCTGGTTGAAGCTTATGGAACCTTTGCCTCTGCCACCTGCACAGTCTGCCAA 
                  ********************* ************************************** 
 
SIRT3CD           AGACCCTTCCCAGGGGAGGACATTCGGGCTGACGTGATGGCAGACAGGGTTCCCCGCTGC 
SIRT3H248YPl      AGACCCTTCCCAGGGGAGGACATTCGGGCTGACGTGATGGCAGACAGGGTTCCCCGCTGC 
                  ************************************************************ 
 
SIRT3CD           CCGGTCTGCACCGGCGTTGTGAAGCCCGACATTGTGTTCTTTGGGGAGCCGCTGCCCCAG 
SIRT3H248YPl      CCGGTCTGCACCGGCGTTGTGAAGCCCGACATTGTGTTCTTTGGGGAGCCGCTGCCCCAG 
                  ************************************************************ 
 
SIRT3CD           AGGTTCTTGCTGCATGTGGTTGATTTCCCCATGGCAGATCTGCTGCTCATCCTTGGGACC 
SIRT3H248YPl      AGGTTCTTGCTGCATGTGGTTGATTTCCCCATGGCAGATCTGCTGCTCATCCTTGGGACC 
                  ************************************************************ 
 
SIRT3CD           TCCCTGGAGGTGGAGCCTTTTGCCAGCTTGACCGAGGCCGTGCGGAGCTCAGTTCCCCGA 
SIRT3H248YPl      TCCCTGGAGGTGGAGCCTTTTGCCAGCTTGACCGAGGCCGTGCGGAGCTCAGTTCCCCGA 
                  ************************************************************ 
 
SIRT3CD           CTGCTCATCAACCGGGACTTGGTGGGGCCCTTGGCTTGGCATCCTCGCAGCAGGGACGTG 
SIRT3H248YPl      CTGCTCATCAACCGGGACTTGGTGGGGCCCTTGGCTTGGCATCCTCGCAGCAGGGACGTG 
                  ************************************************************ 
 
SIRT3CD           GCCCAGCTGGGGGACGTGGTTCACGGCGTGGAAAGCCTAGTGGAGCTTCTGGGCTGGACA 
SIRT3H248YPl      GCCCAGCTGGGGGACGTGGTTCACGGCGTGGAAAGCCTAGTGGAGCTTCTGGGCTGGACA 
                  ************************************************************ 
 
SIRT3CD           GAAGAGATGCGGGACCTTGTGCAGCGGGAAACTGGGAAGCTTGATGGACCAGACAAA--- 
SIRT3H248YPl      GAAGAGATGCGGGACCTTGTGCAGCGGGAAACTGGGAAGCTTGATGGACCAGACAAACTC 
                  *********************************************************    
 
SIRT3CD           ------------------------------------------------------------ 
SIRT3H248YPl      GAGTCTAGAGGGCCCTTCGAACAAAAACTCATCTCAGAAGAGGATCTGAATATGCATACC 
                                                                               
 
SIRT3CD           ------------------------------------------------------------ 
SIRT3H248YPl      GGTCATCATCACCATCACCATATACTGCAGGATGTAGCTGAGCTGATTCGGGCCAGAGCC 
                                                                               
 
SIRT3CD           ------------------------------------------------------------ 
SIRT3H248YPl      TGCCAGAGGGTGGTGGTCATGGTGGGGGCCGGCATCAGCACACCCAGTGGCATTCCAGAC 
                                                                               
 
SIRT3CD           ------------------------------------------------------------ 
SIRT3H248YPl      TTCAGATCGCCCGGGGAGTGGCCTGTACAGCAACCTCCAGCAGTACGATCTCCCGTACCC 
                                                                               
 
SIRT3CD           --------------- 
SIRT3H248YPl      CGAGGCCATTTTTGA                
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GAACAAAAACTCATCTCAGAAGAGGATCTG- Myc tag, CATCATCACCATCACCAT- 
Histidine tag, TGA: Stop codon. CAT→TAT indicates the substitution of histidine to tyrosine 
(H248Y). 
 
2.3 Sequence of SIRT2 Flag from Addgene 
SIRT2CD             ATGGCAGAGCCAGACCCCTCTCACCCTCTGGAGACCCAGGCAGGGAAGGTGCAGGAGGCT 
SIRT2PlAddgene      ATGGCAGAGCCAGACCCCTCTCACCCTCTGGAGACCCAGGCAGGGAAGGTGCAGGAGGCT 
                    ************************************************************ 
 
SIRT2CD             CAGGACTCAGATTCAGACTCTGAGGGAGGAGCCGCTGGTGGAGAAGCAGACATGGACTTC 
SIRT2PlAddgene      CAGGACTCAGATTCAGACTCTGAGGGAGGAGCCGCTGGTGGAGAAGCAGACATGGACTTC 
                    ************************************************************ 
 
SIRT2CD             CTGCGGAACTTATTCTCCCAGACGCTCAGCCTGGGCAGCCAGAAGGAGCGTCTGCTGGAC 
SIRT2PlAddgene      CTGCGGAACTTATTCTCCCAGACGCTCAGCCTGGGCAGCCAGAAGGAGCGTCTGCTGGAC 
                    ************************************************************ 
 
SIRT2CD             GAGCTGACCTTGGAAGGGGTGGCCCGGTACATGCAGAGCGAACGCTGTCGCAGAGTCATC 
SIRT2PlAddgene      GAGCTGACCTTGGAAGGGGTGGCCCGGTACATGCAGAGCGAACGCTGTCGCAGAGTCATC 
                    ************************************************************ 
 
SIRT2CD             TGTTTGGTGGGAGCTGGAATCTCCACATCCGCAGGCATCCCCGACTTTCGCTCTCCATCC 
SIRT2PlAddgene      TGTTTGGTGGGAGCTGGAATCTCCACATCCGCAGGCATCCCCGACTTTCGCTCTCCATCC 
                    ************************************************************ 
 
SIRT2CD             ACCGGCCTCTATGACAACCTAGAGAAGTACCATCTTCCCTACCCAGAGGCCATCTTTGAG 
SIRT2PlAddgene      ACCGGCCTCTATGACAACCTAGAGAAGTACCATCTTCCCTACCCAGAGGCCATCTTTGAG 
                    ************************************************************ 
 
SIRT2CD             ATCAGCTATTTCAAGAAACATCCGGAACCCTTCTTCGCCCTCGCCAAGGAACTCTATCCT 
SIRT2PlAddgene      ATCAGCTATTTCAAGAAACATCCGGAACCCTTCTTCGCCCTCGCCAAGGAACTCTATCCT 
                    ************************************************************ 
 
SIRT2CD             GGGCAGTTCAAGCCAACCATCTGTCACTACTTCATGCGCCTGCTGAAGGACAAGGGGCTA 
SIRT2PlAddgene      GGGCAGTTCAAGCCAACCATCTGTCACTACTTCATGCGCCTGCTGAAGGACAAGGGGCTA 
                    ************************************************************ 
 
SIRT2CD             CTCCTGCGCTGCTACACGCAGAACATAGATACCCTGGAGCGAATAGCCGGGCTGGAACAG 
SIRT2PlAddgene      CTCCTGCGCTGCTACACGCAGAACATAGATACCCTGGAGCGAATAGCCGGGCTGGAACAG 
                    ************************************************************ 
 
SIRT2CD             GAGGACTTGGTGGAGGCGCACGGCACCTTCTACACATCACACTGCGTCAGCGCCAGCTGC 
SIRT2PlAddgene      GAGGACTTGGTGGAGGCGCACGGCACCTTCTACACATCACACTGCGTCAGCGCCAGCTGC 
                    ************************************************************ 
 
SIRT2CD             CGGCACGAATACCCGCTAAGCTGGATGAAAGAGAAGATCTTCTCTGAGGTGACGCCCAAG 
SIRT2PlAddgene      CGGCACGAATACCCGCTAAGCTGGATGAAAGAGAAGATCTTCTCTGAGGTGACGCCCAAG 
                    ************************************************************ 
 
SIRT2CD             TGTGAAGACTGTCAGAGCCTGGTGAAGCCTGATATCGTCTTTTTTGGTGAGAGCCTCCCA 
SIRT2PlAddgene      TGTGAAGACTGTCAGAGCCTGGTGAAGCCTGATATCGTCTTTTTTGGTGAGAGCCTCCCA 
                    ************************************************************ 
 
SIRT2CD             GCGCGTTTCTTCTCCTGTATGCAGTCAGACTTCCTGAAGGTGGACCTCCTCCTGGTCATG 
SIRT2PlAddgene      GCGCGTTTCTTCTCCTGTATGCAGTCAGACTTCCTGAAGGTGGACCTCCTCCTGGTCATG 
                    ************************************************************ 
 
SIRT2CD             GGTACCTCCTTGCAGGTGCAGCCCTTTGCCTCCCTCATCAGCAAGGCACCCCTCTCCACC 
SIRT2PlAddgene      GGTACCTCCTTGCAGGTGCAGCCCTTTGCCTCCCTCATCAGCAAGGCACCCCTCTCCACC 
                    ************************************************************ 
 
SIRT2CD             CCTCGCCTGCTCATCAACAAGGAGAAAGCTGGCCAGTCGGACCCTTTCCTGGGGATGATT 
SIRT2PlAddgene      CCTCGCCTGCTCATCAACAAGGAGAAAGCTGGCCAGTCGGACCCTTTCCTGGGGATGATT 
                    ************************************************************ 
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SIRT2CD             ATGGGCCTCGGAGGAGGCATGGACTTTGACTCCAAGAAGGCCTACAGGGACGTGGCCTGG 
SIRT2PlAddgene      ATGGGCCTCGGAGGAGGCATGGACTTTGACTCCAAGAAGGCCTACAGGGACGTGGCCTGG 
                    ************************************************************ 
 
SIRT2CD             CTGGGTGAATGCGACCAGGGCTGCCTGGCCCTTGCTGAGCTCCTTGGATGGAAGAAGGAG 
SIRT2PlAddgene      CTGGGTGAATGCGACCAGGGCTGCCTGGCCCTTGCTGAGCTCCTTGGATGGAAGAAGGAG 
                    ************************************************************ 
 
SIRT2CD             CTGGAGGACCTTGTCCGGAGGGAGCACGCCAGCATAGATGCCCAGTCGGGGGCGGGGGTC 
SIRT2PlAddgene      CTGGAGGACCTTGTCCGGAGGGAGCACGCCAGCATAGATGCCCAGTCGGGGGCGGGGGTC 
                    ************************************************************ 
 
SIRT2CD             CCCAACCCCAGCACTTCAGCTTCCCCCAAGAAGTCCCCGCCACCTGCCAAGGACGAGGCC 
SIRT2PlAddgene      CCCAACCCCAGCACTTCAGCTTCCCCCAAGAAGTCCCCGCCACCTGCCAAGGACGAGGCC 
                    ************************************************************ 
 
SIRT2CD             AGGACAACAGAGAGGGAGAAACCCCAG--------------------------------- 
SIRT2PlAddgene      AGGACAACAGAGAGGGAGAAACCCCAGGAATTCGGAGGAGACTACAAGGACGACGATGAC 
                    ***************************                                  
 
SIRT2CD             ------ 
SIRT2PlAddgene      AAGTAA 
 
GACTACAAGGACGACGATGACAAG is the DYKDDDDK tag preceding the stop codon TAA. 
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